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ABSTRACT

THE APPLICATION OF MASS SPECTROMETRIC MEASUREMENT
TECHNIQUES FOR THE EVALUATION AND ASSESSMENT OF AUTISM
SPECTRUM DISORDERS

By
Gregory M. Zinn
May 2014

Dissertation supervised by H.M. Skip Kingston
Autism spectrum disorders (ASDs) are neurological developmental disorders that
affect communication and social interaction. They are becoming more important to
society as their rate has risen dramatically over the past 30 years. Presently, there is no
known cure for ASDs and the current research focuses on improvements in diagnosis and
different types of treatments. The most significant contribution of the research described
in this dissertation is the application of advanced mass spectrometric measurement
techniques that provide higher accuracy and precision to the diagnosis and treatment of
ASDs.

The treatment of ASDs was assessed through the evaluation of elemental

contamination in dietary supplements. Elemental contamination was discovered to exist
in the dietary supplements through the application of standard United States

iv

Environmental Protection Agency methods for both sample preparation and analysis.
The diagnosis of ASDs was evaluated through the search for biomarkers. The plasma
zinc/serum copper ratio may be a biomarker that indicates stress on the metallothionein
system of children with ASDs. Biomarkers during treatment in autism were sought in a
cleanroom study demonstrating that the younger children responded better to the
cleanroom experience compared to older children through noteworthy behavioral and
physiological changes. The comparative analysis of children with autism and controls
had results indicating the possibility of children with autism showing characteristics of
the toxicant-induced loss of tolerance theory of disease. Measurement comparisons were
performed between the analytical methods and the commercial clinical laboratory that
demonstrated the superior quality of the analytical measurements. Overall, the work
described in this dissertation demonstrated the power of advanced mass spectrometric
analysis techniques through the application to the diagnosis and treatment of ASDs. A
greater understanding of children with autism has been accomplished through the
discovery of potential biomarkers and characteristics unique to them. The work in this
dissertation can be applied to other diseases and other types of measurements using the
principles described throughout it.

Finally, the work has shown the importance of

measurement in achieving accurate and precise data that leads to the greatest
understanding and knowledge.
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Chapter 1
Introduction
Autism spectrum disorders (ASDs) are neurological developmental disorders that
affect communication and social interaction. Current medical knowledge characterizes
ASDs as psychological disorders which negatively affect development through social
interaction, communication, and repetitive behaviors.

Autism spectrum disorders

manifest biologically through immune system dysregulation, leaky gut syndrome, other
digestive problems, and neurological effects. They are becoming more important to
society as their rate has risen dramatically over the past 30 years. Presently, there is no
known cure for ASDs and the current research focuses on improvements in diagnosis and
different types of treatments. This dissertation addresses these two major areas critical to
autism through the application of advanced mass spectrometric measurement techniques
which provide higher accuracy and precision.
First, Chapter 1 will provide a background of ASDs by reviewing the history of
diagnosis, the changes in diagnosis rate, factors involved in the diagnosis of autism, and
the behavioral rating scales used in clinical diagnosis. In addition, important areas such
as the immune system, immune dysregulation in autism, and problems with
detoxification and digestion are examined. Current autism treatments, notably dietary
supplements, and biomarkers of autism are reviewed to provide foundation for this
research. The important components of analytical measurements are discussed along
with the standard United States Environmental Protection Agency (EPA) methods used in
sample preparation and analysis.
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The application of advanced mass spectrometric measurement techniques to the
diagnosis and treatment of ASDs is the most significant contribution of the research
described in this dissertation. The novel application of these techniques involves using
stable, anthropogenic enriched isotopes to improve the quantification of measurements
achieving better accuracy and precision.

Chapter 2 describes the elemental

contamination found in common types of dietary supplements from four different
manufacturers.

Chapter 3 investigates a known contamination event of a dietary

supplement through the quantification of the known impurity and the evaluation of the
extent of other adulteration of the product.

The next three chapters focus on the

discovery of biomarkers to be applied in the diagnosis of autism. The first of these
studies described in Chapter 4 involved a retrospective review of a clinical biomarker
observed in children with ASDs.

Work was performed to establish the difference

between healthy children and children with ASDs, and among the different diseases
comprising the autism spectrum. Chapter 5 evaluates the effects of the environment on
children with ASDs through the use of a cleanroom where the children slept. The clinical
study described in Chapter 6 sought to determine the differences between children with
autism and matched healthy controls. The children were evaluated to find common
biomarkers of diagnosis and to determine relationships between clinical data and
environmental exposures.

1.1 The Current State of Autism Spectrum Disorders
Autism is currently listed as a psychological disorder in the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) under the heading of
Pervasive Developmental Disorders (PDDs). PDDs, also known as ASDs, affect many
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different areas of development, specifically social interaction and functioning, language
skills, and repetitive behaviors.1 Five disorders comprise PDDs: Autistic Disorder,
Rett’s Disorder, Childhood Disintegrative Disorder, Asperger’s Disorder, and Pervasive
Developmental Disorder-Not Otherwise Specified (PDD-NOS). Many other conditions
can be present with PDDs including genetic aberrations, inherited diseases, and physical
defects of the central nervous system.1
The three most common types of ASDs are Autistic Disorder, Asperger’s
Disorder, and PDD-NOS.

Autistic Disorder has been called early infantile autism,

childhood autism, or Kanner’s autism, and the social communication is aberrant and
decreased while social interactions are limited.1 Asperger’s Disorder is illustrated by
social impairment, improper spoken verbal content, and problems dealing with
compulsive actions and thoughts in normal functioning with no language delays observed
clinically.1 Children with Asperger’s Disorder do not display considerable delays in
language and display at least average mental abilities which are not seen in children with
Autistic Disorder.2 PDD-NOS is used when the criteria is not met for one of the other
PDDs. In PDD-NOS, which includes atypical autism, there is a strong and widespread
deficiency of shared communal contact, both spoken and unspoken, and the actions and
mannerisms are categorized.1 Autism spectrum disorders could be explained using either
one or more than one etiology which result in the spectrum of symptoms seen in affected
children.2
Autism diagnoses typically occur during childhood and are believed to last the
entire lifespan with not only the individual, but the entire family affected.3 There are two
types of autism diagnoses: classical autism, where a child develops autistic symptoms
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from birth, and regressive autism, where a child develops normally for a period then
experiences regression of abilities.4 Before age 3 is when normal symptoms are seen in
children with autism.5 Rogers reviewed studies that found the percentage of children
with autism who displayed regression varied from 25 to 50%.6

In children who

underwent a regression, the loss of skills previously developed was abnormal for the
majority of children from a multiple site study.7 Chakrabarti and Fombonne noted a 26%
prevalence of mental retardation in a study, which was lower than the 40 and 55%
reported in other studies and the traditional rate of 75%.8
Over the past 50 years, a dramatic increase in the incidence of ASDs has been
noted. At the current time, autism is the fastest growing serious developmental disability
in children.9 Children diagnosed with an ASD had medical expenses nine times greater
than other children and 3.5 times higher than children with mental retardation.10 Autism
is found in a ratio of 4:1 in males to females.11-12 Many different areas are being
researched including genetic, neurologic, immunologic, and environmental, as causes for
the dramatic increase in the incidence of ASDs,13 with autism likely being a combination
of these factors. Many different environmental aspects including vaccines, heavy metals,
infections, and prenatal exposures have been explored as potential causes.14 The role of
the environment is seen in the development of autoimmune diseases due to the high
percentage of identical twins discordant for an autoimmune disease.15 At the molecular
level, autism is heterogeneous, implying that the interaction between environment and
genetics produces different gene expression in each individual twin’s brain.16 Many
different factors, notably xenobiotics, pathogens, and immune system response, have
been shown to have an impact on brain development.17
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Genetic, epigenetic,

environmental, and endogenous interactions can be seen in an “integrated metabolic
profile”18 with the effects of the environment evidenced in the epigenetics, neurologic
system, and immune system of children diagnosed with ASDs.

To reinforce the

behavioral diagnosis of autism, there is no current biochemical test18 as autism has “no
established genetic or biochemical biomarkers,” and only behavioral norms through
observation are used in diagnosis.19-20

1.2 The History of Autism Spectrum Disorders
Autism was first described by Leo Kanner, a child psychiatrist from John Hopkins
University, in his textbook Nervous Child in 1943.4

With over twenty years of

experience as a child psychiatrist, Kanner had never observed a child with autism until 8
years after he established the first psychiatric hospital unit for children in the United
States. Kanner’s book discussed case studies using broad descriptions that detailed some
of the symptoms still used today and formed the foundation of “The Refrigerator Mother
Theory.”
In the 1950s, “The Refrigerator Mother Theory” spread in popularity. Bruno
Bettelheim, a University of Chicago educator and scholar, was a strong advocate of this
theory.4

“The Refrigerator Mother Theory” worked under the belief that mothers

withheld love from their children and the children sensed this lack of love with the
outcome being the development of autism. The decrease in social interaction caused by
autism was believed to result from this lack of affection, and Bettelheim believed these
children had to be removed from this environment. The treatment of autism by the
removal of a mother who did not love her child enough helped to cement “The
Refrigerator Mother Theory” and slowed the real treatment of autism.
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By the 1960s, “The Refrigerator Mother Theory” was beginning to become more
questionable as doubts increased that bad parenting and a lack of affection were the true
causes of autism.

An important book, Infantile Autism: The Syndrome and Its

Implications for a Neural Theory of Behavior, was written by Bernard Rimland, who had
a doctorate in experimental psychology.4 Rimland believed the cause of autism had
origins in biology from genetic and neurological factors and not in psychology resulting
from parental care, and he is recognized in shifting the thoughts of autism etiology away
from psychology and towards biology. This change in philosophy about the etiology in
autism allowed for significant advances to be made in the development and
understanding of autism diagnosis and treatments.
In 1967, Dr. Rimland founded the nonprofit Autism Research Institute that has
supported biological autism research. The work by Dr. Rimland caused a change in the
understanding and treatment of autism and allowed for future advances to be made.
Soon, Dr. Eric Schopler developed the Treatment and Education of Autistic and related
Communication-handicapped CHildren (TEACCH) program.4 TEACCH was the first
wide-ranging program which educated children with autism at the state level and used
parents as therapists.
One important idea to come from Dr. Rimland was the shift toward developing a
way to clinically diagnosis autism.

Dr. Rimland worked to develop the Rimland

Checklist, which was published during the 1960s.21

Dr. Schopler expanded on the

Rimland Checklist because he saw that most of the children he observed did not meet
Kanner’s original criteria for autism.21 This observation led to the development of the
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Childhood Autism Rating Scale (CARS) and helped shift towards finding an easier and
faster way to diagnose children with autism.21

1.3 The Change in the Diagnosis Rate of Autism Spectrum Disorders
Over the past 50 years, the frequency of autism diagnoses has continued to rise at
a rapid rate and is currently approaching epidemic proportions. Before the 1970s, an
autism diagnosis was rare and the diagnosis rate was relatively consistent. The frequency
of autism in studies from the 1960s to the 1980s ranged from 2 to 5 in 10,000 over this
period, which could have been determined using a more classic definition of autism.22 In
1978, one study assessed the rate of autism to be 4 in 10,000.23 In 1994, the DSM-IV
listed the frequency of Autistic Disorder at between 2 and 5 in 10,000.1
Two large review studies were completed that looked at autism rates from the
1960s to the 1990s. One review investigated the rate of autism in over twenty studies
from 1966 to 1998 where the epidemiological studies reviewed had a median value of 5.2
occurrences per 10,000 (1 in 1,923).24 In the studies published after 1988 as part of this
review, the median prevalence of autism increased to 7.2 per 10,000 (1 in 1,389).24 From
reexamining these studies, it was determined that both autism definition and better
awareness helped contribute to the increased autism diagnosis rate as time passed.24
Another review discussed results from studies from 1966 to 1997. The results in this
review supported the increase over time with the rate of autism being less than 0.5 in
1,000 children in the earlier studies and the later studies showed an average rate of about
1 per 1,000.25
Another important place to look to compare the rate of autism over time is in
California.

In 1969, California passed the Lanternman Developmental Disabilities
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Services Act, which established places to provide services and allowed for the necessary
records to be kept.26

Hertz-Picciotto and Delwiche published a study showing an

increase in autism diagnosis from 6.2 in every 10,000 births for children born in 1990 to
42.5 for children born in 2001.26 The authors noted that earlier diagnosis, population
movement, adjustments in diagnostic requirements, and the addition of milder cases did
not completely account for the increased prevalence of autism.26 This implication was
supported in a study by Croen et al. that found the diagnosis of autism increased from 5.8
to 14.9 occurrences per 10,000 children from 1987 to 1994.27 The authors stated that a
real rise in autism rates may reflect only better recognition and changes in autism
diagnosis criteria.27 In 2012, a study determined children born in 2003 had a 16.6 times
increase in the likelihood of autism diagnosis compared to children born in 1992.28
Additionally, this study noted that each successive cohort of children had a greater
chance of being diagnosed with autism compared to the previous birth year.28 A 2003
report from the California Department of Developmental Services saw that the rate of
autism increased 634% from 1987 to 2002.29
Many other studies produced in the United States have discussed the diagnosis
frequency of autism. A study of autism rates in North Dakota from 1987 found them to
be 3.26 per 10,000 children for all PDDs.30 In 1989, a study from Utah determined the
autism rate to be 4 in 10,000.31 In 1995, a study out of Arkansas observed 4 out of
10,000 children, by the age of four, were diagnosed with autism or a PDD.32 In 2001, the
Centers for Disease Control and Prevention (CDC) published a study from Brick
Township, New Jersey, where the frequency of ASDs was determined to be 6.7 for every
1,000 children.33
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At the beginning of the 21st century, the rate of autism occurrences continued to
rise and were reported to be between 30 and 60 in 10,000.22

In 2007, the CDC

determined that in data from 2000 the frequency of ASDs had reached 1 in 150 for
children age 8 across the country.34 This held constant in 2002, but the highest rate of
ASDs was found in New Jersey at 1 in 94.35 An update using 2006 data showed that
children age 8 had autism at a frequency of 1 in 110.36 In 2012, the most recent reports
from 2008 have put the occurrence of autism nationwide at 1 in 88 in children 8 years
old, a 23% increase from 2006 data.5 The report noted that the assessment should not be
extrapolated to the entire country as the samples do not equate to an equivalent sampling
of the United States.5 Over the past decade, the national rate of autism has risen 78%
from 1 in 150 children in 2000 and 2002 to 1 in 88 in 2008. The most recent CDC report
also determined the autism ratio between boys and girls to be 4.6:1.5
Other recent studies in the United States reflect the results of the studies from the
CDC. In a study using parent reported data from 2007, the National Survey of Children’s
Health found the rate of autism to be 1 in 91 children ages 3 to 17.22 In this study, the
odds of having a child with autism ages 6 to 8 were 54 and 83% higher when compared
to children ages 9 to 11 and 15 to 17 years of age, respectively.22 The National Health
Interview Survey observed an increase in autism prevalence from 0.19% (1 in 526) in
1997-1999 to 0.74% (1 in 135) in 2006-2008.37
In the North American and European populations, the frequency of autism has
been determined to be similar through research studies.38 In 2001, an English study
published determined the rate of PDDs to be 62.6 per 10,000 children (1 in 160).8
Another study from the United Kingdom using data from the 2003 and 2004 school years
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found the prevalence of autism approached 1% of children ages 5 to 9.23 In comparison
to this data, the first study from South Korea using children ages 7 to 12 assessed the rate
of ASDs to be 2.64% or 1 in 38.38

1.4 The Evolution of the Factors Influencing Diagnosis of Autism Spectrum
Disorders
Because of the increased prevalence in autism over the past 50 years, many
variables have been cited as potential reasons for this rise in diagnosis frequency. Some
of these elements may have been adjusted and others may have grown and evolved over
time contributing to an increased diagnosis rate, while there also may have been a true
rise in autism incidence. Many factors have been noted when comparing the rates of
autism from the past and present including better identification and detection, study
design differences, greater number of diagnostic services, higher level of consciousness
in both parents and medical professionals, change in philosophy that autism can exist
with other disorders, and a broadening of diagnostic measures.23
For identification and detection, primary care physicians and pediatricians play a
key role. During the time when autism was first being studied in the 1960s and 1970s,
there were not many child psychiatrists and pediatricians, and even a lesser number of
general practitioners, who were familiar with and capable of identifying ASDs.39 During
the 1960s, there was knowledge of the occurrence of diseases similar to autism in
children, but they did not reach the standards for diagnosis.39 Over time, the level of
education seen in pediatricians, psychiatrists, psychologists, social workers, and teachers
has increased because of a larger social consciousness of autism.39 Since the 1960s, there
has been a large expansion in the therapeutic and educational services along with a
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greater social consciousness among medical professionals and the general public for
children with ASDs.39 During this period, there was a large variation in the observation
and examination procedures, obstacles involving financial compensation, and not enough
attention paid to surveys completed by parents, with each of these areas having to be
improved to more effectively diagnose autism.40 A study from 2005 demonstrated a
correlation between the rate of autism and financial resources as a higher rate of autism
was seen where increased financial support existed.41
In addition to physician and professional screening, other possible reasons for
delays in autism diagnosis included normal delays in receiving medical treatment,
inefficient communication between parents and primary care providers, or adopting a
philosophy of watching for further development before any action is taken.42 A study
published in 2001 found that more attention needs to be paid to autism in medical school
education as shortcomings were observed related to appearance, diagnosis, and treatment
for ASDs.43

It also emphasized that medical education must include basic autism

diagnosis standards so they can be applied clinically.43 In addition to medical education,
the relationship between parents and primary care physicians may play a role in
diagnosis. A study found children with four or more different primary care physicians
obtained an autism diagnosis 6 months later compared to other children, whereas
pediatricians who noticed developmental apprehensions and referred children to
specialists resulted in earlier diagnoses.44 Factors such as population mobility, decreased
availability to health care, and lower emphasis on constant pediatric care are additional
problems related to the age of autism diagnosis.44
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Over the past 50 years, changes have been made that adjusted the diagnostic
criteria for autism. Although detailed changes have been made in diagnostic criteria, they
have not been the main cause resulting in an increase in clinical diagnosis; however, a
larger number of autism diagnoses are being made under the current standards than the
previous ones.39 A true increase in the rate of ASDs cannot be eliminated because of
better social awareness and broader diagnostic standards.39
During this time, there have been two different types of diagnosis changes which
may be playing a role in the increasing rates of autism: diagnostic substitution and
diagnosis accretion.

Diagnostic substitution occurs when there is a change in the

diagnosis while diagnosis accretion happens when a second diagnosis is made and the
original diagnosis is maintained.45

In the late 1980s, the Diagnostic and Statistical

Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) broadened the
definition of autism.26 Compared to the DSM-III-R, the current DSM-IV definitions are
closer to the ones from the International Statistical Classification of Diseases and
Related Health Problems, 10th edition (ICD-10).26

In 2000, The Diagnostic and

Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
updated the criteria for PDD-NOS, which could have changed the frequency of autism
diagnoses.45
From 1998 to 2002, the California Department of Developmental Services made
diagnostic criteria changes.45 A study published in 2009 from California suggested a
26.4% increase in autism diagnosis because of the changes in diagnostic criteria related to
children with prior mental retardation diagnosis.45 Another study noted 12% of the
increase in autism diagnosis can result from diagnosis at a younger age.26 This study also
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noted a 56% increase because of the addition of milder cases of autism.26 Rutter noted a
study from California where autism increased 210%, while mental retardation only
increased 49% from 1987 to 1998.39 The largest increase in the diagnosis of ASDs
seemed to have occurred in children with non-verbal IQ in the normal range, with all
types of ASDs showing considerable increases in prevalence.39
A couple of studies discussed the difference in diagnosis rates based on race. A
study from Mandell in 2002 found African-American children were diagnosed with
autism an average of 1.6 years later compared to white children.46 A second study in
2007 determined that African-American children were more likely to receive a diagnosis
other than autism by a factor of 2.6 when compared to white children.47 In addition to
race, cultural and social norms are factors which can affect the speed of autism diagnosis.
A study about children in India demonstrated that cultural and social customs focused on
social problems allowed for quicker parental recognition of autistic symptoms.48 In the
United States, there is a greater focus on communication progression and this emphasis
may drive parental concerns.49 Another study from the United States noted the presence
of significant communication shortfalls allowed for a diagnosis of an ASD an average of
1.2 years before other children.44 This study also noted shortcomings in the resources of
rural regions and with families who are near-poor.44

The children in this category

obtained a diagnosis nearly 11 months after children from families who were better-off
financially, and this finding may relate to the insurance status of each family.44 In
addition, children who had hearing problems or were adopted received an ASD diagnosis
nearly 10 months after other children.44 Based on these studies, the social and cultural
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traditions along with the race of each country need to be considered when performing
screenings and diagnostic tests for autism.
In addition to changes in the factors related to autism diagnosis, the stability of
autism diagnosis has been evaluated. Recent studies have shown that diagnoses in very
young children hold up over time and are confirmed later in the child’s development. 50-51
Kleinman and colleagues evaluated the DSM-IV diagnosis between ages 2 and 4 and
found the Autism Diagnostic Observation Schedule (ADOS) had an 83% diagnostic
stability while the diagnostic stability for the CARS was 76%.52

A study in 2005

determined the average age of diagnosis was lowest for Autistic Disorder (3.1 years) and
highest for Asperger’s Disorder (7.2 years) with PDD-NOS in the middle (3.9 years).44
A Canadian study in 2009 observed variation in the average age of diagnosis between
four different areas.53 Similar results were seen in this study with Autistic Disorder being
diagnosed earliest on average and Asperger’s Disorder the last of the three
subcategories.53 It was also determined that boys were diagnosed on average earlier than
girls in each region.53 A “zero” waitlist guideline for children in preschool also resulted
in a lower mean diagnosis age.53 A review from a clinician’s perspective noted that focus
needs to be on the recognition of initial non-verbal social interactions and behaviors in
the second year of life and that the characteristics which define autism may change based
on age.54 Based on the literature, all of these factors have contributed to the increased
diagnosis of autism. Despite these changes and advances, the rate of autism now has
become a major public health concern.
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1.5 The Behavioral Rating Scales Used in the Diagnosis and Assessment of
Autism Spectrum Disorders
Despite all of the scientific research going into discovering common
characteristics of ASDs, there is no physical examination or set of tests that provide a
definitive diagnosis of an ASD. Physicians determine autism diagnosis based on the
natural progression of development over time and the clinical observances of the child’s
social activities.55 Without the availability of a physical test, the clinical diagnosis of
ASDs is performed using psychological diagnosis where psychologists and physicians
utilize behavioral rating scales to confirm the definition of autism. The current gold
standard in the diagnosis of ASDs is the ADOS.56 Over time, the ADOS has been a key
component to both clinical and research procedures involving children with autism.57
Both the ADOS and the Autism Diagnostic Interview-Revised (ADI-R) were created to
quantitatively define the presence or absence of autism based on age and language
development.58 The ADI-R gives insights into the past developmental progressions and
different social interactions of the child while gaining the perspective of the child’s
caregiver,58 and it was used for both the ICD-10 and DSM-IV autism diagnosis
standards.59 However, both the ADOS and the ADI-R are time consuming and require
the screening to be performed by someone who has received proper training.60 The
ADOS relies heavily on the skill of the test administrator and does not include
information on the history of the individual and cannot solely be used to diagnose a
child.61
After a parent has noticed a potential problem, the child is brought to a medical
professional to begin the diagnostic process. When a medical professional first observes
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an individual and concludes that further action is necessary, a primary screening has
occurred.62 A secondary screening would be performed after a developmental difference
has been determined to exist and the specificity of the problem has not yet been
determined. It would be at this time that the child would be seen by a specialist.62 At
both screening levels, the criteria for determining the proper diagnosis need to be rigid.
Many important factors comprise these standards, especially behavioral rating scales, and
they are:

easy to use, time efficient, low cost, age appropriate, and possess good

sensitivity and specificity. The percentage of children properly determined to have a
problem is defined as the sensitivity and should be between 70 to 80% for children with
disabilities,63 while specificity is described as the percentage of children accurately
determined not to have a disability and it needs to be near 80% to prevent over referrals.63
In addition to the ADOS and the ADI-R, there are many other rating scales which
can be completed by physicians, psychologists, or parents. Some of the other rating
scales frequently used in the diagnosis and evaluation of treatments for autism include
CARS, Gilliam Autism Rating Scale (GARS), Social Communication Questionnaire
(SCQ), Aberrant Behavior Checklist (ABC), PDD Behavior Inventory (PDDBI), and
Autism Treatment Evaluation Checklist (ATEC). Each one of the rating scales used in
the studies discussed in later chapters is described, and studies related to their evaluation
or application are reviewed.
1.5.1

Autism Diagnostic Observation Schedule

The ADOS was developed by Catherine Lord, Michael Rutter, Pamela C.
DiLavore, and Susan Risi in 1989.64 Designed to be applicable in clinical and research
settings for children with a mental age of at least 3, the ADOS creates stresses through a
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semi-structured evaluation of socialization, communication, play, and imagination.64 The
ADOS gives a clinician’s perspective based on consistent clinical interpretations of the
child’s social strengths and weaknesses.58 An expansion of the ADOS was created when
the Pre-Linguistic Autism Diagnostic Observation Scale (PL-ADOS) was developed
based on ICD-10 and DSM-IV criteria for children under the age of 6 and who have not
developed speech at the phrase level with the focus of the PL-ADOS being the child’s
communication and socializing.65
In 2000, the Autism Diagnostic Observation Schedule-Generic (ADOS-G) came
out as an expansion of the ADOS and the PL-ADOS, and it wanted to create stresses in
regulated environments to monitor spontaneous actions in a broader age range of children
who could potentially be diagnosed with autism.61 The ADOS-G created four modules
for children of different ages and stages of language capabilities.61

Module 1 was

modeled after the PL-ADOS, and Module 2 was designed for children who are not
completely developed verbally, but possess some communication skills.61 Module 3 is
aimed at the verbally competent and was constructed based on the original ADOS. 61
Module 4 evaluated the socioemotional aspects of the individual’s life and is meant for
verbally competent adolescents or adults.61 Modules 1 and 2 are completed during
activities in a room and Modules 3 and 4 occur while seated at a table.61 Using the
ADOS-G, autism diagnosis is determined by exceeding the cutoff value for the social and
communication domains and the sum of those domains, and it is not envisioned to be the
sole criteria for autism diagnosis.61
In 2007, the algorithms for the ADOS were altered to improve autism
classification.66 Classification is now based on the sum of “social affect” and “restricted

17

repetitive behaviors” domains.66 The modules were also divided to better meet the needs
of diagnosis as Module 1 was split into No Words and Some Words, while Module 2 was
separated into children 4 years old and younger and 5 years of age and older. 66 The
Autism Diagnostic Observation Schedule-Toddler Module (ADOS-T) was proposed in
2009 because the mean age of children where parents start to express apprehension about
autism is between 15 and 18 months.57 The ADOS-T follows Module 1 and is applicable
for children who are younger than 30 months old, 12 months old based on nonverbal
evaluation, and walk independently.57 The ADOS is currently scored on a scale from 0 to
3 where 0 shows no presence of the behavior and 3 indicates the presence of that
behavior. Sometimes a score of 3 is converted to a 2 to decrease the impact of singular
items.67 A score of 7 is given when the abnormal behavior differs from the procedure
and 8 is scored when it is not applicable.68 For the communication module, social
interaction module, and the total ADOS, cutoff values exist for the diagnosis of an ASD
or autism. For the total ADOS, the cutoff for an autism diagnosis is a minimum score of
12 and the cutoff is 7 for an ASD.61

The cutoff for an autism diagnosis for the

communication module is 4 while it is 2 for an ASD.61 The social interaction module has
a cutoff of 4 for an ASD and 7 for autism.61
Many studies have evaluated the application of the ADOS with the ADOS-G
demonstrating both good sensitivity and specificity. Across the different modules and
comparisons, the sensitivities ranged from 80-100% and specificities varied from 68 to
100% with high internal consistencies.61 A German study by Bolte and Poustka in 2004
found sensitivity of 90% and a 48% specificity.69 According to the ADOS-G, Maxefsky
and Oswald observed a 77% agreement with team diagnosis.70
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In addition, many studies have compared the old and new ADOS algorithms.
Using the original and updated algorithms, Gotham and colleagues observed similar
values for the sensitivity and specificities for Modules 1-3.66 Gotham et al. completed
another study that demonstrated better consistency between the modules and the
diagnostic legitimacy based on the ADOS.67 This study also found an increase in the
specificity of Module 1 to 50%.67 An ADOS-T study observed good sensitivity and
specificity using the different modules.57 In a Dutch study, Modules 2 and 3 showed an
increased balance of sensitivity and specificity with the revised algorithms, but decreased
performance was seen from Module 1.71 Malloy and colleagues observed sensitivities
between 67 and 91% for the autism versus non-spectrum groups using the original
algorithms with specificities ranging from 65 to 95%.56 With the new algorithm, the
sensitivities were between 72 and 94% with specificities fluctuating from 55 to 81%.56
Sensitivities varied from 75 to 94% and specificities ranged from 29 to 81% when
comparing the new non-autism ASD group versus the non-spectrum group for the old
algorithm.56

The updated algorithm produced sensitivities from 72 to 100% and

specificities from 29 to 60%.56 The study generally found modest to elevated sensitivities
and poorer specificities compared to prior studies.56 In a study independent from the
creators of the ADOS, Kamp-Becker et al. determined the revised algorithm had a higher
sensitivity for autism and ASD against non-spectrum group using the higher cutoff
value.72 For the autism versus non-spectrum comparison, the original algorithm had a
sensitivity of 79% compared to the 93% for the updated algorithm, but the specificity
decreased from 89 to 81%.72 These studies support the diagnostic capabilities of the
ADOS, but note its shortcomings in classifying autism versus ASDs.
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1.5.2

Childhood Autism Rating Scale

The CARS was developed by Dr. Eric Schopler at the University of North
Carolina at Chapel Hill to diagnose children with autism. It uses a 15 point rating scale
where scores range from 1 to 4 with half interval points with a score of 1 representing
normal behavior and a score of 4 indicating severely abnormal behavior.21 The scores on
the CARS range from 15 to 60 with children scoring 30 or higher being classified as
autistic. To be diagnosed with severe autism, a child must score greater than 36 and have
scored at least a 3 on five or more of the 15 subscales.21 This information can also
provide classification of the degree of autism and the type of symptoms.73 A criticism of
the CARS by the National Research Council was that the diagnostic criteria do not
accurately reflect the current standards because it was based on DSM-III criteria from
1980. But, the CARS was developed from both clinical experience and many different
collections of measures that are related to three sections of DSM-IV criteria.74
Many studies have investigated the application of the CARS for clinical diagnosis
of autism. Eaves and Milner found in a study that the CARS was able to diagnose 98%
of the screened children with autism.75 In 1994, DiLalla and Rogers produced a study
that discovered three distinct domains describing behavior and emotion: Social
Impairment, Negative Emotionality, and Distorted Sensory Response.

The Social

Impairment domain is associated with 10 of the 15 CARS scales.73 When factor scaling
was applied to the subscales, they found the Social Impairment domain, with a cutoff
value of 26, produced an autism diagnosis accuracy of 78% with a 64% sensitivity and
92% specificity.73 Pilowsky led a study in 1998 that compared the CARS and the ADI-R
autism diagnoses and observed an 85.7% agreement between the two rating scales.76 A
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study from 2003 discovered an overlap in 66.7% of cases between the CARS and the
ADI-R, and the CARS diagnosed more instances of autism than the ADI-R did.77 A
study from Italy in 2004 found 100% agreement in the diagnosis of autism by the CARS
using DSM-IV standards.78 In 2005, Perry and colleagues compared the CARS diagnosis
to DSM-IV, and they determined an 88% concordance with a 94% sensitivity and a 85%
specificity.74 A study from Mayes et al. published in 2009 found 97% of children with
low functioning autism and 75% of children with high functioning autism were correctly
determined using the CARS.79 Another study from Mayes and colleagues, where they
used a cutoff value of 25.5 to separate high functioning autism or Asperger’s syndrome
from attention deficit hyperactivity disorder (ADHD), saw 96% agreement using
clinicians’ results and 72% using parents’ results.80
1.5.3

Gilliam Autism Rating Scale

The GARS was created by Dr. James Gilliam in 1995. It can be used on patients
from ages 3 to 22 and has 56 questions divided into four subscales: Social Interaction,
Communication, Stereotyped Behaviors, and Developmental Disturbances.81 The GARS
is scored on a 4 point scale to produce a value that represents the Autism Quotient (AQ).
The AQ is used to determine “the likelihood that a child has autism” and has a standard
score of 100 with a standard deviation (SD) of 15.81 A child is determined to be
“probably autistic” if the AQ is equal to or greater than 90.81

There are seven

classifications for the AQ related to the likelihood of an autism diagnosis: very low, low,
below average, average, above average, high, and very high. The AQ can be determined
from using two, three, or four subscales. The GARS is completed by a parent and has
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been noted to be recommended for use in California.81 It is easy to use, has a low cost,
and has been used in schools and research.81
In 2006, the GARS was updated, and the name of the second edition is the
GARS-2. The GARS-2 follows the diagnostic criteria of the DSM-IV-TR and Autism
Society of America.82 One of the major changes in the GARS-2 was the Parent Interview
replacing the Developmental Disturbances subscale. The Parent Interview determines
lags in normal development or differences in socializing, communicating, and playing,
prior to age 3 and is not a component of the new Autism Index (AI).82 The other three
subscales are very similar to their original versions, and the subscales scoring is added
and now called the AI. An AI value equal to or greater than 85 evokes a “very likely”
presence of autism, a total between 70 and 84 means a child “possibly” has autism, and a
score of 69 or less indicates autism is “unlikely.”82
Many studies have determined the clinical application of the GARS. South et al.
published a study in 2002 that found the average AQ to be 90.10.81 Following the cutoff
for the AQ of equal to or greater than 90 for autism, they determined 52% of children
would not have been determined to have autism using the GARS, which produced a 48%
GARS sensitivity for autism diagnosis.81 The study also noted low sensitivity for the
ADOS-G and the ADI-R of 45%.81

Their analysis showed the Developmental

Disturbances scale was not related to the other three subscales.81 Lecavalier noted the
average AQ was below the cutoff of 90 for 62% of the participants resulting in a 38%
sensitivity.83 Similar sensitivity was observed in the GARS as Mazefsky and Oswald
reported a sensitivity of 39%.70 They also stated that the GARS was less effective in the
diagnosis of PDDs compared to the ADOS-G and the ADI-R.70 Eaves led a study using
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85 as the cutoff for the AQ and found a sensitivity of 83% and a specificity of 68%,84
while the standard cutoff of 90 for the AQ produced a sensitivity of 79%.84 In 2008,
Sikora et al. determined the sensitivity to be 53% and 54% for the specificity for the
GARS.85 A review of these studies by Norris and Lecavalier showed overall poor
sensitivity using the GARS.60
In 2010, a study performed an exploratory and confirmatory factor analyses on
the GARS-2. The results did not provide additional backing of the three subscales of the
GARS-2 and did not address the sensitivity or specificity of the GARS-2.82 Instead, the
study found better diagnostic reliability with a four-factor model of stereotyped/repetitive
behavior,

stereotyped/idiosyncratic

language,

word

use

problems,

and

social

impairment.82 No studies in the literature were discovered that address the sensitivity and
specificity of the GARS-2.
1.5.4

Social Communication Questionnaire

Previously known as the Autism Screening Questionnaire, the SCQ was designed
by Dr. Michael Rutter and Dr. Catherine Lord.59 Two versions of the SCQ were created,
one for children 5 years old and younger and the other for children six years and older. 59
The SCQ is based on the ADI-R and is meant to be completed by the parent of the child
with an ASD.59 It is comprised of 40 yes or no questions arranged in four subscales:
social interaction, communication, abnormal language, and stereotyped behaviors.60 For
each question, a value of 1 is scored for the presence of the abnormal behavior and 0 is
recorded if it not present.59 The scores of the SCQ range from 0 to 39 (not including
current language level), and a cutoff of 15 is used to differentiate ASDs from other
clinical diagnoses with a value of 22 separating autism from other ASDs.59
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The

maximum score for nonverbal individuals is 34.59 The SCQ requires a patient with a
chronological age of at least 4 years old and a mental age of 2 years old.62 One important
characteristic of SCQ is that it appears to include all of the DSM components for autism
diagnosis.60
Many studies have demonstrated the high sensitivities and specificities of the
SCQ. In the original study, the authors observed a sensitivity of 85% and a specificity of
75%.59 A 2006 study led by Eaves determined acceptable sensitivity of the SCQ of 74%,
but observed a lower than satisfactory specificity of 54%.62 Eaves published another
study where the overall sensitivity for the SCQ was 71%, and the specificity varied based
on the clinic.86 In 2007, Chandler et al. found usefulness in the application of the SCQ
due to the high sensitivity and specificity results. When using a cutoff of equal to or
greater than the recommended value of 15, the sensitivity was 88% and the specificity
was 72% for the presence and absence of ASDs.87 When the cutoff was changed to 22,
the sensitivity increased to 90% and the specificity rose to 86%.87 The study also noted
the potential bias in the original SCQ study due to the previous diagnosis on the ADI-R.87
Witwer and Lecavalier in 2007 published a study showing the sensitivity of the SCQ
being 92% with a specificity of 62%.88 The study also found a significant correlation
between the SCQ and age.88 That year Corsello et al. determined the sensitivity and
specificity of the SCQ for the determination of ASDs to both be 71% when a cutoff of 15
was employed.89 When the cutoff was lowered to 12 and the SCQ was used with the
ADOS, the sensitivity was similar to when the ADI-R and the ADOS were used together,
and nearly the same specificity was reached when separating ASD from no ASD with the
ADI-R and the ADOS.89 The study showed the SCQ being a better diagnostic tool in
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children 8 years old or older compared to children age 7 and younger.89 An investigation
in Australia of younger children ages 2-6 found the sensitivity to be 60% and a specificity
of 70%.90 They determined the best sensitivity and specificity was achieved with a cutoff
of 11 when they were 93 and 58%, respectively.90 Of note, the lower cutoff was effective
in the age range of 3-5 with sensitivity of 100% and specificity of 62% and it was
inadequate in the 2-3 year old range.90 A review by Norris and Lecavalier from 2010
noted that many studies and generally found good performance by the SCQ.60
Some studies have observed lower sensitivity and specificity than in the original
study. Wiggens led a study in 2007 which determined the sensitivity was 47% and the
specificity was 89% for the determination of an ASD.91 The optimum cutoff value for
this study was 11 where both the sensitivity and specificity were 89%.91 In 2008, Snow
and Lecavalier found the SCQ, in establishing the presence or absence of an ASD, to
have the sensitivity of 70% and the specificity of 52%,92 with 13 determined to be the
optimum cutoff value.92
1.5.5

Aberrant Behavior Checklist

The ABC was developed by Michael Aman in 1985 and was originally designed
to assess treatments in individuals with intellectual disabilities.93 It can be completed by
parents, teachers, or anyone who knows the individual well.94 The ABC has 58 items
organized into 5 subscales:

(I) Irritability, Agitation, Crying; (II) Lethargy, Social

Withdrawal; (III) Stereotypic Behavior; (IV) Hyperactivity, Noncompliance; and (V)
Inappropriate Speech.93 Each item is scored from 0 to 3 on a 4-point scale with higher
scores indicating a greater degree of problems.93 The ABC has demonstrated good
internal consistency and retest correlations.95 It has been applied to many other diseases

25

such as Fragile X, Prader-Willi, Cri-du-Chat, Smith Magenis, and Angelman’s
syndromes.96
Many different studies have been performed using the ABC to evaluate
treatments. One of the most common applications of the ABC related to autism is in
clinical drug trials. Brinkley and colleagues noted numerous studies of clinical drug trials
related to autism and the sensitivity of the ABC, especially the Irritability subscale. 96
Gabriels noted from a study that the Irritability and Lethargy subscales of the ABC did
not find a significant link with repetitive behaviors.97 A study validating the ADI-R
found strong correlation between the Social and total ADI-R values and the subscales for
Irritability; Lethargy, Social Withdrawal; and Stereotypic Behavior of the ABC. 94 Tse et
al. used the ABC as one measure to evaluate a social skill curriculum, and all of the ABC
subscales were sensitive enough to show significant improvements used to measure
problem behaviors.98
Many studies have demonstrated the sensitivity and diversity of application for
the ABC. In 2007, Cuccaro published a study which compared matched controls with
Asperger’s Disorder and high functioning autism.

They focused on the Stereotype

subscale of the ABC and determined no differences between the two groups for that
subscale.99

The authors believed it further supported the literature that there is no

difference between Asperger’s Disorder and high functioning autism.99 Brinkley led a
study which showed the ABC’s factor structure was strong for a cohort of children with
ASDs. They found 4- and 5-factor components responsible for more than 70% of the
change.96 The authors also noted many studies where the Irritability subscale of the ABC
has demonstrated great sensitivity to treatment.96 The ABC has had increasing amount of
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literature which support it is a good gauge of associated, non-diagnostic components of
ASDs.96 A study published in 2009 from Turkey found good separation between autism
and other behavior disorders and showed higher scores of the Lethargy, Social
Withdrawal and Stereotypic Behavior subscales in children with autism.100 The study
shows the application of the ABC to children as young as 14 months old and significant
differences in the diagnostic groups for the ABC subscales.100 Hartley-McAndrew and
Weinstock noticed elevated hyperactivity and irritability ABC subscales in children with
ASDs who suffer seizures.101
1.5.6

PDD Behavior Inventory

The PDDBI was designed by Ira L. Cohen and Vicki Sudhalter in 1997. 102 It was
created to evaluate how children with PDDs responded to a treatment.102 The PDDBI is
unique because it targets both adaptive and maladaptive behaviors and is arranged in a
priori, or hierarchal structure. It can yield standardized results based on age which many
of the other rating scales cannot do.102 Two different versions of the PDDBI were
created, one for parents and one for teachers,102 and it is separated into 10 domains in the
parental version and eight in the teacher version.
Sensory/Perceptual

Approach

Behaviors,

Specific

The maladaptive domains are
Fears,

Arousal

Problems,

Aggressiveness, Social Pragmatic Problems, and Semantic/Pragmatic Problems. The
Specific Fears and Arousal Problems domains are not administered by teachers. The
adaptive domains are Social Approach Behaviors; Learning, Memory and Receptive
Language; Phonological Skills; and Semantic/Pragmatic Ability.

Each domain is

comprised of a varying number of categories which each contain four questions. They
are scored on a Likert scale from 0 to 3. There are 176 items on parent version of the
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PDDBI and 144 on teacher version.102 The PDDBI uses a standardized score like the
GARS, and scoring in the PDDBI is based on the “Autism Score,” which uses the Tscore system. In the T-score system, 50 is the average score and the SD is 10. The Tscore is calculated using the DSM-IV related subscales and can be age referenced.102 The
Autism Score is calculated by adding the T-score for Sensory/Perceptual Approach
Behaviors, Social Pragmatic Problems, and Semantic/Pragmatic Problems and
subtracting the T-scores from Social Approach Behaviors, Phonological Skills, and
Semantic/Pragmatic Ability.102
In 2005, the PDDBI was updated and modified.

It was separated into two

dimensions called Approach/Withdrawal Problems (AWP), for the maladaptive
behaviors, and the Receptive/Expressive Social Communication Abilities (REXSCA), for
the determination of communication skills.103

The AWP is made up of the

Sensory/Perceptual Approach Behaviors (SENSORY), Ritualisms/Resistance to Change
(RITUAL), Social Pragmatic Problems (SOCPP), Semantic/Pragmatic Problems
(SEMPP), Arousal Regulation Problems (AROUSE), Specific Fears (FEARS), and
Aggressiveness (AGG) domains. There are also two composite scores under the AWP.
The first is the Repetitive, Ritualistic, and Pragmatic Problem Behaviors Composite
(REPRIT/C) and is equal to the sum of SENSORY, RITUAL, SOCPP, and SEMPP. The
other composite is the Approach/Withdrawal Problems Composite (AWP/C) and is the
summation of all of the domains. The domains making up the REXSCA are the Social
Approach Behaviors (SOCAPP); Expressive Language (EXPRESS); and Learning, and
Memory, and Receptive Language (LMRL). There are two composite scores under
REXSCA called Expressive Social Communication Abilities Composite (EXSCA/C)
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(SOCAPP + EXPRESS) and Receptive/Expressive Social Communication Abilities
Composite (REXSCA/C) (SOCAPP + EXPRESS + LMRL).

There are also two

discrepancy scores as a part of the new PDDBI: the SOCAPP-SOCPP Discrepancy
Score and the EXPRESS-SEMPP Discrepancy Score. The dimensions are composed of
independent behavioral domains, which are made up of clusters to characterize that
domain.103 Each cluster is scored on the Likert scale and is comprised of four or more
items.103 The teacher version is comprised of 180 items and the parent version is made
up of 188.103 Each domain generates a T-score with the T-scores for the most important
domains creating an Autism Composite score.103 The Autism Composite is still scored
with a mean of 50 and an SD of 10, which should classify 68% of cases of autism.103 The
Autism Composite is calculated by summing the T-scores from SENSORY, RITUAL,
SOCPP, and SEMPP and subtracting the T-scores from SOCAPP and EXPRESS.103
In 2003, the first study by Cohen et al. demonstrated good internal consistency
between all of the subscales for both the parent and teacher versions.102 The study also
found a high level of correlation among the maladaptive domains and all of the domains
were unidimensional.102 A second study from that publication observed a higher Autism
Score in children with autism compared to children with PDD-NOS in both versions of
the original PDDBI.102 If 40 was used for the cutoff for the Autism Score, the sensitivity
was 91% and the specificity was 80% on the parent version and the teacher version
produced comparable sensitivity and specificity of 89 and 81%, respectively.102 A cutoff
of 42 slightly increased sensitivity on both versions to 85%, but the specificity decreased
to 50 and 52%.102

The adaptive subscales and Social Pragmatic Problems and

Semantic/Pragmatic Problems maladaptive subscales displayed the expected increase
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with age as reflective of an increase in development.102 The authors do not recommend
the use of the original PDDBI for the diagnosis of PDD-NOS and the PDDBI does not
provide the sensitivity to differentiate PDD-NOS from autism.102 The authors do note
this differentiation is difficult for other rating scales such as the ADOS-G or the DSM-IV
standards. From these studies, the authors stress the importance of investigating the
subscales and the potential they have for the discovery of subgroups.102
Cohen completed another study comparing the PDDBI to other rating scales that
found significant correlations between the ADI-R and PDDBI subscales.104 The different
scoring methods between the ADI-R and the PDDBI may have limited the strength of the
correlations.

The Autism Score from both the parent and teacher versions was

significantly correlated to the CARS.104 From this study, Cohen determined the PDDBI
to have prognostic, design, and developmental cogency, and the adaptive domain scores
reflect real improvements in socialization and communication resulting from
treatments.104

Cohen noted the PDDBI can play an important role in the future

evaluation of children with PDDs undergoing treatments.104
In a study with the updated PDDBI, Cohen et al. compared autism, PDD-NOS,
and not spectrum groups. The PDDBI provided distinctly different profiles for the autism
and PDD-NOS groups compared to the not spectrum group.103 The measurements which
showed the greatest differences were the overall Autism Composite score and the domain
and composite scores related to social communication capability.103 The best cutoff
value for the Autism Composite was 32 where the sensitivity was 100% and the
specificity was 79%.103

Because of good sensitivity and specificity, the authors

determined the updated PDDBI to be valuable in ASD diagnosis.103 Reel and colleagues
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published a study which did not observe the diagnostic capabilities of the new PDDBI. 105
They determined the sensitivity of 74% and specificity of 62% were not high enough
when the cutoff was set to 45.105 In this study, the results found children with ASDs were
different from the non-ASD group only on the Autism Composite T-score and the
SOCPP.105
1.5.7

Autism Treatment Evaluation Checklist

To find an easy way to determine small changes in response to treatment, the
ATEC was developed by Bernard Rimland and Stephen M. Edelson in 1999.106 Noncopyrighted, the ATEC is only one page long and can be completed by teachers, parents,
or another person caring for a child. The ATEC has 77 items divided into four subscales:
(I) Speech/Language/Communication (14 items), (II) Sociability (20 items), (III)
Sensory/Cognitive Awareness (18 items), and (IV) Health/Physical/Behavior (25 items).
The first three subscales are scored from 0 to 2 and the last subscale is scored from 0 to 3,
with a higher score indicating the more severe the problem or the greater the development
of that respective characteristic. The ATEC has a maximum score of 179. It has been
reported to have good internal consistency.106
There have not been many studies that have evaluated the ATEC for diagnostic
criteria, but it has been used to monitor autism treatments. Magiati et al. noted studies
where the ATEC was used to evaluate treatments of children with autism.106 However, a
couple of studies have been published which used the ATEC to monitor developmental
progress of children with autism.

Charman led a study that found the

Social/Language/Communication subscale values were lower at the end of the school
year than at the beginning for children with autism.107 The other subscales were not
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significantly different, and the authors noted the ATEC may have some drawbacks.107
Another study from 2011 showed good internal agreement at two independent follow up
times.106

The total ATEC scores foretold 64% of the change between these two

periods.106

The Social/Language/Communication subscale also showed significant

decreases between these times.106

The authors believe the ATEC is a dependable

measure over time, but more work is necessary to advance the legitimacy of the scale.106

1.6 The Immune System and Autism Spectrum Disorders
Now that the behavioral rating scales used to diagnose children with autism have
been reviewed, the focus shifts to the immune system; an alteration in immune system
functioning is one characteristic that children with autism commonly present clinically.
The structure of the immune system is described to provide background information
before discussing studies that describe immune dysregulation along with the impact
genetics and the environment have in autism.
1.6.1

The Structure of the Immune System

The job of the immune system is to distinguish between the body and non-body
and to remove any invading pathogens.108 The human immune system is composed of
two parts: the innate immune system and the adaptive immune system. The innate
immune system encompasses the cells and mechanisms that protect the body from
infections caused by outside pathogens. It is non-specific and provides only short term
defense.

The adaptive immune system is comprised of cells with very particular

functions and affords long term protection.

It possesses the ability to remember a

pathogen and produce a stronger attack when it is encountered again at a later time.
There are two types of adaptive immunity:
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humoral immunity and cell-mediated

immunity.109

Humoral immunity is controlled by antibodies, whose production is

regulated by B lymphocytes. Antibodies, or immunoglobulins, are Y-shaped proteins
which attack certain kinds of pathogens, which can be recognized through memory.
There are five types of immunoglobulins (Ig): IgA, IgD, IgE, IgG, and IgM. IgG is the
dominant antibody, accounting for nearly 80% of the total antibodies in humans,4 and it
attacks viruses and bacterial toxins outside of cells.4 IgM makes up around 10% of the
immunoglobulins and defends the body against blood-borne pathogens. IgA comprises
almost 15% of the antibodies and focuses on fighting bacteria which attack the mucosal
barrier.4 IgE specializes in oversensitive responses to allergens and is attached to mast
cells, which excrete histamine, and IgD acts in regulation of B cell initiation and
termination.4 B cells are produced after T cells release interleukin (IL)-4, a cytokine
produced by T-helper cells. Cytokines, or interleukins, are important messengers of cells
of the immune system involved in controlling leukocyte biology through receptors on
their target cells.110 After being stimulated, B cells can be either plasma cells or memory
cells. Plasma cells are capable of generating vast quantities of antibodies very quickly
and have a shorter life span.4 Memory B cells maintain specificity recognition with the
ability to produce a large number of plasma cells to attack a pathogen.4
T lymphocytes control cell-mediated immunity.

There are three types of T

lymphocytes: T-helper (CD4) cells, cytotoxic or killer (CD8) T cells, and T-suppressor
cells.4 Sixty-five percent of the total number of T cells are helper-inducer cells.111
Clusters of differentiation (CD) are used to describe molecules on the surface of white
blood cells. The CD4 lymphocytes assist B cells in reaching their complete functionality
and in the making of antibodies.109 CD4 helper cells assist in the adaptive immune
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reaction resulting from particular antigens,112 while CD8 cells destroy cells infected with
viruses.109 T-helper lymphocytes can be divided into two groups, Type 1 helper (Th1)
and Type 2 helper (Th2). The Th1 lymphocytes function in cell-mediated immunity and
the Th2 lymphocytes assist B cells in the production of immunoglobulins, most notably
IgE.108, 113 Cytotoxic T lymphocytes attack and kill foreign pathogens in the body, and
then T-suppressor lymphocytes signal the immune system to turn off when the pathogen
has been eliminated from the body.
1.6.2

The Cells of the Immune System

The immune system requires many different types of cells to function properly.
White blood cells, or leukocytes, protect the body from diseases and xenobiotics.
Lymphocytes are a specific kind of leukocyte and are the only cells which possess unique
receptors for specific antigens. They play a large role in the adaptive immune system. 114
T and B cells are categorized as small lymphocytes, one of two categories, while the
other is large granular lymphocytes, also called natural killer (NK) cells. Natural killer
cells destroy tumors and kill cells infected with viruses.115 They function as part of the
innate immune system and do not possess any antigens on their surface like T and B
cells.114

Natural killer cells possibly play a role in immune system control due to

decreases in their number seen in lupus erythematous, multiple sclerosis, and rheumatoid
arthritis;115 however, they do perform a role in controlling the number of antibodies being
made.108 They have CD16 and CD56 or CD57, but do not have CD3 cell surface
receptors.109
Lymphocytes are classified as agranulocytes along with monocytes and
macrophages. Monocytes fight pathogens in blood and can respond quickly to where an
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infection occurs. They can consistently change into macrophages after travelling to other
nearby tissues.116 Macrophages engulf and consume pathogens, microorganisms, and
other molecules that have assisted in phagocytosis.109 Agranulocytes are leukocytes with
general azurophilic granules present in their cytoplasm.

Granulocytes are the other

category of lymphocytes. Granulocytes have granules attached to membranes, which
help in the digestion of particles which have been engulfed as part of the immune
response. There are three types of granulocytes: neutrophils, eosinophils, and basophils.
Neutrophils are the most populous leukocytes and are found in pus and indicate acute
inflammation. Eosinophils block infections from parasites and control allergies and
asthma. Basophils produce IL-4, which plays a very important role in allergies and IgE,
and mast cells are developed from them in tissues.117
Antigliadin antibodies are an additional specific type of immunoglobulins which
may play a role in immune system of children diagnosed with ASDs. They are produced
when exposed to gliadin, a glycoprotein found in wheat. There are three classes of
antiglidin antibodies:

antigliadin IgA, antigliadin IgG, and antigliadin IgE.

These

antibodies can be produced during a response to gluten from the diet. Another special
type of antibody is called tissue transglutaminase (tTGA), which is commonly used as a
marker for celiac disease.

1.7 Evidence of Immune Dysregulation in Children with Autism Spectrum
Disorders
1.7.1

Autism and the Immune System

Many studies have explored the effects autism has on the immune system, with
the numerous findings focusing on immune dysregulation and dysfunction in ASDs.13
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Autism has shown the presentation of multiple atypical values of the immune system and
a large number of studies suggest a connection between autism and the immune
system.108 Children with ASDs demonstrated an increased frequency of immunologic
abnormalities including signs of irregular innate, humoral, and cell-mediated
immunity.118 Successive adaptive immune reactions have resulted from previous innate
immune system responses, and autoimmunity may be the consequence of an improperly
regulated innate immune system.119 Children with autism show an abnormal innate
immune system

reaction,

which may also cause

adaptive immune system

dysregulation.119 In most studies, fifteen to sixty percent of children with autism display
immune system dysfunction.14
A review of past studies regarding autism and the functioning of the immune
system is discussed including B cells, T cells, NK cells, immunoglobulins, and other cells
and components. Next, genetic predisposition is reviewed because some important,
specific genetic sites have been connected to the increased prevalence of autism. Then,
studies debating the impact the environment has on autism are examined. Finally, autism
rates and detoxification are demonstrated to be influenced by the environment.
1.7.2

B Cells and Autism

Results showing mixed B cell abnormalities in autism have been produced. Yonk
led a study which found decreased B (CD20) cells in children with autism.120 Gupta and
colleagues supported this study by discovering that 60% of children with autism had
irregular proportions and 64% had abnormal numbers of CD20 cells.121 Specifically,
48% of the children had lower and 12% had higher proportions of B cells. 121 In addition
to these blood studies of B cell numbers, Ashwood and collaborators detected
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significantly higher amounts of CD19 B cells in every area of the lamina propia studied
when compared to controls.122
Three different studies did not find any difference between autism patients and
controls. Separate studies led by Denney and Warren observed similar numbers of CD20
B cells in children with autism and controls.111, 123 Stern et al. found no abnormalities in
the total number of CD19 B cells.12
1.7.3

Autism and T Cells

Numerous studies have explored the relationship between T cells and autism.
Stubbs et al. were the first to determine that children with autism displayed an
insufficient number of T cells in 1977.124 In 1986, Warren and colleagues furthered the
understanding of T cells in autism by finding a lower number of T cells and an altered
ratio of helper T cells to suppressor T cells.125 Yonk et al. in 1990 discovered numerous
findings including the decreased percentage and number of CD4 helper T cells and the
lower percentage and number of all lymphocytes.120 They also noted that the CD8
percent was significantly increased, but the CD8 number was not higher in children with
autism compared to controls.120 That same year, Warren et al. showed that patients with
autism had decreased numbers of total lymphocytes and CD4+ and a regular amount of
CD8+.123 In 1994, Plioplys and colleagues found that the number and percentage of T
and B cells, the CD4+, and CD8+ subsets were normal in patients with autism.126 While
the mean CD4/CD8 ratio was normal for the cohort, 6 had higher ratios than normal, 5
had lower values than usual, and only 4 were within the healthy range.126 This study also
demonstrated a higher amount of activated T cells in children with autism; however, this
study admits to using different methods in comparison to other studies.126 As of 1996,
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the most frequent discoveries when evaluating the immune system of children with
autism and controls were a decrease in the number or percentage of helper T cells which
resulted in a lower “helper:suppressor ratio” (CD4/CD8) and a lower number of
lymphocytes.111 A study by Denney et al. supported these findings of children with
autism having a decreased percentage of CD4 cells and helper:suppressor ratio when
compared to matched controls.111

The lower CD4 number was caused by the

suppression-inducer subset, and not by the helper subset.111 Suppressor-cytotoxic T cells
were not seen at statistically significant different levels between children with autism and
controls.111 The children with autism displayed a minor decrease in total T cell (CD3)
number.111 As part of a larger study looking at the immune system in children with
autism, Gupta and colleagues observed abnormal numbers of total CD3 T cells in the
children with autism, as 16% were decreased and 36% were increased.121 Helper/inducer
T cells were abnormally distributed in 64% of the children with autism and 48% had an
aberrant number of helper/inducer T cells.121

In this cohort, 60% had an aberrant

CD4/CD8 ratio for T cells as 28% were elevated and 32% were decreased.121 Fiumara
and colleagues led a study which found that female subjects with Rett’s Disorder all had
a higher CD4/CD8 ratio caused by a lower percentage of CD8 suppressor-cytotoxic
cells.127 In 2003, Ferrante and colleagues showed children with autism had a notable
reduction in CD4 naïve cells and an elevated number of CD4 memory T cells.128
In addition to the blood studies previously discussed, Torrente et al. found that
children with autism displayed a higher density of CD8 intraepithelial lymphocytes in
comparison to controls.129 They also observed an overload of lymphocyte (CD3, CD4,
and CD8) infiltration in the lamina propia in children with autism compared to
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controls.129 The only study which showed normal numbers of T cell lymphocytes was
led by Stern, where 96% of patients had regular CD3, CD4, and CD8 values.12
In addition to the studies that have focused on the number and ratio of T cells,
several studies have explored interleukins and other factors that affect T cells. In autism,
there is a problem with the cell-mediated immunity response.130 One way this finding
can be seen is a shift in the ratio between Th1 and Th2 cytokines. This change in Th1
and Th2 responses alters the type of cell-mediated immune response, and it can be seen
through the production of certain interleukins. Th1 cells make IL-2 and interferongamma (IFN-γ), which stimulate the production of T cells and macrophages.131 Th2 cells
are responsible for making IL-4, IL-5, IL-6, IL-10, IL-13, and transforming growth
factor-beta.131 In autism, both Th1 and Th2 cytokines have been found to be in higher
amounts.132 Singh and colleagues found IL-2 at a significantly greater value in the serum
of children with autism compared to healthy children.133 Both helper and suppressor cells
need the unique signaling of IL-2 for production.133 In a second study, Singh observed
IL-2 to have higher production in autism, and IL-2 is made by both the CD4 T
helper/inducer cells and CD8 T suppressor/cytotoxic cells.134

IL-2 is made by T

lymphocytes after interacting with antigen-presenting cells.126 In this study, Singh also
demonstrated IL-12 and IFN-γ to be higher in children with autism, which may indicate
increased Th-1 response resulting in autoimmunity.134 Both IL-12 and IFN-γ assist in
regulation of the immune system, including CD4 T helper cells and this may signify T
cell regulation deficiency.134
Croonenberghs et al. reported that both IFN-γ and IL-1RA were significantly
increased in children with autism along with a shift toward greater amounts of IL-6 and
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tumor necrosis factor-alpha (TNF-α) in whole blood.135 Li and colleagues found that the
brains of patients with ASDs had significantly higher amounts of TNF-α, IL-6,
granulocyte macrophage colony-stimulating factor, IFN-γ, and IL-8 compared to
controls.112 They also showed that the Th2 cytokines, IL-4, IL-5, and IL-10, were not
significantly higher, and the Th1/Th2 ratio was statistically elevated in patients with ASD
compared to controls.112 These results demonstrated a shift toward a Th1 response as
seen in the adaptive immune system.112 Th-17 T lymphocytes, which release IL-17,
TNF-α, and IL-6, have the survival factor IL-23, which has been seen to have a role in
autoimmune disorders and chronic inflammatory diseases.136 Children with autism had
lower amounts of IL-23 in comparison to normal developing, age matched controls.136
IFN-α, IL-6 and TNF-α were not found to be significantly higher in children with
autism.134 Activated T cells resulted in the increased production of TNF-α through the
synthesis of different types of cytokines, which turn on macrophages and microphages
that lead to the making of TNF-α.137 Cell-mediated immunity has been noted to be upregulated according to signs of increased CD3 TNF-α cells and decreased counterinflammatory CD3 IL-10 cells in the mucosal and lamina propria of the small intestine in
children with autism suffering from gastrointestinal symptoms.138

In children with

ASDs, both CD3 TNF-α and CD3 IFNγ were statistically higher than in non-inflamed
controls in both peripheral blood and mucosa.139 In comparison to controls, CD3 IL-4
was found to be elevated in children with ASDs.139 Ashwood and Wakefield showed that
CD3 IL-10 was much lower in peripheral blood and mucosa in children with ASDs who
suffered from gastrointestinal symptoms in comparison to non-inflamed and Crohn’s
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disease control groups.139 In autism, cell-mediated or humoral reaction versus certain
parts of the central nervous system may result from CD4 CD45RA shortage.123
1.7.4

Natural Killer Cells in Autism

Almost all of the previous studies that have focused NK cells and autism have
found abnormalities in either the activity or number of NK cells. In 1987, Warren and
colleagues completed the first study, which found lower activity of NK cells in nearly
40% of the patients with autism, and suggested that NK cell activity is decreased in
autism.115 Reduced NK cell activity has also been seen in schizophrenia.115 Warren et al.
hypothesized that an elevated likelihood of viruses seen in fetuses resulted from a
predetermined inclination derived from decreased NK cell ability.115 Gupta led a study in
1996 that supported the data from the study by Warren, which showed the proportion of
CD3 CD16 NK cells was lower in 44% and higher in 8% of the children with autism. 121
Twenty-five percent of the children had a lower total NK cell number and in 12% the NK
cell number was higher than normal. In addition, 20% of the children had lower number
and proportion of NK cells.121
Vojdani and colleagues conducted a study showing that after using a correction
factor, 45% of children with autism had low NK cell activity that was linked with the
cellular glutathione concentration, compared to 8% of controls.140 They suggested that
lower amounts of glutathione, IL-2, and IL-15 are responsible for the lower level of NK
cell activity as both IL-2 and IL-15 along with other cytokines can activate the production
of NK cells.140 Fiumara led a study that found decreased numbers of NK cells in 75% of
children with Rett’s Disorder.127 They also showed that the younger patients had higher
levels of IL-2.127

In addition, previous studies have demonstrated elevations and
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decrements in NK cell production and increased blood monocyte creation, strongly
supporting altered innate or first pass non-specific immunity, contributing to an increased
multi-tissue inflammatory state.115-116
In contrast to these studies, only two studies did not find any abnormalities in
number of NK cells.

In 1990, Warren and colleagues found that there were no

abnormalities in CD56 NK cells.123 Also, Stern et al. observed that all patients with
autism had regular NK cell counts.12
1.7.5

Immunoglobulins and Autism

Immunoglobulins have been studied in numerous publications related to autism.
The relationship between immunoglobulins and autism has been explored in blood, the
brain, and in relation to diet. Many studies have found both higher and lower than
normal values in the blood, serum, and plasma of patients with autism. Over-exuberant
humoral immunity has been shown in several studies that demonstrated elevations in
serum immunoglobulins and their subclasses in this group of children.141
Different values of immunoglobulins and cytokines are commonly found in
autism including lower levels of IgA, higher IgE and IgG amounts, and elevated IL-12
and IFN-γ values.142

In 1996, Gupta and colleagues completed a study of many

components of the immune system including immunoglobulins that found 56% of the
children with autism had elevated amounts of serum IgM and IgE.121 Twenty percent
lacked a normal concentration of serum IgA and 20% had decreased amounts of IgG
subclasses.121 Singh et al. showed a significantly higher occurrence of IgG isotype
antibodies to neuron-axon filament protein (anti-NAFP) and glial fibrillary acidic protein
(anti-GFAP) in patients with autism in comparison to mentally retarded patients.143
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Fifty-five percent and 32% of the subjects with autism had anti-NAFP and anti-GFAP
antibodies, respectively.143 Jyonouchi et al. found in 2001 that 18% of children with
autism showed higher amounts of IgE seen through allergen-specific IgE antibody or skin
tests.119 The study also discovered that 55% of children with autism displayed the
presence of positive IgG anti-myelin basic protein.119
In 2002, Croonenberghs and colleagues found higher amounts of serum albumin
and IgG in children with autism.144 The elevated levels of IgG suggested the presence of
an autoimmune disease, which may lead to a higher likelihood of frequent illness caused
by viruses.144 Autoimmune B cells may be affected by the abnormalities in the IgG
subclasses seen in the cytokine-dependent effects.144

Statistically significant higher

values of IgG, IgM, and IgA in children with autism in comparison to controls were
found by Vojdani et al. in 2002.145 The next year Vojdani and colleagues showed that
IgG, IgM, and IgA isotypes for both anti-CD26 and anti-CD69 autoantibodies were
elevated in statistically significantly amount in autistic serum samples compared to
controls.146 Trajkovski et al. noted IgM and IgG plasma levels in children with autism
were statistically higher versus levels in their healthy sisters or brothers.141 IgA plasma
amounts were not statistically significantly different in comparison to control siblings.141
They found only IgG to be elevated in female patients with autism when compared to
their healthy sisters.141
In contrast to other studies that demonstrated higher levels of immunoglobulins,
four studies illustrated lower than normal values in children with autism. Warren and
colleagues first saw that patients with autism had a significantly lower average amount of
serum IgA compared to age- and sex-matched controls in 1997.147 They also showed
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20% of these patients with autism had IgA concentrations below the normal lower
bound.147

Additional findings included 42% having haplotypes connected to IgA

shortages and 48% indicating C4B null alleles, with 15% of these individuals displaying
decreased IgA numbers.147 Ashwood and colleagues found that 28% of children with
autism had IgM amounts below the 5th percentile of the pediatric reference values with
only 14% above the 50th percentile.122 Forty percent of IgA concentrations were below
the 5th percentile and no concentrations were above the 50th percentile.122 They also
discovered that serum IgA was negatively correlated with CD4% in blood.122 For IgE,
39% of the amounts in children with autism were above the 95th percentile.122 In 2005,
Stern et al. saw 22 out of 24 patients had normal IgG and IgM levels within reference
ranges and all 24 had normal IgA values.12 More recently, Heuer and colleagues found
children with autism had lower concentrations of IgG and IgM when compared to
typically developing age-matched controls.148 This study also showed that the ABC
scores were correlated negatively with immunoglobulin concentrations for both children
with autism and controls.148 The association between decreased IgG amounts and higher
ABC scores is the best sign for a connection between autistic behavior and the function
of the immune system.148 One study by Bakkaloglu and colleagues showed that serum
amounts of IgG, IgA, and IgM were within age-appropriate bounds for children with
autism, but 13.3% of subjects had higher than normal serum IgE.149
In addition to the study of immunoglobulins in blood, three studies demonstrated
higher amounts of them in the brains of children with autism. Connolly and colleagues
first saw this result in 1999 when they found 27% of children with ASDs had IgG antibrain autoantibodies and 36% had IgM autoantibodies in their sera, and both values were
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significantly more than controls.150 Silva and coworkers supported Connolly’s work in
2004 when finding children with autism exhibited a higher frequency of brain antibodies
than controls at a significant level.151

Connolly et al. showed that brain derived

neurotrophic factor (BDNF) and the average IgG and IgM BDNF autoantibodies (AA)
were higher in children with autism and that IgM AA endothelial cells (EC) titers, IgG
EC AAs, IgM EC AA, and anti-myelin basic protein IgG and IgM titers were greater in
children with both autism and PDD-NOS.152 These results indicate the children with
developmental disorders have greater quantities of AA than controls.152
Immunoglobulins have also been studied to relate autism to the diet and
gastrointestinal system. Many regular dietary protein antigens cause an increased number
of gastrointestinal problems in children with ASDs.119

Only 2-3% of the negative

response dietary proteins are caused by IgE food allergies, with cell-mediated immunity
playing a major role.153 Positive IgE antibodies against dietary proteins are rarely seen in
children with autism during the first two years of their lives.137 One study found IFN-γ
and TNF-α being made by peripheral blood mononuclear cells in opposition to gliadin,
cow’s milk protein, and soy in comparison to dietary protein intolerance in children with
ASDs.137

These children may have a bigger immune response to common dietary

proteins as a result of an abnormal innate immune reaction to endotoxin found in the
intestine.137 A higher rate of dietary protein responsive peripheral blood mononuclear
cells was seen in children with ASDs and showed a connection between dietary proteins
and gastrointestinal problems.137 Parents reported that the condition of children with
autism improved after being on a casein- and gluten-free diet.137
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Autism may result partially from food allergies.154 Behavior improved after an
‘elimination diet,’ removing any food producing a positive cutaneous food allergy.155
Compared to controls, children with autism displayed elevated quantities of IgA specific
antibodies for lactalbumin, β-lactoglobulin, ovalbumin, and casein, and significantly
larger amounts of IgG and IgM for casein and IgM for lactalbumin.155 Renzoni et al.
published a study where the mean total IgE, the occurrence of higher than normal IgE
counts, and the prevalence of IgE for specific foods showed there to be no significance
between children with autism and mentally retarded, non-autism controls.154 This study
did not find sensitivity to specific food allergens to be elevated in children with autism
compared to controls.154 Children with autism did not demonstrate a significant, atypical
IgG or IgM allocation.129 The most notable discovery was seen on the basolateral
epithelial surface, where IgG deposition occurred in 92% of the children with autism
studied, notably on C1q complimentarily.129 This finding implied the involvement of the
immune system related to this disease.129 Kawashti and colleagues found that 83.3% and
50% of children with autism had elevated IgG and IgA antibodies to casein and gluten,
respectively.156 In comparison, only 10% of controls had higher antibodies in response to
casein and 6.7% to gluten.156 A link may be seen between behavioral symptoms and
gastrointestinal issues resulting from an abnormal innate immune system in children with
ASDs.157
1.7.6

Autism and Antigladin A and G

In the entire population of children in North America, only about 10% have any
sensitivity to glutens as marked by increased antigliadin IgG and/or antigliadin IgA
antibody production.

There have only been a few studies which have focused on
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antigliadin A and antigliadin G antibodies and autism. Vojdani et al. found in 2003 that
antigliadin IgG was significantly higher in 44% of children with autism versus
controls.146 Antigliadin IgM was elevated significantly in 36% versus 10% for controls,
and antigliadin IgA was higher in 46% of children with autism compared to 12% of
controls.146 In 2004, Vojdani and colleagues conducted a study which demonstrated
significantly greater amounts of antigliadin IgG, IgM, and IgA in 42%, 34%, and 36%,
respectively, in children with autism.158 Age matched controls showed elevations in 16%
for antigliadin IgG, 8% for antigliadin IgM, and 14% for antigliadin IgA.158 In another
study that year, Vojdani et al. found children with autism had a statistically higher
amount of antigliadin antibodies.159
1.7.7

Tissue Transglutaminase and Autism

There have not been many studies relating the association between tTGA and
autism. Levy and colleagues found children with autism had normal amounts of tTGA,
gliadin IgA and gliadin IgG.160

Only 1% of the North American child population

demonstrates elevated tTGA, suggesting the presence of celiac disease.161 From the
largest multicenter epidemiologic study in the United States, celiac disease was found to
occur in 1 in 133 individuals not in at risk groups.162 Fasano and Catassi suggest that the
prevalence of celiac disease ranges from 0.5-1.0% of the population.163 In children age
2.5 to 15, celiac disease occurrence ranges from between 1 in 80 to 1 in 300.164 No link
between autism and celiac disease has been made.165
1.7.8

Other Immune Cells in Autism

Some studies have focused on the role of other cells in the immune system related
to autism including eosinophils, monocytes, neutrophils, and basophils. Renzoni et al.
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found significance in the average eosinophic absolute number, average percentage of
eosinophils in blood, and frequency of eosinophilia between retarded controls and
children with autism.154 Another study showed children with autism displayed a higher
total amount of eosinophils when evaluated against controls.132 Ninety-two percent of
children with autism exhibited a higher number of non-specific mononuclear cells
(agranulocytes), 56% had a higher number of intraepithelial lymphocytes, and pericryptal
lymphocyte aggregates were discovered in 64% of children with autism.129 In a larger
study, Sweeten and colleagues found that children with autism had a higher average
number of monocytes compared to controls.116 This study also showed no significant
disparity in the total absolute leukocyte count, in the number or percentage of
neutrophils, eosinophils, basophils, or lymphocytes, or in monocyte percentage.116 These
findings do not support autism as an autoimmune disease, as they result in a higher than
normal blood monocyte number.116
1.7.9

Zinc and the Immune System

In addition to the cells of the immune system, many different components are
necessary for the immune system to work optimally. One of these parts needed for
proper functioning of the immune system is zinc. In the body, zinc is found mostly as a
Zn2+ ion attached to cellular proteins and acts as an antioxidant.110 Zinc is required for
normal human maturation and optimized performance of the immune system.166 Zinc
deficiency results in shortcomings in the immune system,167 and lower concentrations
have been connected to the damaged immune reactions in many diseases.168
Zinc affects all of the different cells involved in immune response.168

The

production of T cells is controlled by the amount of zinc;168 and they are the first cells
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affected by zinc deficiency resulting in lower numbers.167

Zinc is required for the

development and maturation of T cells.168 During times where zinc is only somewhat
deficient, the function of T cells can be affected negatively.168 A shift toward a Th2
helper cell response is seen with decreased zinc.

Activation, the making of Th1

cytokines, and assistance of B lymphocytes are all functions of T lymphocytes affected
by zinc shortages.110 Sazawal and colleagues found that in a group of children suffering
from diarrhea, those on zinc supplementation had significantly higher CD3, CD4, and
CD4/CD8 ratio means compared to controls.169
Additional work has noted that zinc deficiency in utero can contribute to
decreased communication between T and B cells of the immune system, leading to an
overabundant humoral immune response to antigens in the mouse model and decreased
splenic size.170 The ability of antibodies, especially IgG, to be produced is decreased
during zinc shortages.110, 167 Naïve B cells suffer greater consequences in times of zinc
scarcity in comparison to memory B cells.167 B lymphocyte production is hindered in the
bone marrow thus reducing the number of B lymphocytes in the spleen.110 For cells
involved in general immunity, including neutrophils and NK cells, zinc is necessary for
proper maturation and performance.110 In addition, NK cells, monocytes, granulocytes,
and macrophages all show decreased functionality in times of lower zinc
concentration.167

Monocytes have a greater concentration of zinc than T cells.168

Macrophage functioning involving the making of cytokines and phagocytosis is also
negatively affected.110 In zinc shortages, the amount of neutrophils is decreased.167
Peripheral blood mononuclear cells “take up” zinc.168 During the third trimester of
pregnancy, the transferring of antibodies from mother to fetus may be compromised by

49

zinc deficiency.110 Child illness may be reduced due to zinc supplementation by mothers,
and enhanced dietary zinc intake or supplements can correct for zinc deficiency.166
Neither plasma nor hair zinc measurements can truly determine zinc status.166
1.7.10 Autism, Metallothionein, and the Immune System
In addition to zinc, metallothionein has a very important role in the immune
system through the regulation of metals including zinc. Metallothioneins are a group of
low molecular weight proteins which are rich in cysteine and the proteins most
responsible for the removal of heavy metals from the body.171 Cysteine contains thiol
groups which have a high reactivity with metals.171 Four isoforms of metallothionein
exist,172 and in humans, all four are closely located on chromosome 16.173-174 Both MT-I
and MT-II are found in all tissues.172 In mice, the brain is the only organ where MT-III is
expressed.173 MT-IV is observed only in stratified squamous epithelia in mice including
in the oral epithelia, esophagus, and upper stomach.174 Quaife et al. have estimated that
80% of all MTs are MT-IV.174

MT-I and MT-II levels are controlled by metals,

hormones, and xenobiotics, and they are responsible for the detoxification of heavy
metals and metalloprotein synthesis.175

MT-III is known to control zinc levels in

neurons.175 MT-IV function is not known.172 The transcription of metallothionein genes
and additional genes in response to heavy metal and oxidative stress are turned on by
metal-regulatory transcription factor-1 (MTF-1).176
In eukaryotes, zinc concentrations are controlled by metallothionein through
evolution.177 Proteins which bind metals, notably metallothionein, control the amount of
available zinc.167 Zinc ions are kept in reserve by metallothionein.178 Both zinc and
metallothioneins have been used to determine zinc shortages.171 Both the amount and
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oxidation state affect the amount of zinc bound to metallothionein.167

In addition,

metallothionein dysfunction may result in improper heavy metal detoxification.171 MT-1
can bind with many heavy metals including zinc, copper, cadmium, and mercury, and
detoxify them from the body.171 Both the elemental and ionic species of divalent metals
are deadly to cells.171 Russo found that members of autistic families had significantly
higher amounts of serum anti-metallothionein IgG in comparison to controls; there was
an association between the making of IgG antibodies and amounts of metallothionein.171
In children with autism, many symptoms, including leaky gut, casein and gluten digestion
problems, and other digestion issues, may result from improper MT functioning.171 Both
the autoimmune reaction and anti-MT synthesis may result from either decreased
metallothionein amounts or their improper synthesis.171 Both estrogen and progesterone
improve metallothionein production.171
1.7.11 The Plasma Zinc/Serum Copper Ratio as a Biomarker Linking
Environmental Toxicity to the Immune System in Autism
In a previous study, the plasma zinc/serum copper ratio (Zn/Cu) was proposed as
a biomarker in ASDs.179 In this study, the average Zn/Cu ratio for the cohort of children
with ASDs studies was 0.608.179 This value was below the 0.7 cutoff value due to
previous reports in literature and clinical assessment marking the lowest 2.5% in healthy
children.179 This study showed a very similar mean Zn/Cu ratio to a previous study of
children with ASDs. In a study of 503 patients with ASDs, Walsh and colleagues
determined the mean Zn/Cu ratio to be 0.61 for the ASD patients and 0.87 for controls.180
Walsh also studied the Zn/Cu ratio of assaultive young males and observed it to be 0.71
with the controls’ mean ratio being 0.98.181 In a study of leishmaniasis patients, Van
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Weyenbergh and colleagues found that humoral and cellular immune reaction was related
to the copper/zinc (Cu/Zn) ratio.182 A disparity in the Cu/Zn ratio may be the result of a
lower Th1 immune response and trace metals are needed for optimal immune response.182
They also demonstrated a very strong association between plasma copper and both antiLeishmania IgG and humoral immune action.182 They saw that higher levels of plasma
copper prevented the production of IFN-γ.182 A normal plasma zinc/serum copper ratio
in a healthy child is 1.0 and it is seen in the assaultive young male study by Walsh and
the leishmaniasis study by Van Weyenbergh.181-182
The plasma zinc/serum copper ratio is important because it is a way to measure
the metallothionein system. Dr. Walsh suggested that patients with autism suffer from
decreased metallothionein functioning and the observed characteristics seen in autism are
the result.180 A metallothionein system resulting from genetic abnormalities could cause
nearly all of the classic signs in autism.180 These functions include detoxification of
heavy metals, development and optimal performance of immune system, gastrointestinal
issues including those related to gluten and casein, and neurological functioning
including production of brain neurons, action of the hippocampus, and socialization and
emotional memory maturation.180 In a study, Walsh and colleagues found that over 99%
of children with ASDs showed aberrant metal metabolism which results from decreased
metallothionein functioning.180 They also showed the mean concentration of unbound
copper to be four times higher in children with autism compared to controls.180 Walsh
proposed that ASD patients suffer from a ‘universal’ metallothionein disease.180 Walsh
indicated four examples of biochemical areas which can result in decreased
metallothionein activity: decreased zinc concentration, glutathione reduction-oxidation
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(redox) system aberrations, lower cysteine concentrations, and anomalies in metal
regulation.180

A hypothesis of genetic predisposition to abnormal metallothionein

functioning and an environmental attack which hinders metallothionein was proposed by
Walsh et al. and can account for the increased rate of autism diagnosis seen in recent
years.180 Based on their structure and function along with their location in the body, a
very strong relationship can be seen between metallothionein and autism. There is more
discussion on this topic in Chapter 4.
1.7.12 Autism, the Immune System, and Genetic Susceptibility
Many different areas of the human genome have been explored in relation to
autism to explain a potential genetic susceptibility with autism. One area of genetic
predisposition relating autism and the immune system appears to be the major
histocompatibility complex (MHC).

The MHC is composed of many genes which

control the immune system including antigen arrangement, controlling peptide joining,
and T cell identification.183

CD4 cells determine antigens sorted and processed by

antigen-presenting cells only for MHC Class II antigens, while CD8 cells only do the
same with MHC Class I antigens.109 Of importance are the C4 genes which are centrally
located on the MHC on chromosome 6.184 The C4 proteins are made up of the products
from the C4A and C4B genes and are involved in the innate immune system and the
complementary cascade.185 Higher rates of bacterial and viral illnesses have been found
with decreased C4 proteins, particularly C4B.186
These components of autoimmune disorders include genetic predispositions such
as the C4 null allele at the complement C4B locus.187 The ability to completely remove
particular viruses before they attack the central nervous system may be affected

53

theoretically due to the presence of one or two C4B null alleles.188 Warren’s first study
found no significance in the frequency of the C4A null allele, but found one with the C4B
null allele.187 Fifty-eight percent of children with autism and their mothers had null C4B
alleles while only 27% of controls did.187 Warren and colleagues conducted a second
study which showed that subjects with autism had significantly lower plasma
concentrations of the C4B protein in comparison to normal controls.188 This study
demonstrated typical concentrations of plasma C4A protein and that parents and siblings
had non-significantly lower amounts of C4B protein.188 A third study led by Warren
observed that the C4B null allele was higher in patients diagnosed with autism, ADHD,
and ‘reading-disabled subjects’ in comparison to controls.184

This study further

reaffirmed a connection between the C4B gene and autism and noted that DRβ1 HVR-3
was found to be significantly higher in children with autism than controls.184
Both the C4A and C4B null alleles have been connected to autoimmune disorders
and IgA insufficiency.185 It is common that either the C4A or C4B allele is null, but
autoimmune diseases display a higher occurrence of C4 null alleles.185

Odell and

colleagues completed a study which showed that 42.4% of children with autism had at
least one null C4B compared to 14.5% of controls.185 Another study led by Sweeten
observed that 50% of the patients with autism had C4B null alleles while only 16.7% of
controls had C4B null alleles.189 This study did not find any connection between C4B
null alleles and the CYP21A2 gene near the C4 gene.189 Warren led another study where
54% of the patients with autism had DR+ T cells.186 DR+ T cells are a sign of activated
T cells, and they were found to be inversely correlated with decreased C4B protein
concentration in plasma.186
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In addition to its association with the C4 genes and proteins, the MHC has also
been found to have a connection to the neurotransmitter serotonin. Warren and Singh
showed that the average serum serotonin concentration was statistically significantly
higher in children with autism than in controls.190 They also demonstrated that the
patients with autism with a B44-DR4 extended haplotype or a C4B null allele also had
statistically significantly greater concentrations of serotonin in serum.190
A genetic susceptibility combined with an environmental prompt may explain the
rise in autism over the last 15 years.20 Many different studies have both discovered and
not discovered associations with certain genes involving detoxification and the immune
system. Rose and colleagues showed a significant increase of the delta aminolevulinic
acid dehydratase (ALAD2) allele with an odds ratio of 1.66 and a significant decrease in
the frequency of both coproporphyin oxidase (CPOX) variants, which is the opposite of
the expected result for CPOX.20

Both ALAD2 and CPOX are enzymes which are

impeded by lead and mercury, respectfully.20 Buyske and colleagues found a correlation
between autism and a homozygous deletion genotype for glutathione S-transferase M1
(GSTM1) as GSTM1 is one of the genes responsible for binding glutathione to toxins.191
Glyoxalase I (Glo1) was demonstrated by Junaid et al. to have a 38% reduction in
enzymic activity in brains of patients with autism.192 It is a dimer with each monomer
binding to zinc and has a high propensity to bind to α-oxoaldehydes.193
glutathione is the cofactor for Glo1.193

Reduced

D’Amelio and colleagues observed that

Caucasian-Americans, but not Italians, had a correlation between paraoxonase gene
(PON1) variations which had decreased activity for the organophosphate diazinon in
vitro and autism.194 Decreased capacity to metabolize and eliminate toxins results from
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lower PON activity.195 PON is involved in the eradication of neurotoxins including nerve
gases and pesticides.195 PON1 uses the P450/PON1 pathway to remove organophosphate
compounds from the body.196 Serajee et al. did not find any connection with PON1,
SLC11A2 (a proton-coupled metal ion transporter), ABCC1 (a multispecific organic
anion transporter), and glutathione S-transferase and autism, but did find one for MTF-1
and SLC11A3, another proton-coupled metal ion transporter.197
In addition to the studies relating autism to the genetic problems with
detoxification, other studies have shown a connection between autism and genetic
immune system abnormalities. One of these genes which have been explored for a
connection to autism involving the immune system is the gene for the MET receptor
tyrosine kinase. MET signaling is involved in gastrointestinal healing and the function of
the immune system.198 A study determined a relative risk of 2.27 for autism with a
frequently found functional form of the MET gene.198 Garbett and colleagues provided
further support for the interaction of many genes involved in autism including MET,
glutamic acid decarboxylase 1, glial fibrillary acidic protein, and reelin.16 They also
proposed the involvement of the innate immune system and a T cell based response
through changes in the IL2RB, TH1TH2, and FAS pathways.16 In addition, studies
discovered a connection between cells of the immune system and autism. Gregg et al.
observed that children with autism differentially expressed the following genes which
relate to NK/CD8+ cells:

PAM, SPON2, IL2RB, PRF1, GZMB, CX3CR1, and

SH2D1B/EAT2.199 Also, Enstrom led a study which showed ‘clear and significant’
changes in NK cell gene expression, incidence, and function.200 Ashwood and colleagues
also found children with autism had significantly decreased amounts of cytokine
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regulating TGFβ-1 in comparison to normally developing controls which may indicate a
dysregulated immune system resulting from lower TGFβ-1 levels.201

1.8 Environmental Toxins and Autism Spectrum Disorders
Since the beginning of the 20th century, the use of chemicals has increased
dramatically. Currently, there are over 80,000 chemicals used in industrial processes,202
but nearly all of these chemicals have not been thoroughly tested to evaluate their effects
on human health. The use of chemicals has continued to increase in the last generation,
and they are required in the production of many everyday goods. However, only a small
amount of testing has been performed on the effects of brain development resulting from
chemicals commonly exposed to children.203 It has been suggested that developmental
disabilities are partially the result of the interaction with household and environmental
chemicals.203
Studies have investigated the general exposure of children with autism to toxins
and the effects they have on the immune system. Landrigan and Goldman noted the
importance of the 1993 National Academies report, Pesticides in the Diets of Infants and
Children to realize the difference chemicals have on children and adults.202 The report
resulted in a philosophical change in toxicity away from the “average adult” to a broader
approach.202 Edelson and Cantor completed a study which found that in comparison to
adult levels, 89% of patients with autism had levels of xenobiotics above those maximum
values.204 Elevated concentrations of numerous toxins are seen in people with ASDs
compared to controls, and their genotypes make them more susceptible to the effects of
these toxins.195 The ability to detoxify the body from environmental interactions may be
decreased due to many different genetic polymorphisms.20 Contact with toxic chemicals
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including heavy metals, notably mercury and lead, and organics, including
polychlorinated biphenyls (PCBs), are capable of changing the gene expression in the
regional brain glial fibrillary acidic protein and astroglial glucose regulated protein.145
Vojdani et al. hypothesized that elevated levels of antibodies (IgG, IgM and IgA) result
from increased porosity of the blood-brain barrier resulting from toxins and infectious
antigens.145
Many studies have been published which implicated chemicals and toxin overload
as a cause of autism. These studies have looked at both the rates of autism as a result of
this exposure and the physical effects the chemicals have in the etiology of autism.
Studies have investigated prenatal exposures, mineral imbalance, immune system
implications, and the detoxification of metals and chemicals.
1.8.1

Environmental Toxins and the Rate of Autism

Many studies have determined the rate of autism in relation to the exposure to
various environmental toxins. DeSoto analyzed the frequency of ASDs in Minnesota
school districts in relation to Superfund sites.195 The rate of ASDs of school districts
within 10 miles of a Superfund site was 1 in 92 while the rate was 1 in 132 in school
districts without a Superfund site within 10 miles.195 These results are significant with
ASD rates statistically higher in school districts close to a National Priority List
Superfund site.195 Windham et al. completed a study which found higher rates of ASDs
as a result of pollutants from the air.205 The pollutants which resulted in the increased
risk of autism included the metals: mercury, cadmium, and nickel, and the organic
solvents: trichloroethylene and vinyl chloride.205 Eskenazi and colleagues observed an
approximate doubling of the possibility of PDDs when the amount of pesticide
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metabolites was increased ten times.206 Roberts led a study in California which showed
that the suggested odds ratio for ASDs was 6.1 for mothers who live close to fields using
organochlorine pesticides.207 Palmer and colleagues found that every 1,000 pounds of
mercury released into the environment resulted in a 43% higher special education rate
and a 61% elevation in the autism rate.208

Palmer led a second study which saw

significant increases of 2.6% and 3.7% in the rate of autism for every 1,000 pounds of
industrial release and power plant emissions, respectively.209 Gbor determined Pittsburgh
to be located in an area of the United States where 73% of total mercury exposure is the
result of human activity.210
1.8.2

Evidence of Prenatal Environmental Exposure to Toxins in Autism

Chemical exposure has been found to affect development and begins prenatally.
The uterus’s environment has been determined to have a growing significance in
determining the long term health of the fetus.211 Lead, methylmercury, PCBs, arsenic,
and toluene are among the industrial chemicals which result in developmental disorders
and decreased brain function.212 In terms of development, the brain is one of the organs
most affected in the body.213 Exposure from these chemicals to fetuses in the womb
resulted in brain damage at lower concentrations compared to adults.212 Maternal illness
during the early and middle parts of a pregnancy may also be linked to high likelihood of
long term brain and behavior problems in children.214 In the general population, lead,
mercury, and PCBs have been found to have negative effects on development.203
Landrigan reviewed studies which showed a connection between autism and chemical
exposure from thalidomide, misoprostol, valproic acid, maternal rubella infection, and
chlorpyrifos, an organophosphate insecticide.215
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1.8.3

Nutrient Status and Toxin Exposure in Children with Autism

Many studies have investigated the mineral balance which exists in the body and
how children with autism vary from the normal profile. In 2004, Audhya presented
results at The International Meeting for Autism Research about the metabolic profile of
children with autism. He demonstrated decreased concentrations of many vitamins in
children with autism compared to controls.216

Children with autism had lower

concentrations of zinc, selenium, magnesium, and copper and higher amounts of total and
organic mercury, arsenic, and lead in red blood cells.216 Additionally, the organic toxins
of perchlorethylene, hexane, pentane, and xylene were elevated in plasma.216 Yorbik et
al. found statistically significantly lower concentrations of zinc in the plasma and red
blood cells of children with autism compared to controls.217 Strambi and colleagues
observed significantly lower levels of plasma magnesium compared to controls.218 Jory
and McGinnis showed there was lower selenium and higher molybdenum amounts in red
blood cells for children with autism.219 In children with autism, they also indicated a
trend of decreased zinc and elevated cobalt and vanadium.219 Faber et al. observed zinc
deficiency in 20% of children with ASDs and copper toxicity in 17%.179
Mercury has been the subject of many publications to determine if it is the cause
of the difference between normal developing children and children with autism. In 2004,
Ip et al. did not observe a relationship between blood mercury concentrations and autism
diagnosis.220

DeSoto and Hitlan reanalyzed this data set in 2007 and did find a

significant connection between mercury blood concentrations and the diagnosis of an
ASD.221 Adams led a study which found mercury concentrations were significantly
elevated in the baby teeth of children with autism, but lead and zinc were not
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significantly different than controls.222 In 2010, Hertz-Picciotto led a study investigating
blood mercury concentrations where the unadjusted mean for typically developing
children was significantly greater than children with ASDs or developmentally delayed
children. When demographic was accounted for, only the difference between the control
and developmentally delayed children maintained significance.223 The same year, Geier
and colleagues published a study which found higher concentrations of mercury in blood
in children with autism compared to controls along with the observation of a threshold
effect.224
Mercury has been investigated because of the many ways it negatively impacts
the body. Mercury has been known to cause changes in the immune system resulting in a
change toward Th2 cytokines from Th1 cytokines, lower NK cell and T cell functioning,
and the beginning of autoimmunity.108 In some vulnerable mice species, mercury causes
an autoimmune disorder in vivo resulting in higher amounts of IgE and IgG1.225 Mercury
can attach to and change the structure of proteins which have sulfhydryl or disulfide
functional groups on the cell surface, which could modify certain key components of the
immune system including MHC class II compounds, receptors of T cells, and other small
proteins.225
1.8.4

Environmental Toxicants Resulting in Oxidative Stress in Autism

Compounds which have thiol groups can protect these proteins against
oxidation.225

One of the most effective cellular systems against oxidation is

glutathione.226 Glutathione is the primary method for heavy metal detoxification and is
the natural chelator in humans.20 Both glutathione and metallothionein are the most
effective detoxification systems of mercury in the brain.226
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Environmental toxins

including heavy metals, PCBs, polycyclic aromatic hydrocarbons, and organophosphate
pesticides among others result in lower cellular glutathione concentrations either directly
or indirectly.20 Both lead and mercury have a high attraction to the thiol group of the
cysteine in glutathione.20 In 2004, Dr. S. Jill James completed a study which showed that
children with autism had lower total glutathione concentrations and higher amounts of
oxidized glutathione in plasma than controls.11 Dr. James led another study in 2006
which showed lower total glutathione and reduced to oxidized glutathione ratios in
children with autism.18 These results show children with autism have experienced a
greater amount of oxidative stress which may result from environmental toxicants.
1.8.5

Detoxification Problems in Children with Autism

One of the most common ways children with autism have been evaluated for
exposure to environmental toxins is detoxification. Two common matrices used in the
evaluation of detoxification in children with autism are hair and fingernails, with hair
being more common. Studies involving the evaluation of detoxification in children with
autism have been performed all around the world.
The most studies have been performed in the United States. In 2003, Holmes and
colleagues completed a study which found significantly lower concentrations of mercury
in the hair of children with autism in comparison to controls.227 When classifying the
children with autism as mildly, moderately, or severely autistic, there were significant
differences in mercury concentrations when pair-wise comparisons were performed.227
Adams and colleagues explored the concentration of elements in hair. They observed
that children with autism had 45% less iodine, and children with autism who had pica had
38% less chromium in their hair when compared to controls.228 A higher quantity of zinc
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and a lower amount of potassium were found in the children with autism who had
decreased muscle tone when compared to controls.228 Kern led a study which discovered
significantly lower concentrations of arsenic, cadmium, and lead in hair of children with
autism compared to matched controls.229 A non-statistically significant trend of lower
mercury concentration in the hair of children with autism was observed.229 In 2008,
Adams et al. supported the earlier studies by finding that children with lesser
concentrations of mercury in their hair were 2.5 times more likely to develop autism.230
Another area of the world that has produced many studies investigating
detoxification is the Middle East. In Kuwait, Fido and colleagues found significantly
decreased concentrations of calcium, zinc, magnesium, copper, manganese, and
chromium in children with autism compared to age and sex matched controls.231 In a
second study, Fido and Al-Saad observed higher amounts of lead, mercury, and uranium
in children with autism.232

In Egypt, El-baz et al. determined that there was a

significantly elevated concentration of mercury in the hair of children with autism
compared to controls.233 In another Egyptian study, Elsheshtawy and colleagues found
higher concentrations of lead and copper in children with autism compared to controls,
but mercury and zinc were significantly lower.234 The study also demonstrated a positive
correlation between the CARS score and both copper and mercury levels.234
Asia has also produced studies exploring the detoxification of children with
autism. Ip et al. did not observe a significant difference in mercury hair concentration of
controls and children with autism.220 In 2005, Yasuda and colleagues found higher
concentrations of selenium and iron in children with autism compared to controls.235 The
children with autism demonstrated lower cobalt, chromium, iodine, molybdenum,
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phosphorus, nickel, boron, cadmium, and lead hair concentrations.235 Mercury was not
shown to be significantly different between the groups.235 In 2010, Lakshmi Priya and
Geetha compared the hair and nail concentration of Indian children with autism and
controls. Copper, mercury, and lead were observed in higher concentrations in the hair
and nails of children with autism compared to controls.236 In children with autism,
magnesium and selenium were detected at significantly lower amounts.236

Low

functioning

zinc

children

with

autism

demonstrated

significantly

decreased

concentrations in hair and nails compared to controls.236 Overall, the concentrations of
copper, lead, mercury, magnesium, and selenium produced strong correlations to autism
severity.236
A couple of studies have been performed in Europe. Lubkowska and Sobieraj
found an elevated concentration of selenium and a decreased amount of iron in the hair of
children with autism versus age matched controls.237 No significant differences were
determined to exist for calcium and zinc.237 Another study from Poland investigated hair
mercury levels. It showed younger children with autism had decreased concentrations of
mercury compared to controls while older children had elevated concentrations.238

1.9 Treatments of Autism Spectrum Disorders
While there is no universal cure or treatment for ASDs, many different types of
treatments have been used, and treatments are best when employed early.239 Symptoms
of ASDs have appeared as soon as 8 months of age, but are more commonly seen at about
12 months.239 Children with ASDs can be separated from normally developing children
and children with different developmental problems as the behavioral signs are easier to
note after the first birthday.240 One study found that 87.5% of children showed indicators
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of having an ASD during the first year of life.241 It has been suggested that screening for
ASDs occur at 18, 24, and 36 months due to the increased consistency of diagnosis.240
1.9.1

Types of Treatments for Autism Spectrum Disorders

There are many different types of treatments used for ASDs. This wide range of
treatments includes acupuncture, yoga, meditation, a hyperbaric chamber, a cleanroom,
prescription medication, Applied Behavior Analysis (ABA) treatment, elimination diet,
chelation, dietary supplements, and many others.

The only prescription medication

approved by the United States Food and Drug Administration for autism treatment is
risperidone.242 Speech therapy, ABA, sensory integration therapy, and auditory therapy
are included in the endorsed educational treatments for autism.243 For ABA treatment, a
study from 2009 demonstrated improvement in 38 children with autism to reach normal
functioning levels.244 Additional methods which have been used include food elimination
and rotation and dietary supplementation.243 One common type of elimination diet is the
gluten- and casein-free diet where foods containing the proteins gluten and casein are
removed from consumption.
Many of the treatments listed are part of complementary and alternative medicine
(CAM). It encompasses a wide variety of treatments which are not currently considered
part of conventional medicine. Complementary medicine is employed in conjunction
with conventional medicine while alternative medicine replaces conventional
medicine.245 In 2006, Hanson and colleagues determined 74% of families used a CAM to
treat a child with an ASD, including 54% using a biologically based treatment. 245
Harrington et al. demonstrated even greater use of CAMs with 95% of parents reporting
their inclusion in autism treatment.246

Senel produced a study which demonstrated
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improvements in communication, learning, health, and behavior after 5 CAM
treatments.247
One of the most debated types of CAM therapies is chelation. Some studies have
noted improvements after employing chelation. Bradstreet led a study which showed
children with autism had higher amounts of urinary mercury compared to controls after
undergoing chelation.248 Adams and colleagues noted an increase in the elimination of
heavy metals and a stabilization of red blood cell glutathione concentration after
chelation.249 Another study by Adams et al. showed a significant positive correlation
between the degree of autism and red blood cell glutathione concentration and the toxic
metal levels in the body after completing chelation.250 Chelation has also had dramatic
effects on the concentration of urinary porphyrins.

Multiple studies have shown

decreases in their concentrations in children with autism after chelation has occurred.251253

The combination of these studies has demonstrated the application of chelation to

mercury toxicity which has been described in children with autism.
When implementing a treatment for ASDs, some of the key areas which the
treatments should address are detoxification, gut flora equilibrium, decreasing oxidative
stress, return toward normal immune system functionality, and nutrients for optimal
digestion.254 With these treatment goals, the use of dietary supplements can improve all
of these areas.
1.9.2

Reasons for the Use of Dietary Supplements to Treat Autism

Spectrum Disorders
Just as children who suffer from ASDs display evidence of immune system
dysregulation, they also commonly demonstrate indications of difficulties in their
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digestive system. Dietary supplements are commonly used to treat ASDs because of the
problems children have in achieving sufficient dietary intake and the “leaky gut” seen
due to digestion issues. One study led by D’Eufemia found higher intestinal permeability
in 43% of children with autism with no controls exhibiting “leaky gut.”255 In children
with autism, gastrointestinal (GI) symptoms and pathology seem to appear in about 3040% of cases.256 Habitual constipation or diarrhea along with intestinal discomfort are
the most frequent symptoms seen in children with autism.256 Seventy-six percent of
children with autism with GI symptoms demonstrated intestinal porousness.254 In another
study, only 28% of controls had a history of GI symptoms compared to 70% of children
with ASDs.257 In a study led by Afzal, 36% of children with autism had mild or severe
constipation compared to 10% of controls.258 The GI pathology symptoms of reflux
esophagitis, chronic gastritis, and chronic duodenitis were found in over 40% of
children.254

Weber noted a study from Rosseneu where dysbiosis, GI bacteria

abnormality, could result from the production of endotoxin from gram-negative bacteria
causing more continuing digestive impairment.256

These digestive problems make

communication even more difficult due to the pain they cause. Kaluzna-Czaplinska and
colleagues demonstrated improved nutritional absorption in children with autism with
lower concentrations of urinary homocysteine observed when folic acid was added to
vitamin B6 and B12 supplementation.259 Adams et al. showed strong correlation in autism
severity based on the ATEC and the degree of GI symptoms.260
Some studies have investigated the specific types of bacteria which may relate to
GI issues in children with autism. Finegold et al. observed 9 species of Clostridium
bacteria present in children with autism which were absent in controls, and 3 additional
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species were discovered in controls, but were not found in patients.261 Song led another
study which showed the cell counts for three species of Clostridium were significantly
elevated in children with autism compared to controls.262 Clostridium histolyticum group
bacteria were more frequently seen in the fecal flora in patients with ASDs compared to
controls.263
1.9.3

Types of Dietary Supplements Used to Treat Autism Spectrum

Disorders
There are many different types of dietary supplements which are used to treat
ASDs. Six of the most common types of supplements employed will be discussed in
greater detail and their applications will be reviewed. These six supplements were
selected due to their application in the study in Chapter 2.
1.9.3.1

Calcium

Calcium has many vital roles in the body. It is important in the movement of ions
in cells and acts as a secondary messenger. Bone growth incorporates calcium and
numerous other processes use calcium to maintain optimum function.

Calcium is

commonly used in the treatment of children with autism. Many children with ASDs are
on gluten- and casein-free diets and do not consume an adequate number of dairy
products. Many dairy products are formulated with the addition of calcium and other
vitamins. Calcium deficiency manifests because children with autism are particular with
the food they consume and the special diets used in autism.
Recently, a few studies have investigated the status of calcium in children with
autism. In 2006, Lindsay led a study which showed 45% of the children with autism
studied had calcium dietary shortages.264 Calcium was determined to be among the
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nutrients not sufficiently consumed in recommended quantities by Lockner et al.265
Herndon and colleagues observed a decrease in the amount of calcium consumed and a
lower number of dairy allocations in children with autism compared to control
children.266
1.9.3.2

Magnesium

Both physiological and biochemical pathways require magnesium for optimal
performance.267 For autism treatment, magnesium is thought to improve the pathway of
magnesium in neurons.267 In membrane channels, magnesium has been shown to control
the movement of ions.267 Low amounts of magnesium can negatively affect osmotic
pressure, acid-base balance, and the amount of potassium and calcium resulting in many
different health problems.218 In supplementation, magnesium is commonly used with
Vitamin B6, which is also known as pyridoxine. This combination of supplements has
been noted to advance social receptiveness for more than 30 years.267 The number of
seizures has been supported to decrease with B6 and magnesium.267 In 2006, Strambi and
colleagues determined children with autism had decreased plasma concentrations
compared to controls.218
Magnesium has a long history of being used in supplementation for autism.
Rimland noted the importance of magnesium supplementation in 1974 especially when
used in conjunction with vitamin B6 to decrease irritability and sensitivities to noise,
while increasing control of urination.268 Two studies did not discover a significant
difference when magnesium and B6 were used as supplementation in children with
autism.269,270 However, one study noted a significant increase in verbal IQ when children
with PDDs were supplemented with pyridoxine.271 A study from Mousain-Bosc and
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colleagues noted an increase in red blood cell magnesium concentration after beginning a
magnesium and B6 supplement program.267 Nearly 70% of the children had a significant
decrease in the symptoms of PDDs and those symptoms returned soon after the
supplementation schedule was ended.267 In a review by Rossignol, many open-label and
double-blind crossover studies demonstrated improvements in speaking, social interface,
and other behaviors common in autism after using a combination of magnesium and
B6.242 A case study by Xia demonstrated an approximate 50% decrease in the ATEC
score after 5 months of magnesium and B6 supplementation.272
1.9.3.3

Zinc

Zinc has many benefits in the body. The importance of zinc related to the
immune system has already been reviewed. It is important to the function of many
enzymes which affect metabolism and growth.

However, one additional area of

importance of zinc related to children with autism is detoxification. It has been proposed
that children with autism suffer from insufficiencies in detoxification due to a suppressed
metallothionein system. Evidence of this has been presented by Walsh. Walsh noted an
increased serum copper/plasma zinc ratio in children with autism.180 This elevated ratio
is indicative of a problem of detoxification through the metallothionein system. Faber
and colleagues supported this research noting a decreased plasma zinc/serum copper ratio
in children with ASDs.179 They also noted a zinc deficiency in 20% of the children with
ASDs.179
No studies have investigated zinc supplementation and how it affects children
with ASDs, but there have been some investigations of zinc on children with ADHD.
Bilici and colleagues observed decreased symptoms of hyperactivity, impulsivity, and
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socialization difficulties in children with ADHD after zinc supplementation.273
Akhondzadeh et al. found zinc supplementation lowered Parent and Teacher Rating Scale
values in children with ADHD during the 6 week duration.274 These studies illustrated
improvements in symptoms similar to what is seen in autism and the methods to evaluate
changes in children with autism.

In addition, zinc is a common component of

multivitamin supplements.
1.9.3.4

Multivitamin

One of the advantages of multivitamin supplements is the ability to provide many
vitamins and minerals simultaneously.

Children with autism have demonstrated

decreased concentrations of vitamins and minerals.275 The multivitamin supplements
commonly contain the elements chromium, magnesium, manganese, molybdenum,
potassium, selenium, and zinc along with numerous vitamins. The benefit of these
supplements is that they provide nutrients which improve the overall nutritional health of
children with autism. They can also make up for the restricted and particular diets
common in children with autism.
Studies have investigated the use of multivitamin supplements in children with
autism as it occurs frequently.276 A survey from 2009 noted that multivitamins were
suggested by 49% of physicians for the treatment of children with autism.277 Cornish
investigated nutrition intake in children with autism. The amount of zinc, calcium, iron,
vitamin A, vitamin B12, and riboflavin were below the Lower Reference Nutrient Intake
recommended levels.278 Fifty percent of children with autism on a gluten- and caseinfree diet were deficient in zinc and calcium.278

In 2004, Adams and Holloway

demonstrated sleep and GI improvements in children with autism who were taking a
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multivitamin/mineral supplement.275

Additionally, they showed significantly higher

concentrations of vitamin B6 in children with autism.275 The vitamin B6 concentration
related to the decreased amount of pyridoxal-5-phosphate and enzymatic activity of
pyridoxal kinase.275 The children with autism had average amounts of vitamin C where
control children had significantly decreased concentrations of vitamin C.275 Adams led
another study from 2011 which showed that children with autism demonstrated improved
methylation, sulfation, and oxidative stress using a multivitamin supplement compared to
the placebo group.276 The markers which were significantly better included total sulfate,
S-adenosylmethionine,

reduced

glutathione,

oxidized/reduced

glutathione

ratio,

nitrotyrosine, adenosine-5’-triphosphate, reduced nicotinamide adenine dinucleotide, and
reduced nicotinamide adenine dinucleotide phosphate.276 Numerous other studies have
investigated individual minerals and vitamins which are components of multivitamins,
but they are too numerous to discuss in this setting.
1.9.3.5

Essential Fatty Acids

There are two types of fatty acids which have been determined to be essential:
omega-3 and omega-6.279 Essential fatty acids are unable to be made in the body and
their intake is required either in the diet or by supplementation for proper functioning and
development of the body.256 An omega-3 fatty acid is a polyunsaturated fatty acid and
the three types of components in the human diet are alpha-linolenic acid, which originates
in plant and nut oils, and docosahexaenoic acid and eicosapentaenoic acid, that both
come from seafood.280 Humans are not able to synthesize these three types of fatty acids
from smaller components, but are capable of producing docosahexaenoic acid and
eicosapentaenoic acid from alpha-linolenic acid.280 Essential fatty acids play a role in the
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production of lipooxygneases and cyclooxygenases.280 It has been found that an antiinflammatory response occurs from omega-3 fatty acids.280

The importance of

docosahexaenoic acid in growth and brain development and function is found in its high
concentration in neural tissue.280 Omega-3 fatty acids are not a sufficient component of
the diet for an average American, especially children with low fish consumption due to
concerns over mercury concentrations.256
Omega-3 fatty acids are regularly employed in the treatment of autism.256
Twenty-five percent of physicians recommended their use as part of autism treatments
based on a survey from 2009.277 Stevens led a study which demonstrated increased
health and learning difficulties in boys with decreased omega-3 fatty acid levels.279
Vancassel et al. observed that children with autism demonstrated 23% lower amounts of
omega-3 fatty acids versus controls.281 In 2004, a parental survey indicated a higher
frequency of an insufficient amount of fatty acids in children with autism and Asperger’s
Disorder compared to controls.282 The ABC was used by Amminger and coworkers to
find an increased reduction in hyperactivity of children with autism after taking omega-3
fatty acids.283 Meguid and colleagues showed an increase in clinical and biochemical
progress in 66% of children with autism after the use of a fish oil.284
1.9.3.6

Probiotic

Any dietary supplement which provides microbial benefits to the digestive system
is defined as a probiotic.285 Lactobacillus and bifidobacterium genera bacteria are the
most frequently employed probiotics.285 In addition to autism, probiotics have been used
to treat allergies, cancer, AIDS, infections, aging, and fatigue.285 Probiotics provide
benefits to the immune system by increasing the number of beneficial bacteria necessary
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for optimal digestion of nutrients. It has been documented that children with autism
suffer from dietary problems which affect the immune system negatively. In one study,
19% of physicians advocated for probiotics to be a part of autism treatment.277
Although many studies have demonstrated problems with the digestive system in
children with autism, not many studies have investigated the difference resulting from
probiotic treatment.

A case study of a 6 year old boy demonstrated behavioral

improvements during the use of a probiotic, but complete regression occurred only 4 days
after the probiotic was stopped.286 In 2002, Brudnak led a study which determined
improvements in all of the types of variables measured children with ASDs over a 12
week period.287

1.10 Biomarkers of Autism Spectrum Disorders
As discussed earlier in this chapter, autism is a complex disease with many
different ideas proposed for its etiology. With this ambiguity, the search for common
features and identifiers, or biomarkers, has taken on greater importance for autism. A
biomarker is a biological marker of a current biological status.288

Biomarkers are

common physical signs which occur frequently and are unique to a disease. Currently,
autism diagnosis is made by clinical observation and psychological rating scales. Neither
of these methods is a physical test and provides no insights into the altered biochemistry
of autism. With the importance of early treatment, an earlier autism diagnosis can result
in quicker intervention which can provide the best possibility for improvements.
In support of clinical and psychological diagnosis, there has been a search for
biomarkers in ASDs. Biomarkers can be used as an early indicator of ASDs and as a
physical test. The search for biomarkers in autism began nearly twenty years ago when
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Martineau and colleagues investigated urine for monoamine neurotransmitter
metabolites.289 Some of the key characteristics for model biomarkers are a focus on a
particular pathway in an accurate and quantitative manner, and they would be better if
they were not invasive.290 Biomarkers which can be applied to clinical treatment are
translational biomarkers as they evaluate response to treatment or lead to new ones.290
Biomarkers must be quantifiable and relate to a specific disease state, constant, and
prognosis.288 Instead of being inevitable or simplifying autism ideas, biomarkers should
provide additional knowledge of the intricacy of ASDs.288

It is not necessary for

biomarkers to be exclusive to one particular disease.291 Statistical analysis techniques
such as cluster analysis and principle component analysis can also be used to determine
biomarkers.290
There could be multiple profiles in ASDs. Certain markers may be able to be
used to identify subgroups which lead to different types of analyses. Schwarz and
colleagues presented a study which noted gender specific biomarkers in autism with both
high sensitivity and specificity.292

Decreased neural and synapse creation at the

molecular and cellular level, immune susceptibility, and digestive issues are some of the
areas where subgroups can be detected.290 Pierce and colleagues proposed a “1-Year
Well-Baby Check-Up Approach” to monitor biomarkers in children with ASDs.293
Walsh and colleagues urged caution in the search for biomarkers to maintain respect and
understanding for the patients with autism and their families.288
Many studies have been performed to investigate different areas of biomarkers in
autism. The areas covered by these studies include genetic, oxidative stress, methylation,
transsulfuration, immune dysregulation, digestive, toxicological, neurological, and
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mitochondrial dysfunction. The clinical recognized biomarkers which can be analyzed
for include genetics, oxidative stress, transsulfuration, porphyrins, neurologic, and
mitochondrial dysfunction.294 The immune dysregulation, digestive, and toxicological
biomarkers have been reviewed earlier in this chapter and these other possible biomarkers
of autism will be discussed now.
1.10.1 Genetic
Genetic biomarkers were the initial focus in autism. Over the past twenty years,
many different genetic loci have been demonstrated to lead to susceptibility for autism.
The extent of these genetic biomarkers has been great and all of the studies cannot be
covered here. Some of the important and frequently referenced studies are reviewed.
From the genetic ASD biomarker research, the most frequently noted position of
interest includes 15q pericentromeric 11-13 region, 17p11, 22q11, 22q13, 16p11.2, and
2q37.294

Schaefer and Mendelsohn noted studies of high genetic variability of the

16p11.2 in autism calling it a “hot spot of genetic instability.”295 They also referenced
two studies which noted the mutations of the Methyl-CPG-Binding Protein 2 (MECP2)
related to Fragile X.295 Genetic testing can account for some autism cases through array
comparative genomic hybridization (10%), high resolution chromosomes (5%), Fragile X
(5%), MECP2 (5% of female autism cases), phosphatase and tensin homolog (3% with
head circumferences greater than 2.5 SDs), and other (10%).295 Another study noted that
less than 10% of cases of autism result from genetic diseases.11
One type of study in the search for genetic biomarkers in autism is to focus on
specific chromosomes and locations on them.

In 2002, Badner and Gershon noted

predisposition at the 7q locus through meta-analysis.296
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Trikalinos and colleagues

supported the importance of the 7q locus in autism through additional meta-analysis.297
Benayed et al. investigated the ENGRAILED 2 (EN2) gene which plays a role in the
function of the cerebellum on chromosome 7.

They found nearly 40% of ASD

incidences could be related to EN2.298 In 2006, Campbell led a study investigating the
pleiotropic MET receptor in a promoter region on chromosome 7.

The study

demonstrated the presence of a frequent C allele in 204 families and in a larger cohort of
539 families.299 The autism diagnosis relative risk factor for the CC genotype was 2.27
and 1.67 for the CG genotype in relation to the GG genotype.299 In contrast to increased
expression, Morrow and colleagues observed deletions in protocadherin 10 and deleted
in autism1, or c3orf58, which were related to the activity of neurons and synapses
connected to learning.300 One important area in genetic exploration is related to the
methylenetetrahydrofolate reductase (MTHFR) gene.

In folate metabolism, a key

enzyme is metabolized by MTHFR.301 Two single nucleotide polymorphisms (677C>T
and 1298A>C) are common in autism resulting in a decrease in the activity of MTHFR.18,
301

In addition to finding specific genes, studies have taken a broader gene expression
approach to find genetic biomarkers. Hu led a microarray study in 2006 in twins noting
the important neurological genes including argininosuccinate synthetase and Nacetylglucosaminidase alpha.302

Baron and colleagues completed another gene

expression study and observed 48 genes which had statistically significant difference in
regulation.

These genes were seen in many different pathways including signal

transduction, metabolism, development and upkeep, and outside stimuli response.303 The
types of commercial genetic biomarker testing available include blood chromosome,
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chromosome microarray, DNA Rett syndrome, Angelman/Prader-Willi syndrome
methylation assay, Fragile X syndrome, and MTHFR testing.294
1.10.2 Oxidative Stress
The surplus creation of reactive oxygen species (ROS), free oxygen radicals,
results in oxidative stress.290 Normal oxygen metabolism produces ROS that are unstable
atoms which can result in the interruption of cell metabolism and cause harm to them.294
Increased amounts of oxidative stress could result from a higher reaction of cells in the
immune system such as neutrophils and monocytes which respond to infection.290
Biomarkers of oxidative stress have been seen in many different diseases including
schizophrenia, Alzheimer’s disease, and HIV, and are not able to be included as an
unique indicative marker in autism.291 Decreased methionine, folate, and vitamin B12 are
noted in times of oxidative stress.
The primary focus of oxidative stress biomarkers in ASDs has been on
glutathione.

Glutathione and cysteine protect the body against heavy metal and

xenobiotic exposures.291 Glutathione production is limited by the production of cysteine
from homocysteine.291 Glutathione is part of the transsulfuration pathway. In 2004,
James and colleagues observed significantly decreased levels of total glutathione and
increased levels of oxidized glutathione in plasma.11 The study also showed an increased
quantity of oxidized stress seen through significantly higher oxidized glutathione and a
decreased ratio of reduced to oxidized glutathione.11 These same results were reported in
another study from James et al.18 In 2009, Geier et al. supported these results by finding
lower concentrations of plasma reduced glutathione and higher amounts of oxidized
glutathione in children with ASDs relative to controls.304 Another study led by Geier also
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observed lower plasma reduced glutathione amounts and more oxidized glutathione in
children with autism.305 A meta-analysis by Frustaci et al. showed reduced plasma
glutathione (27%) and glutathione peroxidase (18%) and elevated oxidized glutathione
(45%) in patients with ASDs.306
The reduced to oxidized glutathione ratio is important for redox balance because
of the numerous roles it controls which include nitrogen and oxygen free radical
scavenging, protein status and enzyme activity, integrity of the cell membrane and signal
transduction, binding of transcription factor and gene expression, phase II detoxification,
and apoptosis.18 A high enough reduced to oxidized glutathione ratio is sustained under
typical glutathione reductase enzyme activity.18 Higher amounts of oxidized glutathione
in the plasma result when glutathione reductase is too overwhelmed to restore normal
cellular redox homeostasis.305

Higher oxidized glutathione levels are a marker for

oxidative stress and decreased quantities of glutathione in cells.18
In addition to glutathione, many different studies have explored additional
markers of oxidative stress in autism. Plasma and red blood cell glutathione peroxidase
and plasma superoxide dismutase, antioxidant enzymes, were all significantly decreased
in children with autism compared to controls.307 Zoroglu and colleagues noted elevated
levels of ROS and increased enzymatic activity for free radical scavenging in the red
blood cells of children with autism.308 Elevated amounts of thiobarbituric acid-reactive
substances are an indicator of higher lipid peroxidation.308 Chauhan led a study where
concentrations of antioxidant proteins, transferrin and ceruloplasmin, were lower in
children with autism versus siblings and where regression of language capabilities related
to lower concentrations of these proteins.309 Ming et al. noticed the elevation of the lipid
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peroxidation biomarker, 8-isoprostane-F2α, in the urine of children with autism versus
controls.310 Compared to controls, elevated homocysteine, an oxidant which produces
ROS, and decreased PON1 were observed to be lower in children with autism by Pasca
and colleagues.311

Yao et al. found three markers, isoprostane F2α-VI (lipid

peroxidation), 2,3-dinor-thromboxane (platelet activation), and 6-keto-prostaglandin F1α
(endothelium activation), which were elevated significantly in the urine of children with
autism.312 An oxidative stress panel and neopterin testing are commercially available.294
1.10.3 Methylation/Transsulfuration
One of the most important metabolic cycles which have been explored in autism
is the methionine cycle. The methionine cycle creates methionine by the movement of a
methyl group to homocysteine from 5-methyltetrahydrofolate in a B12 dependent
reaction.11

The principle donor of the methyl group for the intermediate S-

adenosylmethionine (SAM) is methionine, a key amino acid.291

SAM is the most

important methyl donor involved in the methylation of DNA, RNA, proteins,
phospholipids, and neurotransmitters.11 S-adenosylhomocysteine (SAH) is created from
the transfer of a methyl group from SAM.11 SAH hydrolase catalyzes the reversible
hydrolysis of SAH to homocysteine and adenosine.11

At this point in the cycle,

homocysteine is either converted to methionine by remethylation or permanently
removed from the cycle and begins cysteine and glutathione production as part of the
transsulfuration pathway.18

The methionine cycle is hindered by an oxidized

environment.291
Metabolic studies have investigated alterations in this cycle in children with
autism.

James and colleagues observed lower amounts of methionine, SAM,
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homocysteine, cystathionine, cysteine and larger amounts of SAH and adenosine in the
plasma of children with autism compared to controls.11 The significantly lower ratio of
SAM/SAH indicates a problem with methylation.11

A second study led by James

supported these results. Children with autism had decreased plasma concentrations of
cysteine, methionine, and SAM/SAH ratio compared to controls.18 Plasma cysteine,
taurine, sulfate, and free sulfate were found to be lower in children with autism than
controls by Geier et al.304

Geier and colleagues also showed significantly smaller

amounts of cysteine and sulfate in the plasma of children with autism.305 Frustaci et al.
completed a meta-analysis which demonstrated lower amounts of methionine (13%) and
cysteine (14%) in children with autism.306 Megaloblastic anemia profiling, glutathione,
and taurine testing are commercially available.294
1.10.4 Porphyrins
Porphyrins are intermediate products of the pathway for heme synthesis313 and
provide a way to independently measure exposure to xenobiotics.251 The liver, kidney,
and red blood cells are the location of most of the heme manufacturing.251 In urine,
surplus porphyrinogen metabolites are removed as oxidized porphyrins.251 Woods and
Miller showed that coproporphyrin and uroporphyrin are the most prominent porphyrins
in the kidney cortex of rats.313 The interest in porphyrins resulted from the blocking of
pathways due to heavy metal exposure. Uroporphyrin decarboxylase and CPOX are the
two most common enzymes which block the pathway causing coproporphyrin and
pentacarboxyporphyrin concentrations to rise in urine.251 Porphyrinuria results from
important steps in the pathway being blocked causing higher amounts of porphyrins
expelled from the body.251

Nataf and colleagues noted studies where exposure to
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mercury and lead correlated to porphyrinuria.251 Prior studies have noted the changes in
porphyrin concentrations after chelation treatment.251-253 These studies have combined to
provide a profile of porphyrins related to autism.252
Many studies have noted the differences in urinary concentrations in children with
autism.

In 2006, Nataf et al. published a study showing children with autism had

significantly higher concentrations of coproporphyrin compared to controls.251

In

Asperger’s Disorder, porphyrin amounts were not altered which created a different
profile compared to autism.251 After chelation, the levels of urinary porphyrins decreased
significantly.251 That same year Geier and Geier found that non-chelated children with
autism had a 2.25-fold increase versus controls and non-chelated children with ASDs had
a 2-fold increase for median coproporphyrin amounts.252 Children with PDD-NOS or
Asperger’s Disorder did not have statistically significant elevated median amounts of
coproporphyrin.252 Overall, the study seemed to determine a correlation between the
severity of an ASD and porphyrinuria.252 When comparing chelated versus non-chelated
patients with ASDs, the median coproporphyrin amounts were 1.7-fold higher in nonchelated patients with ASDs.252 The next year Geier and Geier observed significantly
higher amounts of coproporphyrin, pentacarboxyporphyrin, and precoproporphyrin in the
urine of children with autism compared to controls.253 The increased concentrations of
these three porphyrins has been linked to mercury toxicity.253

After chelation,

coproporphyrin and pentacarboxyporphyrin concentrations decreased significantly in
patients with ASDs.253

In 2009, Geier and colleagues noted an elevation of the

concentration of pentacarboxyporphyrin, precoproporphyrin, and coproporphyrin, the
mercury related porphyrins, in the urine of patients with severe ASDs versus patients
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with mild ASDs.305 The study also found an association between these three urinary
porphyrins and rising CARS scores.305 Another study by Geier, Kern, and Geier also
found a correlation between coproporphyrin concentrations and the CARS scores.314
This study saw increased concentrations of coproporphyrin I, coproporphyrin III, and
total coproporphyrin in patients with severe ASD versus those with mild ASDs.314 Kern
led a study in 2010 which showed a connection between urinary porphyrins and the
ATEC and the four ATEC subscales.315 Kern and colleagues found patients with ASDs
had significantly higher amounts of pentacarboxyporphyrin, precoproporphyrin, and
coproporphyrin versus controls.316 Two studies noted no statistical difference in nonmercury associated porphyrins.305,
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The testing of porphyrins is commercially

available in urine and red blood cells.294
1.10.5 Neurologic
Neurological biomarkers have been investigated due to the detrimental effects
seen in children with autism compared to typically developing children. One area of
interest is the neurotransmitters glutamate, serotonin, and gamma-amino butyric acid
(GABA). With neurological differences seen in children with autism, many studies have
explored the levels of these neurotransmitters.

In 1997, Cook Jr. and colleagues

demonstrated a potential connection between the serotonin transporter gene and
autism.317

Chugani led a study which showed significant differences between the

epileptic and autistic groups for serotonin.318 The children with autism demonstrated an
increase in serotonin from ages 2 to 15, reaching 1.5 times the average adult levels and
demonstrating a developmental disturbance.318 Burgess et al. noted that elevated blood
serotonin concentrations were commonly found in one third of children with autism.319
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Glutamate is the main stimulating neurotransmitter in the brain.320

Jamain et al.

demonstrated a connection between the glutamate receptor 6 gene and autism.320 Aldred
and colleagues observed significantly decreased concentrations of glutamine in children
with autism and their families compared to controls.321 However, Fatemi et al. noted that
decreases in glutamic acid decarboxylase 65 and 67 could be the cause of increased blood
glutamate levels.322 Irregular functionality of the GABA system in autism was first
connected by Blatt et al. in 2001.323 The many subunits of the GABA receptor are coded
for at 15q11-q13.324 The contributions of GABA inhibition to autism were noted by
Belmonte and colleagues.324 Proteins involved in the metabolism of GABA may be
connected to atypical amounts of GABA.322
Additional studies have explored proteins related to neurological functioning. In
2006, Sokol et al. found that secreted beta-amyloid precursor protein was at least two
times higher in children with severe autism and aggression compared to children with
autism and up to four times in children with mild autism.325 One study observed a trend
indicating greater amounts of two plasma neuronal proteins, secreted beta-amyloid
precursor protein and nonamyloidogenic secreted beta-amyloid precursor protein, in
children with autism.325

Bailey and colleagues noted significantly higher plasma

concentrations of secreted amyloid precursor protein alpha in 60% of children with
autism compared to age matched controls.326
Studies have also investigated the brain functioning of children with autism using
electroencephalography (EEG). Oberman led a study which used EEG signals to provide
additional evidence of children with high functioning autism possessing a dysfunctional
mirror neuron system.327 Murias and colleagues determined differences in the brains of
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children with autism by using different EEG frequencies.328 Bosl et al. proposed the use
of multiscale entropy to judge development through EEG signals which differed in
infants with significant probability of developing autism compared to controls.329
1.10.6 Mitochondrial Dysfunction
Mitochondrial dysfunction has been investigated because many of the symptoms
are similar to autism. Decreases in intellectual capability, communication shortcomings,
different energy metabolism, frequent GI issues, fatty acid oxidation irregularities, and
higher oxidative stress may be contributed by mitochondrial dysfunction in autism.330
Environmental exposure to toxins has been implicated as the source.330 The higher ratio
of males to females being diagnosed with autism has been proposed to be caused by
oxidative stress and mitochondrial dysfunction.330 Filipek led a study in 2004 which
evoked the presence of slight mitochondrial dysfunction as seen through lower
concentrations of carnitine, mild elevation of lactate, and significantly higher amounts of
alanine and ammonia.331 Carnitine plays an important role in the movement of fatty acids
to the mitochondria from accumulations in the body in times of stress and fasting.331
Pastural and colleagues observed significantly higher amounts of biomarkers of fatty acid
elongation and desaturation in patients with autism compared to controls.332 The authors
cited higher extracellular glutamate concentrations to neurons, astrocytes, and
hepatocytes in vitro as the cause of the elevated lipid biomarkers.332 The study also noted
lower plasma levels of reduced glutathione, methionine, and cysteine because of the
elevated glutamate.332 Included among the commercially available laboratory tests for
mitochondrial function evaluation are carnitine, pyruvic acid, lactic acid, and
ammonia.294
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1.11 Autism and Measurement
Now that all of the important and relevant components of ASDs have been
reviewed, attention shifts to measurement and its future application in this dissertation.
Important characteristics of measurement and the methods are discussed before the novel
application in the subsequent chapters.

1.12 The Importance of Measurement
One of the most important components of this dissertation is the application of
measurement. To be useful, a measurement must have both accuracy and precision.
Accuracy is defined as how near a measurement is to the true value, and precision means
how close they are to one another. When performing a measurement, many important
components are involved. A numerical measurement must have a unit attached to it. The
unit provides a standard understanding of relationship between things. The measurement
must also report a confidence interval. A confidence interval gives a defined range where
the measurement would fall and the reliability of this occurring as a percentage. Without
a confidence interval, the accuracy and precision of a measurement cannot be completely
determined. In order to produce a confidence interval, the measurement must be taken
more than one time. The repeated sampling allows for proper statistical analysis to be
performed. The greater number of times a measurement is taken, the better the precision
can be evaluated. This process requires proper sampling necessary to get a representative
sample. A measurement must also have the right number of significant figures to provide
the correct level of accuracy to the measurement.
One inherent part of every measurement is its error. In order to achieve the best
possible measurement, all potential sources of experimental error must be accounted for
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and either minimized or eliminated if possible. A systematic error is one which results
through the experimental design or problematic equipment. It can be eliminated by the
creation of a standard operating procedure which lists each of the optimal steps necessary
to achieve the best measurement. Random error is not able to be accounted for during the
measurement process. Systematic errors are likely to be biased in one direction while
random errors have an equal probability of making a positive or negative contribution to
the measurement. Quality control can be seen through the development of standard
operating procedures which maintain the accuracy and precision of measurements.
Quality assurance is the quantitative measurement of quality control and makes sure that
the standard operating protocol consistently produces accurate and precise measurements.
With recent technological advances, the capabilities are now available to produce
truly accurate and precise measurements and apply them clinically. These capabilities
are seen through the implementation of mass spectrometers. Mass spectrometers base
their analysis on the mass to charge ratio of an ion. Common types include inductively
coupled plasma, gas chromatography, liquid chromatography, quadrupole-time-of-flight,
and tandem mass spectrometers. In mass spectrometers, the types of mass analyzers used
include quadrupole, time-of-flight, quadrupole ion-trap, and magnetic sector.

The

analytical work described in this dissertation focuses on the inductively coupled plasmamass spectrometer (ICP-MS) which uses a quadrupole mass analyzer.
Over the past forty years, standard analysis methods have been developed through
the United States EPA. These standard methods have been created for both sample
preparation and analysis. In this dissertation, EPA Method 3052 is used for some of the
sample preparation.

The importance of sample preparation cannot be understated.
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Without the proper sample preparation, the correct analysis of the sample cannot be
achieved. The recent development of techniques such as microwave enhanced chemistry
and clean chemistry have made dramatic improvements in sample preparation. EPA
Methods 6020B and 6800 are employed to complete sample analysis described in
subsequent chapters. The measurements described in these methods are performed by
mass spectrometers. Each of these techniques and standard methods is reviewed.
1.12.1 Microwave Chemistry
Some of the sample preparation in this dissertation employs the microwave
digestion of samples. Microwave sample preparation relies on two major principles:
dipole rotation and ionic conductance. Dipole rotation allows molecules to arrange
themselves parallel to the applied electrical field.333 With the variation of the electrical
field, the molecules are forced to move and this movement results in the heating of the
solution as the dipoles are rearranged 5 billion times each second.333 The electromagnetic
field of the microwave forces ionic components to move based on polarity.333 These
principles create unique temperature and pressure relationships which are only seen in
microwaves. With these unique principles, both the speed and efficiencies of processes
can be increased by using a microwave as part of sample preparation.
The first application of microwave chemistry occurred in 1975.334 Since this
time, much advancement has been made in the field.

Current technological

advancements have made microwave enhanced chemistry quick, economical, and
repeatable.333 Microwave chemistry has been applied to the digestion of many different
types of biological and environmental samples and many types of chemical testing
including elemental analysis. Digestion, extraction, and organic synthesis are among the
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different applications of microwave chemistry. Some syntheses can only be completed
through the use of a microwave.
1.12.2 Ultra-trace Analysis and Clean Chemistry
The reproducibility of microwave chemistry has eliminated many sources of error
during sample preparation. Ultra-trace analysis is one area where this has occurred, and
is one of the major types of analyses performed in this dissertation.

Microwave

chemistry has been combined with clean chemistry to produce accurate and precise
results which have reduced sources of contamination. One major source of error in ultratrace analysis is the blank. Clean chemistry has reduced the level of contamination in the
blank during sample preparation by controlling the four major areas affect the amount of
contamination: the environment in which the sample was prepared, the reagent purity,
the materials which directly interact with the sample, and the level of skill possessed by
the analyst.335 For ultra-trace analysis, sample preparation occurs in cleanrooms which
limit the amount of particles and contamination. Cleanrooms are created by the use of
high efficiency particulate air (HEPA) filters. HEPA filters prevent particles of a certain
size from passing through them. The highest quality available reagents with the lowest
concentration of elements present are employed along with materials that are chemically
inert and do not contribute contamination to the sample such as Teflon, quartz, and
fluoropolymers. The analyst can be trained and taught techniques to minimize sample
contamination.
1.12.3 EPA Method 3052
EPA Method 3052 focuses on the acid based digestion of organic samples. The
types of samples which can be analyzed by EPA Method 3052 include soils, sediments,
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oils, ashes, and biological tissues.336 It is used for sample preparation for the total
elemental content of a sample and has been approved for use in the analysis of over 25
elements and can be applied to most others in the periodic table if reproducibility has
been achieved.336

High pressure microwave vessels must be used to withstand the

pressure generated by the microwave. The reagents which can be used as part of EPA
Method 3052 include nitric acid, hydrochloric acid, hydrofluoric acid, and hydrogen
peroxide. The reagents used can be adjusted to meet the needs for the digestion of the
sample and for the analytes of interest.

The method uses a ramp from ambient

temperature to 180 °C and a hold at 180 °C.336 This temperature allows for the complete
digestion of the organic matrix and the ramp and hold times are flexible to meet the
demands of each type of sample.

Current laboratory microwaves are capable of

monitoring the temperature to within ± 2 °C. Many different types of instruments can be
used to analyze samples prepared by EPA Method 3052 including flame atomic
absorption spectrometry, cold vapor atomic absorption spectrometry, graphite furnace
atomic absorption spectrometry, inductively coupled plasma atomic emission
spectrometry, and ICP-MS.336
1.12.4 EPA Method 6020B
One of the standard methods for the analysis of total elements is EPA Method
6020B.337

Analysis of Method 6020B is performed on an ICP-MS at trace

concentrations. A wide range of elements have been approved for analysis by it, and it
has been applied to over 60 elements with accuracy and precision established. A wide
range of samples can be analyzed including aqueous samples, which do not require
digestion, or digested samples from soils, sludges, and other industrial, environmental, or
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biological matrices. Before analysis is undertaken, the proper sample preparation must
have occurred.
For EPA Method 6020B, quantitation is obtained through the use of external
calibration curves for the analytes of interest. A calibration curve consists of solutions of
known concentrations to determine the relationship between the response of an
instrument and the concentration of each analyte. The method recommends a minimum
correlation coefficient of equal to or greater than 0.998.337

EPA Method 6020B

recommends the use of 6Li, 45Sc, 74Ge, 89Y, 103Rh, 115In, 159Tb, 165Ho, and 209Bi as internal
standards.337 An internal standard is an element or compound of known concentration
added to a sample and is used to monitor consistent response of the instrument detector.
There are many ways quality control is maintained as a part of EPA Method
6020B. The internal standard is used as quality control to provide consistent instrument
response to each analyte during sample analysis. In addition, calibration standards and
the calibration blank are repeated at regular intervals throughout the analysis.

The

calibration standards are rerun at the end of the analysis sequence to compare instrument
response during the period of analysis. Despite quality control being addressed in EPA
Method 6020B, there are still many sources of error which are inherent as part of mass
spectrometric analyses. These sources of error are addressed in the next section, EPA
Method 6800.
1.12.5 EPA Method 6800
There are two components of EPA Method 6800:

Isotope Dilution Mass

Spectrometry (IDMS) and Speciated Isotope Dilution Mass Spectrometry (SIDMS).338
This method can be applied to the quantification of total elements, elemental species, or
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molecular species.

The measurement of total elements is completed by IDMS and

SIDMS is used for the quantification of species. Both IDMS and SIDMS use isotopically
enriched spikes to provide an additional mathematical degree of freedom for
quantification. In order to apply EPA Method 6800, an element must have two or more
stable isotopes. The work described in this dissertation only relates to total elemental
IDMS quantification.
The IDMS quantification as a part of EPA Method 6800 varies significantly from
EPA Method 6020B. The most dramatic difference is that EPA Method 6800 does not
use calibration curves. The quantification by IDMS is based on the ratio of isotopes in
the natural sample and isotopically enriched spike seen in Equation 1. The isotopically
enriched spike has unique isotope abundances which do not exist in nature. The addition

(

(
(

)

)
)

Where:

Cs = concentration of sample
Wsp = weight of spike solution
Csp = concentration of spike
Asp = atomic fraction of isotope A in spike
Bsp = atomic fraction of isotope B in spike
As = atomic fraction of isotope A in sample
Bs = atomic fraction of isotope B in sample
R = experimentally measured isotope ratio, A/B
Ws = weight of sample
Equation 1: IDMS equation for calculating the concentration of the analyte from an isotope pair
ratio measurement.

of the isotopically enriched spike must be performed properly and its amount is
determined by the error propagation factor (EPF), with the calculation shown in Equation
2. The ratio of two isotopes used in IDMS must fall within the proper dynamic range.
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The highest level of accuracy is achieved at the optimal EPF and the amount of errors
inherently increases the farther away from the ideal EPF ratio.

√
Equation 2: The equation for the error propagation factor used in IDMS.

Compared to other quantification methods such as standard addition and internal
and external calibration, IDMS demonstrates better measurement quality.339

This

superiority is seen through the mass spectrometric sources of error which are eliminated
in EPA Method 6800, as seen in Figure 1. This method is able to account for all but three
sources of error: mass bias, deadtime, and isobaric and polyatomic interferences. For
elemental analysis, mass bias can be corrected for by running natural elemental standards
and comparing the ratio of the isotopes used in quantification. Deadtime corrections can
also be computed by using the ICP-MS. Isobaric interferences are known and can be
avoided or calculations can be used to determine the contribution of multiple elements at
a single mass to charge ratio. Modern technology, such as the Agilent 7700 ICP-MS, has
collision/reaction cells which can eliminate the polyatomic interferences. Therefore, the
combination of EPA Method 6800 and modern instrumentation can eliminate or account
for all sources of error in mass spectrometric analysis.
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Figure 1: The sources of error inherent to mass spectrometric analysis. The errors found in EPA
Method 6020B are shown at the top and the three errors found in EPA Method 6800 are at the
bottom.

1.13 Conclusions
Autism spectrum disorders play a large role in our society. Their importance has
risen over the past 50 years as the current diagnosis rate is 1 in 88, and if the recent trends
continue, it will only increase in the future. The modern history of autism has played a
role in how it is viewed by today’s society. Initial thoughts hindered progress in truly
understanding the disorder. Once initial theories were overcome, true progress in the
knowledge of autism increased and worked to develop some of the tools currently used in
diagnosis.
Autism is truly a spectrum disease which results in the presentation of many
unique profiles in children. The complexity of the disease requires the integration of
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many areas for both diagnosis and treatment. The factors seen in its diagnosis affect
many different areas of the body including the immune, digestive, neurological, and
detoxification systems and how they relate to each other. There are many different
treatments used to minimize the effects autism has on the body, and specifically, the
dietary supplements commonly applied must be made of the highest quality for these
children.

The standards of diagnosis require high levels of both sensitivity and

specificity, and in the future, there is hope that diagnosis will rely more on biomarkers in
conjunction with the current rating scales.
This dissertation demonstrates the application of advanced measurement
techniques which improve both the diagnosis and treatment of autism. Currently, the
tools are available where this technology, instrumentation, and methodology can be
employed in the clinical setting.

The findings described in the remainder of this

dissertation demonstrate that these measurement techniques can have a significant impact
on the future of autism.
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Chapter 2
Evaluation of Dietary Supplement Contamination by
Xenobiotic and Essential Elements Using MicrowaveEnhanced Sample Digestion and Inductively Coupled PlasmaMass Spectrometry

Dietary supplements were analyzed by evaluating the elemental content in six widely
consumed products manufactured by four well-known companies.

The elements

included the neurotoxic and carcinogenic elements cadmium, mercury, aluminum, lead,
arsenic, and antimony, as well as the essential elements zinc, selenium, chromium, iron,
and copper, which were often not listed as ingredients on the product labels.
Contamination from either xenobiotic or essential elements was found in all samples
analyzed. The samples were prepared using United States Environmental Protection
Agency (EPA) Method 3052, microwave-enhanced digestion. The resulting digests were
analyzed by Inductively Coupled Plasma-Mass Spectrometry based on EPA Method
6020B. The analytical protocols were validated by analyzing a multivitamin standard
reference material, National Institute of Standards and Technology Standard Reference
Material 3280. The application of EPA standard methods demonstrated their utility in
making accurate and precise measurements in complex matrices with multiple ingredients
and excipients.

2.1 Introduction
Dietary supplements are products containing vitamins, minerals, amino acids,
plant materials, and/or other nutritional additives consumed to complement the human
diet.1 They are purchased by the public to resolve nutrient deficiencies, prevent birth
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defects, treat diseases and symptoms, and improve athletic performance.2-4 Supplements
are widely available in retail stores, shopping malls, gyms, gas stations, convenience
stores, and on the internet.5 They continue to garner attention from media exposure from
studies, articles, and advertisements.6 The reasons for the increased popularity of dietary
supplements include hope for the conservation of intellectual capacity, increased energy,
stress relief, mitigation of high healthcare costs, and a perception they contribute to a
healthier lifestyle.4 Physicians routinely incorporate dietary supplements as part of their
patient advice and clinical treatment. It was estimated that globally consumers would
spend at least US$ 60 billion on dietary supplements in 2006,7-8 with a more recent
estimate suggesting that between 21 and 25 billion dollars were spent annually in the
United States (US) alone.9 Based on a National Health Interview Survey, over half the
US adult population includes supplements in their daily diets.10 The wide and growing
consumption of dietary supplements makes it imperative for public health that existing
quality control and assurance methods, some of which are decades old, are updated and
streamlined utilizing advanced measurement tools that will produce consistent, reliable,
and quality data. Minimizing and avoiding unsafe levels of toxins and labeling errors
require the quality control process to include the entire supply chain.
The expectations of the general public for dietary supplements are the same as
they are for food: contribute nutrients and avoid any constituent that will have a negative
health impact. Many reported instances of tainted products suggest that the public’s
expectations are not being met. It has been estimated that 50,000 unreported
contamination incidences occur annually in dietary supplements.10 These contaminants
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included heavy metals, bacteria, toxic plant matter, prescription medications, controlled
substances, rejected drugs, and other compounds.10
The toxic effects of xenobiotic metals on human health have been well
documented in the literature.

These elements, including lead (Pb), mercury (Hg),

cadmium (Cd), and arsenic (As), cause a wide variety of toxicological effects and
symptoms affecting all organ systems, including the central nervous system.11 Lead has
irreversible, detrimental effects that interfere with neuronal signaling in the central
nervous system, heme synthesis, and calcium (Ca) metabolism and function.12-13
Mercury exposure can cause kidney damage and neurological disorders.14 Cadmium
results in reproductive disruption, kidney failure, and weakening of the bones.1 Arsenic
has been connected to hypertension, hypotension, cardiomyopathy, cardiac disease, and
peripheral neuropathy.15 Aluminum (Al) has also been associated with Alzheimer’s
disease.16
In parallel with the negative effects of toxic heavy metals, there is concern about
improper labeling of dietary supplements that omits the presence of essential elements,
such as zinc (Zn), selenium (Se), chromium (Cr), iron (Fe), and copper (Cu). Although
they may not be listed as supplement ingredients, their presence can cause adverse health
consequences, including the disruption of nutritional regimens. Adulteration related to
these essential elements must be considered when evaluating dietary supplements for
elemental contamination, in addition to xenobiotic elements. Essential elements are
common ingredients of dietary supplements because they are needed to maintain crucial
metabolism in the body.17 Human metabolism requires many different metal coenzymes
for the optimal functionality of numerous proteins. Although they are necessary, these
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elements can have negative consequences if present in excess. Zinc is required for the
normal maturation and optimal performance of the immune system;18 however, patients
that exceed the daily recommended allowance for Zn could experience leukopenia,
neutropenia, anemia, sideroblastic anemia, and hypocupremia.2,

19-21

While Se exists

naturally and is needed for proper cellular functioning,22 it is toxic at high levels resulting
in vomiting, nausea, pulmonary edema, renal and liver damage, and death. 23-24
Chromium performs a key function in the metabolism of carbohydrates and fats, and
increases cellular response to insulin;25 however, an overabundance can cause kidney
failure, improper liver functioning, and gastrointestinal bleeding.22 Iron is well known
for promoting oxygen transport and reducing oxygen shortages in cells, thereby
preventing exhaustion and a compromised immune system.25 Excess Fe can negatively
affect the metabolism of other closely related elements such as Zn, Cu, and Ca, and may
result in oxidative stress, digestive disturbances and vomiting.26 Copper plays a role in
many essential reactions needed for the survival of mammals,27 but Cu surplus can cause
liver damage.28 It has been hypothesized that the consumption of inorganic Cu in dietary
supplements might contribute to the development of Alzheimer’s disease.29-30
Despite the known effects of xenobiotics, the regulation of dietary supplements
has become less stringent in the US after the passing of the Dietary Supplement Health
and Education Act (DSHEA) in 199410 as a revision to the Federal Food, Drug, and
Cosmetic Act.31

The testing requirements for the production and sale of dietary

supplements were significantly relaxed in the DSHEA.3

Dietary supplements were

previously classified as being “food additives,” which had mandated evidence of their
safety before being released to consumers.10 The DSHEA created a special category of
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food called “dietary supplements,”31 with provisions that were not applicable to
conventional and functional foods.5 Since dietary supplements do not diagnose, prevent,
or cure disease according to the US Congress, they are not required to have the same
regulatory standards as pharmaceutical drugs.32 Subsequently, there is no US Food and
Drug Administration (FDA) required testing of dietary supplements for safety and
efficacy prior to market release, and approval is not needed before the manufacture and
distribution of these products.33

Under the current guidelines, the FDA will only

recommend testing after a dietary supplement has been determined to be unsafe.34 This
relaxed regulatory requirement is very different from the treatment of prescription drugs,
which require FDA review of safety and effectiveness before reaching the market. 33
Without providing specific guidelines of dietary supplement production, the DSHEA
established Good Manufacturing Practices (GMPs) to maintain the quality of dietary
supplements available to the general public.33

Extensive control over the entire

manufacturing process is required for GMP compliance, including starting ingredients,
finished goods, and quality control.35 The DSHEA does not specify standard analytical
methods, such as those from the US Environmental Protection Agency (EPA), which can
be adopted and implemented for quality assurance as a way to improve public safety and
attain GMP compliance. The US EPA is a globally recognized and respected repository
of workgroup-tested and optimized methods which may be adopted as templates and
optimized as standard quality assurance and testing protocols.
Different government agencies have limits for exposure to certain elements
referred to as maximum contaminant levels (MCLs), which are shown for each agency in
Table 1. The United States Pharmacopeia (USP) has set elemental maximum values in
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dietary supplements for only inorganic As, Cd, Pb, total Hg, and methylmercury.36 This
amount of regulation is much less stringent than what the USP requires for prescription
drugs, where 15 elements are listed with concentration thresholds.37 The FDA does not
have specific elemental limits for dietary supplements, but rather focuses on GMPs to
prevent the adulteration of dietary supplements from heavy metals, pesticides, and other
harmful contaminants, and to ensure the presence of only the listed ingredients.38
California Proposition 65 regulations provide a list of chemicals and compounds which
are known to cause cancer or reproductive toxicity. Daily limits39 and MCLs39 are
provided for some elements, but there is no specific information for dietary supplements.
The EPA provides MCLs in drinking water, but the amount of drinking water consumed
per day is typically much greater than the amount of dietary supplements ingested.40
Recent papers investigating elemental contamination in dietary supplements have
compiled tables with the advocated amounts of selected elements to be consumed each
day.41-42 Commonly, these limits are calculated based on the average adult male; often
they do not take into account women, children and developing fetuses who can be more
susceptible to the effects of these potentially harmful elements and chemicals. It is hard
to assess the quality of dietary supplements based on the current guidelines provided by
these regulatory agencies. However, the USP-published methods do not match the level
of completeness and utility of the EPA methods as many USP methods are either too
brief, inconsistent or too old to be practical or useful today to achieve GMP compliance.
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Table 1: List of inorganic contaminants and their MCLs by regulatory agency.

Aluminum
Antimony

USP Dietary
Supplement
Limit (µg g-1)36
No Limit
No Limit

USP Drug
Product Limit
(µg g-1) 37
No Limit
No Limit

Arsenic

1.5

0.15

Barium
Beryllium

No Limit
No Limit

No Limit
No Limit

Cadmium

0.5

2.5

No Limit

No Limit

No Limit

No Limit
No Limit
No Limit

100
10
No Limit

Lead

1.0

0.5

Manganese
Mercury
(inorganic)
Molybdenum
Nickel
Osmium
Palladium
Platinum
Rhodium
Ruthenium
Selenium
Silver
Thallium
Uranium
Vanadium
Zinc

No Limit

No Limit

No Limit
No Limit
No Limit
15 (Oral)
0.5
No Limit

1.5

1.5

No Limit

No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit

10
50
10
10
10
10
10
No Limit
No Limit
No Limit
No Limit
10
No Limit

No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit

Element

Chromium
(Total)
Copper
Iridium
Iron

Prop 65 NSRL
or MADL
(µg day-1) 39
No Limit
No Limit
0.06 (Inhalation)
10 (Except
inhalation)
No Limit
0.1
0.05 (Inhalation)
4.1 (Oral)

Prop 65
MCL
(mg L-1) 39
1
0.006
0.01

EPA Drinking
Water MCL
(mg L-1) 40
0.05 to 0.2
0.006
0.010

1
0.004
0.005
No Limit

2
0.004
0.005
0.100

1.3
No Limit
No Limit
0.015

1.3
No Limit
0.3

No Limit
0.002

0.05

No Limit
0.1
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
0.002
25
No Limit
No Limit

0.015

0.002
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
No Limit
0.05
0.10
0.002
0.030
No Limit
5

NSRL: No significant risk level; MADL: Maximum allowable dose level
Numerous studies have demonstrated the problem of harmful elemental
contamination in dietary supplements.

Nearly 20 years ago, Pb was discovered in

calcium supplements,12 while a more recent study determined that two-thirds of calcium
supplements contained Pb concentrations that exceeded the 1999 California limits.43
Another study found wide concentration ranges for As, Cd, Hg, and Pb in dietary
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supplements.44 Studies from multiple countries noted xenobiotic and essential elemental
contamination in natural drugs in China,45 herbal remedies in Nigeria,46 and dietary
supplements in Mexico1 and the US.41-42
Other researchers have investigated contamination from essential elements in
dietary supplements. A recent study discussed widespread Se toxicity resulting from
elevated Se quantities in a liquid dietary supplement that also contained a high
concentration of Cr.22 Additional case studies have documented the toxicity caused by Se
in dietary supplements.47-48
The project described in this paper started with an announcement from a US
dietary supplement supplier that one of their supplements had been contaminated. This
study expanded on the original discovery by evaluating elemental content in six common
types of dietary supplements (zinc, essential fatty acids, calcium, magnesium,
multivitamins, and probiotics) from four different manufacturers. The present study
applied additional quality control parameters to the elemental analysis of dietary
supplements through the use of EPA Method 3052 for sample preparation and EPA
Method 6020B for analysis, with National Institute of Standards and Technology (NIST)
Multivitamin/Multielement Tablets, Standard Reference Material (SRM) 3280 used for
validation.

2.2 Materials and Methods
2.2.1

Materials

2.2.1.1 Chemicals and Standards
All reagents were of analytical grade. ARISTAR ULTRA nitric acid (HNO3),
ARISTAR ULTRA hydrochloric acid (HCl), ARISTAR ULTRA water, borosilicate glass
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vessels, and 50 mL polypropylene centrifuge tubes were procured from VWR (Radnor,
PA, USA). Multi-element and single element standards of mercury, iodine, lithium, and
yttrium were bought from Inorganic Ventures (Christiansburg, VA, USA). The tuning
mix for the ICP-MS consisting of 1 ng g-1 lithium, cobalt, yttrium, cerium, and tellurium
in 2% (v:v) HNO3 was purchased from Agilent Technologies (Santa Clara, CA, USA).
The internal standard solution containing 100 µg g-1 of 6lithium, scandium, germanium,
rhodium, indium, terbium, lutetium, and bismuth was also obtained from Agilent
Technologies. Instrument grade liquid argon along with hydrogen and helium gases was
procured from Airgas (Pittsburgh, PA, USA).

SRM 3280 was bought from NIST

(Gaithersburg, MD, USA).
2.2.1.2 Dietary Supplement Samples
Six types of dietary supplements were purchased from four manufacturers in
commercially available form (Table 2). From Company 1, zinc, calcium, and magnesium
supplements were obtained.

Zinc, essential fatty acids, calcium, magnesium, and

multivitamin supplements were tested from Company 2. All six supplement types were
analyzed from Company 3 and Company 4.
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Table 2: The dietary supplements analyzed in the study.
Manufacturer
Supplement
Nutritional Ingredient Type
Zinc
Mineral
Company 1
Calcium
Mineral
Magnesium Mineral
Zinc
Mineral
Essential
Omega-3 fatty acids (Docosahexaenoic acid,
Fatty Acid
eicosapentaenoic acid)
Mineral
Calcium
Company 2
Magnesium Mineral
Vitamins and Minerals (Vitamin A, vitamin C, vitamin D3,
vitamin E, thiamin, riboflavin, niacin, vitamin B-6, folate,
Multivitamin
vitamin B-12, biotin, pantothenic acid, calcium, iodine,
magnesium, zinc, selenium, copper, manganese, chromium)
Mineral
Zinc
Essential
Fatty Acid
Calcium
Company 3

Magnesium

Multivitamin

Probiotic

Fatty acid
(Marine oil concentrate, docosahexaenoic acid,
eicosapentaenoic acid)
Mineral
Mineral
Vitamins and minerals (Vitamin A, vitamin C, vitamin D3,
vitamin E, vitamin K1, thiamine, riboflavin, niacin, vitamin
B6, folate, vitamin B12, biotin, pantothenic acid, calcium,
iodine, magnesium, zinc, selenium, manganese, chromium,
molybdenum, potassium, boron, vanadium, choline, inositol,
citrus bioflavonoids)
Probiotic (Probiotic blend, Lactobacillus acidophilus,
bifidobacterium bifidum)

Other Ingredients
Cellulose, water
Ascorbyl palmitate, cellulose, water
Ascorbyl palmitate, cellulose, water
Plant cellulose, stearic acid, rice flour, carob
Cholesterol, vitamin A, vitamin D3, vitamin
E, natural lemon flavor
Fructose, sorbitol, stearic acid, magnesium
stearate, vanilla, silicon dioxide
Gelatin capsule
Microcrystalline cellulose, dicalcium
phosphate, croscarmellose sodium, stearic
acid, magnesium stearate, ethylcellulose,
hydroxypropyl cellulose
Vitamin C, vitamin B6,
cellulose, vegetarian capsule, L-leucine
Natural mixed tocopherol vitamin E from
soy, natural lemon oil, rosemary extract
Phosphorus, hydroxypropyl methylcellulose,
water, L-leucine, cellulose
Hydroxypropyl methylcellulose, water, Lleucine
Natural citrus flavor

Hydroxypropyl methylcellulose, water, Lleucine

Zinc
Essential
Fatty Acid

Mineral
Omega-3 fatty acid and vitamins
(Docosahexaenoic acid, eicosapentaenoic acid vitamin A,
vitamin D)
Mineral

Calcium
Magnesium

Mineral
Vitamins and minerals (Vitamin A, vitamin C, vitamin D,
vitamin E, vitamin B-1, vitamin B-2, niacinamide, vitamin
B-6, folic acid, vitamin B-12, biotin, pantothenic acid,
calcium, iodine, magnesium, zinc, selenium, manganese,
chromium, molybdenum, coenzyme Q10)

Company 4
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Multivitamin

Probiotic

Probiotic
(Lactobacillus rhamnosus, lactobacillus acidophilus,
bifidobacterium bifidum/lactis, lactobacillus casei,
lactobacillus plantarum, streptococcus therophilus)

Purified water, sorbitol, glycerine, citric acid,
natural raspberry flavor, potassium sorbate
Cod liver oil, purified water, gelatin,
glycerine
Calcium chelate, sodium starch, glycolate,
magnesium stearate, vitamin D-3, plant
cellulose capsule
Magnesium glycinate, L-leucine, plant
cellulose capsule
Dextrose, calcium carbonate, ascorbic acid,
vitamin E acetate, magnesium oxide, zinc
citrate, magnesium glycinate, calcium citrate,
niacinamide, d-calcium pantothenate,
manganese citrate, CoQ10, citric acid, natural
peach mango flavor, starch, stearic acid,
silicon dioxide, magnesium stearate, biotin,
vitamin A acetate, pyridoxine, hydrochloride,
riboflavin, thiamine mononitrate, glycerides
of stearic and palmitic acids, mannitol,
vitamin D-3, selenium chelate, di-calcium
phosphate, beta carotene, cyanocobalamin,
chromium chelate, molybdenum chelate,
sucralose, folic acid, potassium iodide
Stabilized probiotic strains, microcrystalline
cellulose, silicon dioxide, magnesium
stearate, plant cellulose capsule

2.2.1.3 Instrumentation
Sample preparation was accomplished by applying microwave-enhanced
chemistry using a Milestone (Shelton, CT, USA) UltraWAVE laboratory microwave
system equipped with temperature and pressure feedback control. This device accurately
monitored and controlled temperature to within ± 2 °C of the specified values,
automatically adjusting the microwave field output power to achieve the preset
temperatures. The UltraWAVE allowed for extremely high temperature and pressure
conditions of up to 300 °C and 199 bar to be maintained for extended periods during the
digestion of the samples. This capability allowed for different types of samples to be
digested simultaneously since all samples were held under the same conditions. In this
study, borosilicate glass vessels were used for the digestion of 15 samples per batch.
Mass spectrometric analysis was performed using an Agilent 7700 ICP-MS with a
micromist nebulizer, quartz spray chamber, an octopole reaction system, and a
quadrupole mass analyzer.

This instrument has a collision/reaction cell that uses

hydrogen or helium gas for the elimination of polyatomic interferences. All samples and
the internal standard were introduced into the ICP-MS using the peristaltic pump at a
speed of 0.1 revolutions per second (rps) via the micromist nebulizer of the spray
chamber. Before analysis, the samples were placed in a CETAC (Omaha, NE, USA)
ASX-520 autosampler housed inside of an ENC-500 anti-contamination enclosure. The
ICP-MS and autosampler were located in an International Organization for
Standardization Class 6 cleanroom laboratory. The optimized parameters of the ICP-MS
and autosampler are shown in Table 3.
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Table 3: Optimized operating conditions for the Agilent 7700 ICP-MS for the analysis of dietary
supplement samples according to EPA Method 6020B.

Agilent 7700 ICP-MS Parameter
Rf Power
Spray Chamber Temperature
Acquisition Mode
Peak Pattern
Sample Depth
Plasma Gas
Carrier Gas
Makeup Gas
H2 Cell Gas Flow
He Cell Gas Flow
Gas Stabilization Time
Integration Time
Replicates
Nebulizer Pump Speed
Uptake Time
Stabilization Time

2.2.2

Method 6020B Analysis Setting
1550 W
2 °C
Spectrum
3 points mass-1
8 mm
15 L min-1
0.9 L min-1
0.15 L min-1
4.5 mL min-1
5.5 mL min-1
30 sec
0.1-1.0 sec mass-1
4
0.10 rps
30 sec
30 sec

Methods

2.2.2.1 Homogenization of the Dietary Supplements
Four different forms of dietary supplements were analyzed during this study:
tablets, capsules, powders, and liquids.

The procedure given in the Certificate of

Analysis for NIST SRM 3280 was followed for sample homogenization. Fifteen SRM
3280 tablets were homogenized with a clean mortar and pestle and stored in a 50 mL
polypropylene centrifuge tube.

All of the tablet dietary supplement samples were

prepared and stored in the same manner as SRM 3280. For each capsule sample, the
outer casing was removed for 15 capsules and the inside contents were emptied into a 50
mL polypropylene centrifuge tube. For the powder samples, a quantity similar to 15
SRM 3280 tablets was poured into a 50 mL polypropylene centrifuge tube. The liquid
samples were shaken immediately before being added to the microwave digestion
vessels.
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2.2.2.2 Microwave-enhanced Digestion of the Dietary Supplements by EPA
Method 3052
The homogenized samples were digested according to EPA Method 305249-50 to
determine their total elemental content. In each glass vessel, 0.25 grams of sample was
combined with 8 mL HNO3 and 2 mL HCl. Three subsamples were prepared for each
dietary supplement. The samples were digested in the microwave following a program
that implemented a 10 minute ramp to 180 °C with a 10 minute hold at 180 °C.
Complete digestion for all of the types of dietary supplements (tablets, capsules, powders,
and liquids) was achieved resulting in the production of homogeneous, transparent, light
yellow solutions that did not contain any solids. After digestion, each sample was poured
into a 50 mL polypropylene centrifuge tube and diluted with water to approximately 20
mL. The polypropylene centrifuge tubes were weighed before and after the addition of
the sample digests. Six analytical blanks consisting of HNO3 and HCl were digested with
the samples. The samples were stored in a cold room at 4 °C and usually analyzed within
three days of digestion. The microwave vessel caps were cleaned after digestion by
soaking them in 1% HNO3 overnight to prevent cross contamination.
2.2.2.3 Elemental Concentration Determination by ICP-MS Using EPA Method
6020B
The total concentrations of elements in the sample digests were determined
according to EPA Method 6020B.51 On each day of analysis, the system was aspirated
with 2% HNO3 for 30 minutes before tuning the instrument using the Agilent tuning
solution at a concentration of 1 ng g-1 and determining the pulse/analog factor. Analysis
on the Agilent 7700 ICP-MS was performed in three modes: hydrogen, helium, and no
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gas. The amount of hydrogen and helium gas was optimized to eliminate polyatomic
interferences. Table 4 lists the analysis mode for each element. Between analysis modes,
a 30 second delay was employed to equilibrate the presence or absence of collision gas
and/or reaction gas.
Table 4: The analysis information, correlation coefficient, DLs, and BECs for the xenobiotic and
essential elements of interest determined by the Agilent 7700 ICP-MS.

Element
Mg
Al
Ca
V
Cr
Mn
Fe
Co
Ni
Cu
Zn
As
Se
Mo
Cd
Sn
Sb
Hg
Pb
U

m/z
24
27
40
51
52
55
56
59
60
63
66
75
78
95
111
118
121
201
208
238

Mode
He
H2
H2
He
He
He
He
He
He
He
He
He
H2
He
He
He
No gas
No gas
No gas
No gas

r2
0.9976
0.9995
0.9983
0.9999
0.9999
1.0000
0.9985
1.0000
0.9994
0.9999
0.9979
0.9999
1.0000
1.0000
1.0000
0.9999
0.9998
1.0000
0.9999
1.0000

DL (ng g-1)
25.7
3.44
110
0.0537
0.961
0.346
18.8
0.0197
0.411
0.309
9.35
0.0187
0.0178
0.102
0.0477
0.105
0.0866
0.0658
0.00721
0.000834

BEC (ng g-1)
13.15
0.6232
93.86
0.03871
3.761
0.2842
15.4
0.04378
1.784
0.6835
6.387
0.3339
0.02316
0.334
0.05985
0.2946
0.1299
0.02458
0.07522
0.001746

Due to the wide concentration range of the analytes of interest in SRM 3280 and
the dietary supplement samples, calibration standards were prepared for 60 elements at
three different concentration ranges (low, medium, and high) of 0-25, 0-50, and 0-150
ng g-1, respectively. The calibration standards were prepared by acid matching, which
consisted of adding the appropriate percentage of microwave-digested reagent blank to
each calibration standard.
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The sample digests were diluted with water to total factors of 320, 8,000 and
800,000 for the low, medium, and high calibration ranges, respectively. They were
analyzed in three separate sequences with four replicates taken from each subsample.
Analyses were performed in spectrum mode using three points per mass. The integration
times for each element ranged from 0.1-1.0 seconds per point depending on the element’s
ionization energy. The measured concentration value for each element in SRM 3280 and
each dietary supplement sample was determined based on the value that fell within the
range of one of the three calibration curves. After analysis was completed, the data was
exported from the Agilent MassHunter software (version G7201A A.01.01) into
Microsoft Excel for further data analysis.
2.2.2.1 Quality Control
The current study implemented numerous quality control measures previous
mentioned that included the preparation of multiple subsamples, replicate analysis,
preparation of analytical blanks, acid matched calibration standards, and SRM 3280. It
also utilized many of the measures described in EPA Method 6020B. An Agilent internal
standard solution was used at a concentration of 1 µg g-1 in 1% HNO3 and 0.5% HCl, and
its acceptable recovery was maintained between 80 and 120% of the calibration blank.
Between each sample, the autosampler probe was washed in three solutions of 1% HNO3
and 0.5% HCl for 30 seconds each with a nebulizer pump speed of 0.5 rps. After every
nine samples, low- and midpoint calibration checks along with an SRM 3280 assessment
were performed for additional calibration verification to ensure the consistency of the
results during the complete duration of the sample run.

141

2.3 Results
2.3.1

Analytical Figures of Merit and Validation of EPA Methods

All elements displayed linearity on the six or seven point external calibration
curves for each of the three calibration ranges (Table 4). They had correlation coefficient
(r2) values greater than the 0.998 specified in EPA Method 6020B except for magnesium
(Mg, 0.9976) and Zn (0.9979) being just below the cutoff value only for the low
calibration range. When rounded to three significant figures, they meet the specified
requirements of EPA Method 6020B. The four replicates for each calibration point
displayed a variation of less than 5% indicating that the obtained measurements were
highly reproducible.
The elemental detection limits (DL) were defined as the average of the blank
concentration for each element plus three times the standard deviation of the blank
measurements for that element.52 The DLs for all of the elements in Table 4 were below
1 ng g-1 except for Al, Ca, Fe, Mg, and Zn. The background equivalent concentrations
(BECs) were calculated by multiplying the background intensity signal and the
concentration of the analyte and dividing by the difference of the analyte intensity minus
the intensity of the background.53 The BECs were under 1 ng g-1 for all elements other
than Ca, Cr, Fe, Mg, Ni, and Zn (Table 4).
Additional confidence in the accuracy and precision of the results of the present
study was achieved by using SRM 3280 to validate the sample preparation and analysis
protocols. This SRM is certified for both xenobiotic and essential elements with their
concentrations representing the wide range of values seen in commercially available
products. Results obtained for SRM 3280 during this study are shown in Table 5 and
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Figure 2 with the mean (n = 12) and 95% confidence intervals (CIs). The measured
values are in strong agreement with the certified and reference values, within 10% for
nearly every element. The measured values overlapped the certified or reference CIs for
14 elements with the intervals for 2 other elements nearly intersecting, which is the same
number of elements provided in two other studies.41-42 The recovery efficiencies ranged
from 68.2 to 124% based on a comparison of the mean listed values to the average
measured quantities.

Only 3 of the 23 certified or reference elements had either

recoveries that differed by more than 20% from the mean value or that did not overlap
CIs. This study provided measured values for the certified elements As, Cd, and Pb in
SRM 3280 that were not included in two other studies.41-42 The value for As fell within
the CI provided, while Cd had a 118% recovery and Pb had a 70.7% recovery. The
accuracy of all measurements in this study improves with the inclusion of the provided
confidence intervals.
The precision determined by the 95% CIs was within 10% of the measured mean
values for all of the certified or reference elements in SRM 3280, with over half inside of
5% (Table 5). This level of precision for SRM 3280 was maintained for the remainder of
the study as most results had 95% CIs that were less than 10% of their mean value. A
large number of them were lower than 5% and some approached 1%. The other two
studies41-42 which have evaluated elemental content in botanicals and dietary supplements
supplied no standard deviation or confidence interval information for their sample
measurements, listing only standard deviations for their SRM 3280 results.

The

exclusion of standard deviation and confidence intervals provided no information on their
ability to sustain precise measurements for their samples during the remainder of their
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studies. This study provided 95% CIs for all detectable elemental quantities in the
dietary supplement samples.
Table 5: Concentrations of the certified and reference elements determined in SRM 3280 (n =
12, 95% CIs).

Element
B
Ca
Cl
Cu
I
Fe
Mg
Mn
P
K
Zn
As
Cr
Pb
Mo
Ni
Se
Cd
Sb
Co
La
Si
Na
Sr
Sn
V

Certified Value (mg g-1)
0.141 ± 0.007
110.7 ± 5.3
53.0 ± 2.3
1.40 ± 0.17
0.1327 ± 0.0066
12.35 ± 0.91
67.8 ± 4.0
1.44 ± 0.11
75.7 ± 3.2
53.1 ± 7.0
10.15 ± 0.81
Certified Value (µg g-1)
0.132 ± 0.044
93.7 ± 2.7
0.2727 ± 0.0024
70.7 ± 4.5
8.43 ± 0.30
17.42 ± 0.45
Certified Value (ng g-1)
80.16 ± 0.86
Reference Value (µg g-1)
0.159 ± 0.008
0.81 ± 0.01
0.70 ± 0.01
2,010 ± 10
330 ± 20
29.8 ± 0.2
11.1 ± 0.9
8±2
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Measured Value (mg g-1)
0.1219 ± 0.0047
108.4 ± 8.3
Not Determined
1.591 ± 0.117
Not Determined
11.95 ± 0.17
72.60 ± 2.32
1.627 ± 0.161
80.39 ± 1.64
65.67 ± 4.37
11.54 ± 0.43
Measured Value (µg g-1)
0.1625 ± 0.0138
96.09 ± 2.03
0.1973 ± 0.0077
84.12 ± 1.16
5.861 ± 0.299
17.98 ± 0.37
Measured Value (ng g-1)
95.79 ± 8.28
Measured Value (µg g-1)
0.1085 ± 0.0057
0.8572 ± 0.0167
0.6151 ± 0.0118
Not Determined
301.7 ± 16.7
29.96 ± 1.24
11.74 ± 0.62
9.691 ± 0.635

Figure 2: Concentrations of the certified and reference elements determined in SRM 3280 (n =
12, 95% CIs) with the certified or reference values shown in black and the measured results
shown in blue.

2.3.2

Analytical Figures of Merit and Validation of EPA Methods

The elemental analysis results from the four dietary supplement companies are
shown in Tables 6-9, respectively. The results are presented by company and separated
into xenobiotic and essential elements.

Contamination from essential elements was

considered to exist if that element was not listed as an ingredient on the label for that
particular dietary supplement.
2.3.2.1 Xenobiotic Elements
The supplements from Company 1 were found to have less contamination from
xenobiotic elements compared to the other companies (Table 6).
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The calcium

supplement contained tin (Sn) at a concentration over 700 ng g-1 and Pb above 170 ng g-1.
The magnesium supplement had a similar frequency of contamination with vanadium (V)
found at more than 2 µg g-1 along with 23 ng g-1 of Sn and 9 ng g-1 of Pb. The zinc
supplement had concentrations of 117 ng g-1 of Cd and 22 ng g-1 of Sn.
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Table 6: Concentration (µg g-1) of xenobiotic and essential elements determined in dietary supplements from Company 1 (n = 12, 95% CIs).
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Xenobiotic Elements
Al
As
Cd
Hg
Pb
Sb
Sn
U
V
Essential Elements
Ca
Co
Cr
Cu
Fe
Mg
Mn
Mo
Ni
Se
Zn
<DL: below detection limit

Zinc Supplement

Calcium Supplement

Magnesium Supplement

<DL
<DL
0.1168 ± 0.0089
<DL
<DL
<DL
0.02260 ± 0.00895
<DL
<DL

<DL
<DL
<DL
<DL
0.1718 ± 0.0032
<DL
0.7526 ± 0.0355
0.0009512 ± 0.0001482
0.02266 ± 0.00509

<DL
<DL
<DL
<DL
0.009087 ± 0.001802
<DL
0.02330 ± 0.00553
0.004564 ± 0.000150
2.129 ± 0.050

<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
94,200 ± 1,100

257,500 ± 8,600
<DL
<DL
0.3349 ± 0.0236
7.974 ± 1.439
5,578 ± 807
0.3570 ± 0.0306
0.05454 ± 0.01049
<DL
0.04391 ± 0.00265
83.28 ± 2.81

208.3 ± 14.3
0.05117 ± 0.00401
2.430 ± 0.119
0.2421 ± 0.0130
15.81 ± 1.63
138,900 ± 4,800
3.192 ± 0.133
0.5963 ± 0.0210
1.774 ± 0.073
0.02158 ± 0.00451
<DL

The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list.

Similar results were found in the dietary supplements analyzed from Company 2
with a high frequency of contamination by xenobiotic elements (Table 7).

The

concentration of Al in the magnesium, zinc, and multivitamin supplements was
determined to be greater than 10 µg g-1. The magnesium supplement also contained more
than 7.8 µg g-1 of V. Except for the essential fatty acids supplement, Pb contamination
was observed in all supplements, with the zinc supplement having a concentration of 738
ng g-1, the highest of the dietary supplements tested in this study. The multivitamin
supplement had the greatest amount of contamination from xenobiotic elements with As,
Cd, antimony (Sb), Sn, U, and V at concentrations ranging from 50 to 792 ng g-1. The
zinc supplement contained Cd, Sb, Sn, and V in the concentration range between 10 and
70 ng g-1. The calcium supplement had V and As at 53 and15 ng g-1, respectively. The
essential fatty acids supplement was not contaminated with any xenobiotic elements.
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Table 7: Concentration (µg g-1) of xenobiotic and essential elements determined in dietary supplements from Company 2 (n = 12, 95% CIs).
Essential Fatty
Calcium
Magnesium
Multivitamin
Zinc Supplement
Acid Supplement
Supplement
Supplement
Supplement
Xenobiotic Elements
Al
10.75 ± 2.92
<DL
<DL
61.07 ± 15.91
12.20 ± 3.00
As
<DL
<DL
0.01535 ± 0.00353
0.04374 ± 0.00499
0.1484 ± 0.0125
Cd
0.07024 ± 0.01027
<DL
<DL
<DL
0.07948 ± 0.00890
Hg
<DL
<DL
<DL
<DL
<DL
Pb
0.7384 ± 0.0193
<DL
0.03124 ± 0.00598
0.05145 ± 0.00232
0.2479 ± 0.0097
Sb
0.01004 ± 0.00166
<DL
<DL
<DL
0.05058 ± 0.00363
Sn
0.04709 ± 0.00619
<DL
<DL
<DL
0.09608 ± 0.01440
U
0.003061 ± 0.000240
<DL
0.004006 ± 0.000166 0.007497 ± 0.000349
0.3710 ± 0.0159
V
0.03149 ± 0.00577
<DL
0.05367 ± 0.00458
7.849 ± 0.114
0.7924 ± 0.0327
Essential Elements
Ca
547.3 ± 76.6
<DL
815.1 ± 56.7
85,970 ± 1,500
43,210 ± 2,340
Co
0.009075 ± 0.002813
<DL
<DL
0.1777 ± 0.0081
1.015 ± 0.069
Cr
0.3442 ± 0.0370
<DL
<DL
5.971 ± 0.332
97.07 ± 2.34
Cu
3.853 ± 1.519
0.7182 ± 0.2176
<DL
0.5375 ± 0.0933
3,830 ± 193
Fe
26.21 ± 0.83
<DL
0.7639 ± 0.2146
54.64 ± 1.89
40.27 ± 7.52
Mg
318.8 ± 17.2
14.46 ± 5.84
855.0 ± 14.8
634,600 ± 6,248
73,190 ± 3,860
Mn
1.080 ± 0.130
0.5131 ± 0.2153
4.855 ± 1.137
12.20 ± 0.81
3,226 ± 280
Mo
0.1232 ± 0.0106
<DL
<DL
2.154 ± 0.052
0.5949 ± 0.0483
Ni
<DL
<DL
<DL
6.153 ± 0.214
0.4588 ± 0.1118
Se
<DL
0.01464 ± 0.00514 <DL
0.05102 ± 0.00408
51.20 ± 3.05
Zn
25.800 ± 13.580
<DL
<DL
79,120 ± 1,710
29,070 ± 1,380

<DL: below detection limit
The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list.

Among the products tested, Company 3 had the greatest frequency of xenobiotic
contamination in its products (Table 8). The calcium, magnesium, zinc, and multivitamin
supplements contained high amounts of Al with the mean concentrations each above 15
µg g-1. Except for the essential fatty acids supplement, Pb was quantified in all of the
samples with the zinc supplement having the highest concentration at nearly 410 ng g-1.
Of all the supplements tested, the multivitamin supplement had the highest concentration
of As at 513 ng g-1, and the magnesium supplement contained nearly as much As at 432
ng g-1 along with 444 ng g-1 of Sn. In both the calcium and zinc supplements, elemental
contamination from V, As, and Cd was found between 11 and 331 ng g-1. The probiotic
had low concentrations of V, As, Sn, and U ranging from 15 to 47 ng g-1. The essential
fatty acids supplement was clear of contamination from xenobiotic elements with values
below the respective detection limits.
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Table 8: Concentration (µg g-1) of xenobiotic and essential elements determined in dietary supplements from Company 3 (n = 12, 95% CIs).
Essential Fatty Acid Calcium
Magnesium
Multivitamin
Probiotic
Zinc Supplement
Supplement
Supplement
Supplement
Supplement
Supplement
Xenobiotic Elements
Al
15.44 ± 6.29
<DL
26.09 ± 14.17
31.93 ± 4.82
20.88 ± 2.89
<DL
As
0.01153 ± 0.00367
<DL
0.02067 ± 0.00647 0.4323 ± 0.0221
0.5132 ± 0.0238
0.04750 ± 0.00780
Cd
0.03946 ± 0.00618
<DL
0.02777 ± 0.00334 0.06962 ± 0.00489 0.05674 ± 0.00992 <DL
Hg
<DL
<DL
<DL
<DL
<DL
<DL
Pb
0.4092 ± 0.0074
<DL
0.09268 ± 0.00328 0.02407 ± 0.00081 0.04092 ± 0.00155 0.05856 ± 0.00201
Sb
<DL
<DL
<DL
0.02754 ± 0.00169 <DL
<DL
Sn
0.1041 ± 0.0131
<DL
<DL
0.01445 ± 0.00362 0.4440 ± 0.0260
0.02863 ± 0.01034
U
0.0007583 ± 0.0001011 <DL
0.08226 ± 0.00141 0.5130 ± 0.0052
0.1032 ± 0.0017
0.02199 ± 0.00032
V
0.01963 ± 0.00728
<DL
0.3309 ± 0.0123
2.833 ± 0.062
0.01567 ± 0.00683
11.66 ± 3.27
Essential Elements
Ca
87.87 ± 2.78
<DL
1,150 ± 80
614.9 ± 235.3
299,000 ± 79,600
43,000 ± 740
Co
<DL
<DL
<DL
0.02499 ± 0.00344 0.4791 ± 0.0120
0.07519 ± 0.00497
Cr
<DL
<DL
<DL
1.530 ± 0.091
<DL
27.21 ± 0.68
Cu
0.1921 ± 0.0192
<DL
0.1949 ± 0.0535
0.5806 ± 0.0259
0.5046 ± 0.0392
0.9184 ± 0.0264
Fe
<DL
<DL
21.18 ± 3.19
44.97 ± 1.02
43.61 ± 2.28
3.924 ± 0.802
Mg
33.21 ± 3.68
2.480 ± 0.326
2,423 ± 41
708.5 ± 16.6
179,400 ± 3,200
63,310 ± 1,830
Mn
1.206 ± 0.059
<DL
3.539 ± 0.090
7.663 ± 0.246
293.5 ± 4.4
360.8 ± 4.8
Mo
<DL
<DL
0.09942 ± 0.00604 1.448 ± 0.065
0.08321 ± 0.02328
18.30 ± 0.66
Ni
<DL
<DL
<DL
0.8782 ± 0.0715
0.4698 ± 0.0798
<DL
Se
<DL
0.008819 ± 0.001073 0.02959 ± 0.00397 <DL
0.01847 ± 0.00143
50.80 ± 2.73
Zn
<DL
38.69 ± 1.67
4.337 ± 0.233
24.62 ± 2.53
72.08 ± 1.02
2,839 ± 123

<DL: below detection limit
The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list.

Similar to both Companies 2 and 3, Al was a common contaminant among
Company 4’s products, as it was found at nearly 100 µg g-1 in the calcium supplement,
over 30 µg g-1 in the multivitamin supplement, and above 3 µg g-1 in the essential fatty
acids supplement (Table 9). The zinc supplement contained nearly 15 µg g-1 of Sb. In
the calcium supplement, V was quantified at over 1.7 µg g-1 along with determining the
presence of As, Cd, and U between 119 and 320 ng g-1. Vanadium was found at 850
ng g-1 in the magnesium supplement in addition to between 5 and 31 ng g-1 of U, As, and
Sn. An elevated V amount was also observed in the multivitamin supplement at 566
ng g-1 along with Cd, Pb, U, and As ranging from 33 to 90 ng g-1. In the probiotic
supplement, As and U were found at 22 and 16 ng g-1, respectively.
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Table 9: Concentration (µg g-1) of xenobiotic and essential elements determined in dietary supplements from Company 4 (n = 12, 95% CIs).
Essential Fatty Acid Calcium
Magnesium
Multivitamin
Probiotic
Zinc Supplement
Supplement
Supplement
Supplement
Supplement
Supplement
Xenobiotic Elements
Al
<DL
3.424 ± 1.208
91.74 ± 3.42
<DL
31.22 ± 3.050
<DL
As
<DL
0.007569 ±0.00 2793 0.2096 ± 0.0125
0.01163 ± 0.00413
0.09037 ± 0.00767 0.02217 ± 0.00572
Cd
<DL
<DL
0.1194 ± 0.0077
<DL
0.03310 ± 0.00605 <DL
Hg
<DL
<DL
<DL
<DL
<DL
<DL
Pb
0.003119 ± 0.000568 <DL
0.05814 ± 0.00626
<DL
0.06468 ± 0.00132 <DL
Sb
14.85 ± 0.15
<DL
<DL
<DL
<DL
<DL
Sn
<DL
<DL
<DL
0.03139 ± 0.00902
<DL
<DL
U
<DL
<DL
0.3197 ± 0.0057
0.004984 ± 0.000197 0.08917 ± 0.00175 0.01587 ± 0.00036
V
<DL
0.007211 ± 0.002768 1.719 ± 0.035
0.8498 ± 0.0284
0.5660 ± 0.0126
0.01093 ± 0.00424
Essential Elements
Ca
<DL
6.153 ± 1.613
198.7 ± 24.2
73.11 ± 18.88
242,900 ± 4,100
16,760 ± 1,230
Co
<DL
<DL
0.03813 ± 0.00433
0.05813 ± 0.00423
0.2548 ± 0.0055
0.05438 ± 0.00386
Cr
<DL
<DL
2.430 ± 0.201
2.813 ± 0.096
<DL
14.32 ± 0.42
Cu
<DL
<DL
0.2673 ± 0.0250
0.1516 ± 0.0153
0.08997 ± 0.01458 0.3461 ± 0.0134
Fe
<DL
<DL
133.2 ± 2.8
29.04 ± 1.26
39.62 ± 1.22
<DL
Mg
<DL
5.518 ± 0.709
1,459 ± 23
1,440 ± 30
196,500 ± 4,300
19,020 ± 970
Mn
<DL
<DL
44.68 ± 1.31
4.370 ± 0.147
221.0 ± 3.5
920.2 ± 60.5
Mo
<DL
<DL
<DL
0.6047 ± 0.0329
<DL
9.774 ± 0.742
Ni
<DL
<DL
<DL
1.164 ± 0.062
<DL
<DL
Se
<DL
0.02422 ± 0.00209
0.006817 ± 0.001101 0.01070 ± 0.00145
0.01334 ± 0.00159
12.44 ± 1.39
Zn
<DL
4.298 ± 0.260
<DL
10.65 ± 0.23
2,829 ± 81
6,323 ± 220

<DL: below detection limit
The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list.

2.3.2.2 Essential Elements
In addition to the presence of xenobiotic elements, each dietary supplement from
Company 1 had notable contamination by essential elements that were not listed as
ingredients on the dietary supplement labels (Table 6).

Overall, the calcium and

magnesium supplements contained greater quantities of unlabeled essential elements
compared to xenobiotic elements.

In the calcium supplement, Mg was found at a

concentration over 5 mg g-1, Zn at greater than 80 µg g-1, and Fe at 8 µg g-1. The amount
of contamination in the magnesium supplement consisted of Ca quantified at 200 µg g-1,
Fe at about 15 µg g-1 along with Cr, manganese (Mn), and nickel (Ni) between 1.8 and
3.1 µg g-1. In contrast, the zinc supplement contained no detectable quantities of any
essential element.
Similar to Company 1, essential elements not listed as ingredients were found in
the dietary supplements from Company 2 (Table 7). Overall, Company 2 had a high
frequency of these elements at µg g-1 level. Magnesium was quantified at 855 µg g-1 in
the calcium supplement and 318 µg g-1 in the zinc supplement. Calcium was found at
815 and 547 µg g-1 in the magnesium and zinc supplements, respectively. Except for the
essential fatty acids supplement, Fe was observed in all of the samples with the highest
concentration of 54 µg g-1 in the magnesium supplement. The magnesium supplement
was also determined to contain Cr, Mn, molybdenum (Mo), and Ni at concentrations
between 2.1 and 12.2 µg g-1. The calcium supplement had a Mn concentration of nearly
5 µg g-1.

Cobalt (Co), Mo, and Ni were detected at 1015, 595, and 459 ng g-1,

respectively, in the multivitamin supplement. The zinc supplement frequently contained
essential elements, notably Cu at 3.8 µg g-1, Mn at 1 µg g-1, and Cr at 344 ng g-1. The
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essential fatty acids supplement was found to have 25 µg g-1 of Zn, 14 µg g-1 of Mg, and
ng g-1 quantities of Cu, Mn, and Se.
The products from Company 3 also had contamination from unlabeled essential
elements (Table 8). There was nearly 300 µg g-1 of Mn in the probiotic supplement.
Magnesium was quantified at nearly 2.5 mg g-1 in the calcium supplement, 700 µg g-1 in
the probiotic supplement, 33 µg g-1 in the zinc supplement, and 2.5 µg g-1 in the essential
fatty acids supplement. In the magnesium and zinc supplements, 1150 and 88 µg g-1 Ca
was measured, respectively.

Zinc was also found in the calcium, magnesium, and

probiotic supplements between 4 and 38 µg g-1. Iron was detected at 44, 43, 21, and 4
µg g-1 in the magnesium, multivitamin, calcium, and probiotic supplements, respectively.
Manganese was observed at 7.7, 3.5, and 1.2 µg g-1 in the magnesium, calcium, and zinc
supplements.

Copper was found in the calcium, magnesium, zinc, and probiotic

supplements. The magnesium supplement also had Cr at over 1.5 µg g-1, Ni at almost
900 ng g-1, and a lower level of Co at 25 ng g-1. In addition, the multivitamin supplement
contained Co and Ni.
As with the other three companies, the dietary supplements from Company 4 also
contained contamination from essential elements (Table 9), with many at µg g-1 level or
higher. Similar to Company 3, the probiotic supplement from Company 4 had a Mn
concentration close to 250 µg g-1. Magnesium was quantified at greater than 1 mg g-1 in
the calcium and probiotic supplements. Calcium was measured to be 198 µg g-1 in the
magnesium supplement and 73 µg g-1 in the probiotic supplement. Of all the essential
fatty acids supplements, the product from Company 4 was the most contaminated with
essential elements including Ca (6 µg g-1) and Mg (5.5 µg g-1). In the probiotic and
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calcium supplements, Zn was quantified at 10 and 4 µg g-1, respectively. Iron was found
at 133, 39, and 29 µg g-1 in the calcium, multivitamin, and magnesium supplements. In
the calcium supplement, the Mn concentration was determined to be greater than 40 µg g1

with Cr at 2.4 µg g-1. The magnesium supplement had Cr, Mn, and Ni at concentrations

greater than 1 µg g-1. Molybdenum was determined to be above 600 ng g-1 in the
magnesium supplement with low ng g-1 amounts of Co and Se. Except for the zinc and
essential fatty acid supplements, all of the supplements from Company 4 contained
between 90 and 346 ng g-1 of Cu.
Comparisons of particular elemental concentrations in certain types of dietary
supplements were provided to illustrate the differences between the supplement
manufacturers. Examples of these comparisons for the xenobiotics Pb and Cd are shown
in Figures 3 and 4. Figure 3 shows the amounts of Pb in the calcium supplements from
the four supplement companies. All four supplements had measureable quantities of Pb
in their calcium supplements with the mean values ranging from 31 ng g-1 to 172 ng g-1.
Company 1 had the highest concentration, while Company 2 had the lowest. Another
important toxicant comparison is the level of Cd in the zinc supplements seen in Figure 4.
Company 1 had the highest concentration at greater than 117 ng g-1 while Company 4 had
the lowest at below the detection limit, with both Companies 2 and 3 having quantifiable
amounts of 70 and 39 ng g-1, respectively.

156

Figure 3: Concentrations for lead in calcium supplements from the four dietary supplement
companies (n = 12, 95% CIs).

Figure 4: Concentrations for cadmium in zinc supplements from the four dietary supplement
companies (n = 12, 95% CIs). The cadmium concentration for Company 4 was below the DL of
0.0466 ng g-1.
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2.4 Discussion
The high fidelity results obtained in this study were accurate and precise based on
validation with SRM 3280.

The microwave-enhanced sample preparation provided

effective, consistent, and efficient sample decomposition that combined with the robust
ICP-MS analysis demonstrating the feasibility of using EPA methods to routinely
determine both the xenobiotic and essential elemental contamination in dietary
supplements.41-42 Only two other studies have used SRM 3280 to validate the method
protocols employed for multi-element quantification in dietary supplements or botanicals.
This study demonstrated superior analytical and statistical procedures compared to the
two previous studies by Avula et al. through increased quality control and inclusion of
CIs for all sample results. Another important improvement in the current study was
related to the preparation of the calibration standards. The previous studies used a
calibration blank solution of 3.2% HNO3 and 0.8% HCl.41-42 Although these studies
produced accurate results for SRM 3280, that method is not optimal in providing uniform
acid content in all of the digested samples and calibration solutions. However, the
addition of the appropriate amount of an analytical blank solution to each calibration
standard during the subsequent dilution as performed in the current study accomplished
this goal.
This study confirmed the presence of contamination from either xenobiotic or
essential elements in all samples from all four suppliers.

The xenobiotic elements

quantified in this study included Pb, Cd, Sb, Sn, and As, with their concentrations
ranging from low ng g-1 to µg g-1 levels. Only two supplements did not have xenobiotic
elements detected in them, the zinc supplement from Company 1 and the essential fatty

158

acid supplement from Company 2. Particularly alarming was the frequent presence of Al
at µg g-1 quantities in half of the supplements tested. The most common sources of
xenobiotic elemental contamination were V and U. Nearly two-thirds of the samples
contained quantifiable amounts of Pb. Antimony was found in only one supplement at a
concentration greater than 50 ng g-1. One positive note was that the Hg concentrations
were below the detection limit in all of the samples tested.
In addition to the presence of xenobiotic elements, most of the supplements
contained essential elements such as Zn, Mg, Ca, Fe, Cu, Mo, and Se that were not listed
as ingredients on the labels. This study identified a greater frequency of adulteration
from essential elements compared to xenobiotic elements, with Ca being the most
frequent contaminant. The zinc supplements from Companies 1 and 4 were the only two
that did not contain quantifiable amounts of any extra essential element. Iron was almost
always found in µg g-1 concentrations as an impurity. The presence of either xenobiotic
or essential elements in all of the dietary supplements raises the possibility of a systemic
and persistent problem across the industry.
The contamination observed in this study was examined through a comparison of
the four manufacturers. Company 3 had the highest occurrence of xenobiotic elemental
content. Except for the essential fatty acid, each supplement contained at least five
xenobiotic elements. It was also the only company that had four supplements with µg g-1
quantities of Al along with the two highest As concentrations.

Their multivitamin

supplement had the greatest amount of As and V quantified in the study while their zinc
supplement had the second highest concentration of Pb. The elemental adulteration for
Company 4 was nearly as frequent as Company 3. Their calcium supplement had the
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highest concentration of Al with the greatest Sb concentration found in their zinc
supplement. Company 1 had the least amount of xenobiotic content. However, its
calcium supplement contained the highest concentration of Sn, and their zinc supplement
had the second greatest concentration of Cd.

Both the calcium and magnesium

supplements from Company 1 had a similar pattern of xenobiotic contamination from Pb,
Sn, U, and V. The company’s use of the same ingredients in different amounts in their
supplements may provide one explanation (Table 2). These supplement types from
Companies 2 and 3 shared similar elemental adulteration, but this was not observed in
Company 4. Three out of five supplements from Company 2 had at least 10 µg g-1 of Al.
The zinc supplement from Company 2 contained the greatest concentration of Pb.
Some patterns appeared when the supplement types were compared.

The

essential fatty acids were the cleanest for xenobiotic elements as only Company 4’s
products contained over 3 µg g-1 of Al. The essential fatty acids were more likely to
contain essential elements with Mg detected at µg g-1 quantities in all three essential fatty
acid supplements. The zinc supplements were relatively clear of unlabeled essential
elements, except for the one from Company 2 that contained 547 µg g-1 of Ca and 318 µg
g-1 of Mg along with six other essential elements. The contamination frequency was less
for the zinc supplement from Company 3, but it still included µg g-1 quantities of Ca and
Mg. All of the calcium supplements were adulterated with at least 855 µg g-1 of Mg, with
three in the mg g-1 range. The four magnesium supplements contained at least 198 µg g-1
of Ca and 15.8 µg g-1 of Fe.

Even though they had the most elements listed as

ingredients, the multivitamins contained contamination from nearly all of the other
essential elements, notably Fe at approximately 40 µg g-1 in all three. Both of the
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probiotics had over 200 µg g-1 of Mn. Certain bacteria are known to produce Mn,
especially the Lactobacillus genus,54 a common species in this type of supplement. The
bacteria also need the other essential elements that were quantified in the probiotics for
survival, especially Ca and Mg that were found in high concentrations. The media where
the bacteria were grown is a possible contamination source.
The findings of this study are significant because they reveal the quality of dietary
supplements in the current marketplace and the possible threat they pose to public health
as their use increases globally. The long-term health effects from regular intake and
exposure to elemental contaminants from dietary supplements are rarely studied and
insufficiently understood. One of the less publicized aspects of these quality deficiencies
is the presence of essential elements not mentioned on content labels, potentially
negatively affecting supplement regimens designed to improve human health through
nutrient support. With people taking multiple dietary supplements, potential negative
synergistic effects are a realistic possibility and cumulative exposure to these xenobiotic
elements may have long term adverse health outcomes. In addition to the consequences
from the cumulative exposure to these potentially harmful elements, oversupplementation can result from the presence of essential elements that were not listed on
the label, as demonstrated by this study.

2.5 Conclusion
This study demonstrated the application of standardized EPA methods for the
evaluation of elemental contamination and content in dietary supplements. The use of
these methods resulted in finding xenobiotic and/or essential elemental contamination in
all of the dietary supplements analyzed.

161

Their implementation in both sample

preparation and analysis to determine elemental concentrations could serve as the
foundation of a reliable, consistent, and efficient quality assurance program for the
dietary supplement industry and regulatory agencies. The overwhelming trend that
emerged from this study was the widespread contamination in the products from the
different suppliers.

The elemental adulteration observed could result from the

manufacturing process or the raw ingredients that comprise the supplements.

It is

difficult to completely know their sources, but many ingredients, such as Stevia, come
from countries where regulation is not as stringent as in the US. It is clear from this
study that in order to provide the highest quality of dietary supplements possible, all final
products and ingredients must be analyzed for elemental contamination to ultimately
meet the intent of the Good Manufacturing Practice standards of the Dietary Supplement
Health and Education Act of 1994. Further studies are necessary to evaluate the type,
level, and frequency of dietary supplement contamination throughout the industry.
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Chapter 3
An Investigation of a Contaminated Zinc Dietary Supplement:
Total Elemental Quantification by EPA Method 6020B, Zinc
and Antimony Quantitation by EPA Method 6800, and
Qualitative Antimony Speciation
A leading dietary supplement company recalled some of their products due to
antimony (Sb) contamination, which the manufacturer reported to have resulted from one
of their raw materials. An investigation was performed into the adulteration of one of
these items, a zinc liquid dietary supplement, and the suspected contamination source.
Both commercially available products and samples were obtained directly from the
manufacturer with the goal of quantifying the amount and identifying the type of species
responsible. The concentrations of 64 elements in the zinc supplement and the raw
material were determined by United States Environmental Protection Agency (EPA)
Method 6020B using Inductively Coupled Plasma-Mass Spectrometry. Isotope Dilution
Mass Spectrometry (IDMS), a component of EPA Method 6800, was used to quantify the
concentrations of Sb and zinc (Zn) in these samples. Antimony speciation was performed
focusing on three species – inorganic forms, Sb (III) and Sb (V), and an organic species,
trimethylantimony dichloride – with analysis by Ion-exchange ChromatographyInductively Coupled Plasma-Mass Spectrometry.
The complete inorganic elemental analysis found xenobiotics such as aluminum,
arsenic, cadmium, lead, mercury, tin, and uranium at nanogram gram-1 levels in the zinc
dietary supplement and raw material, in addition to Sb concentrations as high as the
microgram gram-1 range. In the zinc dietary supplement, the Sb IDMS analysis revealed
three different concentration levels, while the Zn IDMS quantification determined the Zn
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concentration to be at the labeled level. The Sb speciation results showed only the
presence of the more toxic Sb (III) and Sb (V) in both products. This work discovered
that there was wider contamination in the zinc dietary supplement and raw material
beyond the previously admitted Sb, which was from the more toxic species.

It

demonstrated the importance of evaluating dietary supplements for elemental
contamination, including speciation analysis, to provide the most accurate understanding
of the toxicological impact of adulteration on human health.

3.1 Introduction
3.1.1

Overview

A background on dietary supplements including their use, regulation, and
elemental limits from different government agencies is described in Chapter 2.1 Zinc
(Zn) is a frequent and popular component of dietary supplements, and this study
acknowledges its importance and impact on human health. The health concerns resulting
from antimony (Sb) exposure are reviewed along with the quantification methods
employed.
3.1.2

Zinc Functions and Supplementation

Zinc dietary supplements are most commonly used because of dietary deficiencies
and the beneficial effects Zn has on the body. Zinc performs multiple functions in the
body and is involved in many different systems. These roles include involvement in the
structure or catalysis of proteins; oxidative stress prevention; structural, regulatory, and
anti-oxidant functionality; cytoskeleton composition; and cellular communication.2 It is
also needed for proper DNA production and cell development and differentiation. 3 Both
higher and lower than normal concentrations of Zn can cause oxidative stress and
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negatively affect the transcription factors responsible for cellular functions, propagation,
and survival.2

Zinc may prevent oxidative damage through the activation of

metallothioneins, a group of proteins with a high amount of cysteine, that combine with
redox active metals and are capable of removing oxidizers.2 When free Zn ions exist in
the cell, metallothionein genes are expressed, resulting in an increased number of
metallothionein proteins.4
In addition to all of these important biological functions, Zn is commonly
supplemented because of the beneficial effects it has on the immune system. Zinc is
required for a fully functioning immune system, and people deficient in Zn are more
vulnerable to disease.5 Some of the clinical signs of a slight Zn deficiency include a
suppressed immune system, decreased smell and taste sensitivity, the beginnings of night
blindness, diminishing memory, and lower sperm production in males.5 Serious Zn
shortage is noted by significant reductions in immune system capabilities, higher rates of
illnesses, bullous pustular dermatitis, diarrhea, alopecia, and mental instabilities.5 In the
immune system, Zn scarcity decreases the resistance to diseases along with the
capabilities of the whole immune system through suppressed thymus functioning, Tlymphocyte growth, lymphocyte production, and the performance of T cell-dependent B
cells.3
Abnormal Zn concentration disrupts the performance of the innate immune
system, the first and broad response to pathogens.6 Natural killer cells, one part of the
innate immune system that plays a key role fighting tumors and providing protection
against illnesses, have decreased activity with lower than normal Zn levels.6 Likewise,
both B and T cells are negatively affected by Zn deficiency. B cells, the main type of
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humoral immune cells, undergo changes in their development based on the Zn
concentration. B lymphocytes and their predecessors, mainly pre-B and immature B
cells, are lower in total amount when Zn levels are less than normal, but the change in the
number of mature B cells is not as great.6 In addition, the response to neoantigens is
decreased during Zn shortage due to a lower number of naïve B cells.6 Another way Zn
deficiency manifests is through the deterioration of T cells.4 Zinc plays a role in the
production of T cells and determines cytolytic T cell activity.6 Studies have also shown
that both T cell and natural killer cell counts increase as a result of using zinc
supplements along with improvement of cell-mediated immune response through
significantly more CD4+ T cells and cytotoxic T lymphocytes.6
Because the body does not store Zn, deficiencies must be overcome through diet
and supplementation.3 The World Health Organization recommends 10 milligrams day-1
(mg day-1) of Zn intake for children at least one year old.3 In the United States and
Europe, the average Zn consumption is 8 to 14 mg day-1, while it is 5 to 11 mg day-1 in
developing countries.2 In 2002, the World Health Report approximated worldwide Zn
deficiency at an average of 31% with values ranging from 6 to 73%.2 In the body,
normal plasma Zn concentrations range from 12 to 16 micromol Liter-1 (µmol L-1) with
the total amount of Zn in the body being between 2 and 4 grams (g).6
3.1.3

Antimony Toxicity, Regulation, and Speciation

Antimony is a toxic element present in the environment due to both human
activity and natural processes.

Around 3.8 × 1010 g of Sb are emitted into the

environment each year from human activities alone.7 The manmade release of Sb results
from mining, smelting, and the burning of fossil fuels and plastics.8 Antimony has also
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been incorporated into the production of ceramics, semiconductors, pharmaceutical
products, alloys, and glass fire retardants.9 Diesel soot, worn down tires, and used brake
linings are additional automobile related sources of atmospheric Sb release.8 Along with
the anthropogenic generation of Sb, it exists naturally in the environment. The Sb
concentration is near 0.2 parts per million (ppm) in the earth’s crust.7 Background Sb
concentrations in plants were quantified between 0.2 and 50 parts per billion (ppb).10
Typical concentrations in unpolluted waters are in the nanogram Liter-1 (ng L-1) range
and are normally below 300 ng L-1.11 This value has also been reported to be below 1
microgram Liter-1 (µg L-1) with a concentration of around 100 µg L-1 near natural
contamination sites.7 Levels can be substantially higher in industrial areas near certain
factories and industries.11
Antimony is not necessary for biological functions in plants, animals, and
humans, and exposure to it results in toxic consequences.8 Many diseases including
fibrosis, pneumonitis, destruction of bone marrow, and carcinomas can result from
breathing in Sb.7

Antimony and its species have been determined to be priority

contaminants by the United States Environmental Protection Agency (EPA)7, 12 and the
German Research Council.12

The EPA has proposed13 and set14 the allowable Sb

concentration in drinking water to be 6 ppb. The European Union has regulated a limit of
5 µg L-1 for Sb in drinking water.15 Japan advocates a threshold below 2 µg L-1.7 The
Council of the European Communities established the maximum admissible Sb
concentration in water at 0.01 mg L-1.11

Antimony has chemical and toxicological

properties similar to arsenic,9 and these permissible concentrations are all at or lower than
the 10 ppb limit set for arsenic.16 In 1989, the International Agency for Research on
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Cancer determined Sb, as antimony trioxide, was a possible carcinogen.17 With this
classification for a Sb species, a complete toxicological profile cannot be determined by
only quantifying total elemental Sb; speciation analysis is necessary to provide the most
complete and accurate assessment.
It is vital to study the various species of Sb, as their toxicity is directly related to
their different possible forms.8 Antimony exists inorganically as Sb (III) and Sb (V), and
many organic compounds have been discovered, with more than 3,000 reported in the
literature.11

Three methylated species have been identified in soil along with a

triethylantimony form.18 Organic Sb compounds have been detected in plant extracts.7
In natural water, both methylstibonic acid and dimethylstibinic acid have been
observed.11 In aquatic waters at pH 8, both inorganic oxidation states are significantly
hydrolyzed with Sb (III) observed as Sb(OH)3 and Sb (V) as Sb(OH)6-.11 In neutral
aqueous solutions, it was found that trimethylantimony dichloride ((CH3)3SbCl2) most
likely exists as [(CH3)3SbOH]+.12 For high performance liquid chromatography analysis,
trimethylantimony dichloride is one of two compounds used to represent the oxidized
compound of trimethylstibine.12 In reduced water, Sb (III) is the dominant compound,
while Sb (V) is the major species in oxygenated water.7 The toxicity of elemental Sb is
similar to that of elemental arsenic, but Sb (III) is reportedly ten times more toxic than Sb
(V).7-8, 11 Sb (III) has a great attraction for thiol groups and red blood cells, whereas Sb
(V) is impervious to red blood cells.7-8, 12 When comparing the toxicity of the different
Sb species, the inorganic forms are considered to be more harmful than the organic
species.7 The EPA has not set environmental limits on the amounts of individual Sb
species.
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3.1.4

Analysis Methods: EPA Method 6020B and EPA Method 6800

Many analytical methods and techniques can be used to quantify elements or
species. Included among these are the two used in this study: EPA Method 6020B19 and
EPA Method 6800.20 These two EPA methods are both approved for total elemental
determination with mass spectrometric detection.

EPA Method 6020B employs

Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and uses traditional external
calibration curves to quantify the sample, and it is only capable of measuring the total
amount of an element. In contrast, EPA Method 6800 can either be used to determine the
amount of the total element or a particular species. Because it uses an anthropogenic
enriched analog, the element or species of interest must be polyisotopic, or have more
than one naturally occurring isotope. One component of EPA Method 6800, Isotope
Dilution Mass Spectrometry (IDMS), is the best method for quantifying individual
elements in a sample because it is capable of eliminating many sources of error inherent
in mass spectrometric analysis.21 In IDMS, an enriched spike of the analyte with unique
isotopic ratios is added and equilibrated with the sample. The isotopic ratio measured by
the mass spectrometer is then used to quantify the element. The amount of a species
present can be determined using Speciated Isotope Dilution Mass Spectrometry
(SIDMS), the other part of EPA Method 6800. During this process, the samples are
spiked with a known amount of each isotopically enriched species of interest and
equilibrated with the sample.22 As in IDMS, the isotopic ratios are computed and used to
quantify the species. SIDMS is capable of accounting for any species interconversion
during sample preparation and analysis,23 which is not capable by traditional analytical
methods.24 The quantification abilities seen in EPA Method 6800 can improve and
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support the measurements made by the more traditional EPA Method 6020B. This
principle is applied to the Sb contamination in the zinc liquid dietary supplement in the
current study.

3.2 Materials and Methods
3.2.1

Materials

3.2.1.1 Chemicals and Standards
All reagents were of analytical grade.

Double-deionized (DDI) water with

resistivity of at least 18 MΩ-cm was obtained from a Barnstead NANOpure water system
(Dubuque, IA, USA). Optima grade water, American Chemical Society (ACS) grade
nitric acid (HNO3), ACS grade hydrochloric acid (HCl), and disodium dihydrogen
ethylene diamine tetraacetate salt dihydrate (Na2H2EDTA·2 H2O) were purchased from
Fisher Scientific (Pittsburgh, PA, USA). Antimony oxychloride (SbOCl) was produced
by Pfaltz and Bauer (Waterbury, CT, USA).

Antimony oxide (Sb2O5), potassium

hexahydroxoantimonate (KSb(OH)6), diethyl ether, and methylmagnesium iodide
solution were procured from Sigma Aldrich (St. Louis, MO, USA). Antimony trichloride
(SbCl3), potassium antimonyl tartrate sesquihydrate (PATS), diammonium hydrogen
phosphate ((NH4)2HPO4), anhydrous antimony pentachloride (SbCl5), and potassium
hydrogen phthalate (KHP) were manufactured by Acros (Morris Plains, NJ, USA).
ARISTAR ULTRA grade HNO3 was purchased from VWR (Radnor, PA, USA).
Electronic grade (99.99%) chlorine gas and ultra high purity grade (99.999%) liquid
argon was acquired from Airgas (Pittsburgh, PA, USA). Multi-elemental standards were
procured from High Purity Standards (Charleston, SC, USA). An inorganic mercury
standard and isotopically enriched Zn and Sb were obtained from Applied Isotope
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Technologies (Pittsburgh, PA, USA). The tuning solution for the ICP-MS consisting of
10 nanogram gram-1 (ng g-1) of lithium, yttrium, cerium, and tellurium in 2% (v:v) HNO3
was purchased from Agilent Technologies (Santa Clara, CA, USA). Standard Reference
Material (SRM) 1640a, Trace Elements in Natural Water, was procured from the
National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA).
3.2.1.2 Dietary Supplement Samples
The zinc liquid dietary supplements and the suspected contaminated raw material
were obtained either from the manufacturer or in commercially available form. Thirteen
lots (Lot 387-001 through Lot 387-013) of the zinc liquid dietary supplement and the
alleged contamination source, a Stevia extract (Lot R351-002), were received directly
from the manufacturer (Figure 5).

The commercially available zinc liquid dietary

supplement samples (Figure 6) obtained were Lots 387-003 (3 samples labeled as -1, -2,
and -3), 387-011 (3 samples labeled as -1, -2, and -3), 487-003 (3 samples labeled as -1, 2, and -3), and 487-004.

Figure 5: Supplement and Stevia samples obtained from the manufacturer.
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Figure 6: Some of the commercially available zinc liquid dietary supplements.

3.2.1.3 Instrumentation
An Agilent 4500 ICP-MS with a concentric nebulizer, Scott double-pass spray
chamber, quartz torch, and quadrupole mass analyzer performed the total elemental
quantification, Zn and Sb IDMS, and Sb speciation analyses. The samples for total
elemental and IDMS quantifications were stored in a CETAC (Omaha, NE, USA)
ASX500 autosampler before being analyzed. They were introduced into the ICP-MS
using the peristaltic pump at a speed of 0.1 revolutions per second (rps) via the micromist
nebulizer of the spray chamber. Both the ICP-MS and autosampler were located in an
International Organization for Standardization Class 6 cleanroom laboratory.

The

optimized operating parameters of the ICP-MS and autosampler are shown in Table 10.
Antimony speciation was completed using Ion-exchange ChromatographyInductively Coupled Plasma-Mass Spectrometry (IC-ICP-MS). The Metrohm-Peak
(Riverview, FL, USA) Ion Chromatography (IC) System consisted of two 818 IC pumps,
a 762 IC interface, and an 838 IC autosampler. It included a separation center enclosure
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including a six-port sample injector with a 100 microliter (µL) sample loop. The IC
column outlet was connected to the ICP-MS nebulizer inlet using a piece of
perfluoroalkoxy tubing via a switching valve. A Hamilton (Reno, NV, USA) PRP-X100
(5 micrometer (µm) particle size, 4.1 millimeter (mm) × 100 mm) anion exchange
chromatography column was used. The complete chromatographic settings are listed in
Table 10.
Table 10: Optimized settings for the Agilent 4500 ICP-MS and the Metrohm-Peak IC system for
the total elemental quantification, antimony and zinc IDMS analysis, and antimony speciation.

Agilent 4500 ICP-MS
Rf Power
1475 W
Spray Chamber Temperature 2 °C
Plasma Gas
15.0 L min-1
Auxiliary Gas
1.0 L min-1
Acquisition Mode
Spectrum*#
Time Resolved Analysis†
Peak Pattern
3 points mass-1
Integration Time
0.30 sec mass-1*†
0.50 sec mass-1#
Replicates
4
Total Analysis Time
56 sec Standard A + Hg*
14 sec Standard B*
8 sec Standard C*
Nebulizer Pump Speed
0.10 rps
Uptake Time
30 sec
Stabilization Time
10 sec
Metrohm-Peak IC System
Column
Hamilton PRP-X100 (5 µm, 4.1 mm × 100 mm)
Mobile Phases
A: 20 mM Na H EDTA·2 H2O and 2 mM KHP
2

2

B: 50 mM (NH ) HPO
Gradient Program
Flow Rate
Injection Volume
Column Temperature
Total Analysis Time
* For total elemental analysis
# For Zn and Sb IDMS analysis
† For Sb speciation analysis

4 2

4

0 min, 0% B; 1 min, 0% B; 1.5 min, 100% B; 6 min,
100% B; 6.5 min, 0% B; 9 min, 0% B
1.5 mL min-1
100 µL
Ambient
9 min†
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3.2.2

Methods

3.2.2.1 Total Elemental Concentration Quantification by EPA Method 6020B
For the zinc liquid dietary supplement samples, 1 g of sample was diluted twentyfold in Optima grade water, while 0.5 g of the solid Stevia extract was diluted forty-fold
in Optima grade water and vortexed to produce a homogeneous solution. For each
sample, three subsamples were prepared and stored at ambient conditions until they were
analyzed, typically within 24 hours.
Total elemental quantification was performed according to EPA Method 6020B.
On each day of analysis, the system was aspirated with 2% HNO3 for 30 minutes before
tuning the instrument with the Agilent tuning solution at 10 ng g-1 and determining the
pulse/analog factor. External calibration curves were created at 0, 10, 25, 50, and 100
ng g-1 for 64 elements using the three multi-element and inorganic mercury standards.
Analysis was performed in spectrum mode using three points per mass. An integration
time of 0.3 seconds per point was used. Four replicates were performed from each
subsample, and between each replicate, the autosampler probe was washed with both 2%
ACS grade HNO3 in DDI water and then Optima grade water for 30 seconds each.
SRM 1640a was analyzed to validate the sample preparation and analysis
methodologies. The sample preparation was modified slightly because SRM 1640a is
formulated in 2% HNO3 (v:v). SRM 1640a was diluted four-fold in Optima grade water
to maintain final elemental concentrations above instrument detection limits.

The

calibration curve solutions at the previously mentioned concentrations were prepared in
0.5% ARISTAR ULTRA grade HNO3 to acid match the SRM 1640a sample solutions.
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All other sample preparation, instrument, and autosampler settings were the same as
when the zinc liquid supplement and Stevia samples were analyzed.
3.2.2.2 Zinc and Antimony IDMS Quantification
Zinc and Sb IDMS analyses were completed according to EPA Method 6800. For
the Zn IDMS quantification, each zinc liquid supplement was diluted 1000-fold to make a
stock solution due to the high Zn concentration in the sample. Three subsamples were
created by combining 0.1 g of the stock solution, 0.1 g of a 9.4239 microgram gram-1
(µg g-1) 99.71% 68Zn isotopically enriched solution, and 10 g of Optima grade water. For
the Stevia, 0.1 g of sample was combined with 0.1 g of the same spike solution and
diluted to 10 g using Optima grade water. Elemental standards of naturally occurring Zn
were prepared at 0, 20, 40, 60, 80, and 100 ng g-1 in Optima grade water. Five IDMS
blanks were also made by spiking 0.02 g of the Zn spike solution in 10 milliliter (mL) of
Optima grade water. The IDMS analysis was performed monitoring

66

Zn and

68

Zn, and

both mass bias and deadtime correction were calculated.
Antimony IDMS quantification was performed in a similar manner as 0.2 g of
supplement and 0.2 g of a 99.32% 123Sb isotopically enriched solution were diluted to 10
mL with Optima grade water. Due to the distinct concentration ranges of Sb found in the
EPA Method 6020B results, different concentrations of the spike solution were used to
stay within the optimal sample to spike ratio required for IDMS analysis.21 For the Sb
IDMS analysis of the Stevia, 0.1 g of sample was combined with 0.25 g of a 13.8031
µg g-1 99.32%

123

Sb spike and diluted to 10 mL with Optima grade water. Naturally

occurring elemental Sb solutions were made at 0, 20, 40, 60, 80, and 100 ng g-1 in Optima
grade water. As with the Zn IMDS analysis, five IDMS blanks were prepared using 0.02
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g of the appropriate Sb enriched solution in Optima grade water.
quantification,

121

Sb and

During IDMS

123

Sb were the isotopes used along with the determination of

mass bias and deadtime correction.
Both Zn and Sb IDMS quantification was performed on SRM 1640a using the
same enriched spike solutions. In separate analyses, 5 g of SRM 1640a and 0.1 g of each
respective spike were diluted to 10 g with Optima grade water. Natural standards were
made for both Zn and Sb at 0, 20, 40, 60, 80, and 100 ng g-1 and five IDMS blanks were
prepared as previously described. Mass bias and deadtime correction were calculated in
the same manner as with the samples.
For all IDMS analyses, three subsamples were prepared with four replicates
analyzed from each. The integration time was increased to 0.5 seconds per mass in
spectrum mode. The same wash solutions, wash times, and autosampler settings were
used for the IDMS quantification of Zn and Sb as during the EPA Method 6020B total
elemental analysis
3.2.2.3 Synthesis of Trimethylantimony Dichloride
Trimethylantimony dichloride was synthesized using a modified protocol based
on Doak et al.25 Before beginning, all glassware was flame dried and flushed with
nitrogen. Ten g (43.8 millimol (mmol)) of anhydrous SbCl3 was combined with 25
milliliters (mL) of dry diethyl ether. The solution was cooled to -20 °C in an acetone
bath by the occasional addition of dry ice. Once cooled, 45 mL of 3 molar (135 mmol)
methylmagnesium iodide solution was added drop wise while the solution was stirred.
After 4 hours, all of the SbCl3 was digested, and the mixture turned gray indicating the
end of the reaction. Two layers were formed with the top layer being clear and the lower
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layer a brownish black. The solution was then distilled for one hour at 80 °C in an
oxygen- and moisture free ethanol distillation setup and the trimethylstibine was
collected in a flask. It was cooled in an ice bath, and chlorine gas was purged slowly to
the stirring solution for fifteen minutes until the slurry turned yellowish in color. (Note:
This process must be controlled very carefully as the reaction is exothermic and the
pressure generated by the chlorine gas can be very strong.)

The precipitate of

trimethylantimony dichloride was filtered and washed with diethyl ether. The solid was
recrystallized from DDI water.
3.2.2.4 Antimony Speciation
The Sb speciation analysis focused on three forms, Sb (III), Sb (V), and
(CH3)3SbCl2, to determine the type present in the zinc liquid dietary supplement and
Stevia extract. The Sb (III) species (antimony trichloride, antimony oxychloride, and
PATS), Sb (V) species (potassium hexahydroxyantimonate, antimony pentoxide, and
antimony pentachloride), and trimethylantimony dichloride were each dissolved in
Optima grade water. A small amount of HCl was used to help solubilize the SbCl 3, while
Sb2O5 was not able to be dissolved. The structures for each of the analyzed Sb species
are shown in Figure 7. Each of the Sb species was run through the Hamilton PRP-X100
anion exchange column at a concentration of 100 ng g-1 to determine the respective
elution profile. An isocratic elution of 20 millimolar (mM) Na2H2EDTA·2 H2O with 2
mM KHP and 50 mM (NH4)2HPO4 was performed over a 9 minute period that was
slightly modified from the literature.26-27 All chromatography solvents were filtered
through a 0.45 µm membrane filter.

Antimony speciation was completed in time

resolved analysis mode with an integration time of 0.3 seconds per mass. After the
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elution profile was established for all of the Sb compounds, the zinc liquid supplement
and Stevia were diluted in Optima grade water so the Sb was present in the ng g-1 range,
and analyzed using the previously described method. The optimized elution conditions
for these Sb species are listed in Table 10.
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Figure 7: The chemical structure of the six antimony species investigated.

3.3 Results
3.3.1

Analytical Figures of Merit and Validation of EPA Methods

All elements displayed linearity on the five point external calibration curves for
each of the three standard solutions. They had correlation coefficient values greater than
the 0.998 specified in EPA Method 6020B. The four replicates for each calibration point
displayed a variation of less than 5% indicating that the obtained measurements were
highly reproducible. The elemental detection limits (DLs) were defined as the average of
the blank concentration for each element plus three times the standard deviation of the
blank measurements for that element.28 The DLs for all of the elements were below 1
ng g-1 for nearly all elements.
The validation of the sample preparation and analysis methodologies was
performed by comparing the certified values for SRM 1640a to the measured values
obtained using EPA Method 6020B. The EPA Method 6020B results for all of the
certified elements in SRM 1640a are shown in Table 11 and Figure 8 with the mean (n =
12) and 95% confidence intervals (CIs). The confidence intervals of the measured and
certified values overlapped for iron (Fe), manganese (Mn), vanadium (V), and Zn.
Nearly all of the other confidence intervals were within 10% of the certified values,
validating the sample preparation and measurement protocols. The recovery efficiencies
ranged between 71.6 and 126.5% when comparing the mean certified values to the mean
measured quantities. Only 4 of the 20 certified elements had recoveries that differed by
more than 20% when comparing average values. The accuracy of all measurements in
this study improved with the inclusion of the 95% CIs. The precision determined by the
95% CIs was within 10% of the measured average values for all of the certified elements
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in SRM 1598a, with only 2 elements having values greater than 5%. This precision level
seen for SRM 1598a was sustained for the remainder of the study, as the results for most
elements had CIs of less than 10% of the mean values. This study provided 95% CIs for
all detectable quantities in the dietary supplement and Stevia samples.
Table 11: Concentrations (ng g-1) of the certified elements determined in for SRM 1640a (n =
12, 95% CIs) using EPA Method 6020B.

Certified Value (ng g-1)
Measured Value (ng g-1)
Element
Ag
8.017 ± 0.042
5.79 ± 0.07
Al
52.6 ± 1.8
44.9 ± 0.7
As
8.010 ± 0.067
7.75 ± 0.12
B
300.7 ± 3.1
252 ± 5
Ba
150.60 ± 0.74
134 ± 1
Be
3.002 ± 0.027
2.42 ± 0.14
Cd
3.961 ± 0.072
5.01 ± 0.04
Co
20.08 ± 0.24
19.4 ± 0.2
Cr
40.22 ± 0.28
39.2 ± 0.6
Cu
85.07 ± 0.48
81.9 ± 0.8
Fe
36.5 ± 1.7
41.5 ± 3.2
Mn
40.07 ± 0.35
39.3 ± 0.5
Mo
45.24 ± 0.59
40.9 ± 0.5
Ni
25.12 ± 0.12
23.7 ± 0.3
Pb
12.005 ± 0.40
<DL
Sb
5.064 ± 0.045
3.66 ± 0.04
Se
19.97 ± 0.16
17.0 ± 0.5
Sr
125.03 ± 0.86
120 ± 1
Tl
1.606 ± 0.015
<DL
U
25.15 ± 0.26
18.0 ± 0.2
V
14.93 ± 0.21
15.0 ± 0.2
Zn
55.20 ± 0.32
56.2 ± 1.1
-1
-1
<DL: below detection limit, DL for Pb is 3 ng g for Pb and 0.5 ng g for Tl.
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Figure 8: Concentrations (ng g-1) of certified elements in SRM 1640a using EPA Method 6020B (n = 12, 95% CIs). Measured values not shown
are <DL.
<DL: below detection limit, DL for Pb is 3 ng g-1 and 0.5 ng g-1 for Tl.

After determining the total elemental concentrations by EPA Method 6020B, EPA
Method 6800 was used to quantify Sb and Zn by IDMS. As with the elemental analysis,
SRM 1640a was used to validate the sample preparation and analysis. The EPA Method
6800 results along with those from EPA Method 6020B for Sb and Zn are shown in Table
12. The quantification results for Sb by EPA Method 6800 are more accurate than
Method 6020B results. The Zn and Sb results by EPA Method 6800 are both more
precise than those from EPA Method 6020B.
Table 12: EPA Method 6020B and EPA Method 6800 concentrations (ng g-1) for Sb and Zn in
SRM 1640a (n = 12, 95% CIs).

Element
Sb
Zn

3.3.2

Certified Values
(ng g-1)
5.064 ± 0.045
55.20 ± 0.32

EPA Method 6020B
EPA Method 6800
-1
Concentration (ng g ) Concentration (ng g-1)
3.66 ± 0.04
4.768 ± 0.040
56.2 ± 1.1
52.16 ± 0.002

Total Elemental Quantification Using EPA Method 6020B

With the sample preparation and analysis methodologies validated using SRM
1640a, the focus turned to the zinc liquid dietary supplements and Stevia extract. The
EPA Method 6020B elemental contamination results are shown in Tables 13 and 14 and
Figures 9-11 for selected elements of interest. Antimony was found in concentrations
ranging from 11 to 26 µg g-1 in Lots 387-001 to 387-009. Lots 387-010 to 387-013 had
values between 105 and 450 ng g-1 with 11 and 15 ng g-1 of Sb in lots 487-003 and 487004, respectively. The Stevia contained 27.1 µg g-1 of Sb.
In addition to Sb, the xenobiotics aluminum (Al), arsenic (As), cadmium (Cd),
lead (Pb), mercury (Hg), tin (Sn), and uranium (U) were found at ng g-1 amounts. The Al
levels in the zinc dietary supplement ranged from 27 to 97 ng g-1, and the Stevia had a
concentration of 689 ng g-1. Numerous lots had quantities below the DL for As, but
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others were as high as 33 ng g-1. The highest amount of As was discovered in the Stevia
at 172 ng g-1. The Stevia contained 83 ng g-1 of Cd, while the values ranged from below
the DL to 45 ng g-1. The greatest quantity of Pb was found in the Stevia at 105 ng g-1,
while the levels in the zinc dietary supplement ranged from 24 to 41 ng g-1. As with Pb,
the highest amount of Hg was observed in the Stevia at 277 ng g-1. All lots of the zinc
dietary supplement contained Hg at quantities varying from 71 to 106 ng g-1, and the
highest amounts of Sn and U were found in the Stevia at 120 ng g-1 and 29 ng g-1,
respectively. The level of Sn in the zinc dietary supplements ranged from 31 to 49 ng g-1
with U concentrations fluctuating between 12 and 18 ng g-1. In all of the samples
analyzed, the amount of V present was determined to be below the DL.
Beneficial elements were also detected in the zinc dietary supplement and Stevia.
Chromium (Cr), which is a nutrient as Cr (III), had concentrations of 37 to 254 ng g -1 in
the zinc dietary supplement and 553 ng g-1 in the Stevia. Cobalt (Co) was observed to be
below the DL in some lots of the zinc dietary supplement, but the detectable quantities
ranged from 15 to 19 ng g-1. Low amounts of copper (Cu) were found between 11 and 39
ng g-1 in the zinc dietary supplement and at 401 ng g-1 in the Stevia. Iron was determined
to be 8,190 ng g-1 in the Stevia and the concentrations varied from 146 to 2,580 ng g-1 in
the zinc dietary supplement. Over 500 ng g-1 of (Mn) was observed in the Stevia and
levels from 7 to 38 ng g-1 were seen in the zinc dietary supplement. Molybdenum (Mo)
was found at amounts from 22 to 50 ng g-1 in some lots of the zinc dietary supplement
and at 64 ng g-1 in the Stevia. Finally, selenium (Se), which is beneficial in moderation
and toxic in excess, was discovered at quantities between 433 and 2,440 ng g-1.
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Table 13: Concentrations (ng g-1) for selected xenobiotic elements in the zinc liquid dietary supplements and Stevia extract using EPA Method
6020B (n = 12, 95% CIs).
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Lot
Al
As
Cd
Hg
Pb
Sb
387-001
27.2 ± 3.4
<DL
9.87 ± 0.27 105 ± 0.4
28.3 ± 1.1 12,300 ± 300
387-002
27.9 ± 3.0
<DL
11.5 ± 0.4
102 ± 0.4
29.6 ± 0.6 11,200 ± 500
387-003
30.6 ± 3.7
<DL
11.7 ± 0.4
98.6 ± 0.4 29.8 ± 1.5 11,500 ± 100
387-004
27.5 ± 2.4
<DL
8.14 ± 0.28 98.3 ± 0.9 34.2 ± 5.5 18,000 ± 100
387-005
28.5 ± 2.7
<DL
9.34 ± 0.26 97.3 ± 0.8 28.0 ± 1.5 11,000 ± 100
387-006
27.3 ± 3.2
<DL
9.12 ± 0.27 99.2 ± 0.2 27.8 ± 2.0 12,200 ± 100
387-007
40.4 ± 9.6
<DL
<DL
98.3 ± 11.3 28.4 ± 1.5 16,300 ± 100
387-008
43.6 ± 8.4
<DL
<DL
78.5 ± 1.9 27.7 ± 1.0 25,700 ± 300
387-009
39.6 ± 3.4
<DL
<DL
71.6 ± 1.4 27.3 ± 0.8 16,700 ± 300
387-010
39.7 ± 4.6
<DL
<DL
71.8 ± 0.5 25.5 ± 0.6
237 ± 15
387-011
33.4 ± 5.8
<DL
<DL
71.1 ± 0.6 25.0 ± 0.8
105 ± 2
387-012
35.5 ± 5.6
<DL
<DL
71.6 ± 1.1 24.3 ± 0.6
450 ± 9
387-013
40.8 ± 2.3
<DL
<DL
71.1 ± 0.9 24.8 ± 0.7
386 ± 6
R351-002
689 ± 87
172 ± 21
<DL
277 ± 31
105 ± 7
27,100 ± 700
387-003-1 87.5 ± 11.3 33.2 ± 2.1 83.5 ± 14.8
105 ± 1
38.7 ± 1.3 15,900 ± 200
387-003-2 83.5 ± 7.5 30.8 ± 0.7 45.4 ± 6.7
104 ± 1
38.4 ± 0.4 16,600 ± 200
387-003-3 75.6 ± 3.2 31.3 ± 0.9 34.2 ± 4.2
103 ± 2
38.8 ± 0.7 16,600 ± 200
387-011-1 86.0 ± 3.4 26.2 ± 0.8 30.6 ± 1.2
106 ± 3
39.2 ± 0.6
110 ± 24
387-011-2 88.3 ± 4.8 24.6 ± 0.5 29.2 ± 1.7
100 ± 1
37.6 ± 0.4
87.0 ± 1.8
387-011-3 80.4 ± 5.1 24.7 ± 0.5 27.6 ± 0.9
103 ± 2
39.2 ± 0.4
85.9 ± 2.4
487-003-1 88.7 ± 3.5 24.1 ± 0.3 30.5 ± 1.0
104 ± 1
40.2 ± 0.4
11.1 ± 0.8
487-003-2 95.1 ± 5.1 24.5 ± 0.3 30.2 ± 1.3
106 ± 2
40.5 ± 0.4
11.6 ± 0.7
487-003-3 97.0 ± 5.4 23.5 ± 0.3 33.2 ± 1.8
102 ± 1
40.2 ± 0.6
12.2 ± 1.0
487-004
92.6 ± 5.7 24.0 ± 0.5 33.1 ± 1.4
105 ± 1
41.3 ± 0.7
15.4 ± 1.1
<DL: below detection limit, DL is 1 ng g-1 for As, 0.5 ng g-1 for Cd, and 0.25 ng g-1 for V.

Sn
49.5 ± 0.4
49.2 ± 0.2
48.3 ± 0.1
49.0 ± 0.4
48.4 ± 0.4
49.4 ± 0.1
38.6 ± 1.4
38.7 ± 0.3
37.4 ± 0.6
38.9 ± 0.4
38.6 ± 0.4
39.1 ± 0.6
38.8 ± 0.5
120 ± 1
31.7 ± 0.3
32.0 ± 0.2
32.1 ± 0.5
33.1 ± 1.0
31.6 ± 0.4
32.2 ± 0.7
32.5 ± 0.2
33.0 ± 0.6
32.2 ± 0.4
33.2 ± 0.3

U
13.4 ± 0.1
13.4 ± 0.03
13.2 ± 0.04
13.3 ± 0.1
13.2 ± 0.1
13.5 ± 0.04
12.2 ± 0.4
12.2 ± 0.1
11.8 ± 0.2
12.2 ± 0.1
12.3 ± 0.1
12.4 ± 0.2
12.4 ± 0.1
28.9 ± 0.2
17.4 ± 0.2
17.5 ± 0.1
17.6 ± 0.3
18.1 ± 0.5
17.2 ± 0.2
17.7 ± 0.3
17.8 ± 0.1
18.1 ± 0.3
17.5 ± 0.2
17.9 ± 0.1

V
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL

190
Figure 9: Concentrations (ng g-1) for selected xenobiotic elements in the zinc liquid dietary supplements using EPA Method 6020B (n = 12, 95%
CIs). Values not shown are <DL. DL is 1 ng g-1 for As and 0.5 ng g-1 for Cd. The samples directly from manufacturer are lots 1-13 and the
commercially available samples are lots 3, 11, 14, and 15.

Table 14: Concentrations (ng g-1) for selected beneficial elements in the zinc liquid dietary supplements and Stevia extract using EPA Method
6020B (n = 12, 95% CIs). The samples directly from manufacturer are lots 1-13 and Stevia and the commercially available samples are lots 3, 11,
14, and 15.
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Lot
387-001
387-002
387-003
387-004
387-005
387-006
387-007
387-008
387-009
387-010
387-011
387-012
387-013
R351-002
387-003-1
387-003-2
387-003-3
387-011-1
387-011-2
387-011-3
487-003-1
487-003-2
487-003-3
487-004

Co
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
15.2 ± 4.3
18.6 ± 0.8
17.9 ± 0.4
18.3 ± 0.3
19.3 ± 0.7
18.7 ± 0.5
18.8 ± 0.5
18.6 ± 0.3
19.3 ± 0.6
18.7 ± 0.5
19.0 ± 0.5

Cr
173 ± 8
183 ± 3
254 ± 4
160 ± 5
154 ± 5
209 ± 5
108 ± 12
183 ± 19
99.9 ± 12.7
106 ± 14
57.4 ± 12.2
37.2 ±13.2
59.3 ± 8.1
553 ± 116
101 ± 24
67.9 ± 4.9
75.4 ± 6.4
85.5 ± 13.0
102 ± 11
92.0 ± 9.3
89.7 ± 9.2
92.6 ± 7.2
106 ± 7
118 ± 19

Cu
25.1 ± 1.3
25.7 ± 0.6
25.5 ± 0.7
21.3 ± 0.4
22.1 ± 0.5
22.2 ± 0.5
27.2 ± 13.3
22.7 ± 5.3
16.2 ± 2.7
12.6 ± 1.6
12.8 ± 4.1
12.1 ± 3.2
11.1 ± 3.1
401 ± 34
39.0 ± 5.9
32.2 ± 0.9
33.8 ± 0.8
37.4 ± 1.2
35.2 ± 1.6
35.0 ± 0.9
36.3 ± 0.9
38.2 ± 0.5
39.0 ± 1.1
38.9 ± 2.3

Fe
1,130 ± 300
1,580 ± 150
2,110 ± 220
2,030 ± 190
1,880 ± 340
1,960 ± 180
1,200 ± 400
2,580 ± 780
1,650 ± 370
2,340 ± 370
2,000 ± 980
1,310 ± 400
1,120 ± 320
8,190 ± 1,230
283 ± 165
146 ± 86
329 ± 106
472 ± 113
586 ± 132
749 ± 134
730 ± 156
884 ± 53
1,040 ± 160
1,190 ± 430

Mn
7.55 ± 1.98
9.33 ± 2.09
19.2 ± 1.3
13.2 ± 3.3
14.9 ± 2.5
27.7 ± 3.5
24.8 ± 3.1
38.4 ± 3.4
27.5 ± 1.3
24.6 ± 1.8
22.0 ± 1.8
18.4 ± 1.6
20.5 ± 2.0
525 ± 67
35.2 ± 2.7
32.5 ± 1.2
33.6 ± 0.9
35.6 ± 1.5
34.9 ± 1.2
35.3 ± 1.8
34.6 ± 1.3
35.1 ± 1.0
35.9 ± 1.2
35.3 ± 1.5

Mo
23.5 ± 0.7
24.0 ± 1.3
22.9 ± 0.3
22.9 ± 0.5
22.2 ± 0.5
24.0 ± 0.4
46.8 ± 4.7
50.3 ± 1.9
46.4 ± 2.4
48.7 ± 1.7
47.9 ± 2.1
48.2 ± 1.3
47.7 ± 2.1
64.6 ± 3.5
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL
<DL

Ni
66.6 ± 16.2
42.7 ± 3.9
117 ± 21
47.5 ± 23.5
65.7 ± 21.4
94.6 ± 4.5
6.11 ± 3.71
102 ± 11
46.8 ± 7.4
43.5 ± 4.3
25.1 ± 11.1
<DL
21.8 ± 8.6
272 ± 53
135 ± 26
66.4 ± 13.5
44.7 ± 7.5
48.6 ± 2.2
45.8 ± 2.5
46.2 ± 2.1
40.2 ± 1.9
40.3 ± 2.3
50.2 ± 5.2
52.4 ± 4.2

<DL: below detection limit, DL is 0.8 ng g-1 for Co, 1 ng g-1 for Mo, and 0.1 ng g-1 for Ni.

Se
433 ± 59
663 ± 235
1,360 ± 580
2,440 ± 940
2,330 ± 1,080
2,150 ± 870
1,040 ± 370
1,030 ± 440
730 ± 89
767 ± 128
854 ± 291
659 ± 169
652 ± 157
17.1 ± 10.5
987 ± 205
725 ± 54
883 ± 81
1,230 ± 80
1,300 ± 150
956 ± 142
858 ± 67
887 ± 36
978 ± 76
914 ± 143

Zn
2,560,000 ± 180,000
2,840,000 ± 140,000
2,950,000 ± 140,000
2,560,000 ± 60,000
2,650,000 ± 270,000
2,780,000 ± 210,000
2,620,000 ± 80,000
2,480,000 ± 140,000
2,430,000 ± 130,000
2,490,000 ± 120,000
2,640,000 ± 120,000
2,410,000 ± 180,000
2,330,000 ± 110,000
765 ± 182
2,330,000 ± 90,000
2,240,000 ± 150,000
2,210,000 ± 100,000
2,010,000 ± 120,000
2,120,000 ± 90,000
1,970,000 ± 80,000
2,190,000 ± 180,000
2,200,000 ± 340,000
1,910,000 ± 130,000
3,670,000 ± 450,000
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Figure 10: Concentrations (ng g-1) for selected beneficial elements in the zinc liquid dietary supplements using EPA Method 6020B (n = 12, 95%
CIs). Values not shown are <DL. DL is 0.8 ng g-1 for Cd, 1 ng g-1 for Mo, and 0.1 ng g-1 for Ni. The samples directly from manufacturer are lots
1-13 and the commercially available samples are lots 3, 11, 14, and 15.
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Figure 11: Concentrations (ng g-1) for Fe and Se in the zinc liquid dietary supplements using EPA Method 6020B (n = 12, 95% CIs). The
samples directly from manufacturer are lots 1-13 and the commercially available samples are lots 3, 11, 14, and 15.

3.3.3

Antimony and Zinc IDMS Quantification

The EPA Method 6800 results for Sb are shown in Table 15 with three distinct
concentration ranges. Lots 387-001 through 387-009 had Sb concentrations varying
between 15 and 27 µg g-1. Then, the next four produced (Lots 387-010 to 387-013) had
Sb values ranging from 78 to 450 ng g-1. Finally, Lots 487-003 and 487-004, produced
after the initial Sb contamination was realized, had Sb concentrations of 335 and 630
picogram gram-1 (pg g-1), respectively. The Sb results for Lots 487-003 and 487-004
differed between EPA Method 6020B and EPA Method 6800. The Stevia had a Sb
concentration of 31.6 µg g-1 according to EPA Method 6800. This data indicates that the
Stevia could be a source of contamination in the zinc dietary supplements. A comparison
of the EPA Method 6020B and EPA Method 6800 results for Sb are shown in Figures 12
and 13 and Table 16.
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Table 15: Concentrations (ng g-1) for Sb in the zinc liquid dietary supplements and Stevia extract
using EPA Method 6800 (n = 12, 95% CIs). The samples directly from manufacturer are lots 113 and Stevia extract and the commercially available samples are lots 3, 11, 14, and 15.

Lot
387-001
387-002
387-003
387-004
387-005
387-006
387-007
387-008
387-009
387-010
387-011
387-012
387-013
R351-002
387-003-1
387-003-2
387-003-3
387-011-1
387-011-2
387-011-3
487-003-1
487-003-2
487-003-3
487-004

EPA Method 6800 Sb Concentration (ng g-1)
17,650 ± 150
15,770 ± 250
17,000 ± 70
27,310 ± 280
16,830 ± 240
18,060 ± 80
15,590 ± 90
24,450 ± 160
16,120 ± 60
218.4 ± 24.5
78.84 ± 1.34
454.1 ± 12.2
380.9 ± 29.2
31,620 ± 300
14,430 ± 480
15,720 ± 50
15,370 ± 30
96.15 ± 12.79
79.55 ± 5.29
65.00 ± 1.13
0.4486 ± 0.1586
0.3350 ± 0.0509
0.3040 ± 0.0364
0.6307 ± 0.0968
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Figure 12: Concentrations (ng g-1) for Sb in the zinc liquid dietary supplements and Stevia extract using EPA Method 6020B and EPA Method
6800 (n = 12, 95% CIs). The samples directly from manufacturer are lots 1-9 and Stevia extract and the commercially available samples are lots 3.
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Figure 13: Concentrations (ng g-1) for Sb in the zinc liquid dietary supplements using EPA Method 6020B and EPA Method 6800 (n = 12, 95%
CIs). The samples directly from manufacturer are lots 10-13 and Stevia extract and the commercially available samples are lots 11, 14, and 15.

Table 16: Concentrations (ng g-1) for Sb in SRM 1640a, the zinc liquid dietary supplements, and
Stevia extract using EPA Method 6020B (n = 12, 95% CIs). The samples directly from
manufacturer are lots 1-13 and Stevia and the commercially available samples are lots 3, 11, 14,
and 15.

Lot
SRM 1640a
387-001
387-002
387-003
387-004
387-005
387-006
387-007
387-008
387-009
387-010
387-011
387-012
387-013
R351-002
387-003-1
387-003-2
387-003-3
387-011-1
387-011-2
387-011-3
487-003-1
487-003-2
487-003-3
487-004

EPA Method 6020B Sb
Concentration (ng g-1)
3.66 ± 0.04
12,300 ± 300
11,200 ± 500
11,500 ± 100
18,000 ± 100
11,000 ± 100
12,200 ± 100
16,300 ± 100
25,700 ± 300
16,700 ± 300
237 ± 15
105 ± 2
450 ± 9
386 ± 6
27,100 ± 700
15,900 ± 200
16,600 ± 200
16,600 ± 200
110 ± 24
87.0 ± 1.8
85.9 ± 2.4
11.1 ± 0.8
11.6 ± 0.7
12.2 ± 1.0
15.4 ± 1.1

EPA Method 6800 Sb
Concentration (ng g-1)
4.768 ± 0.0396
17,650 ± 150
15,770 ± 250
17,000 ± 70
27,310 ± 280
16,830 ± 240
18,060 ± 80
15,590 ± 90
24,450 ± 160
16,120 ± 60
218.4 ± 24.5
78.84 ± 1.34
454.1 ± 12.2
380.9 ± 29.2
31,620 ± 300
14,430 ± 480
15,720 ± 50
15,370 ± 30
96.15 ± 12.79
79.55 ± 5.29
65.00 ± 1.13
0.4486 ± 0.1586
0.3350 ± 0.0509
0.3040 ± 0.0364
0.6307 ± 0.0968

Since this dietary supplement was found to be contaminated with many
xenobiotics, IDMS was used to quantify the Zn in the dietary supplement to see if the
concentration on the bottle was accurate. According to the label, a serving size of the
zinc dietary supplement is one teaspoon (5 mL), and a serving size is listed as 20 mg Zn
serving-1. Therefore, the concentration of Zn in the supplement should be no lower than
4,000 µg g-1. As Figure 14 and Table 17 show, the Zn concentrations were at or above
4,000 µg g-1 for all the bottles tested as at least all of the 95% CI overlapped this level.
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Figure 14: Concentrations (µg g-1) for Zn in the zinc liquid dietary supplement using EPA Method 6800 (n = 12, 95% CIs). The samples directly
from manufacturer are lots 1-13 and the commercially available samples are lots 3, 11, 14, and 15. The line at 4,000 µg g-1 represents the
concentration of Zn listed on the label corresponding to the serving size of the zinc dietary supplement.

Table 17: Concentrations (µg g-1) for Zn in the zinc liquid dietary supplement and Stevia using
EPA Method 6800 (n = 12, 95% CIs). The samples directly from manufacturer are lots 1-13 and
Stevia extract and the commercially available samples are lots 3, 11, 14, and 15.

Lot
387-001
387-002
387-003
387-004
387-005
387-006
387-007
387-008
387-009
387-010
387-011
387-012
387-013
387-003-1
387-003-2
387-003-3
387-011-1
387-011-2
387-011-3
487-003-1
487-003-2
487-003-3
487-004
R351-002
3.3.4

EPA Method 6800 Zn Concentration (µg g-1)
4,332 ± 84
4,223 ± 96
4,307 ± 94
4,128 ± 77
4,173 ± 117
4,340 ± 126
3,930 ± 81
4,232 ± 134
4,203 ± 93
4,198 ± 100
4,115 ± 89
4,174 ± 95
4,170 ± 77
4,150 ± 178
4,034 ± 207
4,105 ± 77
4,121 ± 55
4,146 ± 83
4,041 ± 129
3,935 ± 110
4,142 ± 72
4,131 ± 62
4,656 ± 65
0.9347 ± 0.1085

Antimony Speciation

An overlay of the six Sb compounds (PATS, SbCl5, SbOCl, KSb(OH)6,
(CH3)3SbCl2, and SbCl3) analyzed separately at a concentration of 100 ng g-1 by IC-ICPMS is seen in Figure 15. All of the Sb (III) species and all of the Sb (V) species analyzed
had the same elution profile, while (CH3)3SbCl2 had one different than either of the
inorganic Sb species. A chromatogram of the contaminated Stevia is seen in Figure 16,
which illustrates that the Stevia contains some Sb (V) and a lesser amount of Sb (III).
Figure 17 shows a chromatogram of a Lot 387-003-1 sample of the zinc dietary
supplement that had both Sb (III) and Sb (V) in it, with more Sb (III) present. It was also
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not possible to determine the chemical structure of the Sb (III) and Sb (V) present in the
zinc dietary supplement and Stevia.

Figure 15: Overlaid IC-ICP-MS chromatograms of the six antimony compounds (KSb(OH)6,
SbCl5, PATS, SbCl3, SbOCl, and (CH3)3SbCl2). The chromatograms are smoothed using
Savitzky-Golay smoothing with 13 points per peak for a 2nd order polynomial.

Figure 16: Chromatogram of the Stevia using the IC-ICP-MS showing more Sb (V) than Sb
(III) present.
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Figure 17: Chromatogram of Lot 387-003-1 of the zinc dietary supplement from the IC-ICP-MS
indicating contamination from both Sb (III) and Sb (V), with more Sb (III) present.

3.4 Discussion
An investigation into a zinc liquid dietary supplement admitted to be
contaminated with Sb by the manufacturer found three different concentration ranges in
the lots of samples analyzed. Most notably, Sb was discovered at µg g-1 levels in Lots
387-001 to 387-009, while the Sb contamination in Lots 387-010 to 387-013 was found
at ng g-1 concentrations. Finally, Lots 487-003 and 487-004 contained pg g-1 quantities of
Sb. The results for the Sb concentrations for Lots 487-003 and 487-004 differed between
EPA Method 6020B and EPA Method 6800 as the EPA Method 6020B findings
indicated concentrations in the ng g-1 range, while EPA Method 6800 results were in the
pg g-1 level. The values from EPA Method 6020B may have been higher due to the use
of the calibration curve, matrix effects, and the concentration of Sb in the blank solution.
The manufacturer’s suspected source of contamination, the Stevia extract, contained
approximately 30 µg g-1 Sb by both EPA Method 6020B and EPA Method 6800.
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The Sb speciation analysis results showed only the presence of Sb (III) and Sb
(V). No detectable trimethylantimony dichloride was found in the Stevia extract or zinc
liquid dietary supplement. The zinc liquid dietary supplement contained more Sb (III)
than Sb (V), while the opposite results were observed in the Stevia. This discovery and
the small difference in the total Sb concentrations in the zinc supplement and Stevia raise
the possibility that there could be other sources of contamination.

These findings

indicated a more toxic exposure from Sb due to the presence of only inorganic Sb
species. The overall knowledge of Sb speciation is lacking with the only commonly
reported fact being that Sb (III) is ten times more toxic than Sb (V).389-390, 393
In the zinc dietary supplement and Stevia, additional elemental contamination
from many xenobiotics such as Al, As, Cd, Hg, Pb, Sn, and U were found at ng g-1 levels
in addition to the Sb contamination admitted by the manufacturer. The greatest quantities
of each of these toxins were determined to be present in the Stevia. In addition to these
harmful elements, many beneficial elements such as Co, Cr, Cu, Fe, Ni, Mo, Mn, Ni, and
Se were quantified in the zinc dietary supplement and Stevia.

These elements are

necessary dietary components, but they should not be present in a zinc supplement
similar to all of the other harmful contaminates since they were not listed as ingredients.
All of these elements were not known to be present and raise additional contamination
concerns about the quality of dietary supplements. Physicians and the general public
supplement diets with these other essential elements in addition to Zn for nutritional
deficiencies. When these elements are present, along with other dietary supplements
being incorporated into nutritional regimens, the results may no longer be beneficial and
may actually cause negative consequences in a patient.
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In addition to the results obtained for the analyzed samples, further fidelity and
confidence in them was achieved through the validation of the methods employed using
SRM 1640a. As certified standards, SRMs can be used to evaluate sample preparation
and analysis techniques. They can provide a similar matrix to the sample of interest
along with known certified or reference values for elements and molecules at
concentrations close to quantities see in real world samples. The comparison of the
measured quantities to the SRM values validated the procedures used in this study and
gave greater support to the obtained results.
In addition to evaluating the quality of a commercially available dietary
supplement, one of the most important effects this study can have on the measurement
and industrial communities is through the type of testing standards employed and the
quality of analytical testing results obtained.

When performing analytical mass

spectrometric measurements, there are many sources of error which can affect both the
accuracy and precision of each measurement, notably matrix matching, instrument drift,
ionization changes, and analyte stability.

These errors are inherent as a part of

instrumentation and methodology no matter how skilled the analyst. These sources of
error can be eliminated through the use of EPA Method 6800 as it only has three sources
of error and two of these errors (mass bias and deadtime) can be corrected for with the
mass spectrometer.

The remaining source of error, isobaric interferences, can be

determined before analysis, and can either be corrected for or adjustments can be made to
avoid them.
It is important to note that the applicability of the two elemental testing methods
implemented in this study is significantly different. EPA Method 6020B is appropriate
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for total elemental analysis for mono- or polyisotopic elements. EPA Method 6800 is
only applicable to polyisotopic elements, which comprise over 60% of the periodic table.
These polyatomic elements include xenobiotics such as Cd, Hg, Pb, Sb, and Sn as well as
beneficial elements including Cr, Cu, Fe, Mg, Mo, Ni, Se, and Zn. In addition, EPA
Method 6800 allows for the quantification of species of elements such as chromium (III)
and (VI) and inorganic, methyl, and ethyl Hg in addition to the Sb species discussed in
this study. EPA Method 6800 is also applicable to organic molecules as hydrogen,
carbon, nitrogen, oxygen, chlorine, and sulfur are all polyatomic elements. This recent
advancement in methodology has given scientists the capabilities through standard testing
protocols to address the major concern that caused this investigation: the contamination
of dietary supplements.

3.5 Conclusion
Through this research, many contamination issues were found through the
elemental analysis of a zinc liquid dietary supplement and the suspected source, a Stevia
extract. Antimony was found at three different concentration ranges in the zinc dietary
supplement. The Sb adulteration in the first nine lots (387-001 to 387-009) was over
1000 times greater than the current regulatory limit for drinking water set by the US
EPA.14 Despite the improvements made to eliminate the Sb contamination, Al, As, Cd,
Cr, Hg, Pb, and Sn still were found at ng g-1 concentrations in all of the lots investigated.
Selenium was observed at least ng g-1 levels in all lots of the zinc dietary supplement,
despite not appearing on the label. In addition, EPA Method 6800 methodology was used
to quantify Sb and Zn by IDMS.

The IDMS results confirmed the levels of Sb

contamination seen by EPA Method 6020B and provided more precise results for all lots
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and increased accuracy for Lots 487-003 and 487-004. The labeled Zn levels were
confirmed by IDMS analysis. The more recently developed EPA Method 6800 produced
more accurate and precise results in comparison to EPA Method 6020B.

The Sb

speciation analysis showed the presence of only inorganic Sb compounds, the most toxic
Sb species. There is not much information in the literature on the effects of Sb on human
health, and further work is needed to expand the knowledge base of the toxicity of Sb
species and the type of species present in aqueous solutions. The Sb speciation analysis
has shown how important this type of testing is to provide the most accurate toxicological
impact on human health.
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Chapter 4
The Plasma Zinc/Serum Copper Ratio as a Biomarker in
Children with Autism Spectrum Disorders†1
The frequency of zinc deficiency, copper toxicity and low zinc/copper in children with
autism spectrum disorders (ASDs) may indicate decrement in metallothionein system
functioning. A retrospective review of plasma zinc, serum copper and zinc/copper was
performed on data from 230 children with autistic disorder, pervasive developmental
disorder-NOS and Asperger’s syndrome. The entire cohort’s mean zinc level was 77.2
micrograms deciliter (µg dL-1), mean copper level was 131.5 µg dL-1, and mean Zn/Cu
was 0.608, which was below the 0.7 cut-off of the lowest 2.5% of healthy children. The
plasma zinc/serum copper ratio may be a biomarker of heavy metal, particularly mercury,
toxicity in children with ASDs.

4.1 Introduction
4.1.1

Overview

In recent years, much attention has been given to a related group of child
neurological disorders called pervasive developmental disorders, which include autistic
disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS) and
Asperger’s syndrome.1 These disorders cause difficulties with production of language,
the performance of social skills, and the inhibition of non-functional, repetitive behavior
patterns. Asperger’s Syndrome is characterized by impairment in social interaction,
inappropriate speech and difficulty controlling obsessive thoughts and behaviors in the

†

Used with Permission from Informa Healthcare from Faber, S.; Zinn, G.M.; Kern II, J.C; Kingston H.M.S.
The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders.
Biomarkers 2009 14 (3) 171-180.
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setting of normal overall cognitive ability. During the 1970s, the prevalence of autism in
the United States ranged from 1 to 3 in 10,000.2 In the early 21st century the prevalence
of all forms of autism had reached 1 in 150 children under 18.3 The state of New Jersey
currently has the highest prevalence of autism in the United States at 1 in 94 births.4
Recent research has sought to determine common characteristics in children with autism
spectrum disorders (ASDs). This study describes the status of plasma zinc and serum
copper concentrations and the plasma zinc/serum copper ratio in children diagnosed with
ASDs.
4.1.2

Role of Zinc

Zinc (Zn) has a central role in immune system functioning and individuals
deficient in zinc experience an increased susceptibility to various pathogens. Individuals
who suffer from severe zinc deficiency often demonstrate severely suppressed immune
function, repeated infections and emotional disturbances.5 Additionally, zinc provides an
essential building block for metal responsive transcription factor-1 (MTF-1). MTF-1
enhances the transcription of metallothionein genes in response to heavy metal load and
up- and down regulates numerous genes and enzymes responsible for elimination of
heavy metals with potential deleterious effects on mammalian tissue.6-7 Metallothioneins
(MTs) are cysteine-containing, low-molecular weight, intracellular proteins with high
affinity for metals, being the most common intracellular proteins which bind to metals. 8
The MT system is essential to heavy metal detoxification throughout the body.9 Zinc is
the most efficient MT producer.10 Zinc is essential to the transcription of MT-I and MTII present in all vertebrate tissues, including the cerebellum. Increased concentrations of
vesicular zinc support MT-III production in the hippocampus, amygdala and pyriform
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cortex. Zinc promotion of the MTs decreases the neurotoxicity of mercury exposures in
rat models and increases the elimination of free radicals by MTs serving as
antioxidants.11 Thimerosal, which metabolizes to ethyl mercury, can trigger intracellular
zinc release from MT proteins which can be measured by fluorescent signals from
lymphocytes.12 Mercury compounds may then replace zinc in the binding sites of MTs,
leading to eventual removal of mercury from tissues.
The effects of exposing cultured lymphocytes from children with autism and their
siblings to thimerosal, containing 49.6% ethyl mercury by weight, and zinc were studied
by Walker et al.13 Thimerosal exposure caused up regulation of mRNA leading to
increases in several heat shock proteins, and ‘many of the several hundred up regulated
genes represent neurodegeneration and apoptotic pathways, while many of the
significantly down-regulated genes belong to metabolic and cell signaling pathways.’13
Zinc exposure up regulated several genes that promoted MT protein production.
Variations in the familial transmission of single nucleotide polymorphisms
(SNPs) of the metal responsive transcription factor 1 (MTF1) gene were found in a recent
study by Serajee et al.14 The GT haplotype was more frequently transmitted than the GC
haplotype. Given the importance of MTF1 for regulation of MT protein homeostasis in
response to heavy metal exposure, these SNPs may be influencing the conformation of
MT proteins, adversely affecting the efficient utilization of zinc stores for heavy metal
detoxification.
In mammalian models, total body zinc deficiency can be associated with T- and B
cell dysregulation causing dysfunction of the immune system.5 During a state of zinc
deficiency, T cell functionality is among the first lost among immune cells.15 A recent
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study noted decreases in splenic size and lymphocyte number in the spleen and thymus in
intrauterine growth-restricted mice who experienced zinc deficiency in utero.16 Zinc
deficiency can occur in utero from malnutrition or from increased exposure to heavy
metals. Some mammals have decreased MT functionality, beginning in the early fetal
developmental stages.8 In utero, mammals who have decreased functionality of their MT
system may use up their zinc reserves faster than fetuses with normal MT function.
Children who are born with decreased zinc stores remain at risk for zinc deficiency
throughout childhood.

Zinc deficiency is associated with developmental delays,

malabsorption secondary to decreased functioning of intestinal zinc-dependent enzymes,
and postnatal immune dysregulation.17 Low plasma zinc can also lead to copper toxicity,
which can cause liver dysfunction and neurological impairment in children.
4.1.3

Role of Copper

Copper (Cu) has many important roles in the body, including participation in
mechanisms of cell propagation and growth.18 Copper supports an effective immune
response through promotion of interleukin-2 production using lymphocytic cells.19
Copper is involved in the synthesis of MT proteins. These proteins have a high attraction
for copper, and in times of high copper concentrations, MT levels rise.19 In addition to
MT, glutathione peroxidase and superoxide dismutase may be up regulated during times
of high copper concentration.20 Copper has an important role as a cofactor in many
metalloenzymes including cytochrome c oxidase, copper/zinc superoxide dismutase and
lysyl oxidase. It affects responsiveness to oxidative stress, oxidative phosphorylation and
collagen biosynthesis.21 Copper is a cofactor in proteins connected with neurological
diseases including amyotrophic lateral sclerosis, Alzheimer’s disease and Creutzfeldt-
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Jacob disease.20 Oxidative damage to lipids, nucleic acids and proteins can result from
increased copper concentrations.22 Free radical concentrations are increased in tissues
that contain larger amounts of transition metals, including copper.23 Copper can exist in
two different oxidation states, causing copper to be toxic in surplus, promoting the
creation of reactive oxygen species.24

Serum copper concentrations increase as

physiological stress becomes greater in magnitude because of higher concentration of
ceruloplasmin, where most of the copper in serum is located.25
Copper homeostasis needs to be controlled very closely, as copper becomes toxic
in higher than normal concentrations.24 Copper is incorporated into the bloodstream from
the gastrointestinal tract.26 To be excreted from the body, copper needs key contributions
from the liver.24 In comparison to other necessary trace elements, very little copper is
accumulated in the body and adult humans contain less than 100 mg of stored copper.27
During infancy, higher copper levels become dangerously toxic due to incomplete liver
function.19 Changes in the concentrations of heavy metals, including zinc and copper,
have been noted in numerous neurological disorders, including Parkinson’s Alzheimer’s
and Huntington’s Diseases.28 When copper concentrations are not controlled properly, it
becomes toxic to the central nervous system and liver, as occurs in Wilson’s Disease.20
4.1.4

Zinc to Copper Ratio

In recent years, efforts have been made to establish normal values and ratios of
metals in various human media including serum and plasma, with the aim of determining
the ranges which best support mammalian enzymatic activity and health. Zinc and
copper have antagonistic effects with respect to each other. A nearly 1:1 ratio of zinc to
copper in the serum has been associated with more effective immune responsiveness to
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infectious agents.29 Zinc maintains a balance with copper in blood, and the blood levels
of the two tend to be inversely related, with low plasma zinc nearly always being
associated with high serum copper. The zinc/copper (Zn/Cu) ratio has been implicated as
a rapid method of determining the functional state of the MT system. Lower zinc/copper
ratios may reflect total body zinc deficiency and decreased efficiency in eliminating
deleterious heavy metals from tissues and blood through the MT system. One of the
main functions of MTs is to eliminate metal ions, primarily to maintain zinc and copper
homeostasis.11 Since zinc and copper both interact with MT, the Zn/Cu ratio may be seen
as a way to determine the state of MT system functioning.
There are several published studies that state that the normal zinc to copper ratio,
in children and adults, is close to 1:1. In a recent study, Walsh et al.30-31 performed
measurements of the copper/zinc (Cu/Zn) ratio on autistic, PDD-NOS and Asperger’s
syndrome patients. The mean Cu/Zn ratio for the 503 autism spectrum patients was 1.63
and for the control patients was 1.15.30-31 When changed to Zn/Cu ratio, this data
becomes 0.6135 for autism spectrum patients and 0.87 for the control patients.30-31
Additionally, Van Weyenbergh et al.29 tested plasma zinc and copper concentrations and
Cu/Zn ratios in adults with leishmaniasis and healthy controls. In the control group of
this study, it was found that the mean Cu/Zn ratio in plasma was approximately 1. 29
Leishmaniasis patients had lower Zn/Cu ratios than controls.29 Walsh et al. measured
serum copper/plasma zinc ratios in assaultive young males. Walsh found the average
serum copper/plasma zinc ration in controls to be 1.02 while it was 1.40 in the assaultive
subjects.32

When changed to a Zn/Cu ratio, the controls’ value was 0.98 and the

assaultive subjects’ value was 0.71. The subjects in this study ranged from 3 to 20 years
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old with a mean of 9.5.32 This age range is very similar to the one in the current study.
Plasma zinc was noted to be a better measure of zinc status than serum zinc.32
Several studies suggest that mercury toxicity may be a major cause of MT
dysfunction in children with ASDs, which may be reflected in the Zn/Cu ratio. Geier et
al. studied urinary porphyrins in children with mild versus severe ASDs as determined by
the Childhood Autism Rating Scale (CARS) scoring.33 Urinary porphyrins associated
with mercury toxicity displayed significantly greater elevations in the severe ASD group
than the mild ASD group. These urinary porphyrins were positively correlated with
rising CARS scores and plasma oxidized glutathione levels, indicating that a measure of
mercury toxicity was associated with a more severe autistic presentation and oxidative
stress. Decreased levels of trans sulfuration metabolites, cysteine, reduced glutathione
and sulfur were present in children with ASDs compared with normal controls,
suggesting that mercury-induced MT dysfunction contributed to decrements in these
measures of chemical detoxification.
Multiple previous studies strongly suggest that certain urinary porphyrins,
including coproporphyrin and precoproporphyrin, are increased in children with ASDs
compared to controls, supporting the presence of mercury toxicity in many children with
ASDs.34-37
Multiple publications have shown lower levels of mercury in samples of first-cut
hair from children with autism, compared with controls. Adams et al. found that children
with lower levels of mercury in their hair were 2.5 times more likely to demonstrate
autism, indicating that the development of autism may be associated with decreased
ability to eliminate mercury from the body.38
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Holmes et al. also noted lower

concentrations of mercury in the first-cut hair of children with autism compared with
controls and described a pattern of decreasing severity of autism spectrum presentation
with increasing levels of hair mercury.39

This study supported the perspective that

increasing ability to efflux mercury was associated with less neurophysiological
dysfunction in these children. In contrast, a controlled study of toxic trace elements in
the hair of Kuwaiti children found significantly higher concentrations of lead, mercury
and uranium in children with autism.40 Kuwaiti children may be heavily exposed to
mercury from bread containing methyl mercury fungicide, and their environment has
been dramatically disrupted by war-related pollution. These conditions may have caused
autism in Kuwaiti children secondary to overwhelming mercury and other toxin
exposures, even though they maintained adequate MT functioning as indicated by the
efflux of mercury into their hair.
Higher levels of mercury are found in the blood, teeth and chelated urine
specimens of children with autism compared with controls.41-43 A case series of children
with regressive autism described by Geier and Geier noted that these children displayed
elevated androgen levels, which can adversely affect MT functioning, and evidence of
decrease performance of glutathione metabolism necessary for mercury excretion.44
Air pollution containing mercury has been strongly related to the incidence of
autism in children in San Francisco and in Southeastern Texas.45-46 Although the Institute
of Medicine concluded that there is no relationship between exposure to mercury from
vaccines in the form of thimerosal and autism and other neurodevelopmental disabilities,
studies continue to be published which provide concern that such exposure may be
related to the development of neurological disorders.47-49 Thimerosal was present in
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many Rho (D) immune globulin products given to pregnant Rh-negative women prior to
2002. Geier et al. demonstrated that a cohort of children born prior to 2001 with
neurodevelopmental disorders were more frequently born to mothers with Rh negativity
compared with controls, than children with neurodevelopmental disorders born after
2001, when thimerosal was taken out of Rho (D) immune globulin products.50
Given the importance of zinc and copper metabolism for healthy neurological
functioning and heavy metal, including mercury, detoxification, blood zinc and copper
concentrations were measured in the population of children with forms of autism
followed by the Neurodevelopmental Service of The Children’s Institute (Pittsburgh, PA,
USA). This retrospective study sought to determine the frequency of zinc deficiency,
copper toxicity and low plasma zinc/serum copper ratio (under 0.7) in a cohort of
children with ASDs, which may indicate increased risk for decrement in MT system
functioning and malabsorption created by low intestinal zinc-dependent enzyme
concentration.

4.2 Methods
A retrospective review was performed on data from 230 children (179 male, 51
female, mean age 6.3, standard deviation (SD) of 3.67) with autistic disorder, PDD-NOS
and Asperger’s syndrome diagnosed by structured interview, play observation and rating
scales (including the Childhood Autism Rating Scale and the Asperger’s Syndrome
Diagnostic Scale).51-52 Diagnostic and Statistical Manual-IV (DSM-IV) criteria were met
for these disorders and all children were placed in their diagnostic categories by Dr. Scott
Faber’s post-review of the range of data acquired by Scott Faber and other evaluating
clinicians, which often included Autism Diagnostic Observation Scale scores.53 When a
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rare disagreement about diagnostic classification occurred among involved clinicians,
Scott Faber utilized serial observations during follow-up visits to establish the diagnoses
utilized in this study.
This retrospective review of Scott Faber’s patient population was approved by the
Research Committee of The Children’s Institute and the Duquesne University
Institutional Review Board. Plasma zinc, serum copper and plasma zinc/serum copper
ratios were recorded for children with an autism spectrum diagnosis seen by the
Neurodevelopmental Pediatrics Service from July 2004 to December 2006, where this
information was available. The testing was performed by the University of Pittsburgh
Laboratory and Quest Labs (Pittsburgh, PA, USA).

The Associated Regional and

University Pathologists, Inc. (ARUP) national reference laboratory manual states that the
low plasma zinc level for children is 66 µg dL-1, and the high serum copper cut-off is 153
µg dL-1.54 An Excel spreadsheet was created to determine the mean, SD and confidence
intervals from the data. Analysis of variance (ANOVA) studies were performed using
the S Plus program. Only the first plasma zinc and serum copper values obtained after
the initial diagnostic visit were recorded. None of the children were on supplements or
restrictive diets at the time of the collection of the initial blood work.
Recognizing a Zn/Cu ratio value that generally separates healthy from affected
subjects can be accomplished through examination of the normal control groups in two of
Walsh’s cohorts.31-32 In these separate studies, the values of 0.613 and 0.725 were
identified to be exactly 2 SD below the mean Zn/Cu ratio of healthy subjects. Through
clinical assessment and the values of reported in both papers from Walsh et al., a Zn/Cu
ratio of 0.7 was chosen as a cut-off. The 0.7 value approximates the cut-off value
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separating the upper 97.5% from the lower 2.5% of the healthy population, provided
Walsh’s data is approximately normal.

4.3 Results
Analyses were performed to study the entire group as a whole, followed by
parcellation of the data into three subgroups: autistic disorder, PDD-NOS and Asperger’s
syndrome, to determine if significant differences emerged in mean zinc levels, mean
copper levels or zinc/copper ratios among the three groups using ANOVA.
4.3.1

Entire Cohort

Forty-seven children (20.4%) out of the entire group of 230 children with all
forms of autism had low zinc levels below 66 µg dL-1. One hundred seventeen children
(50.8%) of the 230 had zinc levels in the lowest 10% (below 75 µg dL-1) of the normal
range. The mean zinc level of the 230 children was 77.2 µg dL-1 (minimum (min): 44
µg dL-1, maximum (max): 130.4 µg dL-1, SD: 14.5 µg dL-1).
Thirty-nine children (17%) of 230 had high copper levels over 153 µg dL-1.
Seventy children (30.4%) of 230 had copper levels in the highest 10% (over 140 µg dL-1)
of the normal range. The mean copper level of the 230 children was 131.5 µg dL-1 (min:
78.3 µg dL-1, max: 228 µg dL-1, SD: 25.7 µg dL-1).
One hundred sixty seven out of 230 children (72.6%) had zinc/copper ratios under
0.7. The mean zinc/copper ratio of all of the children was 0.608 (min: 0.25, max: 1.01,
SD: 0.16). Male and female subjects did not significantly differ in mean zinc (p-value =
0.326), mean copper level (p = 0.762) or in Zn/Cu ratios (p = 0.774) (Table 18 and
Figures 18-21).
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4.3.2

Children Diagnosed with Autistic Disorder

The 78 children with autistic disorder had a mean zinc level of 76.9 µg dL-1 (min:
54 µg dL-1, max: 113.2 µg dL-1, SD: 14.1 µg dL-1). Fifteen children (19.2%) had low
zinc levels below 66 µg dL-1. Forty-one children (52.6%) had zinc levels in the lowest
10% (below 75 µg dL-1) of the normal range.
Their mean copper level was 129.7 µg dL-1 (min: 78.3 µg dL-1, max: 228 µg dL1

, SD: 29.1 µg dL-1). Twelve children (15.4%) had high copper levels over 153 µg dL-1.

Twenty-four children (30.8%) had copper levels in the highest 10% (over 140 µg dL-1) of
the normal range.
This subgroup’s mean zinc/copper ratio was 0.618 (min: 0.32, max: 0.99, SD:
0.1628). Fifty-six children (71.8%) had zinc/copper ratios under 0.7 (with one at 0.7).
Male and female children with autistic disorder did not significantly differ in mean zinc
(p = 0.6324), copper levels (p = 0.1324) or in zinc/copper ratios (p = 0.2093) (Table 18
and Figures 18-21).
4.3.3

Children Diagnosed with PDD-NOS

The 110 children with PDD-NOS had a mean zinc level of 77.1 µg dL-1 (min: 44
µg dL-1, max: 116 µg dL-1, SD: 13.7 µg dL-1). Twenty-one children (19.1%) had low
zinc levels below 66 µg dL-1. Fifty-four children (49.1%) had zinc levels in the lowest
10% (below 75 µg dL-1) of the normal range.
The mean copper level was 135.6 µg dL-1 (min: 90.7 µg dL-1, max: 197.9 µg dL1

, SD: 23.1 µg dL-1). Twenty-two children (20%) had high copper levels over 153

µg dL-1. Forty children (36.4%) had copper levels in the highest 10% (over 140 µg dL-1)
of the normal range.
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This subgroup’s mean zinc/copper ratio was 0.587 (min: 0.25, max: 1.01, SD:
0.15). Eighty-four children (76.4%) had zinc/copper ratios under 0.7 (one at 0.7). Male
and female children with PDD-NOS did not significantly differ in mean zinc (p =
0.4433), copper levels (p = 0.2872) or in zinc/copper ratios (p = 0.1995) (Table 18 and
Figures 18-21).
4.3.4

Asperger’s Syndrome Patients

The 42 children with Asperger’s disorder had a mean zinc level of 78.2 µg dL-1
(min: 52.3 µg dL-1, max: 130.4 µg dL-1, SD: 17.2 µg dL-1). Eleven children (26.2%)
had low zinc levels below 66 µg dL-1. Twenty-two children (52.4%) had zinc levels in
the lowest 10% (below 75 µg dL-1) of the normal range.
The children’s mean copper level was 124.4 µg dL-1 (min: 87.5 µg dL-1, max:
194 µg dL-1, SD: 23.9 µg dL-1). Five children (11.9%) had high copper levels over 153
µg dL-1. Six children (14.3%) had copper levels in the highest 10% (over 140 µg dL-1) of
the normal range.
This subgroup had a mean zinc/copper ratio of 0.644 (min: 0.36, max: 0.93, SD:
0.157). Twenty-seven children (64.3%) had zinc/copper ratios under 0.7 (one at 0.7).
Male and female children did not significantly differ in mean zinc (p = 0.705) or copper
(p = 0.5472) levels or in zinc/copper ratios (p = 0.9374) (Table 18 and Figures 18-21).
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Table 18: Mean plasma zinc, mean serum copper and mean plasma zinc/serum copper ratio including number of patients in each group. The 12
groups include the entire cohort, separated by diagnosis, gender, and diagnosis and gender. All confidence intervals are taken at the 95th
percentile.
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Plasma Zn (μg dL-1) Serum Cu (μg dL-1)
Entire data set
77.21 ± 1.87
131.37 ± 3.32
All autistic disorder patients
76.89 ± 3.18
129.68 ± 6.57
All PDD-NOS patients
77.07 ± 2.59
135.57 ± 4.37
All Asperger's syndrome patients
78.17 ± 5.36
124.41 ± 7.45
Male autistic disorder patients
77.26 ± 3.70
132.10 ± 6.62
Female autistic disorder patients
75.31 ± 6.36
119.49 ± 21.22
Male PDD-NOS patients
77.66 ± 2.92
134.19 ± 5.09
Female PDD-NOS patients
75.35 ± 5.85
139.59 ± 8.88
Male Asperger's syndrome patients
78.67 ± 6.48
125.50 ± 8.60
Female Asperger's syndrome patients
76.06 ± 8.26
119.75 ± 17.81
All male patients
77.71 ± 2.17
131.81 ± 3.61
All female patients
75.45 ± 3.71
130.57 ± 8.25
PDD-NOS: pervasive developmental disorder-not otherwise specified.

Zn/Cu Ratio
0.608 ± 0.020
0.619 ± 0.037
0.585 ± 0.028
0.644 ± 0.049
0.607 ± 0.041
0.667 ± 0.084
0.597 ± 0.034
0.555 ± 0.054
0.644 ± 0.058
0.648 ± 0.101
0.610 ± 0.023
0.602 ± 0.041

Number of Patients
230
78
110
42
63
15
82
28
34
8
179
51
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Figure 18: The plasma zinc concentrations for each patient in the cohort. The line at 66 µg dL -1 represents the low cut-off value according to
ARUP.54
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Figure 19: The serum copper concentrations for each patient in the cohort. The line at 153 µg dL -1 represents the high cut-off value according to
ARUP.54
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Figure 20: The mean plasma zinc/serum copper ratio and confidence intervals (95%) for Asperger’s syndrome, pervasive developmental
disorder-not otherwise specified (PDD-NOS) and autistic disorder patients. The confidence interval lengths are represented by the purple bars.
The mean values for each group are inscribed within each bar. The black vertical line at 0.8697 is the control mean value from the Walsh et al.
study.31 The dotted lines (0.7947 and 0.9445) represent the 95% confidence limits from the Walsh study. The red line at 0.7 represents the cut-off
line for a significantly low (bottom 2.5%) plasma zinc/serum copper ratio. The green line at 1 represents the normal value for zinc/copper ratio in
children.
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Figure 21: The plasma zinc/serum copper ratio for each individual patient separated by disease. Reference values and intervals are the same as in
Figure 20.

4.3.5

Comparison of Cohort Groups

An ANOVA test for equality of the mean zinc/copper ratio across the three
groups was significant at the 10% level; multiple comparisons revealed a significant
difference only between the mean zinc/copper ratio of the children diagnosed with PDDNOS and Asperger’s syndrome patients, with the PDD-NOS children having the lower
mean ratio (p = 0.03574). However, a Kruskal-Wallis test for equality of mean age
across groups was found to be significant at the 1% level (p = 2.2 ×10-16); multiple
comparisons reveal the mean age of the Asperger’s syndrome group to be greater than
both the PDD-NOS group (p = 2.38 × 10-8) and the autistic disorder group (p = 0.00036).
Zinc/copper ratio was significantly positively correlated with collection age (r = 0.375, p
= 5.24 × 10-9), and regression analyses show disease category to be a non-significant
predictor of the zinc/copper ratio in the presence of age. Therefore, the difference in
mean zinc/copper ratios among the groups cannot be attributed solely to disease type at
this time.
Some significant differences were noted in mean plasma zinc levels and serum
copper levels among all three groups. PDD-NOS patients demonstrated higher copper
levels on average than children with Asperger’s syndrome. The p-value when the mean
copper values for the PDD-NOS and the Asperger’s syndrome children were compared
pair wise was 0.009. There was no significant difference found when the mean copper
concentrations for PDD-NOS patients were compared with the autistic disorder group (p
= 0.1241) or when the autistic disorder group was evaluated against the Asperger’s
Syndrome patients (p = 0.317). When all three group’s mean copper concentrations were
compared, there was a significant difference found (p = 0.041).
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When the mean zinc concentrations of each of the three groups were evaluated,
there was no significant difference found (p = 0.89).

There were no significant

differences found when each of the group’s mean zinc concentrations were compared:
PDD-NOS vs. autistic disorder (p = 0.9267), autistic disorder vs. Asperger’s syndrome (p
= 0.6599), and PDD-NOS vs. Asperger’s syndrome (p = 0.682). The autistic disorder
group contained the only two children with very elevated serum copper levels over 200
µg dL-1.
Overall, 221 out of 230 patients (96.1%) had zinc concentrations below 105
µg dL-1 (the midpoint of normal zinc concentration) with 20.4% below the lower bound
of the normal range. For copper, 223 out of 230 children (96.9%) had concentrations
above 90 µg dL-1 (the midpoint of normal copper concentration) with 17% above the
upper bound of the normal range. For zinc/copper ratio, 229 out of 230 patients (99.6%)
had a ratio below 1.0 and 170 out of 230 (73.9%) had a zinc/copper ratio at or below 0.7.

4.4 Discussion
Children with ASDs from Western Pennsylvania, West Virginia and Southeastern
Ohio, frequently demonstrated low plasma zinc/serum copper ratios compared with
previously determined norms from the literature.29-32 In addition, their plasma zinc/serum
copper ratios frequently fell below 0.7, a demarcation line that was chosen to represent a
significant difference from the near 1:1 ratios seen in previous studies on child and adult
controls. The plasma zinc/serum copper ratio for the entire cohort of the present study
was 0.608, a figure that was quite similar to the ratio, 0.6135, noted on a previous dataset
presented by Walsh et al. in children with ASDs.30-31
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Twenty percent of the entire cohort of children with autism spectrum disorders
was zinc deficient and 17% of the cohort displayed copper toxicity based on normal
ARUP Laboratory ranges. The autistic group contained two children with very high
copper levels and extremely low zinc/copper ratios. Extreme elevations of serum copper
may indicate extraordinary stress on the MT system and may have contributed to the
severity of these children’s presentations. The Asperger’s syndrome and PDD-NOS
groups did not contain any children with this severity of copper toxicity. Zinc deficiency
and copper toxicity contribute to dysregulated neurotransmitter system functioning,
decreased zinc finger protein activity and diminished zinc-dependent gastrointestinal
enzymatic activity. The activation of the glutamatergic neurotransmitter system has been
shown to require zinc uptake to be triggered.55 Synaptic neurotransmission needs zinc as
an intracellular signal factor with its involvement with numerous proteins.55 Low zinc
concentrations can lead to oxidative stress which can change zinc finger motifs involved
as transcription factors in cell signaling.56 Zinc ions control, either directly or indirectly,
the molecular structures of zinc finger proteins.15 Previous literature showed zinc finger
DNA repair proteins could be inhibited by many toxic metals including copper.57 Copper
and other heavy metals prevent the activation of metal-responsive promoters.58
There were no significant differences between the zinc/copper ratios of males
versus females in the overall cohort (p = 0.7744) or in the autistic disorder (p = 0.2093),
PDD-NOS (p = 0.1995) and Asperger’s syndrome (p = 0.9374) groups. Autistic children
appear to demonstrate a similar degree of stress on their MT systems, regardless of their
sex. The 3.53 to 1 ratio of males to females in the study may be partially caused by sex
differences in metalloprotein functioning, as even very low dose pre-pubertal estrogen
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production in human females has been noted to have a salutary effect on metalloprotein
production and performance.59 There was a significant, positive correlation between
zinc/copper ratio and age of collection (r2 = 0.14), which may indicate improved MT
functioning in this study’s children as they age.
Zinc/copper ratios averaged below 0.7 in the autistic disorder, PDD-NOS and
Asperger’s syndrome subgroups. These groups, with significantly different behavioral
phenotypes, may share some degree of common etiology involving different levels of MT
system dysfunction. The conclusions of this study are limited by the selection of a
control group taken from the literature. Nonetheless, several previous studies suggest
that a plasma zinc to serum copper ratio of about 1:1 is normative in children and
adults.29-32 The children with ASDs in this study averaged a plasma zinc to serum copper
ratio of 0.608, suggesting a very significant difference in MT functioning compared with
healthy subjects. This value is below the 0.7 demarcation line indicating the lowest 2.5%
of zinc/copper ratios determined from the Walsh et al. studies.31-32
Western Pennsylvania has been noted to be in the high heavy metal pollution zone
of the United States according to data from the Environmental Protection Agency of the
USA. Pittsburgh is located in a region of the country where industry is responsible for
73% of the total atmospheric mercury emissions.60 Published studies have shown links
between exposure to airborne mercury emissions from coal-fired power plants and
increased autism rates.46, 61 Stress on the MT system of humans triggered by heavy metal
exposure may cause faster use of zinc reserves. This cohort’s overall propensity for
demonstrating decreased zinc levels, elevated copper levels and low zinc/copper ratios
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may be reflective of exposure beginning in utero, and may be affected by their mother’s
lifetime exposure to ambient heavy metals from the environment.
Zinc’s ability to up regulate MT gene expression and reduce toxicity from heavy
metal exposure suggests that the provision of zinc to children with ASDs may be an
important component of a treatment protocol, especially in children with zinc deficiency
(plasma zinc under 66 µg dL-1 according to ARUP) or Zn/Cu ratio under 0.7.54
The plasma zinc/serum copper ratio may be a biomarker that indicates stress on
the MT system of children with ASDs. Children with ASDs, according to data from the
studied cohort, appear at risk for zinc deficiency, copper toxicity, the demonstration of
low zinc/copper ratio, and decreased MT-system functioning. The results of this study
suggest that further work is required to explore MT dysfunction and zinc/copper
metabolism in children with forms of ASDs.
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Chapter 5
A Cleanroom Sleeping Environment’s Impact on Markers of
Oxidative Stress, Immune Dysregulation, and Behavior in
Children with Autism Spectrum Disorders
Ten children with autism slept in a cleanroom for two weeks to evaluate changes in toxin
levels, oxidative stress, immune dysregulation, and behavior. Before and after children
slept in the cleanroom, samples of blood and hair and rating scale scores were obtained to
assess these changes. Five children significantly lowered their concentration of oxidized
glutathione, a biomarker of oxidative stress. The younger cohort, age 5 and under,
showed significantly greater mean decreases in two markers of immune dysregulation,
CD3% and CD4%, than the older cohort. Changes in serum magnesium correlated
negatively while changes in serum iron correlated positively with age. The younger
children demonstrated significant improvements on behavioral rating scales compared to
the older children. In a younger pair of identical twins, one twin showed significantly
greater improvements in 4 out of 5 markers of oxidative stress, which corresponded with
better overall behavioral rating scale scores than the other twin. The cleanroom may
have altered elemental levels, lowered oxidative stress, decreased immune dysregulation,
and improved behavioral rating scales in the younger children.

5.1 Introduction
Autism spectrum disorders (ASDs) cause dysfunction in the areas of expressive
language production and quality, socialization ability, and control of excessive repetitive
thoughts and behaviors.1 Over the past two decades, worldwide incidence and prevalence
of these disorders have increased; however, scholarly opinion varies as to whether this
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rise is due to improved awareness, better age-related screening efforts, higher quality and
quantity of diagnostic centers, an expansion of the spectrum definition, the types of study
methods used, or a true escalation in the incidence and prevalence of autism.2-8 Although
much research has focused on finding a genetic cause of autism, it has not been
successful in explaining a majority of the diagnoses. In children with ASDs, only 21%
display genetic differences from the typically sequenced human DNA.9 Copy number
variants and losses have been strongly associated with the development of autism,10
potentially indicating a mechanism for genetic/environmental interaction.
5.1.1

Effects of Toxin Exposure

A recent review noted the possible contributions of toxin exposure during
gestation and early childhood to the development of autism.11 Emerging literature on the
exposome, which measures environmental, extracellular, and intracellular influences on
the expression of the genome, strongly suggests that adverse neurological outcomes can
be created by pre- and postnatal exposure to toxins.12 With the lack of success in finding
a purely genetic cause for autism, an emerging paradigm suggests that one of the causes
of the increased prevalence of ASDs could be difficulties in heavy metal and chemical
detoxification.13 Multiple studies have previously correlated proximity to coal fired
power plants, pesticide-rich agricultural fields, known toxic chemical sites, and trafficrelated air pollution with the prevalence of ASDs.14-18 It has been hypothesized that
difficulties in detoxification can cause oxidative stress19-23 and immune dysregulation,24-28
leading to or exacerbating ASDs phenotypic presentation.29-30
Exposure to environmental toxins, including heavy metals and chemicals, have
been shown to negatively affect systems of detoxification, involving glutathione31-33 and
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metallothionein,34-35 of which both zinc and selenium are key cofactors.36 Glutathione is
the central antioxidant responsible for environmental toxin detoxification37 and has been
used as a biomarker of oxidative stress to evaluate the methylation and sulfation
systems.38-39

The metallothionein system is also necessary for heavy metal

detoxification40 and can be assessed by the plasma zinc/serum copper ratio.35, 41 Studies
have shown that total glutathione, reduced/oxidized glutathione ratio, and zinc/copper
ratio are often lower in children with ASDs.35,

38-39, 41

Lower amounts of total

glutathione, triggered by increased environmental toxin exposure, have been shown to
also affect the immune system of children with autism, as evidenced by lower natural
killer (NK) cell activity.42
Difficulties in detoxification of heavy metals and chemicals can lead to
autoimmunity43-44 and immune dysregulation.24-25, 27 Forms of autoimmunity which use
NK cells to attack brain tissue45 may contribute to the under-connectivity between distant
areas of the brains of children with autism.46

Certain markers of immunological

regulation and function,47-49 such as the T cell helper/suppressor (CD4:CD8) ratio and
CD4%,50 are indicative of dysregulated innate and humoral immunity.51

Both the

CD4:CD8 ratio and CD4% have been shown to correlate with performance on the Autism
Behavior Checklist,50 indicating a link between immunological function and phenotypic
presentation. In addition, altered cytokine profiles in the immune systems of children
with ASDs have been connected to behavioral instabilities.52 Immune dysfunction has
been found in 15% to 60% of children with ASDs,53 and it was recently shown that, when
compared with controls, children with ASDs exhibited greater evidence of increased
detoxification difficulties, oxidative stress, and immune dysregulation.54

239

5.1.2

Cleanrooms and Detoxification

Given the emerging evidence connecting poor detoxification of environmental
toxins to the biomedical and clinical presentation of ASDs, an intervention that
temporarily decreases environmental exposure may positively impact phenotypic
presentation.55 Concentrations of fine particles and gaseous chemicals can be reduced in
cleanrooms by using high efficiency particulate air (HEPA) filters and activated carbon.
Individuals who have spent time in a cleanroom have presented reduced symptoms
associated with immunological response to IgE mediated allergies and mold.56-58 These
unique allergic and immunological responses cause the release of mast cell mediators that
can affect the central nervous system resulting in detrimental behavioral effects in certain
children with autism.59
The application of cleanroom technology in the treatment of children with ASDs
has been previously undertaken.60-63

These children improved significantly and

obviously in areas of expressive language, socialization, and obsessiveness after the first
several weeks of detoxification in their cleanrooms, and appeared to maintain these gains
even once removed from the clean environment.60-63 It was discovered that children with
milder forms of autism appeared to improve when exposed to lesser levels of
environmental cleanliness, while children with more severe autism needed to be fully
removed from environmental toxicity before gains could be seen. These studies suggest
that a cleanroom, which reduces the burden on detoxification systems, may lead to
decreased oxidative stress and improved immunological and neurological functioning in
children with autism.

Multiple studies have demonstrated the importance of early

treatment interventions.64-66 It has been shown that younger children with autism display
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greater and more rapid response to intensive treatments, and that there may be a crucial
time interval for intervention before the end of early life developmental plasticity.64
This study sought to demonstrate the effects of a cleanroom sleeping environment
on toxin levels and markers of oxidative stress, immune dysregulation, and behavioral
presentation in ten children with autism, ages 3 to 12. These effects were evaluated by
quantifying changes in blood toxin concentrations, glutathione levels, and markers of
immune function, and determining the correlation between age and improvement in these
markers.

5.2 Materials and Methods
5.2.1

Materials

5.2.1.1 Chemicals and Standards
All reagents were of analytical grade. ARISTAR ULTRA nitric acid (HNO3),
ARISTAR ULTRA hydrochloric acid (HCl), and ARISTAR ULTRA H2O that were used
only during sample analysis were procured from VWR (Radnor, PA, USA). American
Chemical Society (ACS) grade HNO3 and ACS grade HCl that were only used for
cleaning were obtained from Fisher Scientific (Pittsburgh, PA, USA). Multi-elemental
standards were purchased from High Purity Standards (Charleston, SC, USA). Applied
Isotope Technologies (AIT, Pittsburgh, PA, USA) provided the inorganic mercury
standard along with all of the isotopically enriched elemental solutions. The Inductively
Coupled Plasma-Mass Spectrometry (ICP-MS) tuning solution consisting of 1 nanogram
gram-1 (ng g-1) of lithium, cobalt, yttrium, cerium, and tellurium in 2% (v:v) HNO3 and
an internal standard solution containing 100 microgram gram-1 (µg g-1) of 6lithium,
scandium, germanium, rhodium, indium, terbium, lutetium, and bismuth were procured
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from Agilent Technologies (Santa Clara, CA, USA).

Standard Reference Material

(SRM) 1598a, Inorganic Constituents in Animal Serum, was purchased from the National
Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) and Certified
Reference Material (CRM) GBW09101b was obtained from the Shanghai Institute of
Nuclear Research of the Chinese Academy of Sciences (Shanghai, China).
5.2.1.2 Materials and Supplies
All tetrafluorometoxil (TFM™) microwave vessels, inserts, and lids were
obtained from Milestone Inc. (Shelton, CT, USA) and the magnetic stir bars were
procured from Big Science Inc. (Huntersville, NC, USA). VWR supplied the 50 mL
polypropylene centrifuge tubes. AIT provided the Isotope Dilution Mass Spectrometry
(IDMS) software. A Thermo Scientific (Pittsburgh, PA, USA) Barnstead EASYpure II
RF/Ultraviolet (UV) Model D7035 water purification system was used to further clean
double-deionized (DDI) water to a minimum resistivity of 18 MΩ-cm from a Barnstead
(Dubuque, IA, USA) NANOpure water system.
5.2.1.3 Instrumentation
The sample preparation for the analytical elemental analysis of the blood and hair
samples was performed using microwave-enhanced chemistry in a Milestone ETHOS 1
laboratory microwave system equipped with temperature and pressure feedback control.
This device accurately monitored and controlled the temperature to within ± 2 °C of the
preset values by automatically adjusting the microwave field output that has a maximum
power of 1500 Watts.

The closed ETHOS 1 system allowed for extremely high

temperature and pressure conditions of up to 300 °C and 100 bar to be maintained for
extended periods of time. The ten TFM™ microwave digestion vessels used in this study
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each contained three 6 mL TFM™ inserts with lids. The TFM™ inserts also have the
capability of withstanding the same temperature and pressure conditions as the digestion
vessels while increasing the number of samples from 10 to 30 per batch.
Mass spectrometric analysis was completed using an Agilent 7700 ICP-MS with a
micromist nebulizer, quartz spray chamber, an octopole reaction system, and a
quadrupole mass analyzer. It possesses a collision/reaction cell that uses hydrogen or
helium gas to eliminate polyatomic interferences. The samples and internal standard
were introduced into the ICP-MS through the micromist nebulizer of the spray chamber
using the peristaltic pump at a speed of 0.1 revolutions per second (rps). The samples
were stored in Agilent’s Integrated Autosampler before being analyzed. Both the ICPMS and autosampler were located in an International Organization for Standardization
(ISO) Class 6 cleanroom laboratory. The optimized parameters of the ICP-MS and
autosampler during analyses are shown in Table 19.
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Table 19: The optimized settings for the Agilent 7700 ICP-MS for EPA Method 6020B in blood,
EPA Method 6800 in blood, and EPA Method 6020B in hair.
EPA Method
EPA Method
EPA Method
Agilent 7700 ICP-MS
6020B Blood
6800 Blood
6020B Hair
Rf Power
1600 W
1600 W
1600 W
Spray Chamber Temperature
2 °C
2 °C
2 °C
Acquisition Mode
Spectrum
Spectrum
Spectrum
Peak Pattern
1 point mass-1
1 point mass-1
1 point mass-1
Sample Depth
9 mm
9 mm
9 mm
Plasma Gas
15 L min-1
15 L min-1
15 L min-1
Carrier Gas
0.9 L min-1
0.9 L min-1
0.9 L min-1
-1
-1
Dilution Gas
0.1 L min
0.1 L min
0.1 L min-1
-1
-1
H2 Cell Gas Flow
2 mL min
2 mL min
1.5 mL min-1
He Cell Gas Flow
2 mL min-1
2 mL min-1
1.5 mL min-1
Gas Stabilization Time
30 sec
30 sec
30 sec
Integration Time
0.1-1.0 sec mass-1
0.5-1.0 sec mass-1 0.1-1.0 sec mass-1
Replicates
4
4
4
Nebulizer Pump Speed
0.10 rps
0.10 rps
0.10 rps
Uptake time
30 sec
30 sec
30 sec
Stabilization time
30 sec
30 sec
30 sec

5.2.2

Methods

The current study was approved by the Institutional Review Board (IRB) of
Duquesne University (Pittsburgh, PA, USA) (IRB #09-131). The study was conducted at
The Children’s Institute (TCI, Pittsburgh, PA, USA). Before enrolling in the study, each
parent was presented with a consent form and each child was offered an assent form.
5.2.2.1

Subject Enrollment and Study Design

Ten children, ages 3-12, with certified psychologist confirmed Autism Diagnostic
Observation Scale (ADOS)67 autistic disorder were recruited from Dr. Scott Faber’s
practice at the Neurodevelopmental Service of TCI. Eligible children had prior evidence
of heavy metal and chemical toxicity and immune dysregulation seen through low plasma
zinc/serum copper ratios and abnormal T and B cell subsets, respectively. With stringent
recruitment due to funding from the Health Resources and Services Administration
(HRSA), the study included six Caucasian males, two females, one African American
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male, and one Asian male. Child #2 was unable to participate in the study because of the
inability to complete a blood draw.

The group intentionally contained two sets of

identical twins with autism (ages 5 and 12). All children selected lived within a thirty
minute drive of TCI.

Children were not eligible if they had severe behavioral

dysregulation, uncontrolled seizure activity, or any other severe chronic medical
condition, other than autism, that required frequent management by general pediatricians.
After signing the consent and being provided the opportunity for child assent,
each child and their family were given a tour of the cleanroom. Each child and a parent
spent two consecutive weeks sleeping in the cleanroom from May to October 2010.
During the day, the child and parent went about their normal activities and therapies.
Each evening, the child and parent arrived at TCI and spent approximately ten hours in
the cleanroom while wearing silk or cotton clothes. A research assistant recorded each
child’s sleep behaviors through an observation window.

The children and family’s

adjustment to the study was monitored by a Family Advocate Psychologist who had no
academic involvement in the study.

Diet, medications, nutrients, and experiential

services were held constant throughout the study.
5.2.2.2

Cleanroom Design

The cleanroom was designed and built at TCI in a modified hospital room. The
cleanroom floor was modified with Ohm-Shield (Static Solutions Inc., Marlborough,
MA, USA) Anti-Static Restorer/Cleaner FC-4500 followed by Ohm-Shield Static
Dissipative AF-6000/AF-6005 No VOC Floor Finish. The walls were covered with
Benjamin Moore (Montvale, NJ, USA) low odor, no VOC acrylic interior latex semigloss paint. Armstrong (Lancaster, PA, USA) Health Zone™ Ultima® cleanroom ceiling
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tiles were also installed. HEPA filters (99.99% efficient for 0.3 µm particles) were fitted
in each of the four air intakes in the room. A Model 7512 Second Wind Air Purifier
(Buffalo, NY, USA) was placed in the room and set to the lowest setting.

These

modifications allowed the cleanroom to have positive pressure compared to the hallway
outside. The room was furnished with ash furniture consisting of two twin beds, a
nightstand, and a table with two chairs from Stevens Woodworks (Allison Park, PA,
USA) which was only kiln dried and sealed with water soluble polyurethane and not
stained. The cleanroom bedding including the mattresses, pillows, pillowcases, mattress
pads, mattress toppers, and sheets was purchased from Naturepedic (Chagrin, OH, USA).
The room used incandescent lighting.

An ultraviolet water purification system was

installed in the adjoining bathroom.
5.2.2.3

Cleanroom Classification

The classification of the cleanroom was performed according to ISO 14644,
“Cleanrooms and associated controlled environments.” The cleanroom classification
from the ISO has been applied to microelectronics, pharmaceuticals, medical devices,
aerospace, and others.68 Part 1 of ISO 14644, ISO 14644-1:1999, “Classification of air
cleanliness,” defines the testing parameters which need to be followed in order for a room
to be classified according to ISO standards. Specifications for testing include the size of
the room, classification level, sample time, sample volume, and number of sampling
locations. The determining factor in the classification of cleanrooms is the concentration
of the particles in the room. Many different particle sizes have been selected with
defined limits for each classification level. Table 20 shows the classification standards
based on the concentration of different particle sizes for cleanrooms according to ISO.
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Table 20: Cleanroom classification table with particle size and concentration according to ISO
14644-1.68

The cleanroom testing was performed using a Hach (Loveland, CO, USA) Met
One HHPC-6 Handheld Airborne Particle Counter. This particle counter is capable of
measuring particles at 0.5, 0.7, 1.0, 2.0, 5.0, and 10.0 micrometers (µm). Data were
reported in concentration mode.
measured during sampling.

The relative humidity and temperature were also

All data were downloaded into PortAll software and

analyzed using PortAll software and Microsoft Excel.
The cleanroom classification was performed at two different stages as defined by
the ISO: ‘as-built’ and ‘at-rest’. After the hospital room at TCI was finished being
modified, the cleanroom was at the ‘as-built’ stage meaning the room is at a “condition
where the installation is complete with all services connected and functioning but with no
production equipment, materials, or personnel present.”68 Once the cleanroom had been
furnished with furniture and bedding, the cleanroom was at the ‘at-rest’ stage. This stage
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is where “installation is complete with equipment installed and operating in a manner
agreed upon by the customer and supplier, with no personnel present.”68 An adjacent
room and the hallway outside of the cleanroom were also classified ‘at-rest.’
Calculations were performed to determine the testing criteria for the cleanroom,
adjacent room, and hallway. The first variable to be established is the particle limit for
each ISO class because the classification of a cleanroom is based on the concentration of
particles. For classification in this study, 0.5 µm particles were used. Under the old
Federal Standard 209, the classification of a cleanroom is based on the amount of
particles ≥ 0.5 µm in one cubic foot of room air which does not exceed the classification
limit.69 This equivalent was converted to the current ISO 14644-1:1999 standards. The
ISO established limits for cleanroom particle concentration using Equation 3,

(

)

Equation 3: The equation for calculating the maximum number of particles at a particular
particle size for cleanroom classification according to ISO.68

where Cn is “the maximum permitted concentration of airborne particles that are equal to
or larger than the considered particle size”, N is the ISO classification number, D is the
particle size measured, and 0.1 is a constant.68

In accordance with the testing

classification, both the average particle concentration and 95% upper confidence limit are
calculated using the appropriate statistical equations.68

Both the average particle

concentrations and the 95% upper confidence limit must not exceed the particle limits for
that classification level as shown in Table 20.
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The next factor to be determined is the number of sampling locations. The size of
the cleanroom dictates the number of sampling locations.

Equation 4 shows the

calculation for the number of sampling locations,

√
Equation 4: The equation for determining the number of sampling locations for cleanroom
classification.68

where NL is the minimum number of sampling locations and A is the area of the room in
square meters.68 The cleanroom is 12’ × 16’ with an area of 192 ft2 or 17.84 m2. From
this equation, it is ascertained that five sampling locations are required by rounding up to
the next whole number as shown in Equation 5.

√

√

√

√

Equation 5: The application of the sampling location equation to the cleanroom built at The
Children’s Institute.

With the number of sampling locations determined, it was necessary to classify the room
according to ISO standards. The room will be attempted to be classified at ISO Class 5
as it is a reasonable classification level for the room in its current condition based on the
improvements made to the room. If the room does not meet ISO Class 5 classification, it
will meet ISO Class 6 level or higher standards.
The first parameter needed to determine class level is the sample volume. The
sample volume is calculated using Equation 6,

Equation 6: The equation for the determination of the minimum sample volume in a single
sample according to ISO.68
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where Vs is the minimum sample volume per location in liters, Cn,m is the limit of the
number of particles for the class, and 20 is the number of particles counted if the room
was at the class limit.68 For ISO Class 5, C = 3,520 and for ISO Class 6 C is 35,200 for
0.5 µm particles. The calculations are shown below in Equation 7.

Equation 7:
cleanrooms.

The determination of the minimum sample volume for ISO Class 5 and 6

The minimum sampling requirements for the ISO are a one minute sampling time
and two liters of air sampled.68

The particle counter samples at 2.83 L minute-1;

therefore, a 2 minute sample is sufficient to meet ISO Class 5 and higher classification
levels because a sample of 2 minute produces a count of 19.92 particles at the minimum
particle concentration for ISO Class 5. The sampling parameters of 5.66 L sampled over
a two minute time period exceed the minimum criteria. With these calculations, all of the
sampling parameters have been determined for ISO Class 5 and are acceptable to all
higher ISO classification cleanrooms.
The cleanroom classification began by sampling the cleanroom, the room adjacent
to the cleanroom, and the hallway outside of the cleanroom. The adjacent room was
evaluated for the improvements made to the cleanroom and the hallway was sampled to
provide a control for both the cleanroom and the adjacent room. The sampling was
performed by placing the particle counter on a 46” ladder to simulate breathing and
sleeping levels. At each of the five sampling locations, three different trials were taken.
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The same random sampling order was used for all three locations. When sampling was
performed in the cleanroom, a ten minute equilibration time interval was used to allow
the room to return to equilibrium before testing began. The testing was performed while
the analyst was wearing a full cleanroom coverall, bouffant, facemask, gloves, sleeve
covers, shoe covers, and goggles to prevent any possible contamination from the analyst.
A zero count filter reading was performed before the sampling began.

All of the

sampling locations were at least one foot away from an air inlet. The bathroom door
remained closed during the testing as it did during the clinical application of the
cleanroom. The layouts of the three sampling areas along with the airflow diagrams are
shown in Figures 22-26.
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Figure 22: Diagram of the airflow of the cleanroom at The Children’s Institute.
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Figure 23: Sampling diagram of the cleanroom at The Children’s Institute.
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Figure 24: Diagram of the airflow of the room adjacent to the cleanroom at The Children’s
Institute.
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Figure 25: Sampling diagram of the room adjacent to the cleanroom at The Children’s Institute.
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Figure 26: Sampling diagram of the hallway outside of the cleanroom at The Children’s Institute.

5.2.2.4 Blood Draw, Hair Collection, and Clinical Testing
Within 24 hours before and after the two week study period, approximately 30
milliliters of blood were drawn by a phlebotomist who specialized in working with
children with developmental disabilities. The draws were completed at the child’s home,
and the blood was processed and stored within 2 hours at Duquesne University. The
blood was separated with a calibrated centrifuge and aliquoted for testing by Quest
Diagnostics (Pittsburgh, PA, USA) and Duquesne University. In addition, a hair sample
was obtained from the back of the head, and it was placed in a clean, sealable
polyethylene bag for transport to Duquesne University for analysis.

The Quest

Diagnostics testing included plasma zinc; serum copper; T and B lymphocyte subsets;
serum IgA, IgG, and IgM immunoglobulins; and complete blood count including
differential and platelets. The Duquesne University analyses included elemental analysis
in serum, plasma, red blood cells (RBCs), and hair; total, oxidized, and reduced
glutathione in RBCs; and benzene, toluene, and o-xylene along with selected
polychlorinated biphenyls (PCBs) in serum.

The glutathione and organic chemical

testing will not be discussed in detail in this chapter as it is part of a larger study. The
remaining serum, plasma, and RBCs to be tested by Duquesne University were stored at 80 °C.
5.2.2.5 Microwave Closed Vessel Preparation and Cleaning
The sample preparation procedures for the elemental analysis in blood and hair
were performed in an ISO Class 6 cleanroom using microwave digestion vessels and
inserts. The 6 mL microwave inserts and lids were cleaned before each digestion with 3
mL of HNO3 and 1 mL of HCl. Outside of the three inserts, 5 mL of HNO3 was added to
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each digestion vessel to allow the temperature of the vessels to be monitored and ensure
that the inserts maintained the proper temperature.

The vessels were microwaved

according to United States Environmental Protection Agency (EPA) Method 305270 using
a 10 minute ramp to 180 °C with a 10 minute hold at 180 °C. After microwaving, the
vessels, lids, and stir bars were rinsed inside and outside with DDI water and dried on
cleanroom wipes overnight.
5.2.2.6 Elemental Analysis of Blood
5.2.2.6.1 Sample Digestion for Elemental Analysis by External Calibration Curve
Three different sample matrices were analyzed: serum, plasma, and RBCs. For
each matrix, child, and sampling time, two subsamples were prepared in clean 6 mL
microwave vessel inserts. After a stir bar was added to each insert, 0.2 grams of sample
from the respective matrix was combined with 3 mL of HNO3 and 0.25 mL of HCl. For
each batch of samples, two subsamples of SRM 1598a were prepared in the same manner
as the samples for quality control. Similar to the vessel cleaning, 5 mL of HNO3 was
added to the microwave digestion vessels outside of the 6 mL inserts. The samples were
microwaved according to EPA Method 3052 resulting in a complete digestion seen
through the production of homogenous, transparent, light yellow solutions that did not
contain any solids. After microwaving, each sample was poured into a 50 mL centrifuge
tube and diluted with a 1% HNO3 and 0.5% HCl solution until the final volume was 10
mL. The centrifuge tubes were weighed before and after the addition of the digests along
with being pre-rinsed with the 1% HNO3 and 0.5% HCl solution. Ten analytical blanks
consisting of HNO3 and HCl were prepared for each set of samples. The microwave
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vessels were rinsed with DDI water after being used and cleaned as previously described.
The samples were stored in a cold room at 4 °C until analysis, typically within 3 days.
5.2.2.6.2 Total Elemental Quantification by EPA Method 6020B
The total elemental concentrations in the sample digests were determined
according to EPA Method 6020B.71 On each day of analysis, the system was aspirated
with 2% HNO3 for 30 minutes before tuning the instrument using the Agilent tuning
solution at a concentration of 1 ng g-1 and determining the pulse/analog factor (P/A).
Analysis on the Agilent 7700 ICP-MS was performed in three analysis modes: hydrogen,
helium, and no gas. The amount of hydrogen and helium gas was optimized to minimize
polyatomic interferences. Between analysis modes, a 30 second delay was employed to
equilibrate the presence or absence of collision gas and/or reaction gas. The analysis
mode for each element is listed in Table 25.
Calibration curves were created for 58 elements using solutions from the sing and
multi-element standards. The calibration solutions were prepared at concentrations of 0,
2.5, 5, 7.5, and 10 ng g-1 in a 1% HNO3 and 0.5% HCl solution by serial dilution. In the
first two sample sequences, four children’s before and after samples (serum, plasma, and
RBCs) were analyzed per run with four replicates taken from each subsample. The last
sequence included all of the samples from the last two children. Analysis was performed
using spectrum mode with one point per mass. The integration times ranged from 0.1-1.0
seconds per point depending on the element’s ionization energy. After analysis, the data
was taken from Agilent MassHunter software (version G7201A A.01.01) and exported
into Microsoft Excel for further data processing.
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5.2.2.6.3 Sample Digestion for Elemental Analysis by IDMS
The blood samples to be analyzed according to EPA Method 6800 were also
prepared using microwave sample digestion. Similar to the EPA Method 6020B sample
preparation, two samples of each matrix, child, and sampling time were prepared. Using
clean microwave vessels, 0.2 grams of sample were combined in each insert with a stir
bar, the appropriate amount of isotopically enriched analyte, 3 mL of HNO3, and 0.25 mL
of HCl. SRM 1598a was also used for quality control of each batch. Similar to the EPA
Method 6020B sample preparation, 5 mL of HNO3 was added to each digestion vessel
outside of the inserts. The samples were digested following EPA Method 3052 with the
same parameters as the EPA Method 6020B sample preparation.

The same post

microwave sample protocol was followed as EPA Method 6020B preparation. After
completing the post microwave procedure, samples were stored at 4 °C in a cold room
until analysis, usually within 2 days. With each batch of samples, ten analytical blanks
consisting of HNO3, HCl, and isotopically enriched versions of the elements of interest
were prepared.
5.2.2.6.4 Total Elemental Quantification by EPA Method 6800
Total elemental quantification using IDMS, a component of EPA Method 680072
was performed for nine elements (antimony, cadmium, chromium, copper, lead, mercury,
molybdenum, selenium, and zinc). On each day of analysis, the ICP-MS was tuned and
the P/A factor was determined as previously described. The IDMS analysis was also
completed using the three different modes with the same collision/reaction gas
parameters. Analysis was performed in spectrum mode with one point per peak with
integration times between 0.5-1.0 seconds per point for each element. Each subsample
260

had four replicates analyzed. The first two sequences contained four children’s sample
while the last one contained the samples from the last two children. Natural abundant
standards of the nine elements were analyzed at 0, 2, 4, 6, 8, and 10 ng g-1 to determine
the mass bias and deadtime correction factors. The Agilent 7700 ICP-MS’s default
deadtime of 38 nanoseconds was used for the IDMS calculations. The concentrations for
each of the isotopically enriched elements were calculated by reverse IDMS analysis
using the multi- or single element standard solutions. The completed data was exported
into the IDMS software provided by AIT in Microsoft Excel from Agilent MassHunter.
The analyte concentrations in the sample solutions were determined by the IDMS
equation (Equation 1).
5.2.2.7 Elemental Analysis of Hair
5.2.2.7.1 Sample Decomposition for Total Elemental Analysis by External
Calibration Curve
The hair elemental analysis samples were also prepared using microwaveenhanced chemistry. Two subsamples of each child and sampling time were analyzed for
the hair analysis. Using clean microwave inserts, 0.1 grams of sample were combined
with a stir bar, 0.5 mL of HNO3, and 0.2 mL of HCl. CRM GBW09101b was used for
quality control with all of the same sample preparation parameters, except 0.2 grams of
CRM GBW09101b were used to meet the specifications of the CRM certificate. As in
the blood analysis, 5 mL of HNO3 was added to the microwave digestion vessels outside
of the inserts. The hair samples were microwaved according to the previously described
parameters of EPA Method 3052. The same post microwave procedure as during the
blood analysis was employed. Eight analytical blanks consisting of HNO3 and HCl were
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digested with each sample batch. The samples were stored in a cold room at 4 °C until
the day of analysis, usually within 3 days.
5.2.2.7.2 Quantification of Total Elemental Concentrations by EPA Method 6020B
The total elemental concentrations in hair were determined in the digests using
EPA Method 6020B. The ICP-MS was tuned and the P/A factor was determined on each
analysis day as previously described. Similar to the blood analysis, the three different
collision/reaction gas modes were used with the previously described parameters.
Using the single and multi-element standards, calibration curves were prepared
for 58 elements. Due to the wide range in concentrations of the elements of interest in
CRM GBW09101b and the hair samples, the analysis performed at two different
calibration ranges as the digests were diluted an additional 100:1 using a 1% HNO3 and
0.5% HCl solution on the day of analysis.

Calibration solutions were prepared at

concentrations of 0, 5, 10, 25, 50, and 100 ng g-1 through serial dilution using the 1%
HNO3 and 0.5% HCl solution.
During each sequence, five children’s before and after hair samples were analyzed
with four replicates taken from each subsample.

The analyses were completed in

spectrum mode using one point per mass. The integration times for each element ranged
from 0.1-1.0 seconds per point based on the ionization energy of each element. The
measured concentration value for each element in CRM GBW09101b and each hair
sample was determined based on the value that fell within the range of one of the two
calibration curves. After analysis, additional data analysis was performed in Microsoft
Excel after being exported from Agilent MassHunter.
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5.2.2.7.3 Quality Control
The current study implemented numerous quality control measures that were
previously mentioned including the preparation of multiple subsamples, replicate
analysis, preparation of analytical blanks, acid or solution matched calibration standards,
and reference materials. It also utilized many of the quality control measures described
in EPA Method 6020B.

The Agilent internal standard solution was used at a

concentration of 100 ng g-1 in a 1% HNO3 and 0.5% HCl solution, and its acceptable
recovery was maintained between 80 and 120% of the calibration blank.

Between

samples, the autosampler probe was washed in three 1% HNO3 and 0.5% HCl solutions
for 30 seconds each with a nebulizer pump speed of 0.5 rps. After every ten samples
during EPA Method 6020B analysis, calibration checks and either SRM 1598a or CRM
GBW09101b assessments were performed as additional calibration verification. During
EPA Method 6800 analysis, SRM 1598a checks were performed at the beginning,
middle, and end of each analysis sequence. These checks ensured the consistency of the
results during the complete duration of the sample runs.
5.2.2.8 Behavioral Rating Scales
The same parent filled out multiple behavioral rating scales within 24 hours of the
beginning and end of the cleanroom experience. The rating scales completed included
the Social Communication Questionnaire (SCQ),73 PDD Behavioral Inventory
(PDDBI),74 Aberrant Behavior Checklist (ABC),75 Gilliam Autism Rating Scale-2
(GARS-2),76 Autism Treatment Evaluation Checklist (ATEC),77 and Childhood Autism
Rating Scale (CARS).78 The SCQ is used to assess the social interactions, language and
communication aptitude, and stereotyped and repetitive behaviors of children with an
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autism spectrum disorder.79 The PDDBI has multiple domains and composites that
measure both adaptive and maladaptive behaviors,80 and the Autism Composite is
calculated using selected domains. The total ABC is the summation of five subscales: (I)
Irritability, Agitation, Crying; (II) Lethargy, Social Withdrawal; (III) Stereotypic
Behavior; (IV) Hyperactivity, Noncompliance; and (V) Inappropriate Speech.75 The
results of these rating scales were recorded and pooled for statistical analysis.
5.2.2.9 Statistical Analysis
All statistical analyses were performed using the R statistical software package.
To investigate an overall cleanroom impact, the n = 10 pre-cleanroom measurements
were subtracted from the corresponding post-cleanroom measurements for each variable.
Paired t-tests were used to identify whether the observed mean differences deviated
significantly from zero. Two separate statistical analyses were performed to investigate
the relationship between measurement change and subject age. Preliminary statistical
analysis indicated the necessity to divide the entire study population into younger and
older cohorts. An independent sample t-test was implemented for each variable to assess
whether the average difference observed for subjects in the younger cohort, age 5 and
under, was significantly different than for subjects in the older cohort, who were age 6
and older. A Pearson correlation between measurement difference and subject age was
also computed for each variable.
Replicate analyses were performed for all chemical and elemental tests, allowing
for confidence intervals to be used as a means of comparing difference in values. The
rating scale and commercial laboratory measurements are single-measurement results and
do not provide such statistical power.

An independent samples t-test was used to
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determine whether the average of the pre-cleanroom replicate measurements for a
particular subject differed significantly from the average of the post-cleanroom replicate
measurements for that subject. The fact that funding constraints allowed for only n = 10
subjects is the greatest statistical limitation of this study. This sample size provided
relatively weak statistical power (as compared to larger sample sizes) for recognizing
small or moderate differences when they exist.

This issue, combined with the

exploratory nature of this study and the fact that variables within a category are often
correlated (as with the rating scale variables), has prompted the authors to consider pvalues at or below the 0.05 significance level as indicative of a noteworthy result.

5.3 Results
5.3.1

Cleanroom Classification

The three different areas were classified according to ISO standards:

the

cleanroom, the adjacent room, and the hallway. After the results were obtained using the
Met One particle counter, they were downloaded in the PortAll software and then
exported to Microsoft Excel. In Excel, the averages of the five sampling locations were
calculated. The standard deviation and confidence interval (CI) were determined using
the five averages. The confidence interval is calculated as a 1-sided confidence interval
since the results are only concerned with the maximum possible value to meet the ISO
classification standards and not with how low the value is for the lower bound. The 1sided confidence interval means that the results are 95% confident that the results are
below the numeric value of 95% upper confidence interval bound.

In a 2-sided

confidence interval, the results are 95% sure they fall within a range symmetric to the
mean. In the initial testing, the cleanroom was at the ‘as-built’ stage and the adjacent
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room and hallway were at the ‘at-rest’ stage. The Excel results from the initial testing are
shown in Tables 21-23. Reports were also made in the PortAll software.
The particle counting results for the cleanroom at the ‘at built’ stage are shown in
Table 21, which indicated that the particle concentration for 0.5 μm particles met the
standards for ISO Class 6 classification with both the average and the 95% upper
confidence limit below the 35,200 0.5 μm particles m-3 threshold.

Of the selected

sampling locations, location #2 was near the window in the room and location #4 was
near the door. The higher particle counts at these locations could have been the result of
outside air entering the room near these sampling locations, but the elevated counts at
these locations did not affect the classification of the room.
Table 21: Particle concentration results for the classification of the ‘as-built’ cleanroom at The
Children’s Institute.
Location

0.5 μm m-3

0.7 μm m-3

1 μm m-3

2 μm m-3

5 μm m-3

10 μm m-3

Cleanroom #1
Cleanroom #2
Cleanroom #3
Cleanroom #4
Cleanroom #5

5,343
18,142
8,631
18,024
14,932

4,580
14,854
7,632
16,674
13,053

3,934
13,327
6,693
15,147
11,723

3,464
10,685
5,460
13,504
9,883

1,468
4,580
2,290
6,693
4,521

352
939
822
1,938
1,233

Average

11,355

9,981

8,936

7,621

3,511

916

Standard
Deviation

6,253

5,427

4,980

4,268

2,116

617

95% Upper
Confidence
Limit

17,311

15,150

13,680

11,686

5,526

1,503

For the adjacent room, the classification results seen in Table 22 meet the
qualifications for an ISO Class 7 cleanroom. Both the average of the sampling locations
and the 95% upper confidence interval bound were less than the 352,000 0.5 μm particles
m-3 limit. All of the sampling locations produced relatively equivalent data, indicating
that the concentration of particles is distributed consistently throughout the room. In
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comparison to the adjacent room, the cleanroom had a twenty-fold decrease in 0.5 μm
particles for the ‘as-built’ results.
Table 22: Particle concentration results for the classification of the ‘at-rest’ adjacent room at The
Children’s Institute.
Location
Adjacent
Room #1
Adjacent
Room #2
Adjacent
Room #3
Adjacent
Room #4
Adjacent
Room #5

0.5 μm m-3

0.7 μm m-3

1 μm m-3

2 μm m-3

5 μm m-3

10 μm m-3

236,429

135,622

104,799

71,040

20,842

8,220

203,845

109,085

81,373

54,777

16,087

6,106

232,085

128,753

96,227

62,762

17,848

6,869

230,147

131,865

98,634

66,226

19,844

7,632

240,715

136,327

101,570

68,046

21,077

7,280

Average

228,644

128,331

96,521

64,570

19,140

7,221

Standard
Deviation

14,452

11,182

9,056

6,242

2,129

796

95% Upper
Confidence
Limit

242,410

138,982

105,147

70,516

21,168

7,980

The classification results for the hallway outside of the cleanroom and adjacent
room are displayed in Table 23. The hallway met the classification standards for ISO
Class 7. The hallway air quality was equivalent to the adjacent room based on the ISO
classification standards, and this result is logical as these areas were unmodified in
comparison to the cleanroom.

The distribution of particles is relatively consistent

throughout the hallway.
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Table 23: Particle concentration results for the classification of the ‘at-rest’ hallway at The
Children’s Institute.
Location

0.5 μm m-3

0.7 μm m-3

1 μm m-3

2 μm m-3

5 μm m-3

10 μm m-3

Hallway #1
Hallway #2
Hallway #3
Hallway #4
Hallway #5

195,860
256,391
200,146
238,954
224,804

102,627
143,666
106,149
136,562
126,111

75,209
107,735
78,027
105,328
93,938

50,257
72,860
53,838
74,035
63,525

15,735
20,784
18,259
23,778
22,251

6,634
7,632
7,398
10,862
9,452

Average

223,231

123,023

92,047

62,903

20,161

8,396

25,648

18,164

15,051

10,788

3,204

1,723

247,663

140,325

106,384

73,180

23,213

10,037

Standard
Deviation
95% Upper
Confidence
Limit

After the furniture and bedding had been installed, the cleanroom was at the ‘atrest’ stage. The testing methods for the ‘at-rest’ cleanroom were the same as the ‘asbuilt’ stage. The same testing protocols were followed, except the particle counter was
held by the analyst at a height approximate to the level during the ‘as-built’ testing
instead of being placed on a ladder.
The ‘at-rest’ results for the cleanroom are shown in Table 24.

The results

indicated that the cleanroom met the criteria for ISO Class 5 classification as both the
average of the five sampling locations and 95% upper confidence limit bound are below
the ISO Class 5 limit of 3,520 0.5 μm particles m-3. The data indicated an increase in the
cleanliness of the air in the cleanroom despite the addition of furniture and bedding. The
five sampling locations also produced more equivalent data in comparison to the ‘asbuilt’ data, suggesting that the air quality is more consistent throughout the room.
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Table 24: Particle concentration results for the classification of the ‘at-rest’ cleanroom at The
Children’s Institute.
Location
0.5 μm m-3 0.7 μm m-3 1 μm m-3 2 μm m-3 5 μm m-3 10 μm m-3
Cleanroom #1
1,057
646
528
352
117
0
Cleanroom #2
1,703
998
881
587
235
0
Cleanroom #3
1,057
705
411
294
117
59
Cleanroom #4
470
470
411
294
176
0
Cleanroom #5
2,172
1,350
939
587
176
117
Average
Standard
Deviation
95% Upper
Confidence
Limit

1,292

834

634

423

164

35

658

346

257

152

49

53

1,918

1,163

879

567

211

85

Upon the completion of cleanroom classification testing, the cleanroom was
classified at ISO Class 6 for the ‘as-built’ state and ISO Class 5 for the ‘at-rest’ status.
The improvements made to the cleanroom improved the air cleanliness from the ISO
Class 7 levels found in the hallway and the adjacent room. The overall air quality in the
cleanroom was approximately twenty times cleaner during the initial ‘as-built’ stage and
175 times better during the ‘at-rest’ testing compared to the unmodified adjacent room.
5.3.2

Elemental Analysis of Blood and Hair

5.3.2.1 Analytical Figures of Merit and Validation of EPA Methods
All elements displayed linearity on the five or six point external calibration curves
for the EPA Method 6020B blood and hair analysis, respectively. They had correlation
coefficient (r2) values greater than the 0.998 specified in EPA Method 6020B, except for
Mg in the blood analysis, which was just below this cutoff at 0.9935 (Tables 25 and 26).
The obtained measurements were highly reproducible because the four replicates for each
calibration point displayed a typical variation of less than 5%.
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Table 25: The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of
interest in blood determined by EPA Method 6020B using the Agilent 7700 ICP-MS.

Element
Mg
Al
V
Cr
Mn
Fe
Co
Ni
Cu
Zn
As
Se
Rb
Mo
Cd
Sb
Te
Cs
Hg
Pb

m/z
24
27
51
52
55
56
59
60
63
66
75
78
85
95
111
121
125
133
202
208

Mode
He
No gas
He
He
He
He
He
He
He
He
He
H2
He
He
He
No gas
No gas
No gas
No gas
No gas

r2
0.9935
0.9983
1.0000
1.0000
0.9999
1.0000
0.9999
0.9996
1.0000
0.9993
1.0000
0.9999
0.9998
1.0000
0.9999
1.0000
0.9997
0.9999
0.9999
0.9999

DL (ng g-1)
2.09
16.3
0.191
19.9
1.33
84.2
69.6
38.2
10.1
5.41
0.0296
0.0225
0.00231
0.248
0.420
0.605
0.0544
0.000649
0.205
0.225
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QL (ng g-1)
5.17
35.0
0.268
46.2
3.59
195
195
98.0
28.1
10.3
0.0598
0.0544
0.00733
0.579
0.802
1.41
0.140
0.00193
0.376
0.506

BEC (ng g-1)
0.885
2.33
0.0565
0.391
0.184
1.19
0.0163
1.67
0.159
0.639
0.0132
0.00806
0.0129
0.00934
0.0491
0.0139
0.0151
0.00170
0.0199
0.0658

Table 26: The analysis information, correlation coefficient, DLs, and BECs for elements of
interest in hair determined by EPA Method 6020B using the Agilent 7700 ICP-MS.

Element
Na
Mg
Al
P
K
Ca
V
Cr
Mn
Fe
Co
Ni
Cu
Zn
As
Se
Sr
Mo
Ag
Cd
Sb
Ba
La
Hg
Pb
U

m/z
23
24
27
31
39
40
51
52
55
56
59
60
63
66
75
78
88
95
107
111
121
137
139
202
208
238

Mode
No gas
No gas
No gas
No gas
No gas
H2
He
He
He
He
He
He
He
He
He
H2
No gas
He
No gas
He
No gas
No gas
No gas
No gas
No gas
No gas

r2
0.9995
0.9999
0.9998
0.9997
0.9988
0.9958
1.0000
1.0000
0.9999
0.9986
1.0000
0.9999
0.9999
1.0000
1.0000
0.9999
0.9999
1.0000
0.9999
1.0000
0.9998
1.0000
1.0000
1.0000
0.9999
0.9997

DL (ng g-1)
31.7
3.06
6.03
13.0
6.87
4.95
0.376
2.05
0.123
1.76
0.0339
1.82
0.0766
0.416
0.140
0.0426
0.0246
0.117
0.0994
0.857
0.552
0.546
0.0000235
0.297
0.177
0.000389

QL (ng g-1)
70.0
5.95
14.9
14.9
15.6
13.8
0.300
2.62
0.306
4.71
0.0679
4.28
0.255
1.21
0.172
0.110
0.0739
0.330
1.95
0.263
1.33
1.48
0.0000729
0.517
0.431
0.00130

BEC (ng g-1)
4.22
1.30
4.46
18.5
78.5
93.0
0.339
0.587
0.105
6.34
0.00855
0.595
0.791
1.73
0.113
0.0778
0.0619
0.0549
0.00583
0.0269
0.0355
0.191
0.00208
0.177
0.0293
0.000603

The detection limits (DLs) were defined as the average of the blank concentration
for each element plus three times the standard deviation of the blank measurements for
that respective element.81 The DLs for all elements were below 1 ng g-1 except for Mg,
Al, K, V, Cr, Mn, Fe, Co, Ni, Cu, and Zn for the EPA Method 6020B blood analysis
(Table 25); Cr, Zn, and Se for the EPA Method 6800 blood testing (Table 27); and Na,
Mg, Al, P, Ca, Cr, Fe, and Ni for the EPA Method 6020B hair analysis (Table 26). The
quantification limits (QLs) were determined by taking ten times the standard deviation of
the blank measurements for each respective element.81 The QLs were all under 5 ng g-1
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except for Mg, Al, K, Cr, Fe, Co, Ni, Cu, and Zn for the EPA Method 6020B blood
testing (Table 25); Cr for the EPA Method 6800 blood analysis (Table 27); and Na, Mg,
Al, P, and Ca for the EPA Method 6020B hair testing (Table 26). The background
equivalent concentrations (BECs) were calculated by multiplying the background
intensity signal with the concentration of the analyte and dividing by the difference of the
analyte intensity minus the intensity of the background.82 The BECs were below 1 ng g-1
for all elements except for Al, Fe, and Ni in the EPA Method 6020B blood testing (Table
25); all elements in the EPA Method 6800 blood analysis (Table 27); and Na, Mg, Al, P,
K, Ca, Fe, and Zn in the EPA Method 6020B hair testing (Table 26).
Table 27: The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of
interest in blood determined by EPA Method 6800 using the Agilent 7700 ICP-MS.

Element
Cr
Cu
Zn
Se
Mo
Cd
Sb
Hg
Pb

Natural
m/z
52
63
66
78
95
114
121
202
208

Enriched
m/z
50
65
68
77
97
112
123
199
206

Mode

DL (ng g-1) QL (ng g-1) BEC (ng g-1)

He
He
He
H2
He
He
No gas
No gas
No gas

4.25
0.186
5.74
1.42
0.0363
0.414
0.117
0.635
0.712

5.40
0.560
11.1
2.53
0.0646
0.881
0.159
1.31
1.24

0.461
0.997
0.604
0.0700
0.0168
0.00381
0.0144
0.145
0.0166

Additional confidence in the accuracy and precision of the results from the
present study was achieved by using SRM 1598a and CRM GBW09101b to validate the
sample preparation and analysis protocols. These standards are certified for multiple
elements at concentrations similar to those found in representative blood and hair
samples, respectively. Results obtained for SRM 1598a during this study using EPA
Method 6020B and EPA Method 6800 are shown in Table 28 with the mean (n = 12) and
95% confidence intervals (CIs). The measured values are in strong agreement with the
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certified and reference values for the EPA Method 6020B analysis, with overlapping CIs
for nearly half of the elements determined above the respective DL.

The percent

recoveries ranged from 64.1 to 205.6% when comparing mean values, but these
recoveries improved when including the CIs.

Mercury had the highest percent

recoveries, but the CIs overlapped for the reference and measured values. Only Fe had a
recovery that differed by more than 20% from the certified, reference or informational
mean value or that did not overlap CIs. For the EPA Method 6800 testing, the measured
CIs overlapped with the certified or reference CIs for 3 of the 4 elements that were able
to be quantified above the respective DL, with Zn being the only exception.
recovery for Zn was 111.4%, but improved to 107.7% when including CIs.
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The

Table 28: SRM 1598a results by EPA Method 3052 sample preparation and analysis by either
EPA Methods 6020B or 6800. All certified, reference, information, and measured values in ng g1
(n = 8, 95% CIs). All values below detection limit are reported as <DL.

Element
Cd
Co
Cs
Cu
Fe
Mn
Ni
Rb
Sb
Se
V
Zn

Al
Ca
Cr
Hg
Mo

As
K
Na
P
S
Te

Certified Value
(ng g-1)
0.047 ± 0.004
1.21 ± 0.07
0.62 ± 0.10
1,538 ± 88
1,635 ± 58
1.73 ± 0.32
0.91 ± 0.18
267 ± 18
0.973 ± 0.15
130.8 ± 5.6
1.83 ± 0.11
857 ± 23
Reference Value
(ng g-1)
2.2 ± 0.6
93 ± 7 (µg g-1)
0.32 ± 0.08
0.31 ± 0.18
5.4 ± 1.0
Information Value
(ng g-1)
0.3
258 (µg g-1)
3,115 (µg g-1)
136 (µg g-1)
915 (µg g-1)
0.032

EPA Method 6020B
(ng g-1)
<DL
<DL
0.7404 ± 0.0928
1,746 ± 69
1,048 ± 99
<DL
<DL
317.4 ± 16.0
<DL
152.2 ± 8.4
<DL
959.2 ± 42.1
EPA Method 6020B
(ng g-1)
<DL
Not Determined
<DL
0.6376 ± 0.2785
3.841 ± 0.707
EPA Method 6020B
(ng g-1)
0.3783 ± 0.1355
Not Determined
Not Determined
Not Determined
Not Determined
<DL

EPA Method 6800
(ng g-1)
<DL
Not Determined
Not Determined
1,605 ± 10
Not Determined
Not Determined
Not Determined
Not Determined
<DL
132.3 ± 4.2
Not Determined
954.8 ± 7.3
EPA Method 6800
(ng g-1)
Not Determined
Not Determined
<DL
<DL
7.209 ± 1.041
EPA Method 6800
(ng g-1)
Not Determined
Not Determined
Not Determined
Not Determined
Not Determined
Not Determined

There were four elements which were measured by both EPA Methods 6020B and
6800 at detectable quantities: Cu, Mo, Se, and Zn. Figure 27 shows the results from
each of the two EPA methods for these four elements. The results from EPA Method
6800 for all of the four elements provided better precision seen through smaller CIs for
Cu, Se, and Zn. Better accuracy was seen for Cu and Se by EPA Method 6800.
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Figure 27: Comparison of EPA Methods 6020B and 6800 results for copper, molybdenum,
selenium, and zinc from SRM 1598a (n = 8, 95% CIs).

Similar accuracy was achieved for CRM GBW09101b during the hair analysis.
Table 29 and Figure 28 show a comparison of the reference and informational values
with the measured results including means (n = 12) and 95% CIs. The measured values
are in strong agreement with the certified and informational values, as the CIs for the
measured values overlapped the certified CIs for 10 out of 21 elements. The recovery
efficiencies ranged from 49.5 to 146.0% based on a comparison of the mean listed values
to the average measured quantities. Only 9 of the 21 elements with certified values had
either recoveries that differed by more than 20% from the mean value or that did not
overlap CIs. The overall accuracy of the elemental measurements in this study improves
with the inclusion of the provided CIs.
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Table 29: CRM GBW09101b results in µg g-1 by EPA Method 3052 sample preparation and
analysis by EPA Method 6020B (n = 8, 95% CIs).

Element
Ag
Al
As
Ba
Ca
Cd
Co
Cr
Cu
Fe
Hg
I
Mg
Mn
Mo
Na
P
Pb
Sb
Se
Sr
Zn
K
La
S
Cl
Ti
V
Br
Ni

Certified Value (µg g-1)
0.037 ± 0.002
23.2 ± 2.0
0.198 ± 0.023
11.1 ± 1.3
1,537 ± 68
0.072 ± 0.010
0.153 ± 0.015
8.74 ± 0.97
33.6 ± 2.3
160 ± 16
1.06 ± 0.28
0.96 ± 0.20
248 ± 14
3.83 ± 0.39
1.06 ± 0.12
445 ± 40
174 ± 43
3.83 ± 0.18
0.12 ± 0.02
0.59 ± 0.04
8.17 ± 0.69
191 ± 16
Information Value (µg g-1)
14.4
0.029
4.62
48.2
2.1
0.089
0.59
5.77
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EPA Method 6020B (µg g-1)
0.03257 ± 0.00255
21.92 ± 0.51
0.2246 ± 0.0209
8.739 ± 0.311
1,334 ± 178
0.05506 ± 0.00712
0.1123 ± 0.0057
6.466 ± 0.415
24.56 ± 2.30
131.9 ± 5.3
1.094 ± 0.095
Not Determined
187.4 ± 18.7
2.602 ± 0.173
0.6944 ± 0.0409
380.1 ± 41.2
86.21 ± 9.28
3.673 ± 0.282
0.1296 ± 0.0039
0.8616 ± 0.0631
7.949 ± 0.620
161.2 ± 11.5
EPA Method 6020B (µg g-1)
12.14 ± 0.28
0.02182 ± 0.00042
Not Determined
Not Determined
Not Determined
0.06349 ± 0.00337
Not Determined
4.232 ± 0.327

Figure 28: Comparison of the EPA Method 6020B results to the CRM GBW09101b certified
and information values (n = 8, 95% CIs).

The precision determined by the 95% CIs was within 10% of the measured mean
values for a large majority of the certified, reference, or information values for elements
in SRM 1598a and CRM GBW09101b, with nearly a third inside of 5% (Tables 28 and
29). This level of precision observed for these reference standards was maintained for
the remainder of the study as most results had 95% CIs that were less than 10% of their
mean value, including a large number of them within 5%. The EPA Method 6800 results
for SRM 1598a were more precise compared to EPA Method 6020B for 5 of the 6
elements that were able to be quantified by both methods. The blood measurements in
this study obtained by EPA Method 6800 were more precise for Cu, Se, and Zn compared
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to those from EPA Method 6020B. The current study also supplied 95% CIs for all
detectable elemental quantities in the blood and hair samples.
5.3.2.2 Elemental Analysis of Blood
Significant results were observed when the two types of age analyses were
performed (Figures 29 and 30). Significant negative correlations with age were found for
changes in serum magnesium (p=0.047, r= − 0.64). Conversely, serum iron significantly
correlated positively with age (p=0.050, r=0.63).

The RBC selenium was nearly

significantly positively correlated with age (p=0.051, r=0.63). In addition, the younger
cohort decreased both their RBC zinc (p=0.028) and RBC selenium (p=0.011) to a
greater degree on average when compared to the older cohort.
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Figure 29: Changes in serum magnesium, serum iron, and RBC selenium versus age. Younger
children had a greater tendency to raise their serum magnesium than older children as it was
negatively correlated with age (p=0.047). There was a significant positive correlation between
the change in iron and age (p=0.050). There was a near significant positive correlation between
age and change in RBC selenium concentration (p=0.051). There are two points at 0 for age 12
for the serum iron change.

Figure 30: Elemental analysis results in RBCs for zinc and selenium. When applying a cutoff at
age 5 which separated the younger four children from the older six children, significant decreases
were seen for RBC selenium (p=0.011) and RBC zinc (p=0.028) in the younger cohort.
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Due to prior research and publications, special attention was paid to the plasma
zinc/serum copper ratio which has been reported to be 1.0.83 Previous research has
shown that plasma zinc/serum copper ratio is below 0.7 only in the lowest 2.5% of
healthy children.41 According to commercial clinical laboratory data, five children had a
plasma zinc/serum copper ratio below 0.7 before participating in the study (Figure 31).
Five out of ten children had a plasma zinc/serum copper ratio below 0.7 based on EPA
Method 6020B data. According to EPA Method 6800 data, eight of ten children had a
plasma zinc/serum copper ratio above 0.7 before participating in the study as they were
taking zinc supplementation which was maintained at the same level throughout the
study. Five out of ten children increased their plasma zinc/serum copper ratio according
to the commercial clinical results. The commercial clinical results saw four out of the
older six children increase their zinc/copper ratio. EPA Method 6020B data saw an
increase in four of ten children. According to EPA Method 6020B, four of the older six
children increased their zinc/copper ratio with one being significant by independent
samples t-test. All four of the younger children decreased their plasma zinc/serum copper
ratio, with two being significant by independent samples t-test. Five of the children
increased their zinc/copper ratio according to EPA Method 6800 during the study. Four
out of the older six children increased their zinc/copper ratio during the study. There
were no significant differences in pre- versus post-zinc/copper ratios in any of the
children on independent samples t-test.
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Figure 31: Before and after cleanroom plasma zinc/serum copper ratio according to the
commercial clinical laboratory, EPA Method 6020B, and EPA Method 6800. Results for Method
6020B and Method 6800 are with n = 8 and 95% CIs.

Plasma zinc increased in seven of ten children by commercial results (Figure 32).
Five out of the six older children increased their zinc. By EPA Method 6020B, three out
of ten increased plasma zinc, with one being significant by independent samples t-test.
Two out of the six older children increased their plasma zinc, including the significant
increase. EPA Method 6800 IDMS plasma zinc results saw increases in six of ten
children. There were no significant changes, but four of six older children raised their
plasma zinc.
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Figure 32: Before and after plasma zinc results (ng g-1) for commercial clinical laboratory, EPA
Method 6020B, and EPA Method 6800 results for the ten children who participated in the
cleanroom study. Commercial clinical laboratory results were divided by 1.025 to produce
comparable units. Results for Method 6020B and Method 6800 are with n = 8 and 95% CIs.

Serum copper dropped in five out of ten children by commercial laboratory results
(Figure 33). Three of the older six children dropped their serum copper. By EPA
Method 6020B, five out of ten lowered serum copper. Four out of older six lowered their
serum copper, including one significantly by independent samples t-test. EPA Method
6800 IDMS copper results saw decreases in six of ten children. Four out of the older six
children lowered their serum copper. In the older children, three of the decreases were
significant while one of the increases was significant by independent samples t-test.
There was one significant increase and decrease in serum copper for the younger
children.
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Figure 33: Serum copper results (ng g-1) for commercial clinical laboratory, EPA Method
6020B, and EPA Method 6800 for the ten children before and after experiencing the cleanroom.
Commercial clinical laboratory results were divided by 1.025 to produce comparable units. For
EPA Method 6020B and Method 6800, results are shown with n = 8 and 95% CIs.

After reviewing the before and after results for plasma zinc, serum copper, and
the plasma zinc/serum copper ratio, trends in the data emerged after comparing the three
different measurement techniques: the clinical commercial laboratory, EPA Method
6020B, and EPA Method 6800 (Figures 31-33). The commercial clinical laboratory
results for zinc and copper were divided by 1.025, the density of serum, to produce
comparable units of mass. For the plasma zinc values, the commercial clinical laboratory
had the lowest mean for 16 of the 20 measurements. EPA Method 6020B was greatest on
1 result and EPA Method 6800 was the highest on the other 3 measurements. The
commercial clinical values were never the highest in any of the 20 results, with EPA
Method 6020B the greatest for 12 measurements and EPA Method 6800 for the other 8
results. For serum copper, the commercial clinical laboratory results were the lowest for
15 measurements, with the EPA Method 6800 values the least for the other 5. EPA
Method 6020B had the highest average copper values for all 20 results. For ratio values,
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the commercial clinical laboratory had the lowest results for 10 measurements, EPA
Method 6020B for 9 measurements, and EPA Method 6800 for 1 measurement. The
clinical laboratory had the highest ratio 2 times while EPA Method 6800 had the highest
ratio for the other 18 values. Figure 34 displays the plasma zinc/ serum copper ratio
results for Child 6 illustrating an example of a comparison between the 3 measurement
techniques, as the commercial clinical laboratory did not provide CIs as were done by
EPA Methods 6020B and 6800, along with the improved precision seen in EPA Method
6800 versus EPA Method 6020B.

Figure 34: The before and after plasma zinc/serum copper ratio measurements from the
commercial clinical laboratory, EPA Method 6020B, and Method 6800 for Child 6 from the
cleanroom study. EPA Methods 6020B and 6800 results provided 95% CIs based on 8
measurements.

5.3.2.3 Elemental Analysis of Hair
No significant changes or age correlations were observed for hair elemental
concentrations. It was noted that each of the children had a unique profile of heavy
metals in their hair as they displayed varying concentrations of aluminum, antimony,
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arsenic, cadmium, chromium, lead, manganese, mercury, nickel, and tin in their hair
before beginning the study. Child 1 had over 200 percent more mercury in hair than any
of the other 9 children. Child 11 was found to have the most aluminum, cadmium,
chromium, lead, manganese, and vanadium of all the children. For the entire cohort,
trends towards post-cleanroom elevations in hair aluminum, chromium, cobalt, and
mercury were noted, while cadmium, lead, tin, and zinc all trended lower in the post
sample. The before and after hair results for notable elements are in Figures 35 to 37.
When correlating age and change in hair concentration, selenium was the only
trend observed (p = 0.118, r = - 0.56). When the younger three (one insufficient sample)
versus the older six children were compared on changes of elemental concentrations in
hair, no significant findings or trends were observed.

Figure 35: EPA Method 6020B cleanroom hair results for aluminum, arsenic, cadmium, lead,
and mercury in ng g-1 (n = 8, 95% CIs). Any values not shown were below detection limits.
There was no after hair sample for Child 9.
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Figure 36: Cleanroom hair results for antimony, cobalt, manganese, nickel, tin, and vanadium in
ng g-1 by EPA Method 6020B (n = 8, 95% CIs). Any values not shown were below detection
limit. There was no after hair sample for Child 9.

Figure 37: EPA Method 6020B cleanroom hair results for copper, selenium, and zinc in ng g-1 (n
= 8, 95% CIs). The after cleanroom hair value for zinc for child 5 was 10,770,000 ± 1,260,000
ng g-1. There was no after hair sample for Child 9.

286

5.3.3

Markers of Immune Dysregulation

Significant clinical results for several markers of immune regulation are
summarized in Table 30. When separated into cohorts, the younger children significantly
decreased their CD3% (p=0.036) and CD4% (p=0.028) compared to the older children.
Total white blood cell (WBC) count significantly increased in the younger children and
decreased in the older children (p=0.031). The younger cohort tended to increase their
IgA levels, while the older cohort tended to lower their IgA levels (p=0.059). The
clinical laboratory plasma zinc/serum copper ratio exhibited a tendency to increase in the
older six children compared to the four younger children (p=0.061). The results for these
markers of immune dysregulation for the two cohorts are shown in Figure 38.
Table 30: Statistically significant and trends in the commercial laboratory results of mean
differences between age groups when a cutoff is applied separating children ages 3-5 from
children ages 6-12.

Commercial Laboratory Variable
CD3%
CD4%
WBC
IgA
Zinc/Copper Ratio

Mean Change
Younger Cohort
− 2.75
− 2.50
2.13
4.25
− 0.08
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Mean Change
Older Cohort
2.33
1.67
− 0.70
− 13.17
0.13

p-value
0.036
0.028
0.031
0.059
0.061

Figure 38: Results of the clinical laboratory differences for CD3%, CD4%, WBCs, IgA, and
zinc/copper ratio when applying a cutoff at age 5, separating the younger four children from the
older six children. Significant decreases were seen for CD3% (p=0.036) and CD4% (p=0.028),
and a significant increase was seen for WBC (p=0.031). Trends for increased IgA (p=0.059) in
the younger cohort and elevated zinc/copper ratios (p=0.061) in the older cohort were present.
For CD3% change, two points overlap at +2 in the older cohort. For CD4% change, two points
overlap at both – 1 and +1 in the older cohort. In the older cohort for IgA change, two points
overlap at – 15.

5.3.4

Behavioral Rating Scales

The before and after cleanroom rating scale results for all 10 children are
summarized in Table 31 with significant correlation coefficients (r) and p-values listed in
Table 32.

The younger cohort demonstrated significant decreases in SCQ means

(p=0.025).

The changes in SCQ versus age were also significant, with a positive

correlation (r=0.68, p=0.030) seen in Figure 39. Additional positive correlations with age
were found in the changes in Autism Composite of the PDDBI (r=0.64, p=0.046) and the
Sensory/Perceptual Approach Behaviors (SENSORY) subscale of the PDDBI (r=0.64,
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p=0.045).

The Receptive/Expressive Social Communication Abilities Composite

(REXSCA/C) showed significant negative correlations with age (r= −0.66, p=0.037),
which indicates language improvement in the younger cohort. None of the other domains
or composites of the PDDBI produced significant results. The change in the total ABC
by age of the ten children was nearly statistically significant with a p-value of 0.054
(r=0.62).

Furthermore, three of the five subscales of the ABC were significantly

positively correlated with age (p=0.034 for subscale III, p=0.024 for subscale IV, and
p=0.035 for subscale V) seen in Figure 40. The two remaining subscales of ABC showed
no significant correlations.

Figure 39: Differences for the SCQ, Autism Composite of PDDBI, and the total ABC rating
scales versus age. The results display significance or near significance for each rating scale with
a p-value of 0.054 for total ABC, 0.030 for SCQ, and 0.046 for Autism Composite. Two points
overlap at age 5 with a difference of +1 for total ABC.
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Figure 40: The change in ABC III (p = 0.034), ABC IV (p = 0.024), and ABC V (with p =
0.035) versus age after the cleanroom experience. For age 12 on ABC V, there are two points at
+4.
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Table 31: Child number, age, and rating scale results for the children who experienced the sleeping cleanroom environment. Child 2 was unable
to participate in the study. Children 3 and 4 and Children 6 and 8 were identical twins.

Rating Scale
ADOS

Subscale
Composite
Communication
Social Interaction

SCQ
Total
I
291

ATEC

II
III
IV
Total
I

ABC

II
III
IV

Child Number
Age
Before
Before
Before
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After

1
6
17
6
11
22
24
51
60
9
10
12
15
19
19
11
16
38
34
11
16
8
2
7
4
10
10

3
12
13
4
9
20
27
85
96
15
15
16
20
14
12
40
49
92
118
13
22
23
26
18
21
33
40

4
12
15
4
11
28
30
101
96
21
18
24
25
22
18
34
35
69
91
17
21
22
26
11
16
14
19

5
11
14
4
10
25
24
59
44
5
6
18
9
14
8
22
21
65
50
11
4
24
16
10
13
20
17

6
5
14
6
8
27
20
62
58
16
16
14
9
26
28
6
5
12
13
6
6
4
4
0
1
1
2

7
8
16
5
11
30
30
95
108
11
10
24
31
14
14
46
53
116
128
37
42
18
25
18
18
43
43

8
5
12
5
7
21
20
55
54
17
16
7
10
25
24
6
4
13
14
6
7
1
3
4
4
2
0

9
4
16
4
12
23
14
55
57
8
7
12
11
19
27
16
12
57
27
21
9
2
1
6
4
26
12

10
3
17
5
12
26
23
52
59
6
6
12
14
17
20
17
19
64
42
5
9
19
7
10
6
30
20

11
12
14
7
7
13
13
51
49
16
15
1
1
31
31
3
2
5
3
1
1
1
1
2
0
1
1

V
CARS
Autism Index

GARS

Stereotyped
Behaviors
Communication
Social Interaction
Autism
Composite

Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
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SENSORY
RITUAL
PDDBI

SOCPP
SEMPP
AROUSE
FEARS
AGG

Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After

2
5
5
0
1
2
9
9
0
0
36
47
46.5
40
34
34
49.5
48
43
36.5
85
119
106
100
79
91
126
117
103
74
8
15
11
12
7
11
16
14
13
7
0
11
11
0
9
0
13
12
0
7
7
13
11
8
4
6
13
12
8
4
57
76
73
61
50
54
84
75
59
44
Approach/Withdrawal Problems
57
76
66
60
44
52
83
72
65
42
38
69
57
45
43
37
71
65
43
37
40
58
66
54
50
41
62
64
44
40
50
62
72
34
42
50
70
71
34
42
51
65
56
63
54
54
66
56
59
38
43
68
73
39
40
45
68
67
39
37
43
48
57
42
46
47
58
54
36
41

0
0
51
50.5
112
115
13
14
0
0
11
11
65
66

0
0
33.5
33
64
81
5
8
4
7
4
6
45
47

2
1
39
26.5
82
64
7
5
0
0
7
4
41
39

0
0
39
38
94
87
9
7
0
8
9
9
57
53

0
0
21
22
76
85
7
9
8
9
4
5
41
42

61
57
68
65
63
66
34
34
59
59
53
52
73
75

42
48
38
41
47
47
39
43
33
35
37
37
38
38

44
38
39
37
42
39
38
48
45
41
48
54
44
41

54
46
53
48
51
54
42
42
61
48
52
48
40
41

52
50
42
43
39
43
38
38
40
35
47
44
42
44

REPRIT/C
AWP/C

SOCAPP
EXPRESS
LMRL
EXSCA/C
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REXSCA/C

Before
47
76
73
50
42
61
After
45
84
78
48
37
59
Before
45
71
71
48
43
63
After
47
78
72
45
35
62
Receptive/Expressive Social Communication Abilities
Before
33
39
38
29
40
38
After
35
35
42
31
38
30
Before
31
40
49
27
41
40
After
33
39
48
26
42
40
Before
25
43
49
35
40
43
After
29
38
43
30
36
46
Before
30
39
49
26
40
39
After
32
37
45
27
39
35
Before
29
40
48
27
40
39
After
31
37
45
27
39
37

38
43
35
38

37
36
40
40

50
46
50
45

41
42
41
41

42
46
41
43
42
39
41
44
41
43

46
54
48
43
40
44
47
48
46
47

45
46
35
36
48
42
39
40
40
40

57
59
45
41
53
53
50
49
51
50

Table 32: Statistically significant difference correlations comparing child age and difference in
rating scale scores. The correlations and p-values are shown for each significant variable.

Rating Scale
SCQ
PDDBI Autism Composite
Total ABC
ABC III
ABC IV
ABC V
PDDBI REXSCA/C
PDDBI SENSORY

r
0.68
0.64
0.62
0.67
0.70
0.67
− 0.66
0.64

p-value
0.030
0.046
0.054
0.034
0.024
0.035
0.037
0.045

There were no significant differences in rating scales results in the paired t-test
analyses of pre- and post- results.

The GARS-2, ATEC, and CARS produced no

statistically significant results for change or age correlation.

In total, six scales,

subscales, domains, or composites used as markers of ASD behavioral presentation
agreed in finding a statistically significant correlation with age between pre-and postcleanroom ratings. Of note, each of the four younger children improved on the SCQ
scale.

Of these four, two raised their GSH/GSSG ratio, with one significant by

independent samples t-test.
5.3.5

Twins

The study contained two sets of identical twins, one younger and one older set.
Children 6 and 8 were five-year-old females. Child 6 significantly improved on four out
of five markers of oxidative stress (reduced glutathione, oxidized glutathione, reduced
glutathione/oxidized glutathione ratio, and total glutathione/oxidized glutathione ratio).
This improvement was mirrored in an improvement or better performance in the rating
scales SCQ and PDDBI; the subscales ATEC I, ATEC II, ABC I, ABC II, ABC V,
GARS-2 Communication, GARS-2 Social Interaction; as well as the Autism Index,
Autism Composites, Approach-Withdrawal Problem domains and composites of PDDBI.
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The corresponding twin, Child 8, did not improve on any markers of oxidative stress and,
likewise, poorer performance on rating scales, subscales, composites, and indexes was
generally observed compared with Child 6.
Children 3 and 4 were twelve-year-old male identical twins. Both children raised
their GSH/GSSG, with Child 4 showing greater improvement. This disparity in
improvement, again, was mirrored in a better performance or more positive change in
many rating scales, subscales, and composites. Child 4 demonstrated a better
performance in the PDDBI and SCQ; ATEC total and subscales; ABC total, I, and IV;
CARS; Communication subscale of GARS-2; SENSORY, and the Social Pragmatic
Problems, Semantic/Pragmatic Problems, Arousal Regulation Problems, Specific Fears,
Aggressiveness, Social Approach Behavior domains along with the Repetitive,
Ritualistic, and Pragmatic Problem Behaviors, Approach/Withdrawal, and Autism
Composites of the PDDBI. In both sets of identical twins, the child with the greatest
improvement in markers of oxidative stress showed the greatest improvements in
behavioral markers of ASDs phenotypic presentation following the study.

5.4 Discussion
(Note: The findings in the discussion section are the professional opinion of Dr.
Scott Faber, MD, developmental pediatrician at The Children’s Institute, as the attending
physician and co-principle investigator at the time of publication and are subject to
further data analysis and interpretation.)
During this study ten children with ADOS certified autism slept in a hospital
cleanroom for a two week period. The cleanroom maintained ISO Class 5 certification,
which minimized the nighttime exposure of both children and parents to heavy metals
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and VOCs. Given the emergent data linking exposure to environmental toxins with
autism etiology, experiencing a cleanroom environment during sleep was hypothesized to
begin the process of detoxification by mobilizing heavy metals and chemicals into the
blood and hair.
Five children significantly lowered their oxidized glutathione (GSSG)
concentrations in RBCs, the component of blood with the highest glutathione
concentration.84 The decrease in GSSG concentrations could indicate a reduction of
oxidative stress, suggesting an increased ability to eliminate inflammation, prevent
infections, and detoxify environmental toxins.85 Three children raised their tGSH/GSSG
ratio, an improvement in an indicator of the balance of glutathione species,86 which was
driven by a decrease in GSSG. In all ten children, an inverse relationship was observed
between the change in glutathione ratios, tGSH/GSSG and GSH/GSSG, and the change
in GSSG concentration.

High GSH/GSSG ratios preserve the necessary reducing

environment inside of cells;87 abnormally low GSH/GSSG ratios may indicate an
inadequacy of glutathione reductase.85

Numerous studies have noted the multiple

functions regulated by the redox balance of GSH/GSSG.33, 85, 88 Decreases in GSSG may
have been the result of improved transulfuration reducing the demand for adenosine,86 the
nucleoside that prevents oxidative damage.89-90
The younger cohort showed significantly greater decreases in RBC zinc and
selenium concentrations than the older cohort. The younger children may have moved
selenium and zinc more rapidly from red blood cells to tissues, increasing metalloprotein
functioning more than the older children. In addition, serum magnesium changes were
significantly negatively correlated with age, increasing in concentration in the younger
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children. Magnesium is a critical micronutrient that is essential in the maintenance of the
calcium/magnesium flow across neuronal cell membranes.91 It also plays a key role in
enzymes related to ATP and nucleic acid metabolism.92 Proper brain development and
homeostasis require magnesium resulting from copper-zinc superoxide dismutase
activity.93 When given as a supplement, magnesium has been shown to have a calming
effect on the behavior of children and adults,94-95 which may explain the link between
increased serum concentrations and improved behavioral presentations observed in this
study. Additionally, iron concentration changes correlated positively with age. The
younger children decreased and the older children increased their respective
concentrations.

Iron is critical for erythrocyte production and the promotion of

oxygenation of tissues; its effects on metabolism depend on local concentration.96 At
higher levels, though, iron can cause an excessive production of reactive oxygen species,
digestive problems, vomiting, and the alteration of other closely related elements such as
zinc, copper, and calcium.97 The observed positive age correlation in serum iron may be
explained by a faster upregulation in the metallothionein system of the younger children.
This upregulation would lead to an increased need for erythrocyte production to enhance
oxygen distribution to tissues, depleting serum iron. Hair selenium concentrations tended
to correlate negatively with age. The younger children had either increases or small
decreases in their hair selenium concentrations compared to the older ones.

The

increased release of selenium in the hair in the younger children may have been
secondary to increased absorption of selenium.
Prior to exposure to the cleanroom, VOCs and PCBs were quantified at
concentrations above the national averages for adolescents98 in many of the children. Out
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of the ten participants, eight decreased mean serum benzene, six increased mean serum
toluene and five increased serum xylene, although none significantly. One possible
explanation for these results is that, throughout the study, VOCs were mobilized from
tissues into the serum at varying rates. In this scenario, benzene would be mobilized and
released from the body first, leading to decreased serum concentrations. Toluene and oxylene, however, could require more time to mobilize and result in the tendency for
increased serum concentrations following the two week exposure to the cleanroom.
Likewise, mean PCB-28 concentrations rose in six out of seven children, which
significantly negatively correlated with age, with three children falling below the
analytical quantification limit.

This result is consistent with the hypothesis of the

cleanroom beginning the process of mobilization of PCB-28 from tissue to serum, but
requiring more time for elimination from the serum.
Following exposure to the cleanroom environment, the children demonstrated
changes in markers of immune system functioning. These changes indicate a decrease of
T cell subtypes instructing B cells to make antibodies. Notably, the younger children
decreased CD3% (total T cell percent) and CD4% (total helper T cell percent)
significantly more than the older cohort. This data provides evidence that the cleanroom
may have decreased dysregulation of the immune system, especially in the younger
children. B cells promote immunoglobulin synthesis and are regulated by CD4 cells.
The observed decrease in CD4% may have lessened cross reactive antibody production in
the younger children, leading to a brief period of decreased brain inflammation. This is
one possible explanation of the significant, but transient, improvement seen in the
behavioral rating scale performances of the younger cohort.
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Significant changes in before and after cleanroom results were seen for rating
scale performance when compared with age. Specifically, the younger children in the
study tended to improve on the behavioral rating scales SCQ, sub-domains of the PDDBI,
and ABC while the older children tended to do slightly worse on these rating scales. The
PDDBI was created specifically to evaluate how children with pervasive developmental
disorders respond to a treatment, with the unique capability to standardize results by
age.80 In contrast with other scales and indices, the PDDBI assesses both adaptive and
maladaptive behaviors, giving a quantitative definition to positive improvements. A
significant age-correlation was noted in the Autism Composite of the PDDBI, with the
younger children showing greater improvements in non-verbal communication, repetitive
behaviors, social interaction, and spoken language.

The SENSORY domain of the

PDDBI produced a significant negative correlation with age indicating more
improvement of nonverbal communication in the younger children compared to the older
children.

The negative correlation with age on the REXSCA/C demonstrates

significantly more improvement in receptive and expressive language attainment in the
younger children compared to the older children. The improvements on the total ABC,
designed to assess treatments for individuals with intellectual disabilities,75 were
primarily driven by the significant improvements on the stereotypical behavior,
hyperactivity, and speech subscales. One possible explanation of these rating scale
results is that the younger children may have had less of an initial body burden of heavy
metals and chemical toxicants, allowing the brief two week period of sleeping in the
cleanroom to have a slightly more positive behavioral effect. The older children, who
may have had a larger body burden of toxicants initially, may have just begun the process
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of mobilization of chemicals and metals as the study ended, resulting in worse behavioral
result changes in relation to the younger children. Younger children may have felt an
extra closeness to their parents during the study, leading to positive behavioral change.
However, age-correlated findings involving changes in elemental, glutathione, and
immune markers observed in this study provide support for physiological change driving
the behavioral improvements in the younger children.
One of the unique results of this study involved the responses of two sets of
identical twins and the manner in which changes in glutathione species corresponded
with behavioral rating scale results.

In both sets, one twin demonstrated greater

improvement in oxidative stress, as evidenced by glutathione markers, and corresponding
greater improvement in behavioral rating scale scores. The GSH/GSSG ratio is a critical
biomarker for determining healthy functioning of the methylation system in children with
autism.99

In the 5-year-old female identical twin pair, the twin who raised her

GSH/GSSG ratio also performed better on two behavioral rating scales, the SCQ and
PDDBI. Notably, this female twin displayed the greatest improvement of oxidative stress
in the study, significantly lowering GSSG and increasing GSH, tGSH/GSSG, and
GSH/GSSG values. In the older male identical twin pair, both children worsened on the
behavioral scales, but the twin with greater GSH/GSSG ratio improvement displayed less
worsening on the SCQ and PDDBI. Despite identical home settings and genomes, it was
found in both sets that each twin responded uniquely to sleeping in the cleanroom,
displaying varying degrees of change in GSH/GSSG levels and behavioral rating scale
performance.

These differences suggest that still unknown epigenetic mechanisms

mediated the varying results between the twins in the study. This study provides further
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support to the assertion of a relationship between glutathione biomarkers and behavioral
rating scores in children with autism.
In this study, ten children with ADOS certified autism spent two weeks sleeping
in a cleanroom. The overall pattern of results indicates greater improvements in immune
dysregulation and behavior in the younger children, age 5 and under. Half of the children
significantly decreased their oxidative glutathione concentrations in addition to
improving other glutathione markers of oxidative stress.

The relationship between

GSH/GSSG and the identical twins’ behavioral performances, the opposite movements of
serum iron and magnesium compared to age, and the tendency for the younger children to
reduce their CD3% and CD4% all suggest the possibility of a significant physiological
role for the cleanroom in explaining some of the behavioral changes. Younger children
performed better on rating scales after their two week exposure, while the older children
performed slightly worse on rating scales.

Psychological issues, such as greater

attachment towards the parent in the cleanroom, may explain some of this difference;
however, the noted biological differences in how the younger children performed versus
older children suggest that the cleanroom may have had a more than psychological effect.
The children only slept or stayed for approximately ten hours a night in a cleanroom for
two weeks; yet, significant changes in markers of oxidative stress, immune dysregulation,
and behavior were observed. In addition, an age correlated difference in detoxification
physiology is suggested by the results. At the age of 5, a significant difference tended to
occur in the direction of change for some elemental nutrients (iron, magnesium,
selenium, and zinc), organic toxicants (benzene and PCB 28), and immune markers
(CD3% and CD4%). The younger children may have started their detoxification process
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faster or had less to detoxify, thus explaining their significant improvement in global
rating scales (SCQ, PDDBI, and ABC) compared with the older children.

The

differential response to the cleanroom by the identical twins suggests that epigenetic
changes may be playing a role in affecting responses to a detoxifying environment. The
performance of a controlled study of 24 hour per day cleanroom exposure for children
with autism appears to be an appropriate next step, given the physiologic changes from
the limited exposure to a cleanroom environment noted in this study.
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Chapter 6
Elemental Quantification in the Blood and Hair of Children
with Autism and Controls
Autism spectrum disorders (ASDs) are characterized by social defects and expressive
language problems along with abnormal cognitive functions and repetitive behaviors.
Over the last 30 years, the frequency of autism has risen dramatically and now is greater
than 1 percent. During this time, an emerging paradigm has suggested that the majority
of children with autism display a pattern of genetic/environmental interactions that makes
them susceptible to difficulties with detoxification of the in utero and post birth heavy
metal and chemical environment. Children with autism have demonstrated increased
difficulty with the performance of methylation and sulfation systems that are required for
the elimination of chemicals from human tissue and dysfunction of their metalloprotein
systems necessary for the elimination of heavy metals from their bodies. They have also
demonstrated important differences in oxidative stress and immune dysregulation.
Current research has focused on understanding the mechanisms of these systems and the
resulting biomarkers to comprehend why autism rates have increased and improve
diagnosis and treatments. A new theory of disease was proposed by Dr. Claudia Miller in
1996 called toxicant-induced loss of tolerance (TILT), to reflect the impact the
environment has on human health.1 To evaluate this disease theory, 30 children, ages 2-9
years old, recently diagnosed with an ASD had their serum, plasma, red blood cells, and
hair analyzed for elemental content along with 30 age, gender, and socioeconomically
matched controls. For the analytical measurements completed in blood and hair, the
samples were prepared using United States Environmental Protection Agency (EPA)
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Method 3052, microwave-assisted digestion. After sample preparation, the samples were
analyzed by either EPA Method 6020B or EPA Method 6800 using Inductively Coupled
Plasma-Mass Spectrometry. EPA Method 6020B uses external calibration curves that
determined the concentration of 58 elements in each sample while EPA Method 6800
utilizes enriched, stable isotopes of unique ratios to quantify elements directly through
mathematical solutions. In addition to the elemental testing, behavioral rating scales
were completed, clinical blood testing including T and B cell subsets was performed, and
the content of glutathione and organic toxins were evaluated.

These results were

analyzed using paired samples t-tests to determine any potential significant differences
between the groups and cross correlations of the results were performed between the
different types of analysis to determine potential connections between the different
variables. EPA Method 6020B and EPA Method 6800 results for selected variables were
also compared to commercial clinical results to evaluate quality control. From this study,
the results and analyses demonstrated that the children with autism illustrated the TILT
theory of disease according to the attending physician, and they could potentially be used
to determine a biomedical screening diagnostics test and more effective treatments for
ASDs.

6.1 Introduction
6.1.1

Background

Autism spectrum disorders (ASDs) are characterized by social defects and
expressive language problems along with abnormal cognitive functions and repetitive
behaviors manifested through a wide range of symptoms with differing severity. Over
the last 30 years, the frequency of autism has risen dramatically and now is greater than 1
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percent. The most recent data from the Centers for Disease Control and Prevention
(CDC) using data from 2008 noted the overall rate of autism to be 1 in 88 children in 8
years old.2 Compared to data from 2000 and 2002, this frequency is a 78% increase
when the rate was 1 in 150.3-4 Because of this dramatic escalation in recent years,
worldwide incidence and prevalence of these disorders have increased; however,
scholarly opinion varies as to whether this rise is due to improved awareness, better agerelated screening efforts, higher quality and quantity of diagnostic centers, an expansion
of the spectrum definition, the types of study methods used, or a true escalation in the
incidence and prevalence of autism.5-11 More recently, greater attention has been given to
an emerging paradigm that presents the view that one of the causes of the increased
prevalence of ASDs is the children’s difficulties with detoxification of heavy metals and
chemicals.12
During this time, an emerging paradigm has suggested that the majority of
children with autism display a pattern of genetic/environmental interaction that makes
them susceptible to difficulties with detoxification of the in utero and post birth heavy
metal and chemical environment. Children with autism have demonstrated increased
difficulty with the performance of methylation and sulfation systems that are required for
the elimination of chemicals from human tissue and dysfunction of their metalloprotein
systems necessary for the elimination of heavy metals from their bodies. Children with
autism have also demonstrated important differences in oxidative stress and immune
dysregulation. With all of these different areas affected in children with autism, current
research has focused on understand the mechanisms of these systems and the resulting
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biomarkers to understand why autism rates have increased and improve diagnosis and
treatments.
6.1.2

Autism: The Manifestation of a New Disease Theory

Within the last 20 years, a new theory of disease was presented in response to the
increased rate in many different diseases. Proposed by Dr. Claudia Miller in 1996, this
new theory called toxicant-induced loss of tolerance (TILT) reflects the impact the
environment has on human health.1

In the scientific literature, many studies had

presented the idea of the development of disease symptoms in response to being exposed
to extremely low quantities of chemicals in the environment.13 The sensitivity of people
to food and chemicals was first discussed by Randolph in 1962.13 Dr. Miller proposed
TILT to describe a new disease theory where patients clinically presented symptoms in a
two-step progression.13 The first step, called initiation, occurs when vulnerable people
lose tolerance after an acute or chronic exposure to different toxins.13 The second step,
triggering, is the resulting symptoms that are activated after the previous tolerance of
these compounds, medications, foods, or combinations of them is lost.13 TILT replaced
the previous terminology of multiple chemical sensitivity (MCS) because the important
initiation that is started by the toxic exposure was not described by the prior term. 13
TILT also provided a bigger scope of susceptibility after an exposure that is not limited to
food, caffeine, drugs, and alcohol.13

The manifestation of a TILT state has been

determined to cause autoimmunity as the result of exposure to detrimental foreign agents
and environmental toxins such as infection, xenobiotics, and implants.14 Reflecting the
modern environment, TILT is a theory of disease, which Dr. Miller proposes to be similar
to the germ theory and immune theory that have developed over the past century.13
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Miller noted that support of TILT as a mechanism for a group of disorders would result in
seeing TILT as a validated disease theory.13 In recent times, TILT has become an
accepted method of the advancement of disease14 with the TILT concept has been
determined to exist in twelve countries by multiple researchers.15
TILT and the resulting sensitivity-related illness (SRI) are becoming a greater
proportion of modern diseases as the result of the increased amount of contact with toxins
and their ensuing bioaccumulation.14

SRI results in unfavorable clinical conditions

caused by allergens, chemicals, food, biological mixtures, or responses to electrical
impulses.14 The clinical presentation of SRI results from the insult of a primary toxin.
This foreign insult could be biological, chemical, surgical, or radiological.14

This

exposure results in TILT causing hypersensitivity to chemicals and a reduction in the
tolerance to chemicals which occurred during the initiation step through exposure to
chemicals, allergens, food, biologicals, or electronic stimuli.14 The resulting clinical
reaction is observed through immunoglobulins, cytokines, and other signs and symptoms
that affect multiple organ systems.14 Theories of MCS focus on changes of the immune
system, the nervous system, biochemical metabolism, and psychological and
neurobehavioral capabilities.16 Caress and Steinemann cite studies connecting MCS to
neurological disorders and immune system dysfunction.17

A biomarker specifically

linking decreased tolerance and increased immune dysregulation would be the perfect
way to relate the environmental toxin exposure to SRI through the TILT mechanism.14
The increased prevalence of autism has created a greater emphasis and awareness
possibly relating it as an effect of the modern environment.

The environment has

changed over time while the genome has remained relatively static.14
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The natural

environmental levels of toxic metals and nearly all metals have been exceeded through
the industrial emissions of the past 200 years.18

Miller noted the difference in

environmental exposures between rural and urban areas.13

The interaction of the

environment with a vulnerable genome is becoming the emerging hypothesis of chronic
diseases in the scientific literature.14 The field of epigenetics focuses on the changes
made to a genome due to interactions with the environment. Over the past 20 years, the
occurrence and rate of many illnesses related to allergies such as asthma, hay fever,
atopic dermatitis, food allergens, conjunctivitis, and eosinophilic esophagitis have
increased dramatically.14 Attention deficit hyperactivity disorder, autoimmune disorders,
and depression rates have also increased during this time.15

Currently, the most

predominant illnesses caused by the environment may follow the TILT mechanism.15
Chemical sensitivity manifests itself through many different systems of the body
including

neuropsychological,

cardiovascular,

respiratory,

gastrointestinal,

musculoskeletal, skin, and others.13 Many of these symptoms are seen in children with
autism, notably the neuropsychological and gastrointestinal difficulties.

Common

neuropsychological symptoms of TILT include sensitivity to many different chemicals,
attention deficit hyperactivity disorder, depression, migraines, and seizures. 13 Irritable
bowel syndrome and reflux are frequently observed gastrointestinal indicators of TILT.13
People who frequently comprise chemically sensitive groups include industrial workers,
office workers, and contaminated communities.16 The children with autism would fall
into the last group who have exposures to chemicals from indoor air, pesticides, drugs,
and other products.16 Children can be more sensitive to the effects of TILT as the result
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of age-specific behaviors of children that can put them at greater risk of pesticide
toxicity.19
6.1.3

Genetic Predisposition to Autism

Much research has been published that attempt to explain a potential genetic
predisposition to autism. However, in children with ASDs, only about three percent
demonstrate positive genetic findings on high resolution chromosome, Fragile X, and 15
q duplication studies. When genomic microarray studies are added, another 18% of
children with autism display some area of genetic difference from the normal sequenced
human DNA, although these findings often come with the caveat that they have not been
correlated with any known human pathology.20 Recently, copy number variants and
losses have been strongly connected to the development of autism.21 These copy number
variants may be contributing to an adverse genetic/environmental interaction, likely
beginning in utero. The genetic, epigenetic, environmental, and endogenous interactions
can be seen in an “integrated metabolic profile” that affects metabolic pathways.22 The
effects of the environment are seen in the epigenetics, neurologic system, and immune
system of children diagnosed with ASDs. A hypothesis of genetic predisposition to
abnormal metallothionein functioning combined with an environmental attack which
hinders metallothionein was proposed by Walsh et al. and can account for the increased
rate of autism diagnosis seen in recent years.23
6.1.4

Exposure to Environmental Toxins in Autism

Two areas have demonstrated a potential TILT relationship between
environmental toxins and autism: increased autism rates correlated to environmental
toxin exposure and elevated concentrations of toxins in children with autism. In Texas,
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two studies showed a connection between a higher rate of autism and the amount of
mercury released from coal fired power plants.24-25 A study led by Gbor found that
human activities are responsible for 73% of the mercury released around the Pittsburgh
area.26

Another study noted Minnesota school districts near National Priority List

Superfund sites had significantly greater rates of autism.27

Studies have also

demonstrated elevated autism rates resulting from organic toxins. In California, a study
found pollutants in the air raised the rate of ASDs.28 Roberts led another study in
California that demonstrated a higher occurrence of autism in mothers who lived closer to
agricultural sites during pregnancy which used organochlorine pesticides.29 Eskenazi et
al. discovered the possibility of developing a pervasive developmental disorder
approximately doubled every time the amount of pesticide metabolites increased ten
times in the environment.30
Also, many studies have compared the amounts of specific chemicals and toxins
in children with autism and controls. One study noted higher amounts of total and
organic mercury, arsenic, and lead in the red blood cells of children with autism
compared to controls.31

This same study found children with autism had greater

concentrations of plasma perchlorethylene, hexane, pentane, and xylene.31 DeSoto and
Hitlan completed a reanalysis of a prior data set and discovered a significant correlation
between diagnosis of an autism spectrum disorder and the concentration of mercury in
blood.32 Hertz-Picciotto and colleagues observed controls having higher concentrations
of mercury in the blood than children with autism spectrum disorders33 while Geier et al.
found the opposite in another study.34 Another study investigating mercury content saw
greater amounts of it in the baby teeth of children with ASDs compared to controls.35
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6.1.5

Detoxification Difficulties in Autism

Many studies have investigated the detoxification capabilities of children with
autism through the study of elemental concentrations in hair. In 2003, Holmes led a
study that discovered children with autism had significantly less mercury in their hair
compared to controls.36 When pair wise comparisons were performed between children
with mild, moderate, and severe cases of autism, significant differences were observed.36
The more severe children had lower concentrations of mercury in their hair indicating a
decreased ability to move xenobiotics to their effluent. Compared to matched controls,
Kern et al. found significantly lower amounts of arsenic, cadmium, and lead in the hair of
children with autism.37 Another study found children with lower amounts of mercury in
their hair were 2.5 times more likely to be diagnosed with autism.38
One biomarker that has been suggested for evaluating heavy metal toxicity and
metallothionein capabilities is the plasma zinc/serum copper ratio. The discovery of a
lower plasma zinc/serum copper ratio in children with ASDs was first discovered by
Walsh and colleagues.23 They found the average plasma zinc/serum copper ratio to be
0.613 in over 500 children with ASDs while controls had an average ratio of 0.870.23 In
a paper discussing leishmaniasis patients, controls had a plasma zinc/plasma copper ratio
of approximately 1.39 Additional evidence of a decreased plasma zinc/serum copper ratio
was provided by Faber et al., where an average plasma zinc/serum copper ratio of 0.608
was observed in 230 patients with ASDs.40
The status of the metallothionein system could be seen through the plasma
zinc/serum copper ratio. Metallothioneins are proteins which have many cysteines and
remove heavy metals from the body.41 In cells, metallothionein is the primary protein
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that binds with zinc.42

The homeostasis of zinc and copper are also regulated by

metallothioneins.43 Along with glutathione, metallothionein is the best detoxifier of
mercury in the brain.44 A study from Walsh et al. observed a metallothionein problem in
over 99% of children with ASDs.23 A reduction in the removal of heavy metals, immune
system dysfunction, and neurological changes are seen through abnormalities in the
functioning of the metallothionein system in children with ASDs.41 Children with autism
demonstrated some of the following symptoms that could be the result of metallothionein
function:

leaky gut syndrome, digestion difficulties with casein and gluten, yeast

difficulties, decreased stomach acid production, and lower secretin from the pancreas.41
Metallothionein production is increased by both estrogen and progesterone.41
6.1.6

Oxidative Stress and Autism

Another area where studies have seen differences in children with autism and
typical developing children is related to oxidative stress. One marker of oxidative stress
commonly seen to be differentiated in children with autism is glutathione. Glutathione is
a tripeptide which uses the thiol group of cysteine to have a great attraction for toxins.
Because glutathione is a natural chelator, glutathione is the primary way heavy metals are
removed from the body.45

Contact with heavy metals, polychlorinated biphenyls,

polyaromatic hydrocarbons, and organochlorine and organophosphate pesticides has
resulted in lower glutathione concentrations.45 Lower amounts of total glutathione and
higher levels of oxidized glutathione in plasma have been seen in children with autism
compared to controls.22,

46

Other studies have shown elevated quantities of oxidized

glutathione with lower amounts of reduced glutathione in plasma in children with autism
compared to controls.47-48
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6.1.7

Immune Dysregulation in Autism

Based on the TILT mechanism, the exposure to environmental toxins and the
ensuing oxidative stress is manifested through dysregulation of the immune system in
children with autism. Many atypical values have been seen in children with autism that
suggest a connection between environmental toxins and the immune systems of children
with autism.49

Children with autism spectrum disorders demonstrated an increased

frequency of immunologic abnormalities of innate, humoral, and cell-mediated
immunity.50

Successive adaptive immune reactions resulting from previous innate

immune system responses and autoimmunity may be the outcome of an improperly
regulated innate immune system.51

Children with autism show an abnormal innate

immune system reaction that may also cause adaptive immune system dysregulation.51 In
most studies, fifteen to sixty percent of children with autism display immune system
dysfunction.52

Autoimmune attack by the innate immune system, as performed by

natural killer cells, has been shown to be present in the brains of children with autism.53
A study of immune functioning of children with ASDs at The Children’s Institute
demonstrated that 49% of the studied children had increased T cell helper/suppressor
(CD4/CD8) ratios, causing many of the children to display over-reactive innate and
humoral immunity, seen through higher serum immunoglobulin levels and the number
and percent of natural killer cells.54 This study also noted that 4.5% of the children
demonstrated low CD4/CD8 ratios, a finding that the World Health Organization has
determined may result from chemical toxicity.55 In leishmaniasis patients, a lower Th1
immune response and immunodeficiency could be caused by a lower zinc/copper ratio,
suggesting the zinc/copper ratio could be a marker of immune dysfunction.39
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With the growing importance of the TILT mechanism relating the modern
environment to the increased prevalence of autism, a study was designed to test the
previously described theory of disease in children with autism. It involved 30 newly
diagnosed children with autism and 30 matched controls that were tested for behavioral
rating scales, glycophorin A (GPA) analysis, elemental concentrations in blood and hair,
selected organic toxins, glutathione status, and clinical laboratory testing. Statistical
analysis evaluated the differences between the two groups and correlations were
completed to evaluate potential pathophysiological relationships.

6.2 Materials and Methods
6.2.1

Materials

6.2.1.1

Chemicals and Standards

All reagents were of analytical grade. ARISTAR ULTRA nitric acid (HNO3),
ARISTAR ULTRA hydrochloric acid (HCl), and ARISTAR ULTRA H2O that were used
only during sample analysis were procured from VWR (Radnor, PA, USA). American
Chemical Society (ACS) grade HNO3 and ACS grade HCl that were only used for
cleaning were obtained from Fisher Scientific (Pittsburgh, PA, USA). Multi- and single
element standards of iodine, lithium, and yttrium along with the isotopic standards for
lithium and tin came from Inorganic Ventures (Christiansburg, VA, USA). The mercury
standard was obtained from High Purity Standards (Charleston, SC, USA). Applied
Isotope Technologies (AIT, Pittsburgh, PA, USA) provided the remaining isotopically
enriched elemental solutions. The Inductively Coupled Plasma-Mass Spectrometry (ICPMS) tuning solution consisting of 1 nanogram gram-1 (ng g-1) of lithium, cobalt, yttrium,
cerium, and tellurium in 2% (v:v) HNO3 and an internal standard solution containing 100
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µg g-1 of 6lithium, scandium, germanium, rhodium, indium, terbium, lutetium, and
bismuth were procured from Agilent Technologies (Santa Clara, CA, USA). Standard
Reference Material (SRM) 1598a, Inorganic Constituents in Animal Serum, was
purchased from the National Institute of Standards and Technology (NIST, Gaithersburg,
MD, USA). Certified Reference Material (CRM) GBW09101b was from the Shanghai
Institute of Nuclear Research of the Chinese Academy of Sciences (Shanghai, China).
6.2.1.2

Materials and Supplies

All tetrafluorometoxil (TFM™) microwave vessels, inserts, and lids were
obtained from Milestone Inc. (Shelton, CT, USA) and the magnetic stir bars were
procured from Big Science Inc. (Huntersville, NC, USA). VWR supplied the 50 mL
polypropylene centrifuge tubes. AIT provided the Isotope Dilution Mass Spectrometry
(IDMS) software. A Thermo Scientific (Pittsburgh, PA, USA) Barnstead EASYpure II
RF/Ultraviolet (UV) Model D7035 water purification system was used to further clean
double-deionized (DDI) water to a minimum resistivity of 18 MΩ-cm from a Barnstead
(Dubuque, IA, USA) NANOpure water system.
6.2.1.3

Instrumentation

The sample preparation of the blood and hair samples was performed using
microwave-enhanced chemistry in a Milestone ETHOS 1 laboratory microwave system
equipped with temperature and pressure feedback control.

This device accurately

monitored and controlled the temperature to within ± 2 °C of the preset values by
automatically adjusting the microwave field output that has a maximum power of 1500
Watts.

The closed ETHOS 1 system allowed for extremely high temperature and

pressure conditions of up to 300 °C and 100 bar to be maintained for extended periods of
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time. The ten TFM™ microwave digestion vessels used in this study each contained
three 6 mL TFM™ inserts with lids. The TFM™ inserts also have the capability of
withstanding the same temperature and pressure conditions as the digestion vessels while
increasing the number of samples from 10 to 30 per batch.
Mass spectrometric analysis was completed using an Agilent 7700 ICP-MS with a
micromist nebulizer, quartz spray chamber, an octopole reaction system, and a
quadrupole mass analyzer. It possesses a collision/reaction cell that uses hydrogen or
helium gas to eliminate polyatomic interferences. The samples and internal standard
were introduced into the ICP-MS through the micromist nebulizer of the spray chamber
using the peristaltic pump at a speed of 0.1 revolutions per second (rps). The samples
were stored in a CETAC (Omaha, NE, USA) ASX-520 autosampler housed inside of an
ENC-500 anti-contamination enclosure before being analyzed. Both the ICP-MS and
autosampler were located in an International Organization for Standardization (ISO)
Class 6 cleanroom laboratory. The optimized parameters of the ICP-MS and autosampler
during analyses are shown in Table 33.
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Table 33: The optimized settings for the Agilent 7700 ICP-MS for EPA Method 6020B in blood,
EPA Method 6800 in blood, and EPA Method 6020B in hair.

Agilent 7700 ICP-MS
Rf Power
Spray Chamber
Temperature
Acquisition Mode
Peak Pattern
Sample Depth
Plasma Gas
Carrier Gas
Makeup Gas
H2 Cell Gas Flow
He Cell Gas Flow
Gas Stabilization Time
Integration Time
Replicates
Nebulizer Pump Speed
Uptake time
Stabilization time

6.2.2

EPA Method
6020B Blood
1550 W

EPA Method
6800 Blood
1550 W

EPA Method
6020B Hair
1550 W

2 °C

2 °C

2 °C

Spectrum
1 point mass-1
8 mm
15 L min-1
0.7 L min-1
0.2 L min-1
2 mL min-1
2 mL min-1
30 sec
0.1-1.0 sec mass-1
4
0.10 rps
30 sec
30 sec

Spectrum
1 point mass-1
8 mm
15 L min-1
0.7 L min-1
0.2 L min-1
2 mL min-1
2 mL min-1
30 sec
0.5-1.0 sec mass-1
4
0.10 rps
30 sec
30 sec

Spectrum
1 point mass-1
10 mm
15 L min-1
0.99 L min-1
0.15 L min-1
4 mL min-1
4.5 mL min-1
30 sec
0.1-1.0 sec mass-1
4
0.10 rps
30 sec
30 sec

Methods

The study was approved by the Institutional Review Board (IRB) of Duquesne
University (Pittsburgh, PA, USA) (IRB #10-36) and it was conducted at The Children’s
Institute (TCI, Pittsburgh, PA, USA) and Duquesne University.
6.2.2.1

Subject Enrollment

Thirty children with autism or Pervasive Developmental Disorder-Not Otherwise
Specified (PDD-NOS), who were seen for their first visit at Dr. Scott Faber’s
Neurodevelopmental Disabilities Service at TCI, participated in this study along with
thirty age, sex, and socioeconomic status (SES) matched controls. From May 2010 to
May 2012, Dr. Faber asked the parents of each child who was newly diagnosed with
autism or PDD-NOS and who achieved the study criteria met with a research coordinator
where consent was achieved and the child’s assent was obtained whenever possible. The
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children then met with a psychologist with research certification in the performance of
the Autism Diagnostic Observation Scale (ADOS),56 where they were successfully
enrolled once exceeding the total ADOS cutoff for an autism diagnosis. Two children
who demonstrated autistic features did not meet ADOS criteria for a diagnosis on the
autism spectrum and did not participate further in the study.
Each child with autism or PDD-NOS was paired with an age, gender, and SES
matched control child who was recruited by a poster that was approved by the Duquesne
IRB from May 2010 to June 2012.

After talking to the research coordinator and

reviewing the inclusion and exclusion criteria, a parent or guardian consented to the study
and each control child assented to the study. A meeting with Dr. Faber occurred to
perform a brief history and physical examination; to rule out presence of a genetic,
developmental, or neuropsychiatric disorder; the presence of a nuclear family member
who met criteria for an ASD; and assess other exclusionary items. After each control
child joined the study, an appointment with a psychologist was made to undergo ADOS
evaluation. Once the child scored below the cutoff for an ASD on the total ADOS, the
child became eligible to participate.
None of the children who partook in the study used dietary supplements, were on
an exclusionary diet, had a significant traumatic brain injury, or had a known genetic
disorder. Children who had mercury amalgam dental fillings, any form of liver or kidney
disease, or a diagnosis of inflammatory bowel disease or celiac disease was not eligible to
participate. For the three months prior to the study, none of the children received
systemic steroids or immune compromising drugs. All children selected for this study
lived within a sixty minute drive of TCI. Based upon their SES, the children were
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separated into three groups: household income below $30,000, between $30,000 and
$100,000, and over $100,000 per year, per parental or guardian self-disclosure.
6.2.2.2

Blood Draw, Hair Collection, and Clinical Testing

Two blood draws consisting of approximately 30 mL each, occurring within two
to four weeks of each other, were obtained by a phlebotomist who specialized in working
with children with development disabilities. The blood was drawn at the child’s home
and then brought to Duquesne University for preprocessing within two hours. The blood
was centrifuged and aliquoted for testing at Quest Diagnostics (Pittsburgh, PA, USA),
Duquesne University, and Nova Southeastern University (Fort Lauderdale, FL, USA).
The Quest Diagnostics testing from the first blood draw included a complete blood count
(CBC) with differential; erythrocyte sedimentation rate; T and B cell lymphocyte subsets;
serum IgA, IgG, and IgM immunoglobulins; total protein and albumin; aspartate
aminotransferase; alanine transaminase; alkaline phosphatase; tissue transglutaminase;
antigliadin IgG and IgA antibodies; anti-casein, anti-gluten, and anti-soy IgG antibodies;
thyroid functioning tests; and iron studies. On children diagnosed with autistic disorder
or PDD-NOS, high resolution chromosomes, Fragile X, and oligomeric microarray
analyses were also performed. One milliliter of whole blood from the first blood draw
was aliquoted for analysis of glycophorin A (GPA), a measure of somatic mutation, by
Nova Southeastern University.
From the second blood draw, Quest Diagnostics performed plasma zinc and
serum copper and selenium analyses.

They also analyzed serum folate and serum

methylmalonic acid. The Duquesne University analyses from the second blood draw
included elemental analyses in serum, plasma, and red blood cells (RBCs); total,
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oxidized, and reduced glutathione; the organic toxins benzene, toluene, o-xylene, and
selected polychlorinated biphenyls (PCBs), certain polybrominated diethyl ethers
(PBDEs), carefully chosen organochlorine and organphosphate pesticides, and a
phthalate. The glutathione, organic chemical testing, and GPA analysis will not be
discussed in further detail in this chapter as it is part of a larger study. The remaining
serum, plasma, and RBCs to be tested by Duquesne University were stored at -80 °C until
analysis. After the second blood draw for each child, a hair sample was obtained from
the back of the head. The hair sample was placed in a plastic bag for transport to
Duquesne University where it underwent elemental analysis.
6.2.2.3

Behavioral Rating Scales

During the time period when the blood draws were obtained, multiple behavioral
rating scales were filled out by a parent or guardian, as required by the directions of the
rating scales. For this study, the rating scales completed were the Social Communication
Questionnaire (SCQ),57 Aberrant Behavior Checklist (ABC),58 Gilliam Autism Rating
Scale (GARS),59 Autism Treatment Evaluation Checklist (ATEC),60 PDD Behavior
Inventory (PDDBI),61 and Childhood Autism Rating Scale (CARS).62 After they were
completed, the results were recorded and pooled for future statistical analysis.
6.2.2.3.1 Autism Diagnostic Observation Scale
The ADOS is a measure that remains the clinical gold standard for autism
diagnosis.63 In this study, two ADOS modules were scored, communication and social
interaction, which were summed to provide the total ADOS score. The cutoff for an
autism diagnosis is a minimum score of 12 and the cutoff is 7 for an ASD diagnosis.64
For the communication module, the cutoff for an autism diagnosis is 4 while it is 2 for an
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ASD.64 The cutoff for the social interaction module for the confirmation of an ASD is 4
and it is 7 for autism.64
6.2.2.3.2 Social Communication Questionnaire
The SCQ is used to evaluate the social relationships, language and
communication ability, and stereotyped and repetitive activities of children with an
ASD.65 It is an important behavioral rating scale because it takes into account all of the
previous Diagnostic and Statistical Manual of Mental Disorders diagnostic components
for autism.66 The SCQ consists of 40 yes or no questions arranged in four subscales:
social interaction, communication, abnormal language, and stereotyped behaviors.66 For
each question, a value of 1 is scored for the presence of the abnormal behavior and 0 is
recorded for it not being present.65 For the SCQ, scores range from 0 to 39 and a cutoff
of 15 is used to separate ASDs from other clinical diagnoses and a cutoff of 22 is used for
separating autism from other ASDs.65
6.2.2.3.3 Autism Treatment Evaluation Checklist
The ATEC was created to monitor the implementation of treatments in children
with autism and is typically not used in diagnosis. The ATEC is a one page survey that is
divided into four subscales: (I) Speech/Language/Communication, (II) Sociability, (III)
Sensory/Cognitive Awareness, and (IV) Health/Physical/Behavior.

The first three

subscales are scored from 0 to 2 and the last subscale is scored from 0 to 3, with a higher
score indicating a more severe the problem or greater development of that respective
characteristic with a maximum score of 179.
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6.2.2.3.4 Aberrant Behavior Checklist
The ABC rating scale was designed to evaluate treatments in individuals with
intellectual disabilities.58

The ABC has 58 items organized into 5 subscales:

(I)

Irritability, Agitation, Crying; (II) Lethargy, Social Withdrawal; (III) Stereotypic
Behavior; (IV) Hyperactivity, Noncompliance; and (V) Inappropriate Speech.58 Each
item is scored from 0 to 3 on a 4-point scale with higher scores indicating a greater
degree of problems.58 The Total ABC is determined by adding up each of the subscale
scores and has a maximum value of 174.
6.2.2.3.5 Childhood Autism Rating Scale
The CARS was created as a way to diagnose children with autism. It uses a 15
point rating scale with scores ranging from 1 to 4 with half interval points.67 A score of 1
represents normal behavior and a score of 4 indicates severely abnormal behavior.67 The
scores on the CARS range from 15 to 60 with children scoring 30 or greater being
classified as autistic. To be diagnosed with severe autism, a child must score higher than
36 and have scored at least a 3 on five or more of the 15 subscales.67 The information
can also provide classification on the degree of autism and the type of symptoms.68
6.2.2.3.6 Gilliam Autism Rating Scale-2
The GARS was designed to monitor and diagnose autism in children.69 It can be
used on patients from ages 3 to 22 and has 56 questions divided into 4 subscales: Social
Interaction, Communication, Stereotyped Behaviors, and Developmental Disturbances.69
The GARS is scored on a 4 point scale to produce a score which represents the Autism
Quotient (AQ). The AQ is used to determine “the likelihood that a child has autism” and
has a standard score of 100 with a standard deviation of 15.69 A child is determined to be
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“probably autistic” if the AQ is equal to or greater than 90.69 In 2006, GARS-2 was
created and it follows the diagnostic criteria of the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision and the Autism Society of America.70
One of the major changes in the GARS-2 was that the Parent Interview replaced the
Developmental Disturbances subscale. The Parent Interview determines lags in normal
development or differences in socializing, communicating, and playing, prior to age three
and is not a component of the new Autism Index (AI), which replaced the AQ.70 The
Parent Interview was not included in the study design. The scores from the other three
subscales are very similar and the scores from the other three subscales are added and
give the value for the AI. An AI value equal to or greater than 85 evokes a “very likely”
presence of autism, between 70 and 84 mean a child “possibly” has autism, and a score of
69 or less means autism is “unlikely.”70
6.2.2.3.7 PDD Behavior Inventory
The PDDBI was designed to evaluate how children with pervasive developmental
disorders responded to a medication.71 The PDDBI is unique because it targets both
adaptive and maladaptive behaviors and is arranged in a priori, or hierarchal structure. It
can yield standardized results based on age which many of the other rating scales cannot
do.71

The PDDBI is separated into two dimensions called Approach/Withdrawal

Problems (AWP), for the maladaptive behaviors, and the Receptive/Expressive Social
Communication Abilities (REXSCA), for the determination of communication skills. 72
The dimensions are composed of independent behavioral domains, which are made up
clusters to characterize that domain.72 The AWP is made up of the Sensory/Perceptual
Approach Behaviors (SENSORY), Ritualisms/Resistance to Change (RITUAL), Social
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Pragmatic Problems (SOCPP), Semantic/Pragmatic Problems (SEMPP), Arousal
Regulation Problems (AROUSE), Specific Fears (FEARS), and Aggressiveness (AGG)
domains. There are also two composite scores under the AWP. The first composite is
the Repetitive, Ritualistic, and Pragmatic Problem Behaviors Composite (REPRIT/C) and
is equal to the sum of SENSORY, RITUAL, SOCPP, and SEMPP. The other composite
is the Approach/Withdrawal Problems Composite (AWP/C) and is the summation of all
of the domains.

The domains making up the REXSCA are the Social Approach

Behaviors (SOCAPP), Expressive Language (EXPRESS), Learning, and Memory and
Receptive Language (LMRL). There are two composite scores under REXSCA called
Expressive Social Communication Abilities Composite (EXSCA/C) (SOCAPP +
EXPRESS) and Receptive/Expressive Social Communication Abilities Composite
(REXSCA/C) (SOCAPP + EXPRESS + LMRL).
The PDDBI uses a standardized score like the GARS to determine autism
diagnosis called the Autism Composite. Each cluster is scored on a Likert scale from 0 to
3 and is comprised of four or more items.72 Each domain generates a T-score with the Tscores from most important domains creating the Autism Composite score.72 The Autism
Composite is scored with a mean of 50 and a standard deviation of 10 which should
classify 68% of cases of autism.72 The Autism Composite is calculated by summing the
T-scores from SENSORY, RITUAL, SOCPP, and SEMPP and subtracting the T-scores
from SOCAPP and EXPRESS.72
6.2.2.4 Microwave Closed Vessel Preparation and Cleaning
All sample preparation procedures for the elemental analysis in blood and hair
were performed in an ISO Class 6 cleanroom using microwave digestion vessels and
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inserts. The 6 mL inserts and lids were cleaned before each digestion using 3 mL of
HNO3 and 1 mL of HCl. Outside of the three inserts, 5 mL of HNO3 was added to each
digestion vessel to allow the temperature of the vessels to be monitored and ensure that
the inserts maintained the proper temperature. The vessels were microwaved according
to EPA Method 305273 following a program of a 10 minute ramp to 180 °C with a 10
minute hold at 180 °C. After microwaving, the vessels, lids, and stir bars were rinsed
inside and outside with DDI water and dried on cleanroom wipes overnight.
6.2.2.5 Elemental Analysis of Blood
6.2.2.5.1 Sample Digestion for Elemental Analysis by External Calibration Curve
Three different blood matrices were analyzed for elemental analysis: serum,
plasma, and RBCs. For each patient and matrix, three subsamples were prepared in clean
6 mL microwave vessel inserts. After placing a stir bar inside each insert, 0.2 grams of
sample was combined with 3 mL of HNO3 and 0.25 mL of HCl. For each sample batch,
three subsamples of SRM 1598a were prepared in the same manner as the patient samples
for quality control. Similar to when the vessels were cleaned, 5 mL of HNO3 was added
to the microwave digestion vessels outside of the 6 mL inserts. Each batch of samples
was microwaved following EPA Method 3052 resulting in a complete digestion through
the production of homogenous, transparent, light yellow solutions that did not contain
any solids. After digestion, each sample was poured into a 50 mL centrifuge tube and
diluted to 10 mL with a 1% HNO3 and 0.5% HCl solution. They were weighed before
and after the addition of the sample digests along with being pre-rinsed with the 1%
HNO3 and 0.5% HCl solution. Twelve analytical blanks consisting of HNO3 and HCl
were prepared for each set of analyzed samples. The microwave vessels were rinsed with
334

DDI water after being used and cleaned as previously described. The samples were
stored in a cold room at 4 °C until analysis, typically within 2 days.
6.2.2.5.2 Total Elemental Quantification by EPA Method 6020B
The total elemental concentrations in the sample digests were determined
according to EPA Method 6020B.74 On each day of analysis, the system was aspirated
with 2% HNO3 for 30 minutes before tuning the instrument using the Agilent tuning
solution at a concentration of 1 ng g-1 and determining the pulse/analog (P/A) factor.
Analysis on the Agilent 7700 ICP-MS was performed in three analysis modes: hydrogen,
helium, and no gas. The amount of hydrogen and helium gas was optimized to minimize
polyatomic interferences. Between analysis modes, a 30 second delay was employed to
equilibrate the presence or absence of collision and/or reaction gas. The analysis mode
for each element is listed in Table 35.
Calibration curves were created for 58 elements using solutions prepared from the
single and multi-element standards.

The calibration solutions were prepared at

concentrations of 0, 2.5, 5, 7.5, 10, and 25 ng g-1 in a 1% HNO3 and 0.5% HCl solution
through serial dilution. In each sequence, five children’s samples (serum, plasma, and
RBCs) were analyzed per run with four replicates taken from each subsample. Analyses
were performed in spectrum mode using one point per mass. The integration times for
each element ranged from 0.1-1.0 seconds per point depending on the element’s
ionization energy. After analysis was completed, the data was exported from the Agilent
MassHunter software (version G7201A A.01.01) into Microsoft Excel for further data
analysis.
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6.2.2.5.3 Sample Digestion for Elemental Analysis by IDMS
The blood samples to be analyzed according to EPA Method 6800 were also
prepared using microwave sample digestion.

Using clean microwave vessels, three

subsamples of each child and matrix were prepared in the 6 mL microwave vessel inserts.
After adding a stir bar, 0.2 grams of sample was combined in each insert with the
appropriate amount of each isotopically enriched analyte, 3 mL of HNO3, and 0.25 mL of
HCl. Three subsamples of SRM 1598a used for quality control of each batch. Similar to
the EPA Method 6020B analysis, 5 mL of HNO3 was added to the microwave digestion
vessels outside of the 6 mL inserts. The samples were digested following EPA Method
3052 according to the previously described parameters and the same post microwave
sample protocol was followed as the EPA Method 6020B sample preparation. The
samples were subsequently stored at 4 °C in a cold room until analysis, which usually
occurred within 2 days. With each batch of analyzed samples, twelve analytical blanks
consisting of HNO3, HCl, and isotopically enriched versions of the elements of interest
were prepared.
6.2.2.5.4 Total Elemental Quantification by EPA Method 6800 Quantification
Total elemental quantification using IDMS, a component of EPA Method 6800,75
was performed for twelve elements (antimony, cadmium, chromium, copper, iron,
lithium, lead, mercury, molybdenum, selenium, tin, and zinc). On each day of analysis,
the ICP-MS was tuned and the P/A factor was determined as previously described. The
IDMS analysis was also completed using the three different modes with the same
collision/reaction gas parameters. Analysis was performed in spectrum mode with one
point per peak, and the integration time was set to 0.5-1.0 seconds per point for each
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element. Each subsample had four replicates analyzed with five children’s samples
comprising each sequence. Naturally abundant standards of the twelve analytes were
analyzed at 0, 2, 4, 6, 8, and 10 ng g-1 to determine the mass bias and deadtime correction
factors. The Agilent 7700 ICP-MS’s default deadtime of 38 nanoseconds for the detector
was used for the IDMS calculations. The concentrations for each of the isotopically
enriched elements were measured and verified by reverse IDMS analysis using the multior single element natural abundant standard solutions. The completed data was exported
into the IDMS software provided by AIT in Microsoft Excel from Agilent MassHunter
software. The concentrations of the analytes in the sample solutions were obtained using
the IDMS equation (Equation 1).
6.2.2.6

Elemental Analysis of Hair

6.2.2.6.1 Sample Decomposition for Total Elemental Analysis by External
Calibration Curve
The hair elemental analysis samples were also prepared using microwaveenhanced chemistry. Using clean inserts, a stir bar was added to each insert and 0.1
grams of sample was combined with 0.5 mL of HNO3 and 0.2 mL of HCl. Three
subsamples were prepared for each child. For quality control, CRM GBW09101b was
used with all of the same parameters as the samples except for using 0.2 grams to meet
the CRM certificate specifications. Similar to the blood analysis, 5 mL of HNO3 was
added to the microwave digestion vessels outside of the inserts. The hair samples were
microwaved according to EPA Method 3052 as previously described. The same post
digestion procedure was followed as during the blood analyses. Nine analytical blanks
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consisting of HNO3 and HCl were digested with each sample batch. Prior to analysis, the
samples were stored in a cold room at 4 °C until analysis, usually within 3 days.
6.2.2.6.2 Quantification of Total Elemental Concentrations by EPA Method 6020B
The hair elemental concentrations were determined in the digests using EPA
Method 6020B. The ICP-MS was tuned and the P/A factor was determined on each day
of analysis as previously described. Similar to the blood analysis, the three different
collision/reaction gas modes were used with the previously described parameters.
Using the single and multi-element standards, calibration curves were prepared
for 58 elements. The analysis was performed at two different calibration ranges due to
the wide concentration range of the analytes of interest in CRM GBW09101b and the hair
samples. The solutions for the low concentration range were prepared at 0, 5, 10, 15, 20
and 25 ng g-1 in a 1% HNO3 and 0.5% HCl solution. The high concentration range
solutions were also made in a 1% HNO3 and 0.5% HCl solution at concentrations of 0, 5,
10, 25, 50, and 100 ng g-1. The calibration standards were prepared by acid matching,
which consisted of adding the appropriate percentage of microwave-digested reagent
blank to each calibration standard.
The post microwave sample digests were diluted an additional 10:1 for the low
concentration analytes and an additional 100:1 for the high concentration analytes in the
1% HNO3 and 0.5% HCl solution.

The low and high concentration analytes were

analyzed in independent runs with four replicates taken from each subsample. The
children’s samples were analyzed in four separate sequences with 18 in each of the first
three sequences and 6 in the last one. Analyses were completed using spectrum mode
with one point per mass. The integration times for each element varied from 0.1-1.0
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seconds per point based on the ionization energy of each element.

The measured

concentration value for each element in CRM GBW09101b and each hair sample was
determined based on the value that fell within the range of one of the two calibration
curves. Following analysis, additional data processing was performed in Microsoft Excel
after being exported from Agilent MassHunter.
6.2.2.7 Quality Control
The current study implemented numerous quality control measures that were
previously mentioned including the preparation of multiple subsamples, replicate
analysis, preparation of analytical blanks, acid or solution matched calibration standards,
and reference materials. It also utilized many of the quality control measures described
in EPA Method 6020B.

The Agilent internal standard solution was used at a

concentration of 100 ng g-1 in a 1% HNO3 and 0.5% HCl solution, and its acceptable
recovery was maintained between 80 and 120% of the calibration blank.

Between

samples, the autosampler probe was washed in three 1% HNO3 and 0.5% HCl solutions
for 30 seconds each with a nebulizer pump speed of 0.5 rps. After every nine samples
during EPA Method 6020B analysis, low- and midpoint calibration checks along with
either SRM 1598a or CRM GBW09101b assessments were performed as additional
calibration verification. During EPA Method 6800 analysis, SRM 1598a checks were
performed at the beginning, middle, and end of each analysis sequence. These checks
ensured the consistency of the results during the complete duration of the sample runs.
6.2.2.8

Statistical Analysis

Differences between the control subjects and their paired child with autism
counterparts were computed for each variable. The resulting thirty differences for a
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given variable were then used to conduct a paired-samples t-test. This test determines
whether the observed average difference is far enough from zero to conclude a
statistically significant difference between the control and autistic responses for that
variable. In this study, far enough from zero is represented by the 0.05 significance level.
Correlation analyses were also performed as a part of this study. For a given
variable, correlations were computed between the thirty measurements on children with
autism and the thirty corresponding subject ages, and for the thirty measurements on
children with autism with every other variable measured in the study. Correlations were
also computed between the thirty control measurements and the thirty corresponding
subject ages and with the control measurements of every other variable.
For nearly all variables, there were no significant correlations between the
measurements for the children with autism and corresponding control measurements, nor
was there a significant correlation between either set of measurements and age. In such
cases, there is no evidence that the subject pairing matters. That is, the data for several
variables suggests knowing the control subject measurement provides no information
about the corresponding measurement of the child with autism.

The control

measurements and measurements on children with autism for such variables can therefore
be viewed as independent, and used to conduct a logistic regression analysis. Since the
number of control subjects is fixed to equal the number of subjects with autism, the
logistic regression analysis must be adjusted to reflect an assumed autism
prevalence.76 These analyses provide an autism diagnosis probability as a function of a
particular variable of interest.
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In addition to comparisons made between the children with autism and their
matched controls, measurement comparisons were completed between three different
measurement techniques: the commercial clinical laboratory, EPA Method 6020B, and
EPA Method 6800. Among these three analysis methods, comparisons were completed
for four variables: plasma zinc, serum copper, plasma zinc/serum copper ratio, and
serum selenium. The correlation was determined for each variable comparing each pair
of the three measurement techniques along with the resulting p-value. This p-value
represents how closely the measurement values by two different techniques are related to
each other and the value for a variable by one technique provides information about what
the value is by the other measurement technique. Additionally, histograms were created
to display the relative percent differences between a given pair of measurement
techniques for each variable. The p-value from the histogram determines whether the
average difference between the two measurement techniques contains zero, which means
there is no average difference between the measurement techniques for that variable. Just
as in the previously described comparisons, significance was based on 0.05 level.

6.3 Results
6.3.1

Behavioral Rating Scales

The means (n = 30 pairs) and 95% CIs were determined for all of the behavioral
ratings scales with the results seen in Table 34. All of the children with autism or PDDNOS (mean: 5.5, SD: 2.1, 95% CI: 0.8) met the criteria for an ASD by ADOS. All
potential control children had total ADOS scores that were below the cutoff for an ASD.
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Table 34: The behavioral rating scale results (n = 30 pairs, 95% CIs) for children with autism
and controls, with the p-value representing the difference between the two groups.

Rating Scale
ADOS
SCQ

ATEC

ABC

CARS
GARS

PDDBI

Subscale
Total
Communication
Social Interaction

Control
Autism
P-Value
2.6 ± 0.7
14.6 ± 1.3
5.1 × 10-16
0.7 ± 0.2
4.9 ± 0.7
2.8 × 10-13
2.0 ± 0.6
9.7 ± 0.9
2.5 × 10-15
2.8 ± 0.9
18.4 ± 2.6
2.8 × 10-11
Total
66.1 ± 1.2
75.3 ± 5.0
9.3 × 10-4
I
27.9 ± 0.1
17.4 ± 2.8
1.5 × 10-8
II
0.8 ± 0.4
14.4 ± 2.7
5.7 × 10-11
III
35.8 ± 0.2
23.8 ± 2.3
4.8 × 10-12
IV
1.6 ± 0.9
19.6 ± 3.7
4.7 × 10-10
Total
4.4 ± 2.8
57.5 ± 9.4
3.0 × 10-11
I
1.9 ± 1.1
14.5 ± 3.3
1.1 × 10-7
II
0.2 ± 0.2
11.9 ± 2.8
3.1 × 10-9
III
0.03 ± 0.07
6.5 ± 1.6
6.5 × 10-9
IV
2.0 ± 1.4
21.4 ± 3.6
1.4 × 10-10
V
0.2 ± 0.2
3.3 ± 1.1
1.5 × 10-6
15.4 ± 0.3
32.5 ± 2.7
2.5 × 10-13
Autism Index
29.9 ± 9.6
86.8 ± 6.8
8.6 × 10-10
Stereotyped Behaviors
1.8 ± 0.7
7.9 ± 1.0
6.6 × 10-11
Communication
1.2 ± 0.7
8.4 ± 1.5
8.1 × 10-9
Social Interaction
1.0 ± 0.06
7.3 ± 1.2
2.3 × 10-9
Autism Composite
18.1 ± 1.1
51.1 ± 4.8
3.1 × 10-14
Approach/Withdrawal Problems
SENSORY
35.2 ± 0.8
48.4 ± 3.4
2.2 × 10-8
RITUAL
35.7 ± 1.1
53.2 ± 4.7
7.1 × 10-8
SOCPP
31.8 ± 1.3
50.7 ± 3.7
1.2 × 10-10
SEMPP
37.9 ± 1.5
52.3 ± 3.4
8.9 × 10-9
AROUSE
29.6 ± 1.9
51.0 ± 3.9
6.5 × 10-11
AGG
38.1 ± 1.6
51.2 ± 4.5
1.1 × 10-7
REPRIT/C
28.9 ± 1.0
51.8 ± 4.4
2.9 × 10-11
AWP/C
29.5 ± 1.5
52.5 ± 4.2
3.2 × 10-11
Receptive/Expressive Social Communication Abilities
SOCAPP
73.6 ± 1.7
51.3 ± 4.5
1.8 × 10-10
EXPRESS
71.7 ± 2.5
51.2 ± 4.0
2.0 × 10-9
LMRL
65.5 ± 1.8
51.6 ± 3.2
2.1 × 10-8
EXSCA/C
74.9 ± 2.5
51.4 ± 4.2
3.0 × 10-10
REXSCA/C
73.5 ± 2.3
51.5 ± 4.0
2.6 × 10-10
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6.3.1.1

Autism Diagnostic Observation Schedule

The children with autism had higher mean scores than controls on the Total
ADOS and the two modules (Table 34 and Figure 41). The children with autism had an
average Total ADOS composite score of 14.6 ± 1.3, while controls had a mean of 2.6 ±
0.7. For the communication module, the mean for the controls was 0.7 ± 0.2, and the
average for children with autism was 4.9 ± 0.7. The children with autism had a mean
score of 9.7 ± 0.9 for the social interaction module while controls averaged 2.0 ± 0.6.

Figure 41: The mean values for the communication module, social interaction module, and total
ADOS for each of the two groups (n = 30 pairs, 95% CIs).

6.3.1.2

Social Communication Questionnaire

The children with autism had an average SCQ score of 18.4 ± 2.6, while controls
had a mean score of 2.8 ± 0.9 (Table 34 and Figure 42). The average SCQ score for
children with autism is above the cutoff for an ASD, but below the cutoff for autism.
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Figure 42: For the control and autism groups, the mean Social Communication Questionnaire
results (n = 30 pairs, 95% CIs).

6.3.1.3

Autism Treatment Evaluation Checklist

The results for the four ATEC subscales and total ATEC score are shown in Table
34 and Figure 43. The total ATEC was higher in the autism group with an average of
75.3 ± 5.0 compared to 66.1 ± 1.2 for controls. For subscales II and IV, the autism group
had the greater mean score; however, the control group had the larger average for
subscales I and III.
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Figure 43: The mean results (n = 30 pairs, 95% CIs) for the ATEC subscales and total ATEC.
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6.3.1.4

Aberrant Behavior Checklist

For the Total ABC, the children with autism demonstrated a greater mean score of
57.5 ± 9.4 compared to the controls that averaged 4.4 ± 2.8 (Table 34 and Figure 44).
The children with autism had a higher mean score compared to the control children for
each of the five subscales.

Figure 44: For the control and autism groups, the ABC subscale and total ABC results. The
average values are shown for each group (n = 30 pairs) with 95% CIs.
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6.3.1.5

Childhood Autism Rating Scale

The children with autism had a mean CARS score of 32.5 ± 2.7 while controls
averaged 15.4 ± 0.3 (Table 34 and Figure 45). The average score for the children is
above the autism cutoff of 30, but it is below the cutoff of 36 for severe autism. The
controls’ average score was very close to the lowest possible value of 15.

Figure 45: The results for each group (n = 30 pairs, 95% CIs) for the Childhood Autism Rating
Scale.

6.3.1.6

Gilliam Autism Rating Scale-2

For the Autism Index of GARS-2, the children with autism averaged 86.8 ± 6.8
and the controls had a mean value of 29.9 ± 9.6 (Table 34 and Figure 46). The value for
the children with autism indicates the “very likely” presence of autism, while the score
for the control children suggests that autism is “unlikely.” The children with autism
scored higher than the control children for each of the three scored subscales.
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Figure 46: For the GARS-2, the results for the stereotyped behaviors, communication, and social
interaction subscales and the Autism Index for the control and autism group. The average and
95% CIs are shown for each group of 30 children.

6.3.1.7

PDD Behavior Inventory

The PDDBI behavioral rating scale results are shown in Table 34 and Figures 4749. On the Autism Composite, the children with autism had a mean value of 51.1 ± 4.8,
while the control children had an average of 18.1 ± 1.1 (Figure 47). The children with
autism had higher average scores for each of the domains and composites of the
Approach/Withdrawal problems dimension of the PDDBI (Figure 48). The results for the
domains and composites for the Receptive/Expressive Social Communication Abilities
dimension of the PDDBI showed that the control children had greater mean values
compared to the children with autism (Figure 49).
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Figure 47: The Autism Composite results for the PDDBI (n = 30 pairs, 95% CIs).
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Figure 48: The mean and 95% CIs of each group for the domains and composites for the
Approach/Withdrawal Problems dimension of the PDDBI.
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Figure 49: For the control and autism groups, the results (n = 30 pairs, 95% CIs) of the domain
and composites for the Receptive/Expressive Social Communication Abilities dimension of the
PDDBI.
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6.3.2

Elemental Analysis

6.3.2.1

Analytical Figures of Merit and Validation of EPA Methods

All elements displayed linearity on the six point external calibration curves for the
EPA Method 6020B blood and hair analysis. They had correlation coefficient (r2) values
greater than the 0.998 specified in EPA Method 6020B, except for Ca in the blood
analysis, which was just below this cutoff at 0.9974 (Tables 35 and 36). The obtained
measurements were highly reproducible because the four replicates for each calibration
point displayed a typical variation of less than 5%.
Table 35: The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of
interest in blood determined by EPA Method 6020B using the Agilent 7700 ICP-MS.

Element
Mg
Al
Ca
V
Cr
Mn
Fe
Co
Ni
Cu
Zn
As
Se
Rb
Mo
Cd
Sb
Te
Cs
Hg
Pb

m/z
24
27
40
51
52
55
56
59
60
63
66
75
78
85
95
111
121
125
133
201
208

Mode
He
H2
H2
He
He
He
He
He
He
He
He
He
H2
He
He
He
No gas
No gas
No gas
No gas
No gas

r2
0.9998
0.9999
0.9974
0.9998
0.9998
0.9998
0.9999
0.9998
0.9998
0.9994
0.9998
0.9999
0.9999
0.9999
0.9998
0.9998
0.9999
0.9998
0.9999
0.9999
0.9999

DL (ng g-1)
6.58
8.82
57.6
4.80
0.306
0.0903
12.2
0.370
0.0666
0.114
2.52
1.04
0.0710
0.0000472
0.0218
0.0656
0.0414
0.0177
0.00288
0.106
0.0205
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QL (ng g-1)
9.02
16.7
139
8.12
0.572
0.207
29.1
1.11
0.206
0.278
3.98
1.84
0.164
0.000150
0.0604
0.154
0.101
0.0541
0.00822
0.226
0.0470

BEC (ng g-1)
0.632
3.69
177
1.99
0.698
0.306
8.03
0.0144
0.652
6.42
1.29
0.999
0.129
0.0228
0.0548
0.00684
0.0340
0.0301
0.00320
0.0132
0.0155

Table 36: The analysis information, correlation coefficient, DLs, and BECs for elements of
interest in hair determined by EPA Method 6020B using the Agilent 7700 ICP-MS.

Element
Na
Mg
Al
P
K
Ca
V
Cr
Mn
Fe
Co
Ni
Cu
Zn
As
Se
Sr
Mo
Ag
Cd
Sb
Ba
La
Hg
Pb
U

m/z
23
24
27
31
39
40
51
52
55
56
59
60
63
66
75
78
88
95
107
111
121
137
139
202
208
238

Mode
No gas
No gas
No gas
No gas
No gas
H2
He
He
He
He
He
He
He
He
He
H2
No gas
He
No gas
He
No gas
No gas
No gas
No gas
No gas
No gas

r2
0.9999
0.9997
0.9994
0.9995
0.9998
0.9989
0.9989
0.9996
0.9990
0.9999
0.9994
0.9998
0.9998
0.9998
0.9994
0.9995
0.9991
0.9987
1.0000
0.9985
1.0000
0.9999
0.9982
1.0000
1.0000
0.9999

DL (ng g-1)
0.932
0.0102
0.261
6.30
3.93
2.17
0.0738
0.489
0.134
0.711
0.138
0.189
0.0610
0.828
0.0311
0.00986
0.0220
0.0558
0.00212
0.0942
0.00495
0.622
0.00335
0.0621
0.0630
0.00170

QL (ng g-1)
2.68
0.0317
0.759
5.87
13.1
1.59
0.210
1.44
0.408
2.02
0.392
0.558
0.193
2.21
0.0948
0.0311
0.0653
0.169
0.00567
0.280
0.0134
1.74
0.00931
0.122
0.188
0.00439

BEC (ng g-1)
5.97
0.717
1.34
19.9
4.02
22.9
0.0354
1.16
0.192
2.58
0.0621
0.572
0.182
2.18
0.0891
0.0280
0.0424
0.0523
0.0158
0.0450
0.0364
0.205
0.00935
0.0554
0.0716
0.00880

Detection limits (DLs) were defined as the average of the blank concentration for
each element plus three times the standard deviation of the blank measurements for that
respective element.77 The DLs for all elements were below 1 ng g-1 except for Mg, Al,
Ca, V, Fe, Zn, and As for the EPA Method 6020B blood analysis (Table 35); Fe and Zn
for the EPA Method 6800 blood testing (Table 37); and P and K for the EPA Method
6020B hair analysis (Table 36). The quantification limits (QLs) were determined by
taking ten times the standard deviation of the blank measurements for each respective
element.77 The QLs were all under 2 ng g-1 except Mg, Al, Ca, V, Fe, and Zn for the
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EPA Method 6020B blood testing (Table 35); Fe for the EPA Method 6800 blood
analysis (Table 37); and Na, P, K, Fe, and Zn for the EPA Method 6020B hair testing
(Table 36).

The background equivalent concentrations (BECs) were calculated by

multiplying the background intensity signal with the concentration of the analyte and
dividing by the difference of the analyte intensity minus the intensity of the
background.78 The BECs were below 2 ng g-1 for all elements except for Al, Ca, Fe, and
Cu in the EPA Method 6020B blood testing (Table 35); Fe and Cu in the EPA Method
6800 blood analysis (Table 37); and Ca, Fe, Na, P, K, and Zn in the EPA Method 6020B
hair testing (Table 36).
Table 37: The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of
interest in blood determined by EPA Method 6800 using the Agilent 7700 ICP-MS.

Element Natural
m/z
Li
7
Cr
52
Fe
56
Cu
63
Zn
66
Se
78
Mo
95
Cd
114
Sn
118
Sb
121
Hg
202
Pb
208

Enriched
m/z
6
50
57
65
68
77
97
112
122
123
199
206

Mode

DL (ng g-1) QL (ng g-1) BEC (ng g-1)

No gas
He
He
He
He
H2
He
He
He
No gas
No gas
No gas

0.00563
0.689
2.49
0.973
1.02
0.646
0.0220
0.168
0.232
0.0207
0.425
0.0404

0.0188
0.366
2.74
1.25
1.97
0.937
0.0546
0.485
0.585
0.0562
0.943
0.0358

0.0224
0.448
4.45
2.37
0.569
0.0571
0.0214
0.0261
0.0195
0.00584
0.0262
0.00945

Additional confidence in the accuracy and precision of the results from the
present study was achieved by using SRM 1598a and CRM GBW09101b to validate the
sample preparation and analysis protocols. These standards are certified for multiple
elements at concentrations similar to those found in representative blood and hair
samples, respectively. Results obtained for SRM 1598a during this study using EPA
Method 6020B and EPA Method 6800 are shown in Table 38 with the mean (n = 12) and
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95% confidence intervals (CIs). The measured values are in strong agreement with the
certified and reference values for the EPA Method 6020B analysis, with overlapping CIs
for all elements above the respective DL except for Ca. The percent recovery for Ca was
124% when comparing mean values, but improved to 113% when including the CIs. For
the EPA Method 6800 testing, the measured CIs overlapped with the certified or
reference CIs for all 6 elements that were able to be quantified above the respective DL.
Table 38: Concentrations (ng g-1) of the certified, reference, and informational elements
determined in SRM 1598a by EPA Methods 6020B and 6800 (n = 12, 95% CIs).

Certified Value
(ng g-1)
Cd
0.047 ± 0.004
Co
1.21 ± 0.07
Cs
0.62 ± 0.10
Cu
1,538 ± 88
Fe
1,635 ± 58
Mn
1.73 ± 0.32
Ni
0.91 ± 0.18
Rb
267 ± 18
Sb
0.973 ± 0.15
Se
130.8 ± 5.6
V
1.83 ± 0.11
Zn
857 ± 23
Reference Value
(ng g-1)
Al
2.2 ± 0.6
Ca
93 ± 7 (µg g-1)
Cr
0.32 ± 0.08
Hg
0.31 ± 0.18
Mo
5.4 ± 1.0
Information Value
(ng g-1)
As
0.3
K
258 (µg g-1)
Na
3,115 (µg g-1)
P
136 (µg g-1)
S
915 (µg g-1)
Te
0.032
<DL: below detection limit
Element

EPA Method 6020B
(ng g-1)
<DL
<DL
0.7999 ± 0.1615
1,567 ± 17
1,874 ± 235
<DL
<DL
272.0 ± 3.3
1.328 ± 0.450
124.9 ± 2.7
<DL
888.5 ± 16.3
EPA Method 6020B
(ng g-1)
<DL
115.0 ± 2.5
<DL
<DL
3.278 ± 1.465
EPA Method 6020B
(ng g-1)
<DL
Not Determined
Not Determined
Not Determined
Not Determined
<DL
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EPA Method 6800
(ng g-1)
<DL
Not Determined
Not Determined
1,622 ± 11
1,614 ± 10
Not Determined
Not Determined
Not Determined
1.166 ± 0.122
131.1 ± 3.8
Not Determined
879.7 ± 8.0
EPA Method 6800
(ng g-1)
Not Determined
Not Determined
<DL
<DL
6.386 ± 0.908
EPA Method 6800
(ng g-1)
Not Determined
Not Determined
Not Determined
Not Determined
Not Determined
Not Determined

There were six elements which were measured at detectable quantities by both
EPA Method 6020B and EPA Method 6800: antimony, copper, iron, molybdenum,
selenium, and zinc. The results from each of the two EPA methods for these six elements
are shown in Figure 50. Both EPA Method 6020B and EPA Method 6800 produced
results that were accurate, within the provided CIs for all six elements, while EPA
Method 6800 provided better precision for all of these elements except for selenium.
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Figure 50: A comparison of EPA Method 6020B and EPA Method 6800 results for antimony,
copper, iron, molybdenum, selenium, and zinc for SRM 1598a (n = 12, 95% CIs).
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Similar accuracy was achieved for CRM GBW09101b during the hair analysis.
Figure 51 and Table 39 show a comparison of the reference and informational values
with the measured results including means (n = 12) and 95% CIs. The measured values
are in strong agreement with the certified and informational values, as the CIs for the
measured values overlapped the certified CIs for 19 out of 21 elements. The recovery
efficiencies ranged from 64.0 to 125.8% based on a comparison of the mean listed values
to the average measured quantities. Only 2 of the 21 elements with certified values had
either recoveries that differed by more than 20% from the mean value or that did not
overlap CIs. The overall accuracy of the elemental measurements in this study improves
with the inclusion of the provided CIs.

Figure 51: Comparison of the EPA Method 6020B results to the CRM GBW09101b certified
and information values (n = 12, 95% CIs).
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Table 39: Concentrations (µg g-1) of the certified and informational elements determined in
CRM GBW09101b by EPA Methods 6020B (n = 12, 95% CIs).

Element
Ag
Al
As
Ba
Ca
Cd
Co
Cr
Cu
Fe
Hg
I
Mg
Mn
Mo
Na
P
Pb
Sb
Se
Sr
Zn
K
La
S
Cl
Ti
V
Br
Ni

Certified Value (µg g-1)
0.037 ± 0.002
23.2 ± 2.0
0.198 ± 0.023
11.1 ± 1.3
1,537 ± 68
0.072 ± 0.010
0.153 ± 0.015
8.74 ± 0.97
33.6 ± 2.3
160 ± 16
1.06 ± 0.28
0.96 ± 0.20
248 ± 14
3.83 ± 0.39
1.06 ± 0.12
445 ± 40
174 ± 43
3.83 ± 0.18
0.12 ± 0.02
0.59 ± 0.04
8.17 ± 0.69
191 ± 16
Information Value (µg g-1)
14.4
0.029
4.62
48.2
2.1
0.089
0.59
5.77

EPA Method 6020B (µg g-1)
0.03253 ± 0.00354
25.88 ± 2.41
0.2337 ± 0.0664
7.108 ± 0.596
1,432 ± 49
0.06029 ± 0.02139
0.1363 ± 0.0207
8.028 ± 0.502
34.91 ± 1.01
151.8 ± 7.0
1.220 ± 0.061
Not Determined
246.4 ± 6.2
2.799 ± 0.205
0.9018 ± 0.0647
469.9 ± 10.9
157.4 ± 2.5
4.488 ± 0.637
0.1282 ± 0.0053
0.5940 ± 0.0660
8.152 ± 0.092
208.8 ± 12.1
EPA Method 6020B (µg g-1)
10.64 ± 1.01
0.03647 ± 0.00507
Not Determined
Not Determined
Not Determined
0.06904 ± 0.02800
Not Determined
5.113 ± 0.361

The precision determined by the 95% CIs was within 10% of the measured mean
values for a large majority of the certified, reference, or information values for elements
in SRM 1598a and CRM GBW09101b, with nearly half inside of 5% (Tables 38 and 39).
This level of precision observed for these reference standards was maintained for the
remainder of the study as most results had 95% CIs that were less than 10% of their mean
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value, including a large number of them within 5%. The EPA Method 6800 results for
SRM 1598a were more precise compared to EPA Method 6020B for 5 of the 6 elements
that were able to be quantified by both methods. Overall, the blood measurements in this
study obtained by EPA Method 6800 were more precise compared to those from EPA
Method 6020B. The current study also supplied 95% CIs for all detectable elemental
quantities in the blood and hair samples.
6.3.2.2

Elemental Analysis of Blood

Paired-samples t-tests were performed on the elements in the three blood matrices
to determine significance differences between the children with autism and controls. The
elements that produced significant results with p-values below 0.05 are shown in Table
40. Significant results were observed for Mg in plasma, serum, and RBCs, where
children with autism had greater concentrations compared to controls with p-values of 1.3
× 10-4, 2.4 × 10-4, and 6.8 × 10-4, respectively (Figures 52-54). Another significant
finding was seen in Figure 55 with RBC Fe as the children with autism had greater mean
quantities than the control children (p-value = 0.0076). Plasma Mo produced the final
significant difference illustrated in Figure 56 with the children with autism having a
greater average concentration compared to controls (p-value = 0.012). The dashed lines
in each figure indicate the matched pairs of children.
Table 40: The statistically significant results of the elemental blood analyses, with the children
with autism displaying higher levels of each element along with the corresponding p-value from
the paired-samples t-test.
Variable
P-Value
Plasma Mg
0.00013
Serum Mg
0.00024
RBC Mg
0.00068
RBC Fe
0.0076
Plasma Mo
0.012
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Figure 52: The mean values of plasma magnesium in children with autism and controls with an
n = 30 pairs. The children with autism had significantly higher plasma magnesium than controls
with a p-value of 1.3 × 10-4.

Figure 53: For n = 30 pairs, the average serum magnesium concentrations in children with
autism were higher compared to controls (p-value = 2.4 × 10-4).
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Figure 54: The average red blood cell magnesium values for n = 30 pairs of children with autism
and controls. The children with autism had significantly higher red blood cell magnesium
concentrations than controls (p-value = 6.8 × 10-4).

Figure 55: The children with autism had significantly higher red blood cell iron concentrations
than controls according to the average values for 30 pairs of children (p-value = 0.0076).
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Figure 56: For n = 30 pairs, the average plasma molybdenum concentrations in children with
autism were higher compared to controls (p-value = 0.012).

Although the results were not significant using paired-samples t-tests, the results
for the plasma zinc/serum copper ratio did indicate an important finding. Both children
with autism and controls demonstrated a suppressed zinc/copper ratio by all three
measurement techniques as seen in Table 41. These indicators agreed well with each
other and differed significantly from a normal healthy zinc/copper ratio.
Table 41: The plasma zinc/serum copper ratio results for children with autism and controls from
a commercial clinical laboratory, EPA Method 6020B, and EPA Method 6800.
Autism
Control
Commercial Laboratory
0.625 ± 0.046
0.661 ± 0.066
EPA Method 6020B
0.6258 ± 0.0681
0.6841 ± 0.0691
EPA Method 6800
0.6532 ± 0.0550
0.6652 ± 0.0641

6.3.2.3

Elemental Analysis of Hair

No elements analyzed in hair produced a significant difference between the two
cohorts of children using a paired-samples t-test; however, trends of near significance
were observed for two elements. The results for Cr were nearly significant with a p-value
of 0.051 as the children with autism tended to have lower concentrations of Cr in their

363

hair compared to controls (Figure 57). A similar trend was seen for Pb in Figure 58, with
an inclination of control children to have greater concentrations of Pb in their hair
compared to children with autism (p-value = 0.057).

Figure 57: The average chromium hair concentrations for children with autism and matched
controls. The control children had nearly significantly greater concentrations of chromium in
their hair compared to children with autism (p-value = 0.051).

Figure 58: For the 30 pairs of children who had their hair analyzed, a trend was observed with
controls having more lead in their hair compared to controls (p-value = 0.057).
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6.3.3

Clinical Laboratory Testing

Upon completion of the clinical testing, the means (n = 30 pairs) and 95% CIs
were calculated for all measured variables as part of the statistical analyses. All of the
clinical testing results are shown in Table 42. The statistically significant findings from
the clinical laboratory testing are shown in Table 43.
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Table 42: The results of the clinical laboratory testing performed for the children with autism
and controls (n = 30 pairs, 95% CIs).

Grouping

Test
Control
Autism
-1
Plasma Zinc (µgdL )
70.6 ± 4.7
72.3 ± 5.1
Serum Copper (µg dL-1)
111.4 ± 9.4
118.3 ± 8.7
Plasma Zinc/Serum Copper Ratio 0.661 ± 0.066 0.625 ± 0.046
Metals/Elements
Selenium (µg L-1)
120.8 ± 4.3
125.5 ± 5.6
-1
Calcium (mg dL )
9.80 ± 0.13
9.97 ± 0.14
Phosphorus (mg dL-1)
4.81 ± 0.20
4.87 ± 0.26
-1
Lymphocyte Number (cells µL )
3,113 ± 397
4,108 ± 591
CD3 Number (cells µL-1)
2,123 ± 262
2,759 ± 403
CD3 Percent (%)
68.6 ± 2.2
67.2 ± 2.8
CD4 Number (cells µL-1)
1,240 ± 161
1,628 ± 239
CD4 Percent (%)
39.7 ± 2.5
39.8 ± 2.6
CD8 Number (cells µL-1)
797 ± 133
1,008 ± 190
Lymphocyte
CD8 Percent (%)
25.1 ± 2.4
24.0 ± 2.1
Subset Panel
CD4/CD8 Ratio
1.71 ± 0.23
1.75 ± 0.20
CD19 Number (cells µL-1)
681 ± 125
791 ± 170
CD19 Percent (%)
21.7 ± 2.3
19.1 ± 2.3
Natural Killer Cell Number
235.4 ± 49.6 470.7 ± 121.4
(cells µL-1)
Natural Killer Cell Percent (%)
7.83 ± 1.31
11.8 ± 2.7
-1
IgA (mg dL )
107 ± 16
108 ± 24
Serum
IgG (mg dL-1)
965 ± 106
961 ± 124
Immunoglobulins
IgM (mg dL-1)
86.5 ± 10.7
88.1 ± 14.8
-1
White Blood Cells (thousands µL ) 7.45 ± 0.74
9.15 ± 1.04
Red Blood Cells (million µL-1)
4.35 ± 0.12
4.49 ± 0.12
-1
Hemoglobin (g dL )
12.6 ± 0.3
12.9 ± 0.3
Hematocrit (%)
36.8 ± 0.9
37.6 ± 1.1
Mean Corpuscular Volume
84.7 ± 0.9
83.9 ± 1.3
(femtoliters)
Mean Corpuscular Hemoglobin
29.1 ± 0.4
28.7 ± 0.5
(pictograms)
Mean Corpuscular Hemoglobin
Complete Blood
34.3 ± 0.2
34.2 ± 0.3
Concentration (g dL-1)
Count Including
Red Blood Cell Distribution Width
Differential and
13.6 ± 0.2
13.5 ± 0.3
(%)
Platelets
Platelet Count (thousands µL-1)
287 ± 18
323 ± 29
-1
Neutrophil Number (cells µL )
3,595 ± 538
4,366 ± 668
Neutrophil Percent (%)
47.9 ± 3.9
47.7 ± 3.6
-1
Lymphocyte Number (cells µL )
3,099 ± 368
3,919 ± 525
Lymphocyte Percent (%)
42.2 ± 4.0
43.2 ± 4.0
Monocyte Number (cells µL-1)
532 ± 62
598 ± 86
Monocyte Percent (%)
7.3 ± 0.7
6.6 ± 0.7
Eosinophil Number (cells µL-1)
183 ± 47
222 ± 70
Eosinophil Percent (%)
2.4 ± 0.5
2.2 ± 0.7
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Iron and Total
Iron Binding
Capacity (TIBC)

Liver Function

Immune
Tolerance

Protein Status

Thyroid Studies

Vitamin Status

Basophil Number (cells µL-1)
Basophil Percent (%)
Erythrocyte Sedimentation Rate
(mm hr-1)
Total Iron (µg dL-1)
TIBC (µg dL-1)
Percent Saturation (%)
Ferritin (ng mL-1)
Aspartate Aminotransferase
(units L-1)
Alanine Aminotransferase
(units L-1)
Alkaline Phosphatase (units L-1)
Liver Isoenzyme (%)
Bone Isoenzyme (%)
Intestine Isoenzyme (%)
Macrohepatic Isoenzyme (%)
Placental Isoenzyme (%)
IgG Gliadin (units)
IgA Gliadin (units)
Tissue Transglutaminase Antibody
(units mL-1)
Gluten IgG (µg mL-1)
Soybean IgG (µg mL-1)
Casein/Cowmilk IgG (µg mL-1)
Albumin (g dL-1)
Ceruloplasmin (mg dL-1)
Cholesterol (mg dL-1)
Total Protein (g dL-1)
Thyroid Stimulating Hormone
(milli-international units L-1)
T3 Free (pg mL-1)
T4 Free (ng dL-1)
Serum Folate (ng mL-1)
Serum Methylmalonic Acid
(nmol L-1)
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38 ± 12
0.4 ± 0.2

39 ± 6
0.3 ± 0.2

5.0 ± 2.3

5.7 ± 2.2

74.4 ± 10.1
369 ± 18
20.4 ± 2.8
30.9 ± 6.1

89.7 ± 12.3
367 ± 19
25.0 ± 3.9
28.4 ± 5.6

30.3 ± 1.8

28.2 ± 2.0

15.5 ± 2.0

14.6 ± 1.8

209 ± 11
26.4 ± 2.3
69.7 ± 2.4
3.9 ± 1.8
0±0
0±0
3.7 ± 0.8
7.9 ± 9.7

235 ± 36
27.6 ± 3.0
69.9 ± 2.6
2.5 ± 1.3
0±0
0±0
3.2 ± 1.0
3.5 ± 1.6

3.3 ± 0.6

2.9 ± 0.5

11.6 ± 5.3
3.3 ± 1.1
13.8 ± 5.3
4.62 ± 0.10
30.5 ± 1.7
149 ± 9
7.00 ± 0.14

27.0 ± 13.1
4.4 ± 1.3
27.4 ± 13.1
4.74 ± 0.13
30.4 ± 1.9
157 ± 9.4
7.22 ± 0.20

2.31 ± 0.38

2.55 ± 0.38

3.83 ± 0.14
1.15 ± 0.06
22.2 ± 1.1

3.83 ± 0.13
1.17 ± 0.08
21.6 ± 1.6

130 ± 14

193 ± 40

Table 43: The statistically significant results and trends from the clinical laboratory testing with
the corresponding p-value from the paired-samples t-test.
Grouping
Variable
P-Value
Natural Killer Cell Number
0.0020
Lymphocytes
0.0039
CD3 Number
0.010
Lymphocyte Subset Panel
CD4 Number
0.010
Natural Killer Cell Percent
0.019
CD8 Number
0.052
Lymphocytes
0.0096
Complete Blood Count including
Neutrophils
0.049
Differentials and Platelets
Platelet Count
0.037
White Blood Cells
0.0051
Gluten IgG
0.0092
Immune Tolerance
Casein IgG
0.051
Vitamin Status
Methylmalonic Acid
0.0042

The lymphocyte subset panel demonstrated greatest number of significant
findings using paired-samples t-tests.

The most statistically significant finding was

natural killer cell number with a p-value of 0.0020 (Figure 59), with the children with
autism having a greater number compared to controls. The natural killer cell percent was
also higher in the children with autism as seen in Figure 60 (p-value = 0.010). The
children with autism had a larger number of lymphocytes compared to controls with a pvalue of 0.0039 (Figure 61). The children with autism had elevated CD3, total T cell, (pvalue = 0.010) and CD4, helper T cell, (p-value = 0.010) numbers compared to controls
seen in Figures 62 and 63, respectively. In addition to these statistically significant
findings, a trend of higher CD8 numbers in children with autism compared to controls
was observed with a p-value of 0.052 (Figure 64).
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Figure 59: The mean natural killer cell concentration in children with autism and controls. For n
= 30 pairs, the children with autism had significantly higher blood natural killer cell numbers than
controls with a p-value of 0.0020.

Figure 60: For the 30 pairs of children studied, the children with autism had a significantly
higher percentage of natural killer cells compared to controls with a p-value of 0.019.
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Figure 61: The average CD3 number in children with autism and controls. The children with
autism had significantly higher CD3 numbers than controls for n = 30 pairs with a p-value of
0.010.

Figure 62: For n = 30 pairs, the children with autism had significantly higher CD4 numbers than
controls with p = 0.010.
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Figure 63: The lymphocyte concentration from the lymphocyte subset panel for the children
with autism and controls. The children with autism had significantly higher concentrations of
lymphocytes with p = 0.0039.

Figure 64: For n = 30 pairs, the mean of CD8 numbers for children of autism and controls
indicated a trend of higher CD8 numbers in children with autism with a p-value of 0.052.

The complete blood count with differential and platelets was another area where
significant differences were observed between children with autism and controls. The
white blood cells produced the most significant discovery from this part of the clinical
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testing. They were elevated in the children with autism compared to controls with a pvalue of 0.0051 (Figure 65). The lymphocytes measured as part of the complete blood
count were also found to be significant as part of the complete blood count, just as they
were in the testing performed as part of the lymphocyte subset panel. The children with
autism displayed greater numbers of lymphocytes versus controls as seen in Figure 66 (pvalue = 0.0096). The next most significant finding was for platelets, with the children
with autism having a higher number compared to controls with a p-value of 0.037 (Figure
67). The final finding from the complete blood count was for neutrophils. The children
with autism had higher quantities of neutrophils compared to controls as illustrated in
Figure 68 (p-value = 0.049).

Figure 65: For n = 30 pairs, the children with autism demonstrated significantly higher white
blood cell counts than controls with p = 0.0051.
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Figure 66: The average lymphocyte count from the complete blood count for children with
autism and controls. The children with autism had significantly higher lymphocyte counts than
controls for n = 30 pairs with a p-value of 0.0096.

Figure 67: The average platelet counts in children with autism were higher compared to controls
for n = 30 pairs (p-value = 0.037).
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Figure 68: For the 30 pairs of children studied, the mean neutrophil number was significantly
greater in children with autism compared to controls with p = 0.049.

In addition to the other areas of the immune system studied, the results for
immunoglobulins produced a significant result. A higher amount of gluten IgG was
observed in children with autism versus controls as illustrated in Figure 69 (p-value =
0.0092). A nearly significant trend was also seen with casein IgG with a p-value of
0.051, as greater quantities found in children with autism compared to controls (Figure
70).
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Figure 69: The average gluten IgG concnetrations in children with autism and controls. The
children with autism had significantly greater amounts of gluten IgG with a p-value of 0.0092.

Figure 70: For the 30 pairs of children study, a trend was observed of greater quantities of casein
IgG in children with autism versus controls with a p-value of 0.051.

The other area of clinical testing that produced significant results was vitamin
status, involving the testing of methylmalonic acid. The children with autism had greater
quantities of methylmalonic acid compared to controls with a p-value of 0.0042 (Figure
71).
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Figure 71: The mean serum methylmalonic acid concentrations for children with autism and
controls.
The children with autism had statistically significant greater quantities of
methylmalonic acid with p = 0.0042.

One additional variable that was examined due to prior research was the
plasma zinc/serum copper ratio. The children with autism did a lower average plasma
zinc/serum copper ratio compared to controls in this study, but the results were not
statistically significant. The children with autism had greater concentrations of both
plasma zinc and serum copper compared to controls. The other clinical tests performed
did not produce any statistically significant results.
6.3.4

Age Correlations

A correlation (r) with age was computed to evaluate the effects development had
on producing significant results in either of the two groups of children for each variable
measured in this study. The age correlation results were separated according to each
group of children, with plots made for the variables with significant correlations with age.
For each significant correlation, the plots for that variable from each of the two groups
were displayed next to each other.
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6.3.4.1

Behavioral Rating Scales

6.3.4.1.1 Autism Group
The behavioral rating scales were first group of variables investigated for age
correlations, with the statistically significant results shown in Table 44.

The only

significant correlation with age found in the children with autism was for ATEC I. The
children with autism tended to increase their ATEC I score as they get older with an r =
0.37 and a p-value of 0.045 (Figure 72). This increase in ATEC I score with age was not
seen in the control children as they nearly all scored the highest possible score of 28
independent of their age.
Table 44: The significant results of the rating scale results correlating with age along with the r
and p-values for each group.
Control
Autism
Rating Scale
Subscale
r
p-value
r
p-value
ATEC
I
0.25
0.18
0.37
0.045
Autism Composite
0.39
0.045
0.81
0.035
Approach/Withdrawal Problems
RITUAL
- 0.45
0.0013
0.99
0.013
-7
SOCPP
- 0.78
- 0.015
0.94
4.5 × 10
SEMPP
- 0.82
0.087
0.65
3.5 × 10-8
-4
REPRIT/C
- 0.63
0.073
0.70
1.7 × 10
PDDBI
Receptive/Expressive Social Communication Abilities
SOCAPP
- 0.77
- 0.008
0.97
8.2 × 10-7
EXPRESS
- 0.85
- 0.059
0.75
1.9 × 10-9
-15
LMRL
- 0.95
- 0.086
0.65
2 × 10
EXSCA/C
- 0.88
- 0.015
0.94
2.4 × 10-10
-11
REXSCA/C
- 0.89
- 0.035
0.85
7.6 × 10

The statistically significant findings are bolded.
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Figure 72: The age correlation for ATEC I for the control and autism groups. The children with
autism demonstrated a significant positive correlation with age with an r value of 0.37 and a pvalue of 0.045. The control children had a non-significant p-value of 0.18 with r = 0.25.

6.3.4.1.2 Control Group
The age correlation produced many significant findings associated with the
PDDBI behavioral rating scale in the control group. The overall Autism Composite of
the PDDBI was found to be significantly positively correlated with age in the control
children with a correlation of 0.39 and a p-value of 0.035, while the children with autism
had a p-value of 0.81 and an r of 0.045 (Figure 73). In addition to the Autism Composite,
some of the maladaptive behaviors measured on the AWP dimension produced
significant correlations with age. The results for the SEMPP domain are shown in Figure
74, with a significant negative correlation with age seen in the control group (r = - 0.82,
p-value = 3.5 × 10-8) and not in the children with autism (r = 0.087, p-value = 0.65). The
SOCPP domain also saw a significant negative correlation with age in the control
children. The control children had an r of - 0.78 with a p-value of 4.5 × 10-7, while the r
was - 0.015 with a p-value of 0.94 for the children with autism (Figure 75). Figure 76
shows the age correlation for the RITUAL domain, with the control children having an r
of - 0.45 with a p-value of 0.013 and the children with autism having an r of 0.0013 and a
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p-value of 0.99. In addition to the AWP domains that produced significant correlations,
the REPRIT/C composite yielded a significant age correlation in the control children (r =
- 0.63, p-value = 1.7 × 10-4) that was absent in the children with autism (r = 0.073, pvalue 0.70), seen in Figure 77.

Figure 73: The age correlation results for the Autism Composite of the PBBDI for children with
autism and controls. The control group had a significant positive correlation of age with r = 0.39
and a p-value of 0.035, while the children with autism had a p-value of 0.81 and an r of 0.045.

Figure 74: The control children demonstrated a significant negative correlation with age (r = 0.82, p-value = 3.5 × 10-8) for the SEMPP domain of the PDDBI while the children with autism
did not produce a significant correlation (r = 0.087, p-value = 0.65).
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Figure 75: The age correlation for the SOCPP domain of the PDDBI for children with autism
and controls. The control children had a significant negative correlation with age (r = - 0.78, pvalue = 4.5 × 10-7). The children with autism did not show a significant correlation with age with
r = - 0.015 and a p-value of 0.94.

Figure 76: The age correlation for the RITUAL domain of the PDDBI for children with autism
and controls. The control children had a significant negative correlation with age with r = - 0.45
and a p-value of 0.013, while the results from children with autism did not correlate significantly
with age with r = 0.0013 and a p-value of 0.99.
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Figure 77: For the REPRIT/C composite of the PDDBI, the control children produced a
significant negative age correlation with r = - 0.63 and a p-value equal to 1.7 × 10-4. The results
for the children with autism were not significant with r = 0.073 and a p-value of 0.70.

Additional significant correlations with age were found for the REXSCA
dimension.

All of the REXSCA domains and composites produced negative age

correlations in the control children. The most significant domain was LMRL (Figure 78),
with a significant negative correlation with age seen in the control group (r = - 0.95, pvalue = 2 × 10-15) and not in the children with autism (r = - 0.086, p-value = 0.65). The
EXPRESS domain also saw a significant negative correlation with the age in the control
children. The control children had an r of - 0.85 with a p-value of 1.9 × 10-9, while the r
was - 0.059 with a p-value of 0.75 for the children with autism (Figure 79). The final
significant domain finding was for SOCAPP, with the control children having an r of 0.77 with a p-value of 8.2 × 10-7 and the children with autism having an r of - 0.008 with
a p-value of 0.97 (Figure 80).

In addition to the REXSCA domains that yielded

significant correlations, both composites produced significant correlations.

The

REXSCA/C saw a negative correlation in the control children (r = - 0.89, p-value = 7.6 ×
10-11) that was not present in the children with autism (r = - 0.035, p-value = 0.85) seen in
Figure 81. The EXSCA/C results are shown in Figure 82, with a significant negative
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correlation with age seen in the control group with an r of - 0.88 and a p-value of 2.4 ×
10-10 and not in the children with autism who had an r of - 0.015 and a p-value of 0.94.

Figure 78: The control children demonstrated a significant negative correlation with age (r = 0.95, p-value = 2 × 10-15) for the LMRL domain of the PDDBI, while the children with autism did
not produce a significant correlation (r = - 0.086, p-value = 0.65).

Figure 79: The age correlation for the EXPRESS domain of the PDDBI for children with autism
and controls. The control children had a significant negative correlation with age (r = - 0.85, pvalue = 1.9 × 10-9). The children with autism did not show a significant correlation with age with
r = - 0.059 and a p-value of 0.75.
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Figure 80: The age correlation for the SOCAPP domain of the PDDBI for children with autism
and controls. The control children had a significant negative correlation with age with r = - 0.77
and a p-value of 2 × 10-15 while the results from children with autism did not correlate
significantly with age with r = - 0.0008 and a p-value of 0.97.

Figure 81: The age correlation for the REXSCA/C composite of the PDDBI for children with
autism and controls. The control children had a significant negative correlation with age with r =
- 0.89 and a p-value of 7.6 × 10-11, while the results from children with autism did not correlate
significantly with age with r = - 0.035 and a p-value of 0.85.
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Figure 82: For the EXSCA/C composite of the PDDBI, the control children produced a
significant negative correlation with age with r = - 0.88 and a p-value equal to 2.4 × 10-10. The
results for the children with autism were not significant with r = - 0.015 and a p-value of 0.94.

6.3.4.2

Elemental Analysis of Blood

6.3.4.2.1 Autism Group
The elemental analysis results of blood were the next group of variables
investigated for age correlations.

The statistically significant positive and negative

results are listed in Table 45. Four elements in blood were determined to have significant
correlations with age in the children with autism. The most significant finding was for
Zn in RBCs using EPA Method 6020B (Figure 83). The children with autism had a
correlation of 0.46 and a p-value of 0.0097, while the control children had an r = 0.24 and
a p-value of 0.20. The age correlation for RBC Se by EPA Method 6020B for the
children with autism was r = 0.42 with a p-value of 0.023, whereas the control children
had r = 0.20 and a p-value equal to 0.28 (Figure 84). Serum Fe by EPA Method 6800
was found to significantly negatively correlate with age as the children with autism
having an r = - 0.38 and a p-value = 0.036 and the control children having a correlation
value of - 0.20 and a p-value of 0.29 (Figure 85). The final significant correlation was
plasma Se by EPA Method 6020B seen in Figure 86. The children with autism had a
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significant positive age correlation of 0.36 and a p-value of 0.050 and the control children
had r = 0.16 and a p-value of 0.41.
Table 45: The significant results of the elemental blood concentrations correlating with age
along with the r and p-values for each group.

Control
Variable
r
P-Value
EPA Method 6020B RBC Zn
0.24
0.20
EPA Method 6020B RBC Se
0.20
0.28
EPA Method 6800 Serum Fe
- 0.20
0.29
EPA Method 6020B Plasma Se
0.16
0.41
EPA Method 6020B Serum Cu
- 0.46
0.011
EPA Method 6020B Plasma Cu
- 0.44
0.015
EPA Method 6020B RBC Cu
- 0.40
0.030
EPA Method 6020B Serum Mo
- 0.40
0.030
EPA Method 6800 Plasma Cu
- 0.43
0.018
EPA Method 6800 RBC Zn
0.41
0.023
EPA Method 6800 Serum Mo
- 0.39
0.032
EPA Method 6800 Serum Cu
- 0.38
0.037
The statistically significant findings are bolded.

Autism
r
P-Value
0.46
0.0097
0.42
0.023
- 0.38
0.036
0.36
0.050
0.044
0.81
0.10
0.58
0.10
0.59
- 0.22
0.25
0.047
0.80
0.25
0.18
- 0.22
0.25
0.025
0.90

Figure 83: The age correlation for red blood cell zinc by EPA Method 6020B for children with
autism and controls. The children with autism had a significant positive correlation with age with
r = 0.46 and a p-value of 0.0097, while the results from children with autism did not significantly
correlate with age with r = 0.24 and a p-value of 0.20.
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Figure 84: The correlation with age for red blood cell selenium by EPA Method 6020B for
children with autism and controls. The children with autism had a significant positive correlation
with age (r = 0.42, p-value = 0.023). The control children did not show a significant correlation
with age with r = 0.20 and a p-value of 0.28.

Figure 85: The children with autism demonstrated a significant negative correlation with age (r
= - 0.38, p-value = 0.036) for serum iron by EPA Method 6800, while the control children did not
produce a significant correlation (r = - 0.20, p-value = 0.29).
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Figure 86: For plasma selenium by EPA Method 6020B, the children with autism produced a
significant positive correlation with age with r = 0.36 and a p-value equal to 0.050. The results
for the control children were not significant with r = 0.16 and a p-value of 0.41.

6.3.4.2.2 Control Group
The EPA Method 6020B blood elemental results produced four significant age
correlations in the control group. The most significant finding was a negative correlation
of serum Cu with age (Figure 87). The control group’s correlation value was - 0.46 with
a p-value of 0.011, while the children with autism had a correlation value of 0.044 and a
p-value of 0.81. The plasma Cu correlation for the control group was r = - 0.44 with a pvalue of 0.011, whereas the children with autism had an r = 0.044 and a p-value of 0.81
(Figure 88). Similar to serum and plasma, the RBC Cu concentrations were found to be
significantly negatively correlated in the control children (r = - 0.40, p-value = 0.030),
but not in the children with autism (r = 0.10, p-value = 0.59) seen in Figure 89. The final
significant finding by EPA Method 6020B was serum Mo (Figure 90). The control
children’s correlation value was - 0.40 and the p-value was 0.030, while the children with
autism had a correlation value of - 0.22 and a p-value of 0.25.
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Figure 87: The age correlation for serum copper by EPA Method 6020B for children with
autism and controls. The control children had a significant negative correlation with age with r =
- 0.46 and a p-value of 0.011, while the results from the control children did not significantly
correlate with age with r = 0.044 and a p-value of 0.81.

Figure 88: The correlation with age for plasma copper by EPA Method 6020B for children with
autism and controls. The control children had a significant negative correlation with age (r = 0.44, p-value = 0.015). The children with autism did not show a significant correlation with age
with r = 0.10 and a p-value of 0.58.
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Figure 89: The control children demonstrated a significant negative correlation with age (r = 0.40, p-value = 0.030) for red blood cell copper by EPA Method 6020B, while the children with
autism did not produce a significant correlation (r = 0.10, p-value = 0.59).

Figure 90: For serum molybdenum by EPA Method 6020B, the control children produced a
significant negative correlation with age with r = - 0.40 and a p-value equal to 0.030. The results
for the children with autism were not significant with r = - 0.22 and a p-value of 0.25.

Similar to EPA Method 6020B, the EPA Method 6800 results generated four
significant age correlations in blood.

The most significant finding was a negative

correlation with plasma Cu seen in Figure 91. The control group’s correlation value was
- 0.43 with a p-value of 0.011, whereas the children with autism had a correlation value
of 0.047 and a p-value of 0.80. The positive correlation value for RBC Zn in the control
group was = 0.41 with a p-value of 0.023, while the children with autism had r = 0.25 and
a p-value of 0.18 (Figure 92). Serum Mo concentrations were found to be significantly
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negatively correlated in the control children (r = - 0.39, p-value = 0.032), but not for the
children with autism (r= - 0.22, p-value = 0.25) shown in Figure 93. The final significant
finding was for serum Cu (Figure 94). The control children’s correlation with age was 0.38 and the p-value was 0.037, while the children with autism had a 0.025 correlation
and a p-value of 0.90.

Figure 91: The age correlation for plasma copper by EPA Method 6800 for children with autism
and controls. The control children had a significant negative correlation with age with r = - 0.43
and a p-value of 0.018, while the results from the control children did not significantly correlate
with age with r = 0.047 and a p-value of 0.80.

Figure 92: The correlation with age for red blood cell zinc by EPA Method 6800 for children
with autism and controls. The control children had a significant positive correlation with age (r =
0.41, p-value = 0.023). The children with autism did not show a significant correlation with age
with r = 0.25 and a p-value of 0.18.
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Figure 93: The control children demonstrated a significant negative correlation with age (r = 0.39, p-value = 0.032) for serum molybdenum by EPA Method 6800, while the children with
autism did not produce a significant correlation (r = - 0.22, p-value = 0.25).

Figure 94: For serum copper by EPA Method 6800, the control children produced a significant
negative correlation with age with r = - 0.38 and a p-value equal to 0.037. The results for the
children with autism were not significant with r = 0.025 and a p-value of 0.90.

6.3.4.3

Elemental Analysis of Hair

6.3.4.3.1 Autism Group
The elemental analysis results in hair were also evaluated for age correlations.
The significant age correlations with elements in hair are shown in Table 46. The
children with autism demonstrated four significant correlations with age. The most
significant one was for Zn with r = 0.54 and a p-value of 0.002, while the control children
had r = 0.27 and a p-value of 0.15 (Figure 95). The correlation for Mg was significant for
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both the children with autism (r = 0.47, p-value = 0.0088) and controls (r = 0.43, p-value
= 0.018) seen in Figure 96. The Mo concentrations were found to have a significant
negative correlation with age in the children with autism (r = - 0.42, p-value of 0.020),
whereas the control children had non-significant results of r = - 0.026 and a p-value of
0.89 (Figure 97). The final significant finding was Sn shown in Figure 98. The children
with autism had a correlation with age of - 0.42 and a p-value of 0.021, while the control
children had a - 0.25 correlation and a p-value of 0.19.
Table 46: The significant results of the elemental hair concentrations correlated with age with
the r and p-values for each group.

Control
Autism
Element
r
P-Value
r
P-Value
Zn
0.27
0.15
0.54
0.002
Mg
0.43
0.47
0.018
0.0088
Mo
- 0.026
0.89
- 0.42
0.020
Sn
- 0.25
0.19
- 0.42
0.021
U
0.55
- 0.033
0.86
0.0016
Cu
0.47
0.36
0.0086
0.048
Ce
0.38
- 0.0056
0.98
0.040
The statistically significant findings are bolded.
The result for Cu in the autism group is not significant due to Cook’s distance
assessment.

Figure 95: The age correlation for zinc in the hair of children with autism and controls. The
children with autism had a significant positive correlation with age with r = 0.54 and a p-value of
0.002 while the results from the control children did not significantly correlate with age with r =
0.27 and a p-value of 0.15.
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Figure 96: The correlation with age for hair magnesium for children with autism and controls.
The positive correlation was significant for both the children with autism (r = 0.47, p-value =
0.0088) and controls (r = 0.43, p-value = 0.018).

Figure 97: The children with autism demonstrated a significant negative correlation with age (r
= - 0.42, p-value = 0.020) for molybdenum in the hair, while the control children did not produce
a significant correlation (r = - 0.026, p-value = 0.89).
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Figure 98: For tin in the hair, the children with autism produced a significant negative
correlation with age with r = - 0.42 and a p-value equal to 0.021. The results for the control
children were not significant with r = - 0.25 and a p-value of 0.19.

6.3.4.3.2 Control Group
The element that had the most significant correlation in the control children was
U seen in Figure 99. The control group’s correlation value was 0.55 with a p-value of
0.0016, while the children with autism had a correlation of - 0.033 and a p-value of 0.86.
The Cu correlation with age in the control group was 0.47 with a p-value of 0.0086, and
the children with autism had results of r = 0.36 and a p-value of 0.048 (Figure 100).
Although this p-value for the autism group is below the 0.05 cutoff, the correlation is
driven by one nine year old child with a very high Cu concentration relative to all of the
other children in the study. A common way to measure the influence a data point has on
the parameter estimates of a linear regression model is through the use of Cook's
distance.79 If a data point is removed and the resulting parameter estimates change
drastically, then the Cook's distance for this point will be large.

Recommended

thresholds for identifying influential observations include a Cook's distance greater than
4/n,80 where n is the number of data points or even a Cook's distance greater than
1.81 The high Cu hair concentration for the nine year old child in the autistic group has a
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Cook's distance of 1.8, which is reflective of a highly influential observation (the next
highest Cook's distance is below 0.1). Since the correlation between Cu hair and age for
the autistic group is not significant (0.18) when this influential point is removed, the
correlation between Cu hair and age for the autistic group will not be deemed significant.
The final significant correlation was observed for Ce seen in Figure 101. The control
children’s correlation value was 0.38 with a p-value of 0.040, while the children with
autism had a - 0.0056 correlation and a p-value of 0.98.

Figure 99: The age correlation for uranium in the hair of children with autism and controls. The
control children had a significant positive correlation with age with r = 0.55 and a p-value of
0.0016, while the results from the children with autism did not significantly correlate with age
significantly with r = - 0.033 and a p-value of 0.86.
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Figure 100: The control children demonstrated a significant positive correlation with age (r =
0.47, p-value = 0.0086) for copper in the hair, while the children with autism did produce a
significant correlation (r = 0.36, p-value = 0.048) which was driven by one child.

Figure 101: For cerium in the hair, the control children produced a significant positive
correlation with age with r = 0.38 and a p-value equal to 0.040. The results for the children with
autism were not significant with r = - 0.0056 and a p-value of 0.98.

6.3.4.4 Clinical Laboratory Testing
6.3.4.4.1 Autism Group
The clinical laboratory testing results were the final group of variables
investigated for age correlations.

The statistically significant positive and negative

results are listed in Table 47. Four variables produced significant positive correlations
with age in the children with autism. The most significant positive correlation with age
in children with autism was for IgG seen in Figure 102. The children with autism had an
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r of 0.52 with a p-value of 0.003, while the control children had a correlation of 0.33 and
a p-value of 0.072. The neutrophil percent was also significant in the children with
autism (r = 0.48, p-value of 0.0079), but not in the control children (r = 0.36 and a pvalue of 0.053) shown in Figure 103.

The children with autism had a significant

correlation with age for casein IgG seen in Figure 104. The children with autism had an r
of 0.47 and a p-value = 0.009 and the control children had an r of 0.11 and a p-value of
0.55. The final significant positive correlation with age in children with autism was IgA
(Figure 105). Both the children with autism (r = 0.40, p-value = 0.029) and the control
children (r = 0.46, p-value = 0.011) produced significant positive age correlations with
IgA.
Table 47: The significant results of the clinical laboratory testing correlated with age with the r
and p-values for each group.
Control
Autism
Variable
r
p-value
r
p-value

IgG
0.33
Neutrophil Percent
0.36
Casein IgG
0.11
IgA
0.46
CD19 Number
- 0.57
Lymphocytes (subset)
- 0.48
Lymphocytes (CBC)
- 0.46
Lymphocyte Percent
- 0.39
CD4 Number
- 0.28
CD19 Percent
- 0.57
CD3 Number
- 0.37
AST
- 0.41
MCV
0.50
CD3 Percent
0.47
CD4 Percent
0.40
Percent Iron Saturation
0.39
Serum Copper
- 0.45
The statistically significant findings are bolded.
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0.072
0.053
0.55
0.011
0.0011
0.0078
0.010
0.033
0.13
0.0011
0.043
0.025
0.0049
0.0091
0.029
0.033
0.013

0.52
0.48
0.47
0.40
- 0.64
- 0.50
- 0.48
- 0.48
- 0.47
- 0.46
- 0.42
- 0.38
0.088
0.12
0.12
- 0.24
- 0.012

0.003
0.0079
0.009
0.029
0.0001
0.0052
0.0067
0.0067
0.0092
0.011
0.021
0.036
0.64
0.52
0.52
0.19
0.95

Figure 102: The age correlation for IgG of children with autism and controls. The children with
autism had a significant positive correlation with age with r = 0.52 and a p-value of 0.003, while
the results from the control children did not correlate with age significantly with r = 0.33 and a pvalue of 0.072.

Figure 103: For neutrophil percent, the children with autism produced a significant positive
correlation with age with r = 0.48 and a p-value equal to 0.0079. The results for the control
children were nearly significant with r = 0.36 and a p-value of 0.053.
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Figure 104: The correlation with age for casein IgG for children with autism and controls. The
children with autism demonstrated a significant positive correlation with r = 0.47 and a p-value of
0.009 while the control children did not produce a significant correlation with r = 0.11 and pvalue of 0.55.

Figure 105: The children with autism demonstrated a significant positive correlation with age (r
= 0.40, p-value = 0.029) for IgA while the control children also produced a significant correlation
(r = 0.46, p-value = 0.011).

In addition to the positive correlations, eight negative correlations with age were
observed in the children with autism from the clinical laboratory testing. The most
significant negative correlation with age was for the CD19 number seen in Figure 106.
The children with autism had an r of - 0.64 with a p-value of 0.0001, and the control
children also had a significant negative correlation with age with an r of - 0.57 and a pvalue of 0.0011. The lymphocytes had a negative age correlation from the both the
lymphocyte subset and the CBC (Figures 107 and 108). From the lymphocyte subset, the
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children with autism had an r of - 0.50 and a p-value of 0.0052, and the control children
also had a significant negative correlation with age with an r of - 0.48 and a p-value of
0.0078. The lymphocytes measured as a part of the CBC were also negatively correlated
with age for both the children with autism (r = - 0.48, p-value = 0.0067) and controls (r =
- 0.46, p-value = 0.010). The children with autism (r = - 0.48, p-value = 0.0067) and
control children (r = - 0.39, p-value = 0.033) both produced significant negative
correlations with age for lymphocyte percent seen in Figure 109. The CD4 number was
found to be significantly negatively correlated with age in both groups of children (Figure
110). The children with autism had an r of - 0.47 and a p-value of 0.0092, while the
control children’s r was - 0.28 with a p-value of 0.13. The age correlation with CD19
percent for children with autism and controls was also found to be significant (Figure
111). The children with autism had an r of - 0.46 and a p-value of 0.011 and the control
children had r = - 0.57 and a p-value equal to 0.0011. CD3 number was also significantly
negatively correlated with age in both the children with autism and controls (Figure 112).
The values for the children with autism were r = - 0.42 and p-value = 0.021, while the
controls had values of r = - 0.37 and p-value = 0.037. The AST correlation was the last
significant finding negatively correlating with age (Figure 113).

The children with

autism had a significant negative correlation (r= - 0.38, p-value = 0.036), while the
control children also had a significant negative correlation (r = - 0.41, p-value = 0.025).
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Figure 106: The age correlation for the CD19 number for children with autism and controls.
The control children had a significant negative correlation with age with r = - 0.64 and a p-value
of 0.0001, while the results from the control children also did negatively correlate with age
significantly with r = - 0.57 and a p-value of 0.0011.

Figure 107: Both the children with autism (r = - 0.50, p-value = 0.0052) and control children (r
= - 0.48, p-value = 0.0078) demonstrated a significant negative correlation with age for
lymphocytes from the lymphocyte subset.
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Figure 108: The correlation with age for lymphocytes from the CBC for children with autism
and controls. The children with autism had a significant negative correlation with age (r = - 0.48,
p-value = 0.0067). The control children also did show a significant correlation with age with r = 0.46 and a p-value of 0.010.

Figure 109: For lymphocyte percent, the children with autism produced a significant negative
correlation with age with r = - 0.48 and a p-value equal to 0.0067. The results for the control
children were also significant with r = - 0.39 and a p-value of 0.033.
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Figure 110: The age correlation for the CD4 number for children with autism and controls. The
control children had a significant negative correlation with age with r = - 0.47 and a p-value of
0.0092, while the results from the control children did not correlate with age significantly with r =
- 0.28 and a p-value of 0.13.

Figure 111: Both the children with autism (r = - 0.46, p-value = 0.011) and control children (r =
- 0.57, p-value = 0.0011) demonstrated a significant negative correlation with age for CD19
percent.
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Figure 112: The correlation with age for CD3 number for children with autism and controls.
The children with autism had a significant negative correlation with age (r = - 0.42, p-value =
0.021). The control children also did show a significant negative correlation with age with r = 0.37 and a p-value of 0.043.

Figure 113: For AST, the children with autism produced a significant negative correlation with
age with r = - 0.38 and a p-value equal to 0.036. The results for the control children were also
significant with r = - 0.41 and a p-value of 0.025.

6.3.4.4.2 Control Group
The clinical laboratory testing also produced four positive and one negative
significant age correlations that were unique to the control group. The most significant
positive correlation of clinical variables in the control group was MCV (Figure 114). The
control children had an r of 0.50 with a p-value of 0.0049, while the children with autism
had a correlation of 0.088 with a p-value of 0.64. The age correlation for CD3 percent
was significant for the controls (r = 0.47, p-value = 0.0091), but not for the children with
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autism (r = 0.12, p-value = 0.52) seen in Figure 115. The CD4 percent was also
significantly positively correlated with age in the control children (r = 0.40, p-value =
0.029), while the children with autism did not (r = 0.12, p-value = 0.52) as shown in
Figure 116. The final significant positive correlation with age in the control children was
percent iron saturation (Figure 117). The control children had a significant positive
correlation with age (r = 0.39, p-value = 0.33), but the children with autism did not (r = 0.24, p-value = 0.19). The only negative significant correlation with age observed in the
control group was for commercial clinical laboratory serum copper (Figure 118). The
control group had an r of - 0.45 and a p-value of 0.013, while the children with autism
had an r of - 0.012 with a p-value of 0.95.

Figure 114: The age correlation for MCV in children with autism and controls. The control
children had a significant positive correlation with age with r = 0.50 and a p-value of 0.0049
while the results from the children with autism did not correlate significantly with age with r =
0.088 and a p-value of 0.64.
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Figure 115: The correlation with age for CD3 percent for children with autism and controls.
The positive correlation was significant for the control children (r = 0.47, p-value = 0.0091), but
was not significant for children with autism (r = 0.12, p-value = 0.52).

Figure 116: The control children demonstrated a significant positive correlation with age (r =
0.40, p-value = 0.029) for CD4 percent while the children with autism did not produce a
significant correlation (r = 0.12, p-value = 0.52).
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Figure 117: For the percent saturation of iron, the control children produced a significant
positive correlation with age with r = 0.39 and a p-value equal to 0.033. The results for the
children with autism were not significant with r = - 0.24 and a p-value of 0.19.

Figure 118: The age correlation for commercial clinical laboratory serum copper concentrations
in children with autism and controls. The control children had a significant negative correlation
with age with r = - 0.45 and a p-value of 0.013 while the results from the children with autism did
not correlate significantly with age with r = - 0.012 and a p-value of 0.95.

6.3.5

Logistic Regression

For all of the variables determined to be significant by the paired-samples t-test,
logistic regression analysis was completed. For each of the variables analyzed, a 1%,
2%, and 3% prevalence of autism was used to determine the probability of an autism
diagnosis for each statistically significant variable based on literature values.
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6.3.5.1

Blood Elemental Logistic Regression Results

For the elements in blood found to be statistically significant by the pairedsamples t-test, logistic regression analysis was performed.

In terms of diagnostic

probability for a child with autism, the best indicator was for magnesium in plasma,
serum, and RBCs. The logistic regression analysis for plasma magnesium with a p-value
of 0.0018 is seen in Figure 119. For the highest concentration value found in this study,
the diagnosis probability exceeds 40% using a 1% assumed prevalence, while a 60%
likelihood is achieved based on the 3% frequency. For serum magnesium, the logistic
regression analysis is shown in Figure 120 with a p-value of 0.0020. The diagnostic
probabilities for serum magnesium are not as high as the plasma magnesium values, but
for the greatest observed value they do reach over 20% for the 1% prevalence and 40%
for the 3% prevalence. For RBC magnesium, the p-value was 0.0085 for the logistic
regression analysis seen in Figure 121 while the 1% prevalence reaches probabilities
greater than 10% and the 3% prevalence approaches 30%. The red blood cell iron
concentration logistic regression is illustrated in Figure 122 with a p-value of 0.043.
Compared to the magnesium logistic regression analysis curves, the diagnostic
probabilities are not as clear for the red blood cell iron, but the autism possibility is
greater than 5% based on a 1% prevalence and reaches nearly 15% with a 3% prevalence.

408

Figure 119: Logistic regression results for plasma magnesium versus autism diagnosis
probability for a 1%, 2%, and 3% prevalence of autism (p-value = 0.0018).

Figure 120: For 30 pairs of children, the serum magnesium logistic regression analysis with 1%,
2%, and 3% autism prevalence (p-value = 0.0020).
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Figure 121: Logistic regression results for red blood cell magnesium versus autism diagnosis
probability for a 1%, 2%, and 3% prevalence of autism (p-value = 0.0085).

Figure 122: For 30 pairs of children, the red blood cell iron logistic regression analysis with 1%,
2%, and 3% autism prevalence (p-value = 0.043).

6.3.5.2 Clinical Laboratory Testing
After completing the logistic regression analysis for all of the significant variables
from the clinical laboratory testing, the two best indicators of diagnosing a child with
autism are natural killer cell number and percent. For the highest natural killer cell
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number value, the diagnostic probability of autism rises as high as 40% assuming only a
1% prevalence of autism and this value reaches over 60% when assuming a 3% autism
frequency as seen in Figure 123. The diagnosis probability is similar for natural killer
cell percent as it approaches 20% with a 1% prevalence and is over 40% with a 3%
occurrence for the highest observed value shown in Figure 124. The logistic regression
curves for both lymphocyte measurements are presented in Figures 125 and 126. They
both approach 20% with a 3% autism prevalence. The logistic regression curves for CD3
number and CD4 number are seen in Figure 127 and 128.

For CD3 number, the

diagnostic probability exceeds 20% for the highest values seen in the study with a 3%
prevalence and 10% with a 1% prevalence. The diagnostic probability is as high as 10%
assuming a 3% prevalence for CD4 number and over 5% with a 1% prevalence.
Indicators of loss of immune tolerance markers of white blood cells, and anti-gluten IgG
antibodies, and platelets are seen in Figures 129-131. White blood cells were the best
immune tolerance indicator as the diagnostic probability reached over 60% with a 3%
prevalence and nearly 40% with a 1% prevalence. The IgG gluten antibodies produced
results that showed nearly a 20% diagnostic probability with a 1% prevalence and a 40%
diagnostic probability with a 3% prevalence. For the highest values in the study, the
platelets had nearly a 20% diagnostic probability with a 3% prevalence and 10% with a
1% prevalence. The logistic regression for methylmalonic acid is seen in Figure 132. The
diagnostic probability reaches 100% for the highest value for a child with autism in the
study. For the next highest value, the diagnostic probability is over 50% for a 3%
prevalence and almost 25% for a 1% prevalence.
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Figure 123: Logistic regression results for natural killer cell number versus autism diagnosis
probability for a 1%, 2%, and 3% prevalence of autism (p-value = 0.0030).

Figure 124: For 30 pairs of children, the natural killer cell percent logistic regression analysis
with 1%, 2%, and 3% autism prevalence (p-value = 0.015).
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Figure 125: From the lymphocyte subset panel, the logistic regression analysis for a 1%, 2%,
and 3% prevalence of autism (p-value = 0.010).

Figure 126: With a p-value of 0.016, the logistic regression, with 1%, 2%, and 3% autism
prevalence, of lymphocytes from the complete blood count was significant.
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Figure 127: The logistic regression of CD3 number assuming a 1%, 2%, and 3% prevalence of
autism (p-value = 0.010).

Figure 128: For the 30 pairs of children analyzed, the logistic regression of CD4 number with
1%, 2%, and 3% autism prevalence (p-value = 0.012).
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Figure 129: With a p-value of 0.015, the logistic regression of white blood cells was significant
and shown with 1%, 2%, and 3% autism prevalence.

Figure 130: For the 30 pairs of children analyzed, the logistic regression of gluten IgG with 1%,
2%, and 3% autism prevalence (p-value = 0.027).
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Figure 131: The logistic regression of the platelet count assuming a 1%, 2%, and 3% prevalence
of autism (p-value = 0.046).

Figure 132: With a p-value of 0.0037, the logistic regression of methylmalonic acid was
significant and shown with 1%, 2%, and 3% autism prevalence.

6.3.6

Comparison of Commercial Clinical Laboratory and Analytical

Testing Methods
Due to the results from the sleeping cleanroom study, a further comparison of the
three different testing methods was completed for selected analytes. SRM 1598a was
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tested for copper, iron, selenium, and zinc by three different testing methods:
commercial clinical laboratory, EPA Method 6020B, and EPA Method 6800. SRM
1598a is a standard with known quantities and is traceable to NIST. A comparison of the
results from the commercial clinical laboratory to the certified results is shown in Figure
133. For copper, the commercial clinical laboratory results were 13.9% below the mean
value for SRM 1598a and 8.7% below the lower bound of uncertainty. The commercial
clinical laboratory results for iron were 27.4% under the mean SRM 1598a value and
24.7% under the lower bound of uncertainty. For selenium, the commercial clinical
laboratory results were 20.5% above the mean value for SRM 1598a and 16.2% above
the upper bound of uncertainty. The commercial clinical laboratory results for zinc were
14.8% below the mean SRM 1598a value and 12.4% below the lower bound of
uncertainty. For all of the commercial clinical laboratory results, only a mean value is
provided without a confidence interval because only one measurement is performed.
This shortcoming of the commercial clinical results is not seen with the results
from EPA Method 6020B or EPA Method 6800. Both EPA Methods 6020B and 6800
provide 95% confidence intervals because their results are based on multiple
measurements, and in this study they are based on 12 total measurements from three
independently prepared subsamples. Results from the three different testing methods for
SRM 1598a are shown in Table 48 and Figure 134. For all four elements tested, the
results from both EPA Method 6020B and EPA Method 6800 are within the bounds of
uncertainty for all four elements. Based on these data, the results from both EPA Method
6020B and EPA Method 6800 are more accurate than the commercial clinical results
along with providing precision through the use of confidence intervals. These results for

417

SRM 1598a provided the foundation of a further investigation comparing the different
testing methods. This investigation looked specifically at plasma zinc, serum copper, the
plasma zinc/serum copper ratio, and serum selenium with the three testing methods
compared against each other for these four variables.

Figure 133: Results for SRM 1598a from the commercial clinical laboratory for copper, iron,
selenium, and zinc. The certified SRM 1598a values are shown with a coverage factor of 2,
approximating the 95% confidence intervals. The commercial clinical laboratory results do not
provide confidence intervals.
Table 48: Concentrations (ng g-1) of the elements determined in SRM 1598a by the commercial
clinical laboratory, EPA Method 6020B, and EPA Method 6800. The EPA Method 6020B and
EPA Method 6800 results are shown with n = 12 and 95% CIs.
Certified
Commercial Clinical
EPA Method
EPA Method
-1
-1
-1
Value (ng g )
Laboratory (ng g )
6020B (ng g )
6800 (ng g-1)
Element
Serum Copper
1,538 ± 88
1324
1,567 ± 17
1,622 ± 11
Serum Iron
1,635 ± 58
1187
1,874 ± 235
1,614 ± 10
Serum Selenium
130.8 ± 5.6
158
124.9 ± 2.7
131.1 ± 3.8
Plasma Zinc
857 ± 23
730
888.5 ± 16.3
879.7 ± 8.0
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Figure 134: SRM 1598a results for copper, iron, selenium, and zinc from the commercial
clinical laboratory, EPA Method 6020B, and EPA Method 6800. The certified SRM 1598a
values are shown with a coverage factor of 2, approximating the 95% confidence intervals. No
confidence intervals are provided with commercial clinical laboratory results. The measurements
from EPA Methods 6020B and 6800 are with n = 12 and 95% CIs.

6.3.6.1

Commercial Clinical Laboratory Versus EPA Method 6020B

The commercial clinical laboratory and EPA Method 6020B were compared first.
For plasma zinc, the commercial clinical laboratory results were an average of 10.3%
below the EPA Method 6020B measurements with a 95% CI of 7.0 to 13.6% below
(Figures 135 and 136). The correlation for these measurements is r = 0.72, which is
significantly greater than zero (p-value of 4.1 × 10-6). As expected, these results were
significantly correlated, yet there was a consistent low-bias observed in the commercial
clinical laboratory results.
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Figure 135: The plasma zinc concentrations from the commercial clinical laboratory and EPA
Method 6020B. The plot demonstrates the strong correlation between the measurement
techniques (r = 0.72, p-value = 4.1 × 10-6).

Figure 136: A histogram of the relative percent difference of plasma zinc concentrations of the
commercial clinical laboratory to EPA Method 6020B. The commercial clinical laboratory
results were an average of 10.3% lower than the EPA Method 6020B results with a 95% CI
ranging from 7.0 to 13.6% below (p-value = 4.3 × 10-8).

The comparison of the results was similar for serum copper. In the samples, the
commercial clinical laboratory results were an average of 9.8% below the EPA Method
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6020 with a 95% CI ranging from 6.7 to 12.9% below (Figures 137 and 138). The results
have a significant positive correlation of r = 0.81 (p-value of 2.3 × 10-8).

Figure 137: A comparison of serum copper results from the commercial clinical laboratory and
EPA Method 6020B. With a correlation value of r = 0.81, the plot shows the strong correlation
between the measurement techniques (p-value = 2.3 × 10-8).

Figure 138: The relative percent difference of serum copper concentrations from the commercial
clinical laboratory compared to EPA Method 6020B. The histogram illustrates the commercial
clinical results (p-value = 2.9 × 10-8) for serum copper being an average of 9.8% less than the
EPA Method 6020B results (95% CI - 6.7 to 12.9% below).
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While the commercial clinical laboratory results for both the plasma zinc and
serum copper were on average 10.3% and 9.8% below the EPA Method 6020B results,
respectively, the plasma zinc/serum copper ratio results did not illustrate this bias. A
significant positive correlation was seen between the testing methods (r = 0.77, p-value of
2.9 × 10-7). The average commercial clinical laboratory result was 0.5% higher than the
corresponding EPA Method 6020B measurement with the 95% CI ranging from 3.8%
below to 4.7% above (Figures 139 and 140). This interval contains zero, indicating no
statistically significant difference between the two measurement techniques for this
variable.

Figure 139: The plasma zinc/serum copper ratios from the commercial clinical laboratory and
EPA Method 6020B. The plot illustrates the significant positive correlation between the
measurement techniques (r = 0.77, p-value = 2.9 × 10-7).
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Figure 140: A histogram of the relative percent difference of plasma zinc/serum copper ratios of
the commercial clinical laboratory to EPA Method 6020B. The commercial clinical laboratory
results were an average of 0.5% greater than the EPA Method 6020B results with a 95% CI
between 3.8 below to 4.7% above (p-value = 0.83).

When comparing the results from the commercial clinical laboratory and EPA
Method 6020B for serum selenium, the results are similar to what was observed for SRM
1598a. The commercial clinical laboratory results were an average of 6.6% greater than
the EPA Method 6020B results with a 95% CI from 3.2 to 10.0% (Figures 141 and 142).
The correlation is significantly greater than zero (r = 0.68, p-value = 2.0 × 10-5).
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Figure 141: The serum selenium concentrations comparing commercial clinical laboratory and
EPA Method 6020B results. With a correlation value of r = 0.68, the plot shows the strong
correlation between the measurement techniques (p-value = 2.0 × 10-5).

Figure 142: The relative percent difference of serum selenium concentrations from the
commercial clinical laboratory compared to EPA Method 6020B. The histogram illustrates the
commercial clinical results (p-value = 2.4 × 10-4) for serum selenium being an average of 6.6%
more than the EPA Method 6020B results (95% CI-3.2 to 10.0%).
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6.3.6.2

Commercial Clinical Laboratory Versus EPA Method 6800

A second comparison of results was completed between the commercial clinical
laboratory and EPA Method 6800. The commercial clinical laboratory results for plasma
zinc were an average of 8.7% under the values from EPA Method 6800 (Figures 143 and
144). The 95% CI ranged from 6.3 to 11.1% below the EPA Method 6800 values. The
results had a correlation of r = 0.83, which is significantly greater than zero (p-value of
6.2 × 10-9). As with the comparison between the commercial clinical laboratory and EPA
Method 6020B, the commercial clinical laboratory results demonstrated a consistent low
bias.

Figure 143: The plasma zinc concentrations from the commercial clinical laboratory and EPA
Method 6800. The plot demonstrates the significant positive correlation between the
measurement techniques (r = 0.83, p-value = 6.2 × 10-9).
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Figure 144: A histogram of the relative percent difference of plasma zinc concentrations of the
commercial clinical laboratory to EPA Method 6800. The commercial clinical laboratory results
were an average of 8.7% lower than the EPA Method 6800 results with a 95% CI between 6.3 to
11.1% lower (p-value of 9.0 × 10-10).

The results for the comparison of serum copper for the commercial clinical
laboratory were an average of 6.1% below the EPA Method 6800 results (Figure 145 and
146). The 95% CI spans from 3.2 to 9.0% lower than the EPA Method 6800 results with
a significant positive correlation of r = 0.82 and a p-value of 1.4 × 10-8.
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Figure 145: A comparison of serum copper results from the commercial clinical laboratory and
EPA Method 6800. With a correlation value of r = 0.82, the plot displays the strong correlation
between the measurement techniques (p-value = 1.4 × 10-8).

Figure 146: A comparison of serum copper results from the commercial clinical laboratory and
EPA Method 6800. With a 95% CI between 3.2 and 9.0% lower, the commercial clinical
laboratory results are an average of 6.1% below the EPA Method 6800 results (p-value = 8.1 ×
10-5).

The comparison of the plasma zinc/serum copper ratios for the commercial
clinical laboratory and EPA Method 6800 were very similar to the comparison between
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the commercial clinical laboratory and EPA Method 6020B. The commercial clinical
laboratory results were an average of 2.0% lower than the EPA Method 6800 results
(Figures 147 and 148). However, the 95% CI overlaps zero, spanning from 4.7% below
to 0.7% above, which indicates no significant difference between the measurement
techniques for the plasma zinc/serum copper ratio. The correlation for the results was r =
0.91 and they had a p-value of 2.1 × 10-12.

Figure 147: The plasma zinc/serum copper ratios from the commercial clinical laboratory and
EPA Method 6800. The plot illustrates the significant positive correlation between the
measurement techniques (r = 0.91, p-value = 2.1 × 10-12).
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Figure 148: A histogram of the relative percent difference of plasma zinc/serum copper ratios of
the commercial clinical laboratory to EPA Method 6800. The commercial clinical laboratory
results (p-value = 0.14) were an average of 2.0% lesser than the EPA Method 6800 results (95%
CI-4.7% less than to 0.7% greater than).

Figures 149 and 150 illustrate the results comparing the commercial clinical
laboratory and EPA Method 6800 results for serum selenium. The commercial clinical
laboratory results for serum selenium were an average of 0.3% below the EPA Method
6800 results. The 95% CI ranged from 2.5% under to 1.9% above the EPA Method 6800
values. The results had a correlation of r = 0.72 and a p-value of 4.4 × 10-6.
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Figure 149: The serum selenium concentrations comparing commercial clinical laboratory and
EPA Method 6800 results. With a correlation value of r = 0.72, the plot shows the strong
correlation between the measurement techniques (p-value = 4.4 × 10-6).

Figure 150: The relative percent difference of serum selenium concentrations from the
commercial clinical laboratory compared to EPA Method 6800. The histogram illustrates the
commercial clinical results (p-value = 0.72) for serum selenium being an average of 0.3% less
than the EPA Method 6800 results (95% CI-2.5% below to 1.9% above).
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6.3.6.3

EPA Method 6020B Versus EPA Method 6800

The final method comparison was completed for EPA Method 6020B and EPA
Method 6800. The plasma zinc concentrations for EPA Method 6020B were an average
of 2.4% higher than the EPA Method 6800 results (Figures 151 and 152). Unlike the
comparisons between EPA Method 6020B and EPA Method 6800 with the commercial
clinical laboratory, the 95% CI for plasma zinc nearly overlapped zero as it spanned from
0.5 to 4.4% above the EPA Method 6800 values. The results had a significant positive
correlation of r = 0.89 and a p-value of 2.1 × 10-11.

Figure 151: The plasma zinc concentrations from EPA Method 6020B and EPA Method 6800.
The plot demonstrates the significant positive correlation between the measurement techniques (r
= 0.89, p-value = 2.1 × 10-11).
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Figure 152: A histogram of the relative percent difference of plasma zinc concentrations of EPA
Method 6020B to EPA Method 6800. The EPA Method 6020B results (p-value = 0.017) were an
average of 2.4% higher than the EPA Method 6800 results (95% CI-0.5 to 4.4%).

The serum copper comparison between EPA Method 6020B and EPA Method
6800 was similar to the comparison for those methods for plasma zinc. Compared to the
EPA Method 6800 results, the EPA Method 6020B results were only an average of 4.8%
higher with the 95% CI ranging from 2.2 to 7.4% above, close to containing zero (Figures
153 and 154). The results have a correlation of r = 0.89 and a p-value of 2.8 × 10-11.
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Figure 153: A comparison of serum copper results from EPA Method 6020B and EPA Method
6800. With a correlation value of r = 0.89, the plot displays the strong correlation between the
measurement techniques (p-value = 4.4 × 10-11).

Figure 154: A comparison of serum copper results from EPA Method 6020B and EPA Method
6800. With a 95% CI between 2.2 and 7.4%, the EPA Method 6020B results are an average of
4.8% above the EPA Method 6800 results (p-value = 5.4 × 10-4).

The comparison of the EPA Method 6020B and EPA Method 6800 results for the
plasma zinc/serum copper ratio saw that the EPA Method 6020B results were an average
of 0.4% below the EPA Method 6800 results (Figures 155 and 156). The 95% CI
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spanned zero ranging from 4.8% below to 4.0% above the EPA Method 6800 results.
With the interval containing zero, there is no significant statistical difference between the
measurement techniques. The results had a correlation of r = 0.84 and a p-value of 3.1 ×
10-9.

Figure 155: The plasma zinc/serum copper ratios from EPA Method 6020B and EPA Method
6800. The plot shows the significant positive correlation between the measurement techniques (r
= 0.84, p-value = 2.1 × 10-9).
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Figure 156: A histogram of the relative percent difference of plasma zinc/serum copper ratios of
EPA Method 6020B to EPA Method 6800. The EPA Method 6020B results (p-value = 0.86)
were an average of 0.4% less than the EPA Method 6800 results (95% CI-4.8% less than to 4.0%
greater than).

The final comparison performed between EPA Method 6020B and EPA Method
6800 results was serum selenium. The mean values of the EPA Method 6020B results
were an average of 5.5% below the EPA Method 6800 results (Figures 157 and 158).
The 95% CI ranged from 2.7 to 8.3% lower, close to containing zero. The correlation is
0.67 and the p-value is 2.9 × 10-5.
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Figure 157: The serum selenium concentrations comparing EPA Method 6020B and EPA
Method 6800 results. With a correlation value of r = 0.67, the plot displays the strong correlation
between the measurement techniques (p-value = 2.9 × 10-5).

Figure 158: The relative percent difference of serum selenium concentrations from EPA Method
6020B compared to EPA Method 6800. The histogram illustrates the EPA Method 6020B results
(p-value = 2.2 × 10-4) for serum selenium being an average of 5.5% less than the EPA Method
6800 results (95% CI-2.7 to 8.3%).
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6.4 Discussion
(Note: The findings in the discussion section are the professional opinion of Dr.
Scott Faber, MD, developmental pediatrician at The Children’s Institute, as the attending
physician and co-principle investigator at the time of publication and are subject to
further data analysis and interpretation. The executive summary which encompasses the
findings of this study is shown in Appendix A.)82
Thirty children newly diagnosed with autism or PDD-NOS were compared to 30
age, sex, and SES matched control children in this study of toxicity exposure,
immunological functioning, markers of liver, kidney, and thyroid functioning.

The

genetic testing eliminated the possibility of genetic contributions in autism diagnosis, and
without genetic contributions, ASD diagnosis was completely confirmed by behavioral
rating scales. The behavioral rating scale results clearly demonstrated that the children
with autism or PDD-NOS indeed met the full, research based criteria for autism and the
matched control children functioned within the normal range on the ADOS, the gold
standard for clinical autism diagnosis,63 and the numerous other behavioral rating scales.
The two groups of children were found to differ profoundly in functioning on the
measures of the ADOS and other behavioral rating scales, as intended by the study
design.
In this study, one of the unique components was the application of multiple
behavioral rating scales to control children in addition to children with autism. The study
found the Social Communication Questionnaire, Aberrant Behavior Checklist, Childhood
Autism Rating Scale, Gilliam Autism Rating Scale-2, and PDD Behavior Inventory all
demarcated the differences between the two groups of children nearly as accurately as the
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total ADOS did, as it had the smallest paired-samples t-test value. Only the CARS and
Autism Composite of the PDDBI had a lower p-value from a paired-samples t-test
compared to the Communication subscale of the ADOS and no behavioral rating scale
paired-samples t-test p-values were smaller than the p-value for the Social Interaction
subscale of the ADOS. For all of the subscales for all of the behavioral rating scales, the
paired-samples t-test p-values were larger than the total ADOS and the Communication
and Social Interaction ADOS subscales.
Only one of the other behavioral rating scales utilized in this study, the Autism
Treatment Evaluation Checklist, demonstrated less separation between the autism and
control groups when compared to the other rating scales, as determined by the p-values of
the paired-samples t-tests.

The total ATEC had the largest p-value of all of the

behavioral rating scales and subscales in this study. This finding is the result of how the
ATEC scale was designed. On two of the subscales, ATEC I and ATEC III, higher
scores were found in the control children because they demonstrate better communication
and awareness. On, ATEC II and ATEC IV, which describe sociability and behavior, the
control children had lower scores because these subscales were designed to determine
shortcomings in these areas. When the total ATEC is determined as a summation of the
four ATEC subscales, the more significant differences seen for each of the four subscales
determined by smaller paired-samples t-test p-values are eliminated because the control
children score near the highest value possible on two subscales and near the lowest
possible score on the other two subscales. If the scoring was inverted for ATEC I and
ATEC III, this loss of differentiation seen in the total ATEC could be eliminated and the
ATEC could become a more useful tool in the diagnosis of autism and follow-up of
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treatment effects. This design of the ATEC could be the reason why the scientific
literature has focused on using the ATEC to monitor improvement in children with
autism when evaluating a treatment and not as a diagnostic tool differentiating children
with autism from neurotypical children. An additional contribution of this study is the
finding that the CARS, which was originally validated for use by a trained clinician,67
was able to very accurately differentiate children with autism from controls when
completed by parents.
In addition to using the behavioral rating scales to differentiate the two groups of
children, the behavioral rating scales were correlated with age to determine the
differences between the two groups taking development into account. The PDDBI saw
significant differences in age correlations between the control and autism groups for the
Autism Composite and some of the maladaptive and adaptive domains and composites.
In control children, the significant positive age correlation for the Autism Composite
demonstrated either even greater maladaptive characteristics or smaller increases in
adaptive behaviors as they develop, but the Autism Composite scores along with the
domains that comprise it were consistently much lower than the cutoff value for autism
diagnosis.

This normal development in the control children was seen through the

negative correlation with age of the adaptive domains (SOCAPP, EXPRESS, and LMRL)
and composites (EXSCA/C and REXSCA/C). The control group also demonstrated
multiple negative correlations in maladaptive domains (RITUAL, SOCPP, and SEMPP
and the REPRIT/C composite). These results supported a previous study that noted that
the adaptive domains and the SOCPP and SEMPP maladaptive domains were able to
display the expected increases with age.71 The PDDBI was created to tackle this problem
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and the PDDBI offers age-dependent scores and the authors of that study note the
difficulty of assessing adaptive behaviors with age due to the normal development.71
However, this application of the PDDBI to normal, neurotypical, control children may be
unique to this study because the PDDBI was designed to only be applied to children with
an ASD.71 The other significant age correlation was with ATEC I in the children with
autism. This result showed children with autism significantly increased their speech,
language, and communication skills with age. These results reflect the ability of children
with autism to improve these skills based on the criteria on the ATEC I subscale. These
criteria are basic verbal communication markers that nearly all of the control children
completely demonstrated no matter how old they were. Of note, some of the older
children with autism were able to score close to the maximum value for ATEC I. The
ATEC I may be a good way to monitor the communication skills of children with autism
while taking age into account.
Upon completion of this study, the children with autism demonstrated
characteristics of the TILT principle seen in many ways through the elemental, toxin, and
glutathione testing that were a part of this study. The elemental analysis findings are
discussed first. In this study, the children with autism displayed a set of elements that
were significantly higher in concentration than their matched controls, most notably,
plasma, serum, and red blood cell magnesium. A normal concentration of magnesium is
necessary for proper functioning of the central, peripheral, and autonomic nervous
systems. The metabolism of proteins, fats, nucleic acids, and carbohydrates is performed
using many enzymes that utilize magnesium. Proper brain development and homeostasis
require magnesium resulting from copper-zinc superoxide dismutase activity.83

440

Magnesium is a critical micronutrient that is essential in the maintenance of the
calcium/magnesium flow across neuronal cell membranes. It plays a key role in enzymes
related to ATP and nucleic acid metabolism.84

Electrical activity propagates down

neuronal axons through bursts of functioning of calcium channels. The significantly
higher concentrations of magnesium in children with autism may modulate calcium flow
induced action potentials, decreasing already increased long term potentiation and
dampening the effects of glutamate excitotoxicity. Magnesium may also be preferentially
mobilized from non-brain tissue, creating a risk for magnesium depletion in other body
tissues, including the heart. If this physiology is observed in subsequent studies, the
increased incidence of autonomic instability in children with autism may be at least
partially explained. In addition, if the heart is depleted of magnesium, it may be at an
increased risk for arrhythmia, supporting the careful monitoring of heart functioning by
electrocardiogram in children with autism who receive psychopharmacological
management. Elevated concentrations of magnesium in blood are manifested through
low blood pressure, drowsiness, decreased heart rate, reduction in bone-tendon reflexes,
flaccid paralysis, hypoventilation, coma, and cardiac arrest.84

The concentration of

certain proteins in serum have the ability to affect magnesium concentrations in plasma
because 80% of magnesium in serum is attached to proteins.84 The homeostasis of
magnesium is not accurately reflected by plasma concentrations because nearly all
magnesium is accumulated in tissues.84
Many studies have investigated magnesium concentrations in blood in children
with autism.

Strambi led a small study which found children with ASDs had

significantly decreased concentrations of plasma magnesium compared to controls.84
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Audhya presented findings at the International Meeting for Autism Research conference
where children with autism had lower red blood cell magnesium concentrations.31
Magnesium was found to be at lower concentrations in the serum and whole blood of
children with autism compared to controls at a possible significance in a study from
Adams et al., but the differences for RBC magnesium concentrations were not found to
be significant.85

However, this study showed strong correlations for magnesium

concentrations between different blood matrices.85 A study from Saudi Arabia found no
significant difference in the plasma magnesium concentrations of children with autism
and controls, and while not significant, the children with autism had a greater mean
concentration of magnesium compared to controls.86 The authors of this study suggest
this is the result of adenylate energy charge equilibration fixing the decreased free energy
resulting from the higher amount of ATPase in the Na+/K+ ion pump.86

Jory and

McGinnis completed a study that found no difference in the amounts of magnesium in the
red blood cells between children with autism and controls.87 The current study’s findings
of increased magnesium in multiple matrices in children with autism, compared to
controls, may be a function of the high heavy metal and chemical toxicity environment of
the Western Pennsylvania area where the study was done. The elevated magnesium may
serve as a compensatory physiology for factors that are increasing glutamate and calcium
caused neuronal excitotoxicity for children with autism living in this region.

The

relationship of blood magnesium could be related to the concentration of magnesium in
the hair of children with autism.

Studies have shown children with autism had

significantly decreased concentrations of magnesium in their hair compared to controls.8890

One study noted smaller concentrations of magnesium in the hair of girls with autism
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versus healthy girls.83 A study noted lower magnesium amounts in females with epilepsy
compared to controls.91 Lech completed a study which observed lower hair magnesium
concentrations in children with neurological diseases compared to controls.92
Magnesium levels in hair in the current study did not differ between the two groups.
Red blood cell iron was also significantly higher in children with autism than
matched controls. Iron is critical for hemoglobin functioning and deposition of oxygen to
tissues. It also has a key role in brain performance particularly at the early stages of
development.93 If iron is increased in tissues, it can cause significant oxidative stress.
Adams and colleagues completed a study that found children with autism had
significantly higher concentrations of iron in red blood cells compared to controls.85 In
the Adams study, 42% of children with autism had RBC iron concentrations higher than
the 90th percentile of the reference range for normal children.85 It also found significant
correlation between RBC iron concentrations and PDDBI scores.85 This correlation
could be an indicator of greater oxidative stress caused by surplus iron, but the authors
call for further research.85 Concentrations of transferrin, an iron-binding protein, were
determined to be significantly lower in children with autism compared to normal
neurological developed siblings as an indicator of greater oxidative stress.94 An earlier
study noted the presence of iron deficiency in a minority of children with ASDs. 93
Further study is required to determine if the increased red blood cell iron concentrations
are a response to or contributor to oxidative stress in children with autism.
Plasma molybdenum was found to be significantly greater in concentration in the
children with autism. This element plays a key role in sulfur metabolism, a component of
chemical detoxification that is deficient in some children with autism. Molybdenum is a
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trace element that integrative practitioners have provided to treat pica in children with
autism, with some success. Molybdenum may play a role in balancing the plasma
zinc/serum copper ratios in children with autism. The higher amounts of molybdenum in
children with autism observed may indicate increased mobilization from tissues or
increased uptake by the body to serve the previously described needs.

Jory and

McGinnis found elevated amounts of molybdenum in the red blood cells of children with
autism compared to controls.87 They state that there is no known framework for this
finding in the autism literature.87
The plasma zinc/serum copper ratio is a potential biomarker of metallothionein
functioning that determines the efficacy of the body’s elimination of toxic heavy metals
such as mercury, arsenic, lead, cadmium, antimony, and chromium VI. Although the
results were not significant, all three measurements of the plasma zinc/serum copper ratio
completed in this study indicated lower plasma zinc/serum copper ratios in children with
autism compared to controls. Poor detoxification of heavy metals has been implicated in
liver dysfunction, the development of interstitial nephritis, and decreased function of the
endocrine glands, especially the thyroid gland. In a previous study by our research
group, 230 children with autism were found to have a plasma zinc/serum copper ratio
mean of 0.61, which was far lower than the 0.7 value representing the cutoff for the
lowest 2.5% plasma zinc/serum copper ratios in the literature.95 Increased sensitivity to
proteins has been connected with low zinc/copper ratios and the children in this study did
create more IgG antibodies to glutens than controls.89
Age correlations with the elements analyzed in blood resulted in the discovery of
many significant findings with key elements. The children with autism demonstrated
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significant positive correlations between age and red blood cell zinc, red blood cell
selenium, and plasma selenium. The control children also showed a significant positive
correlation with age for red blood cell zinc. The increasing amounts of zinc and selenium
in the red blood cells as the children aged may be secondary to the inducement of
absorption of these micronutrients through the intestinal villi. In addition, the young
females in the study produced microestrogens by the time they were 5 or 6 years of age,
inducing a positive increase in metallothionein system functioning96 that could feedback
on intestinal enzymatic absorption characteristics. These positive correlations between
selenium and age were entirely absent in the control children. The children with autism
demonstrated a significant negative correlation with age for serum iron that was not seen
at a significant level in the control children. One study did not observe a change in iron
concentrations with age in healthy children.97 This finding could relate to autism severity
as Adams et al. found a strong positive correlation between RBC iron and PDDBI
score.85 The control children demonstrated significant negative correlations of age with
serum, plasma, and red blood cell copper concentrations. The children with autism did
not illustrate this correlation. One study found serum copper concentrations decreasing
with age in healthy children,97 and this finding was supported in another study.98 The
serum correlation with age is likely secondary to the control children’s much more
efficacious and efficient functioning of their metallothionein system. Of note, serum
molybdenum had a negative correlation with age only in the control children, and a
micronutrient necessary for supporting zinc/copper homeostasis may be less induced for
absorption in children with healthier zinc/copper and metallothionein functioning. There
are limited age correlations with elemental concentrations in the blood of children with
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autism discussed in the scientific literature, and this study discovered some significant
age correlations with elements in blood that can be expanded upon in future studies.
Another area that can provide insight into the manifestation of the TILT
mechanism is the concentration of elements in hair. The concentrations of elements in
hair reflect both the total body concentrations of these elements and the ability of the
body to maintain each element’s effluent and the ability to release it into the hair follicle
cell.

Exposure to environmental pollution has been studied through the elemental

analysis of children’s hair.99 In this study, the pattern of the release of elements into the
hair of children with autism differed significantly from controls, and elemental analysis
in hair may be a relatively non-invasive method of early detection of metallothionein
dysfunction in children with autism (i.e., cut a lock of hair from a child at 9 months of
age and send it for elemental analysis by mass spectrometry). Although not significant,
the children with autism demonstrated lower concentrations of chromium and lead in hair
than controls.

Children with autism have an increased risk of developing insulin

dependent diabetes mellitus (IDDM).100 Since chromium plays an important part in the
cellular response to insulin and glucose tolerance factor,101 abnormal absorption or
excretion of it may play a role in the increased incidence of IDDM in children with
autism. Many studies have investigated the concentrations of elements in children with
autism. In Kuwait, Fido and colleagues found significantly decreased concentrations of
chromium in children with autism compared to age and sex matched controls.102 In a
second study, Fido and Al-Saad observed higher amounts of lead in children with
autism.103 Yahuda and colleagues noted decreased chromium and lead concentrations in
children with autism compared to controls.101
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Kern led a study which discovered

significantly lower concentrations of lead in hair of children with autism compared to
matched controls.37 Lakshmi Priya and Geetha found higher concentrations of lead in the
hair of children with autism compared to controls in India.89 Blaurock-Busch et al. also
observed higher amounts of lead in the hair of children with autism.90 Overall, many
studies have been published which indicate lower concentrations of toxic metals, most
notably mercury, in the hair of children with autism which support the hypothesis of
detoxification problems in children with autism.36, 104-105 The results of this study give
further credence to this hypothesis.

Although chromium is a nutrient, chromium

speciation is necessary to evaluate toxicity, but this analysis was not completed as a part
of this study due to the limitation of hair sample size.
Similar to the elemental concentrations in blood, the elemental concentrations in
hair were correlated with age to determine any possible differences in development
between the two groups of children. Hair concentrations were positively correlated with
age of the children with autism for the critical micronutrients zinc and magnesium. As
children with autism age and their metalloprotein system becomes more inefficient, the
maintenance of critical micronutrient concentrations may falter secondary to passive
effluence into the hair. Alternatively, the children with autism may be demonstrating
compensation for increased heavy metal toxicity as they age, increasing both intestinal
absorption of zinc and magnesium and hair effluent of these elements. The control
children also showed a positive correlation of magnesium concentration with age. The
children with autism demonstrated a negative correlation with age for molybdenum and
tin. Molybdenum could become greater in need as children age and the immune system
continues to develop. The negative tin correlation could indicate a greater ability for the
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detoxification of tin or greater tin exposure with age.

The control children had a

significant positive correlation with age for uranium, copper, and cerium. The uranium
and copper correlations show the increased detoxification capabilities of the control
children for these elements as they aged, which were not found in the children with
autism. Cerium is a rare earth element with low to moderate toxicity, but an increased
exposure to diesel fuel could result with age since cerium does not have a biological
function in humans. As with the blood elemental age correlations, the literature is limited
in the number of studies that discuss correlating elemental concentrations in hair with age
in children with autism, but the significant findings in this study can be supported with
additional work. A study from South Korea observed positive age correlations with zinc,
calcium, magnesium, copper, and mercury concentrations in hair.106 The authors called
for addition research in hair elemental concentrations for the evaluation of diet and
relationship of the environment to diseases in children.106 Another study observed a
decrease in hair zinc concentrations with age.107 Further studies are necessary to support
and expand upon these findings in children with autism.
The initiation of TILT that is seen through changes in elemental concentrations,
toxin accumulation, and variations in glutathione concentrations may have manifested
differences in immunological functioning between the two groups of children in the
current study. Much research in the literature supports the presence of a dysregulated
immunological system in children with autism.108

The current study supports the

literature by demonstrating significantly increased parameters of immunological
functioning in children with autism compared to controls. The children with autism
demonstrated significantly increased concentrations of white blood cells compared to
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matched controls. White blood cells play a large role in the adaptive immune system and
an elevated number of white blood cells could be an indicator of inflammation.
Neutrophils were significantly elevated in children with autism. Neutrophils primarily
attack bacteria and fungi. Both measures of lymphocytes in this study indicated greater
numbers of them in children with autism compared to controls. Lymphocytes can be
identified as T cells, B cells, and natural killer cells. Natural killer cell number and
percent, a measure of innate immune system functioning, were very significantly higher
in the children with autism that participated in this study compared to controls. Ashwood
et al. observed 40% higher levels of natural killer cells in children with autism compared
to controls.109 The authors of that study suggest children with autism have a greater
autoimmune response observed through the higher natural killer cell number resulting
from elevated levels of cytokines and other homeostatic and growth factors.109 Many
studies have shown natural killer cell activity is decreased in children with autism. 110-112
One of these studies noted a correlation of natural killer cell activity to the intracellular
level of glutathione.

112

Another study found elevated amounts of perforin, granzyme B,

and interferon gamma while studying the natural killer cells in children with autism. 113
Enstrom and colleagues noted the important role natural killer cells play in the
dysregulation of the immune system of children with ASDs.113 The lower activity of
natural killer cells in children with autism could explain the larger number and higher
percentage of natural killer cells.
The findings of the lymphocyte subset panel show support of changes in the
adaptive immune system of children with autism compared to controls.

The CD3

number, the total T cell number and a marker of the number of CD3 T cells need for
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immune system activation or suppression, were greater in children with autism against
matched controls. The CD4 number was significantly increased in children with autism
versus controls. CD4 cells, helper T cells, regulate and activate B cells. CD4 cell
overproduction can lead to over creation of cross reacting antibodies that attack the
body’s own tissues. Compared to controls, a trend of elevated CD8 numbers in children
with autism was seen. CD8 T cells, suppressor T cells, are responsible for controlling B
cell production of antibodies. One study noted increased CD3 and CD8 frequency in the
mucosal lamina propia of children with autism.114 A study demonstrated higher numbers
of total lymphocytes, T lymphocytes, and suppressor/cytotoxic T lymphocyte ratio in
low-functioning children with autism compared to high-functioning children with autism,
and this study also correlated intelligence quotient with these three immune system
markers.115 However, the children in that study were older than those in the current
study.

One study has shown that abnormal innate immune system reactions could

produce changes to the adaptive immune system.51 Overall, these results support the
overstimulation of the innate and adaptive immune systems in children with autism
compared to controls.
The altered lymphocyte subset panel results and differences in complete blood
counts of children with autism suggest the presence of overreacted immune responses in
children with autism. Children with autism in this study had significantly higher platelet
counts than controls. In the clinical setting, elevated platelet count has been noted to be
present in the context of chronic intestinal inflammation. This study demonstrated that
anti-gluten IgG antibodies were significantly elevated in children with autism compared
to controls, suggesting that the IgG gluten antibodies were superior to antigliadin
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antibodies in delineating which children were sensitive to gluten. In the clinical milieu,
anti-gluten IgG antibodies have predicted significant gluten sensitivity. Children with
autism demonstrated a trend towards higher concentrations of anti-casein IgG antibodies
versus controls.

In 2013, Lau and colleagues published a study that demonstrated

elevated IgG antibodies in children with autism compared to controls.116 This study also
showed higher anti-gliadin IgG antibodies in children with autism who had
gastrointestinal symptoms compared with children who did not suffer from them.116
Another study found 83.3% of children with autism had increased amounts of IgG and
IgA casein antibodies and 50% had increased IgG and IgA antibodies.117 A study of girls
with Rett syndrome demonstrated significantly higher levels of IgA antibodies to gliadin,
gluten, and casein and IgG antibodies to gliadin and gluten compared to controls.118 The
elimination of both of these proteins has resulted in increased digestion and
improvements in behavior in children with ASDs.119-120

Children with autism

demonstrated higher concentrations of serum methylmalonic acid compared to controls.
These elevated concentrations of methylmalonic acid could be indicative of a deficiency
of vitamin B12 and greater oxidative stress. Vitamin B12 status can most precisely and
accurately be determined by methylmalonic acid.121 Excess urinary methylmalonic acid
is a sign of vitamin B12 deficiency.

Adams led a study that showed urinary

methylmalonic acid concentrations decreased in children and adults with autism after the
use of a vitamin/mineral supplement.122 In another study by Adams et al., children with
autism had a greater mean urine methylmalonic acid concentration, but it was not
significantly greater than neurotypical children.85 This study also found a significant
correlation between urinary methylmalonic acid concentration and PDDBI score.85
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Clinical testing produced significant correlations with age that showed the
differences in development of the immune system in children with autism and controls.
Both groups of children displayed a negative age correlation for lymphocytes and
lymphocyte percent.

Lee et al. showed lymphocyte numbers and percent decrease

gradually with age in healthy children.123 A study from Saudi Arabia observed declines
with age in total lymphocytes with age in healthy children.124 The T and B cell subsets
produced numerous significant age correlations in each group of children in this study.
Both the CD19 number and percent demonstrated significant negative correlations with
age in both groups of children.

One study noted a 6.5-fold decrease in CD19 B

lymphocytes from age 2 until adulthood in healthy subjects.125 Another study showed
decreased CD20 B cell number and percent with age.123

The Saudi Arabian study

observed decreases in the percentage and number of B cells with age.124 Both groups of
children showed significant negative correlations for CD3 number. One study noted a
three-fold decrease from age 2 to adulthood in CD3 lymphocytes in healthy subjects.125
The authors note the importance of number of immune cells as opposed to the percentage
of these cells.125 T cells were noted to decline with age in healthy children with age in
the study from Saudi Arabia.124 Lin et al. showed T cell counts declined with age in
healthy Chinese children.126 Only the children with autism had a significant negative age
correlation for CD4 number; however, the control children had a negative trend with age.
The control children showed a significant positive correlation with age in the control
children for CD3 percent and CD4 percent. The study by Lee et al. showed an increase
in CD3 percent with age in neurotypical children.123 The children with autism and
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control children showed a positive correlation with age for the neutrophil percent,
indicating no significant difference in physiology between groups for this marker.
The children with autism lacked a significant age correlation with the percent of
iron saturation that was seen in the control children suggesting that poorer absorption of
iron could be occurring in older children with autism.

The AST was negatively

correlated with age in both groups of children, possibly indicating increased liver
functioning with age. Only the control children had a negative correlation of serum
copper with age. This finding is similar to what was observed during the analytical
elemental analysis indicating a greater ability to detoxify and subsequent more efficient
metallothionein system functioning in control children compared to the children with
autism.
The children with autism demonstrated positive correlations with age for IgG and
IgA antibodies. The control children also had significant positive age correlation for IgA
antibodies and a trend of increasing IgG antibodies indicating that both groups have a
development of the humoral immune system antibody production with age. The results
of the current study are supported by Heuer et al. noting that very small amounts of IgG
are produced during infancy and adult concentrations are reached between ages 6 and
8.127 The children with autism displayed a positive correlation with age for anti-casein
IgG antibodies, while control children did not have a significant age correlation for anticasein IgG antibodies. This finding indicates older children with autism had a propensity
to overproduce these antibodies and had an increased sensitivity to casein, which could
be a result of their exposure to toxicants and resultant in loss of immune tolerance. The
results observed in the current study of the changes in the immune system between
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children with autism and controls are supported by the scientific literature, but further
scientific research is needed to evaluate changes in the immune system with age in
children with autism.
Upon completion of this study, the children with autism who were studied
demonstrated the potential characteristics of TILT. Children growing up in Pittsburgh
and the surrounding area are exposed to an environment where 73% of mercury
emissions are the result of anthropogenic activity.26 The toxicant insult is added upon by
the exposure to other heavy metals; organic toxins including PBDEs, PCBs, and VOCs;
pesticides; and molds, fungi, and other biologicals that occur every day.

It is this

overload of toxic exposure in the modern environment, which has been exposed to the
effects of over 80,000 chemicals, that forms the foundation of the toxic exposure that
could manifest itself through the different characteristics observed in children with
autism. The children with autism in this study demonstrated poorer effluent of certain
chemical and metal toxins, more immune dysregulation, and a significant loss of immune
tolerance to glutens, compared to their matched peer controls. The children with autism
illustrated more oxidative stress, as noted by having significantly less reduced/oxidized
glutathione rations than controls. A potential link between glutathione concentrations
and immune dysregulation was shown in another research team’s study where a greater
percentage of oxidized glutathione, a smaller amount of reduced glutathione, and a lower
reduced/oxidized glutathione ratios were observed in the activated CD4 T cells in
children with autism.
In addition to determining the differences in children with autism and controls and
discovering correlations in each group, the study was able to perform logistic regression
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analysis on the variables which produced significant differences between children with
autism and controls. The logistic regression analysis allows for the probability of autism
diagnosis to be determined based on the measured value for a particular variable. This
data can potentially be used for diagnostic purposes in a clinical setting. The ability to
combine multiple measured variables and combine them with the diagnostic probability
for autism could provide the possibility of creating a screening test for the early diagnosis
of autism.

A large screening set of these biomarkers that could be collected by a

fingerstick or a single vacutainer tube could potentially create a means of prediction of
physiological risk for the development of autism and other neurodevelopmental
disorders. This study may yield a means of assessing “actionable data” that allows for
early prediction or perhaps amelioration of some of the physiologic mechanisms
underlying decreased detoxification capabilities and the immune dysregulation that
contributes to the development of autism.
One other area where this study differentiates itself from the other studies
conducted is the quality and fidelity of the measurements that were used to determine the
statistically significant findings through higher accuracy and precision. In this study,
many steps were taken to ensure that the measurements were of the greatest quality
possible. Accuracy was validated using SRMs, CRMs, or standards traceable to NIST
and, they were implemented in all of the analytical measurements in this study. The use
of these standards allowed for the validation of the sample preparation, analysis
parameters, and instrument performance. The sample preparation was meticulous in all
of the types of analytical analysis in this study as it was performed exclusively in a
cleanroom environment. The glutathione sample preparation was performed in a nitrogen
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glove box to prevent species interconversion from oxygen in the air to minimize
oxidation and species interconversion. The blood used for the VOC analysis was drawn
into special VOC free tubes that were prepared by and obtained from the Centers for
Disease Control. The sample preparation and analysis was completed using standardized
EPA Methods for the elemental and persistent organic pollutant analyses. Enriched,
stable isotopes were used in conjunction with these standardized methods to improve the
accuracy and precision of the measurements. The measurements that were obtained were
achieved through the use of multiple subsamples from a single sample and multiple
replicate measurements were performed from each subsample. This use of measurements
allowed for proper statistics to be implemented that allowed for the most statistical data
to be extracted from the results. The values from the commercial clinical laboratory only
provide a single value with no statistics. The new values with statistics and confidence
intervals provide a better assessment of a measurement and the test results can create
better clinical understanding and more actionable data improving clinical care.
Overall, this study accomplished many diverse things in multiple different
disciplines.

This study observed many statistically significant differences between

children with autism and age, gender, and SES matched controls. The results of this
study establish the presence of greater metallothionein system dysfunction, chemical
detoxification disturbances, immune dysregulation, and subsequent loss of immune
tolerance in the children with autism compared to controls, and support the presence of
the TILT theory of disease progression in children with autism. This study is one of the
first to demonstrate changes in elemental, chemical, glutathione, and immune parameters
in children with autism and controls in relation to age. The study results suggest that
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various chemicals are detoxified differently between children with autism and controls.
The magnesium, zinc, selenium, and glutathione data support the presence of a
compensatory physiology in children with autism, exposed to high heavy metal and
chemical stress of living in Western Pennsylvania.

Benzene, toluene, and xylene

concentrations in children with autism and controls were much higher than previously
determined

national

norms,

suggesting

increased

exposure

for

all

Western

Pennsylvanians to these toxins. Overall, these changes demonstrated that children with
autism present with characteristics of the TILT theory of disease. Further research
studies are necessary to support and continue the findings observed in this study.
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Appendix A

(Note: The findings in Appendix A are the professional opinion of Dr. Scott
Faber, MD, developmental pediatrician at The Children’s Institute, as the attending
physician and co-principle investigator at the time of publication and are subject to
further data analysis and interpretation.)1
Quantification of Inorganic and Organic Compounds in the Blood and Hair of
Children with Autism and Controls Along with Correlation with Autism Severity:
Executive Summary
In late 2009 and early 2010 a team composed of members of The Children’s
Institute clinical staff, faculty and graduate students at Duquesne University’s Chemistry
and Biochemistry Department, and researchers at the Nova Southeastern Medical School,
created a research project designed to study a marker of genetic mutation, elemental
concentrations, chemical toxins, and behavioral rating scale and Autism Diagnostic
Observation Schedule (ADOS) results in children with autism versus age, sex, and
socioeconomically matched controls. The study was vetted by a team of international
experts prior to acceptance by the Institutional Review Board of Duquesne University in
the spring of 2010. Enrollment of children with autism and controls occurred from 5/10
to 6/12 at The Children’s Institute. New methods of studying chemical concentrations
were developed at Duquesne University, including the first accurate measurement of
glutathione and its subtypes, a critical protein supporting metal and chemical
detoxification, along with a unique method of measuring volatile organic compounds.
For two years blood and hair samples were obtained by a nurse especially adept at
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obtaining blood work from children with autism, and transported to Duquesne University
for subsampling, separation, analysis and storage. Blood values results were obtained
from equipment that worked often 24 hours a day for weeks at a time at Duquesne
University, to obtain the elemental and chemical xenobiotic data, a private lab which
provided biomedical and immunological results, and a research lab at Nova Southeastern
University in Florida, which performed the genetic mutation studies. Data analysis, done
in conjunction with the Department of Computer Science and Mathematics at Duquesne
University, has been ongoing since early 2012 and the full set of elemental, chemical,
genetic mutation, and behavioral rating scale data, comprising over 300,000 data points,
became available for analysis in early 6/13. This summary seeks to provide a brief
overview of the underlying reasons for embarking on such a study, the key findings to
date, and early interpretations of the meaning of this data for children with autism.
The incidence of autism has been increasing significantly over the past 30 years,
according to numerous studies emanating from the MIND Institute of the University of
California at Davis and the Center for Disease Control of the United States. The increase
of diagnostic prevalence, from approximately 1 in 10,000 children to 1 in 50 children,
including large increases in autism diagnosis for the most severe children, speaks against
this phenomenon being created solely by genetic etiology. The presence of adverse
genetic / environmental interaction increasing the incidence and prevalence of autism has
been supported by studies in the recent literature implicating exposure to air pollution in
utero and during the first years of life, exposure to pesticides while in utero, and chemical
and heavy metal pollution from living near busy highways and industrial sources. In the
spring of 2010 studies were published supporting the concept that copy number variant
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changes, small areas of duplication and deletion of DNA, were associated with the
diagnosis of autism.

Many theorists wondered whether these copy number variant

changes were being created by increased exposure to environmental toxicants and
whether they adversely affected chemical and metal detoxification.
In the 1990s a new theoretical model of development of disease called the
Toxicant Induced Loss of Tolerance or TILT model was promoted. Researchers from
Harvard University and the University of Texas at San Antonio wrote theoretical and
case report work supporting the concept that certain individuals were prone to being
sensitized to chemicals and heavy metals, leading to over functioning of certain aspects
of the immune system, also called immune dysregulation, and subsequent loss of immune
tolerance to chemical, metal, and food stimuli. This loss of immune tolerance caused a
host of central nervous system symptoms in this model. Given the extraordinary increase
in prevalence of autism over the past few decades, this model appeared extremely
promising at explaining at least some of the symptomatology seen in children with
autism.
Over the past two decades some studies have demonstrated that children with
autism have deficiencies in detoxifying heavy metals as they display differences in
selenium and zinc levels needed for removal of toxic metals, compared to controls.
Children with autism also have demonstrated significantly decreased methylation and
sulfation abilities compared to controls in the literature, which adversely affects their
ability to remove xenobiotic chemicals.
Over the past decade, a new field of scientific inquiry called exposomics was
developed, which sought to explain disease causation and progression from the level of
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DNA (genomics), the prime code for protein production, to messenger RNA, the signal
and template for protein production, to the qualities and levels of protein concentrations
(proteomics), up to epigenetic mechanisms, the numerous ways that protein production
from DNA can be modified without changing the genome. The current study, in a similar
fashion, was designed to measure numerous levels of possible causative mechanisms in
children with autism, through genetic mutation using the Glycophorin A test, noting the
levels of heavy metal and chemical concentration through exacting measurement,
studying immune functioning through the performance of t and b cell subsets, examining
the degree of loss of immune tolerance to certain proteins through the performance of
IgG antibody levels to casein, gluten, and soy, and studying behavioral phenotype
through rating scale and ADOS performance.
The initial round of data analysis has revealed the following findings from this
study:
1. A subset of 3 children with autism appeared to experience much more total allele
loss and duplication mutation than other children with autism, suggesting the
presence of a group of children with the behavioral phenotype of autism who may
be especially susceptible to such mutation.
2. Children with autism had significantly increased blood levels of magnesium and
iron compared to controls suggesting that their metalloprotein system essential in
heavy metal elimination was more stressed than controls and they were increasing
blood levels of magnesium and iron to compensate. Magnesium can calm central
nervous system excitotoxicity, and increased iron may promote oxygenation in
stressed tissues. The children with autism also had increased molybdenum levels
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compared to controls. Molybdenum supports methylation and sulfation essential
for chemical detoxification.
3. The children with autism demonstrated a trend towards less chromium and lead in
their hair compared to controls suggesting difficulty with effluent of these
elements from the body.
4. The children with autism displayed a strikingly different pattern of chemical
toxicity concentration compared to controls, as they tended to have higher blood
concentrations of compounds associated with automobile exhaust and one flame
retardant. The control children were found to have higher levels of chlorinated
pesticides in their blood. This data supports the literature which implicates
exposure to highway pollutants as a possible contributor to the development of
autism. This data also suggests that children with autism may have particular
difficulty with mobilizing pesticides from their tissues.
5. Children with autism and the control group had numerous blood concentrations of
chemicals that greatly exceeded published national averages, including pesticides
and hydrocarbons such as xylene, toluene, and benzene. Children in Western
Pennsylvania may be at high exposure risk for these compounds.
6. Children with autism had a strong trend towards positive correlation between their
total ADOS scores (indicating autism severity) and mean toxin concentration.
7. Children with autism had significantly higher levels of total glutathione and
reduced glutathione compared to controls, while they had significantly less total /
oxidized and reduced / oxidized glutathione compared to controls. This data
indicates that children with autism in Western Pennsylvania are producing more
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reduced and total glutathione than their healthy peers and children with autism
who live in less toxic regions of North America, in response to the increased toxic
burden of this region, as a compensatory physiology. However, they demonstrate
decreased reduced / oxidized and total / oxidized glutathione ratios compared to
their peers, similar to other children with autism described in the literature. Their
compensatory physiology fails to control their increased oxidative stress in this
region.
8. Children with autism demonstrated significant immune dysregulation compared to
controls, as displayed by significantly elevated CD3 / total T cell number, CD4 /
helper cell number, natural killer cell number and natural killer cell percent,
compared to controls. They had significantly increased platelet counts compared
to controls, supporting the presence of more generalized inflammation in their
bodies, than controls.
9. Children with autism had significantly elevated anti-gluten IgG antibodies
compared to controls and a strong trend towards elevated anti-casein IgG
antibodies compared to controls. As children with autism aged their anti-casein
IgG antibodies increased significantly, a finding not noted in control children.
These results support recent literature suggesting increased gluten and casein
sensitivity in children with autism compared to controls.
10. Methylmalonic acid levels were tested as higher concentrations of methylmalonic
acid in serum may indicate a vitamin B12 deficiency. In this study, the children
with autism had significantly greater quantities of blood methylmalonic acid
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compared to controls supporting the presence of relative B12 deficiency in
children with autism compared to controls.
11. Logistic regression results for natural killer cell number, white blood cell number,
antigluten IgG antibody concentration, and methylmalonic acid concentration are
most promising of the variables measured for determining diagnostic probability
of autism in children age 2-9.
12. Of interest, control children could increase uranium and cerium significantly in
their hair as they aged while children with autism demonstrated small negative
correlations with these substances as they aged. This finding suggests that
children with autism may have more difficulty eliminating these elements from
their bodies as they age.
Overall, the results of this study establish the presence of greater metallothionein
system dysfunction, chemical detoxification disturbances, immune dysregulation, and
subsequent loss of immune tolerance in children with autism compared to controls, and
support the presence of the Toxicant Induced Loss of Tolerance or TILT model of disease
progression in children with autism. This study is one of the first to demonstrate changes
in elemental, chemical and immune parameters in children with autism in relation to age.
The study results suggest that various chemicals are detoxified differently between
children with autism and controls. The magnesium, zinc, selenium, and glutathione data
support the presence of compensatory physiology in children with autism, exposed to the
high heavy metal and chemical stress of living in Western Pennsylvania. Benzene,
toluene, and xylene concentrations in children with autism and controls were much
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higher than previously determined national norms, suggesting significant exposure for
Western Pennsylvanian children to these toxins.
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